

| Ex. No | Date | Description | BegBates | EndBates | Admission Stip. | Plaintiffs' Limited Advance Objections | Plaintiffs' Other Objections | Defendants' Limited Advance Objections | Defendants' Other Objections | Family Exhibits Over 10 Documents | Joint | Offered | Admitted/ Not Admitted |
|---------|------------|--|----------------------|----------------------|-----------------|--|------------------------------|--|------------------------------|-----------------------------------|-------|---------|------------------------|
| P-00004 | 1/11/2011 | Re: High Quantity Stores 682971 | WAGFLDEA00000852 | WAGFLDEA00000862 | | | | | | | | | |
| P-00007 | 5/12/2012 | CAH 2012 Settlement Agreement | CAH_MDL2804_00135203 | CAH_MDL2804_00135210 | | | | | | | | | |
| P-00009 | 6/22/2007 | Settlement and Release Agreement between DEA and AmerisourceBergen Drug Corporation | ABDCMDL00279854 | ABDCMDL00279865 | | | | | | | | | |
| P-00010 | 5/2/2008 | McKesson 2008 Settlement Agreement | MCK-AGMS-006-0001048 | MCK-AGMS-006-0001071 | | | | | | | | | |
| P-00015 | 6/11/2013 | WAG 2013 Settlement Agreement | WAGMDL00490963 | WAGMDL00490974 | | | | | | | | | |
| P-00021 | 9/12/2013 | NEJM Abusive Prescribing of Controlled Substances - A Pharmacy View (TAB 050C) | N/A | N/A | | | | | | | | | |
| P-00027 | 12/16/2012 | FW: Proposed org chart; Controlled Substance Reporting; Pharmaceutical Integrity Organization PPT by Tasha Polster; RxIntegrity Proposed Org Chart 12.2012 POLSTER | WAGMDL00659270 | WAGMDL00659274 | | | | | | | | | |
| P-00028 | 3/21/2013 | Re: New MPD Corporate Orientation; Pharmaceutical Integrity Overview One Pager; Pharmaceutical Integrity Overview One Pager | WAGMDL00303029 | WAGMDL00303031 | | | | | | | | | |
| P-00029 | 8/2/2013 | Email FYI - this is work in progress but a good read. Data is still being validated so is preliminary 2013 08 01 Purdue core team working session vF PPT | PPLPC004000365800 | PPLPC004000365802 | | | | | | | | | |
| P-00034 | 12/27/2007 | McKesson Rannazzisi Letter #2 | MCKMDL00478910 | MCKMDL00478911 | | | | | | | | | |
| P-00035 | 9/27/2006 | WAG #1 & #2 Rannazzisi Letters | WAGMDL00757790 | WAGMDL00757797 | | | | | | | | | |
| P-00036 | 12/27/2007 | 2007 WAG Rannazzisi Letter #2 | WAGMDL00757798 | WAGMDL00757801 | | | | | | | | | |
| P-00037 | 10/27/2017 | Re: DEA will hold Drug Take Back Day to snag unused opioids | WAGMDL00386743 | WAGMDL00386745 | | | | | | | | | |
| P-00045 | 1/23/2008 | Cegedum Dendrite letter to Jodi Avergun from Ronald Buzzeo regarding their findings and recommendations on CAH's SOM System | CAH_MDL2804_03309960 | CAH_MDL2804_03309971 | | | | | | | | | |

Some of the documents listed herein are copies, including non-identical copies, of documents which have different document production numbers or may have been produced by different parties than the versions listed herein or bear deposition exhibit stickers. Plaintiffs reserve the right to use at trial any version of the documents listed herein, including versions that bear one or more deposition exhibit stickers.

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------------------|----------------------------------|--|--|--|--|--|--|--|--|--|
| P-00055 | 5/17/2006 | DEA letter to Mr. Polarolo regarding completed regulatory investigation of Walgreen Company | WAGMDL00709510 | WAGMDL00709512 | | | | | | | | | |
| P-00056 | 5/27/2006 | Memorandum, Meeting Between Office of Diversion Control (OD) and McKesson Corp. | WAGMDL00709508 | WAGMDL00709509 | | | | | | | | | |
| P-00057 | 12/22/2008 | Walgreens Internal Audit Report, DEA Compliance - Perrysburg Distribution Center | WAGMDLPER00000001 | WAGMDLPER00000019 | | | | | | | | | |
| P-00058 | 8/3/2010 | Re: Suspicious Controlled Drug Orders with screenshots | WAGMDL00660331 | WAGMDL00660337 | | | | | | | | | |
| P-00059 | 1/4/2013 | Re: Ceiling Update | WAGMDL00414048 | WAGMDL00414049 | | | | | | | | | |
| P-00060 | 3/1/2013 | Walgreens Memo to Rex Swords from Tasha Polster, DEA Strategy Meeting Agenda | WAGMDL00302949 | WAGMDL00302950 | | | | | | | | | |
| P-00062 | 5/23/2016 | Email State of Integrity, Attachment State of Rx Integrity 10 PPT | WAGMDL00010887 | WAGMDL00010928 | | | | | | | | | |
| P-00063 | 9/7/2007 | Summary of the DEA-HDMA Meeting on Suspicious Orders, Meeting Date: Sept. 7, 2007 | HDS_MDL_00135664 | HDS_MDL_00135665 | | | | | | | | | |
| P-00100 | 10/27/1970 | 21 USC Sections 801, 812, 821 and 823; Pertinent Sections of CSA | PLTF_2804_000067826 | PLTF_2804_000067829 | | | | | | | | | |
| P-00101 | 4/24/1970 | 21 CFR Section 1301.74 (Whole Reg) | N/A | N/A | | | | | | | | | |
| P-00102 | 1/9/2008 | 1984/1993 NWDA Suspicious Order Monitoring System | CAH_MDL_PRIORPROD_DEA07_00869965 | CAH_MDL_PRIORPROD_DEA07_00870002 | | | | | | | | | |
| P-00103 | 4/7/1987 | U.S. Department of Justice, Seminar Report, Controlled Substances Manufacturers and Wholesalers Seminar | US-DEA-00025656 | US-DEA-00025659 | | | | | | | | | |
| P-00104 | 4/16/1996 | U.S. Department of Justice, DEA, Diversion Investigators Manual, letter to Robert Giacalone | CAH_MDL2804_02203353 | CAH_MDL2804_02203363 | | | | | | | | | |
| P-00107 | 9/6/2012 | Email Reminder RAC Call - Today at 2pm | CAH_MDL2804_01530076 | CAH_MDL2804_01530086 | | | | | | | | | |
| P-00120 | 4/9/2014 | Re: Report on House Energy & Commerce Subcommittee Hearing on DEA and FDA Transparency | MCKMDL00661483 | MCKMDL00661485 | | | | | | | | | |
| P-00121 | 8/13/2014 | Letter from Department of Justice to Mr. Hobart Re: Possible Civil Action Against McKesson Corporation for Violations of the Controlled Substances Act | MCKMDL00409224 | MCKMDL00409246 | | | | | | | | | |
| P-00124 | 1/20/2011 | Email Ft Pierce | WAGFLDEA00000872 | WAGFLDEA00000884 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|------------------|------------------|--|--|--|--|--|--|--|--|--|
| P-00125 | 7/31/2011 | DEA statistics for WAG July 2011 show alarming number of orders being cut or reduced as opposed to being reported | WAGMDL00492171 | WAGMDL00492171 | | | | | | | | | |
| P-00126 | 2/28/2012 | Fw: Spreadsheet Rolling 12 for top ten stores | WAGFLDEA00001733 | WAGFLDEA00001734 | | | | | | | | | |
| P-00127 | 4/7/2012 | Fw: Update Rx Supply Chain Contingency Plan for Jupiter, Suspicious Ordering Reporting | WAGMDL00709395 | WAGMDL00709397 | | | | | | | | | |
| P-00128 | 4/23/2012 | Fw: DEA Suspicious Order - Phase III; Functional Requirements & (Macro) Design, DEA Suspicious Ordering - Phase III, (Controlled Substance Threshold), Project Number W0018238 | WAGMDL00325170 | WAGMDL00325191 | | | | | | | | | |
| P-00129 | 7/17/2012 | Walgreen Co. Controlled Substance Anti-Diversion and Compliance Program PPT | WAGMDL00659801 | WAGMDL00659856 | | | | | | | | | |
| P-00130 | 10/11/2012 | RE: CSR Version Summary 100812 with attachment Controlled Substance Ordering, Evolution of Controlled Substance Ordering Process | WAGMDL00667936 | WAGMDL00667943 | | | | | | | | | |
| P-00131 | 11/12/2012 | FW: November 8th DEA meeting at NABP | WAGMDL00426251 | WAGMDL00426254 | | | | | | | | | |
| P-00132 | 11/28/2012 | Email Walgreens State Controls Summaries; Attachment Walgreens_Analysis-States; Walgreens Map Control Percent Flagged | WAGMDL00774715 | WAGMDL00774720 | | | | | | | | | |
| P-00133 | 1/18/2013 | Re: 13659 hydros 7.5/500 | WAGMDL00246275 | WAGMDL00246279 | | | | | | | | | |
| P-00134 | 2/4/2013 | U.S Department of Justice/Drug Enforcement Administration Subpoena to Walgreen Corporation | WAGMDL00493694 | WAGMDL00493696 | | | | | | | | | |
| P-00135 | 2/5/2013 | Walgreens Corporation Administrative Inspection Warrant Perrysburg, OH | WAGMDL00493697 | WAGMDL00493700 | | | | | | | | | |
| P-00136 | 1/10/2013 | Email DEA Update Presentation For Market Leadership; DEA Market Leadership Scrubbed Version Jan 2013 | WAGMDL00049752 | WAGMDL00049772 | | | | | | | | | |
| P-00137 | 2/20/2013 | Letter from Latham & Watkins Re: Walgreens Perrysburg, Ohio Distribution Center | WAGMDL00674280 | WAGMDL00674281 | | | | | | | | | |
| P-00138 | 4/16/2013 | FW: Shrink Set | WAGMDL00429246 | WAGMDL00429248 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-00139 | 8/19/2013 | Re: Controlled Substances Order Quantity Override Form | WAGMDL00021425 | WAGMDL00021427 | | | | | | | | | |
| P-00140 | 5/7/1969 | US Government Memorandum to The Honorable John W. Dean, III from Michael R. Sonnenreich, Subject: Department of Health, Education, and Welfare's staff papers regarding the "Controlled Dangerous Substances Act of 1969" | PLTF_2804_000296556 | PLTF_2804_000296564 | | | | | | | | | |
| P-00141 | 12/23/2003 | GAO Report to Congressional Requesters, Prescription Drugs, OxyContin Abuse and Diversion and Efforts to Address the Problem | PURCHI-000742458 | PURCHI-000742520 | | | | | | | | | |
| P-00142 | 5/10/2007 | United States of America vs. The Purdue Frederick Company, Inc., Plea Agreement | PLTF_2804_000252605 | PLTF_2804_000252805 | | | | | | | | | |
| P-00143 | 6/18/2007 | 2006 Allergan Rannazzisi Letter | ALLERGAN_MDL_02467796 | ALLERGAN_MDL_02467799 | | | | | | | | | |
| P-00204 | 2/21/2020 | At Walgreens, Complaints of Medication Errors Go Missing - by Ellen Gabler The New York Times | N/A | N/A | | | | | | | | | |
| P-00211 | 3/25/2020 | Walmart Was Almost Charged Criminally Over Opioids. Trump Appointees Killed the Indictment. | N/A | N/A | | | | | | | | | |
| P-00286 | 10/4/2010 | ROI 1 | US-DEA-00027328 | US-DEA-00027356 | | | | | | | | | |
| P-00290 | 5/28/2002 | CVS Meeting 5/21/02 | PKY181855117 | PKY181855121 | | | | | | | | | |
| P-00298 | 12/19/2011 | Summary of DEA-HDMA Meeting By the Healthcare Distribution Management Association; December 2010 Held Orders | ABDCMDL00139009 | ABDCMDL00139031 | | | | | | | | | |
| P-00352 | 3/26/2020 | How Johnson & Johnson companies used a 'super poppy' to make narcotics for America's most abused opioid pills | N/A | N/A | | | | | | | | | |
| P-00447 | 2016 | 2016 Year-End Performance Review for Nicole J Harrington | CVS-MDLT3-000140100 | CVS-MDLT3-000140106 | | | | | | | | | |
| P-00448 | 2019 | 2019 Year-End Performance Review for Nicole J Harrington | CVS-MDLT3-000140127 | CVS-MDLT3-000140132 | | | | | | | | | |
| P-00455 | 2/9/2016 | Guide for Pharmacist Review; Pharmacy Supervisor Guide 2016 Pharmacist Performance Review_V1 (3) | CVS-MDLT3-000069359 | CVS-MDLT3-000069362 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|-------------------------|--|--|--|--|--|--|--|--|--|
| P-00459 | 2/19/2015 | Email 2015 LP Presentation Attachment Our Communities, Our Response PPT | CVS-NYAG-000073103 | CVS-NYAG-000073128.0019 | | | | | | | | | |
| P-00460 | 3/25/2020 | Email CS Standards Grad Training 2020 Attachment CS Standards Grad Training 2020 PPT | CVS-MDLT3-000120296 | CVS-MDLT3-000120372 | | | | | | | | | |
| P-00511 | 4/20/2021 | State of Ohio Board of Pharmacy Pharmacist Workload Survey April 2021 | N/A | N/A | | | | | | | | | |
| P-00517 | 7/23/1998 | 1998 DEA Approval Letter of OMP | ABDCMDL00269347 | ABDCMDL00269358 | | | | | | | | | |
| P-01050 | 9/30/2019 | Inspector General Report - Review of DEA Opioid Enforcement | N/A | N/A | | | | | | | | | |
| P-01051 | 5/5/2015 | Testimony of Rannazzisi | N/A | N/A | | | | | | | | | |
| P-01052 | N/A | 21 U.S. Code section 826 - Production quotas for CSs | N/A | N/A | | | | | | | | | |
| P-01098 | 5/16/2014 | Formatting the Raw Data | CVS-MDLT1-000112721 | CVS-MDLT1-000112734 | | | | | | | | | |
| P-01142 | 6/11/2013 | WAG 2013 Settlement Agreement | WAGMDL00490963 | WAGMDL00490978 | | | | | | | | | |
| P-01207 | 6/24/2008 | Department of Justice: Remarks by Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, before the House Judiciary Committee Subcommittee on Crime, Terrorism, & Homeland Security Regarding "Online Pharmacies and the Problem of Internet Drug Abuse" | N/A | N/A | | | | | | | | | |
| P-01208 | 4/7/2014 | Department of Justice, Statement of Joseph T. Rannazzisi before the Subcommittee on Health Committee on Energy and Commerce U.S. House of Representative for a hearing entitled "Improving Predictability and Transparency in DEA and FDA Regulation" presented on April 7, 2014 | N/A | N/A | | | | | | | | | |
| P-01239 | 5/25/2015 | Washington Times Article: Report: Closed pain clinic practices put patients at risk | N/A | N/A | | | | | | | | | |
| P-01253 | 10/27/2010 | Department of Justice -DEA East Main Street Pharmacy: Affirmance of Suspension Order | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------------------|---------------------------------|--|--|--|--|--|--|--|--|--|
| P-01750 | 4/19/2012 | 15th Annual Controlled Substance, PDMA and State Conference, It's What You Know and Who You Know by Linden Barber PPT | Anda_Opioids_MDL_0000476052 | Anda_Opioids_MDL_0000476080 | | | | | | | | | |
| P-02008 | 3/1/2019 | Harper Sentencing Memorandum | PLTF_2804_000013676 | PLTF_2804_000013695 | | | | | | | | | |
| P-02030 | 1998 | 1998 Report to U.S. Attorney General from Suspicious Orders Task Force | CAH_MDL_PRIORPROD_HOUSE_0002207 | CAH_MDL_PRIORPROD_HOUSE_0002298 | | | | | | | | | |
| P-02094 | 6/21/1993 | NWDA Suspicious Order Monitoring System | CAH_MDL2804_01465723 | CAH_MDL2804_01465761 | | | | | | | | | |
| P-02229 | 2/22/2010 | Above Average Order Monitoring Policy Procedure; Procedures-Above average order monitoring procedure 2.10 | Rite_Aid_OMDL_0015077 | Rite_Aid_OMDL_0015081 | | | | | | | | | |
| P-02234 | 9/12/2011 | 2011 Pill Mill Emails for Dr. Adolph Harper | MCKMDL00632923 | MCKMDL00632925 | | | | | | | | | |
| P-02235 | 5/13/2015 | DEA Press Release - MD Florida (public); United States Reaches \$22 Million Settlement Agreement with CVS for Unlawful Distribution of Controlled Substances | N/A | N/A | | | | | | | | | |
| P-02237 | 2/12/2016 | DOJ Press Release - Maryland (public); DEA Reaches \$8 Million Settlement Agreement with CVS for Unlawful Distribution of Controlled Substances | N/A | N/A | | | | | | | | | |
| P-02238 | 10/20/2016 | DOJ Press Release - Connecticut (public); CVS Pharmacy Pays \$600,000 to Settle Controlled Substances Act Allegations | N/A | N/A | | | | | | | | | |
| P-02239 | 7/11/2017 | DOJ Press Release - ED California (public); CVS Pharmacy, Inc. Pays \$5M to Settle Alleged Violations of the Controlled Substances Act | N/A | N/A | | | | | | | | | |
| P-02240 | 8/22/2018 | DEA Press Release - ND Alabama (public); CVS Pharmacy pays one million penalty in settlement with DOJ for violations of the Controlled Substances Act | N/A | N/A | | | | | | | | | |
| P-02241 | 4/16/2019 | DOJ Press Release - Rhode Island (public); CVS To Pay \$535,000 for Filling Invalid Prescriptions | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-----|-----|--|--|--|--|--|--|--|--|--|
| P-02244 | 11/30/2006 | GAO Report (2006) Improvements Needed in FDA's Oversight of Direct-to-Consumer Advertising | N/A | N/A | | | | | | | | | |
| P-02245 | 12/31/2018 | Press Release on Rite Aid Settlement; \$300,000 for filling CIII's in excess of statutory maximums | N/A | N/A | | | | | | | | | |
| P-02249 | 10/15/2017 | Washington Post Article: The Drug Industry's Triumph Over the DEA - Higham and Bernstein | N/A | N/A | | | | | | | | | |
| P-02250 | 1/1/2016 | Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report; Increases in Drug and Opioid Overdose Deaths -United States, 2000-2014 | N/A | N/A | | | | | | | | | |
| P-02251 | 12/16/2016 | Centers for Disease Control and Prevention; Increases in Drug and Opioid-Involved Overdose Deaths -United States, 2010-2015 | N/A | N/A | | | | | | | | | |
| P-02252 | 2/13/2018 | Altarium article: Economic Toll of Opioid Crisis in U.S. Exceeded \$1 Trillion since 2001 | N/A | N/A | | | | | | | | | |
| P-02253 | 1/1/2015 | National Institute on Drug Abuse "National Overdose Deaths" | N/A | N/A | | | | | | | | | |
| P-02254 | 8/30/2017 | Centers for Disease Control and Prevention: Understanding the Epidemic | N/A | N/A | | | | | | | | | |
| P-02255 | 5/23/2018 | Letter from the Surgeon General to Colleagues. | N/A | N/A | | | | | | | | | |
| P-02257 | 2/9/2017 | Centers for Disease Control and Prevention -Opioid Data Analysis | N/A | N/A | | | | | | | | | |
| P-02259 | 7/24/2013 | CNBC New Article Health Care Deadly Epidemic: Prescription drug overdoses | N/A | N/A | | | | | | | | | |
| P-02260 | 5/29/2018 | HDA Executive Committee | N/A | N/A | | | | | | | | | |
| P-02262 | 1/1/2010 | Regulatory Section DEA Headquarters ODG Presentation | N/A | N/A | | | | | | | | | |
| P-02263 | 3/6/2018 | U.S. Health and Human Services - What is the U.S. Opioid Epidemic | N/A | N/A | | | | | | | | | |
| P-02264 | 7/22/2016 | 21 USC § 823 | N/A | N/A | | | | | | | | | |
| P-02270 | 3/20/2018 | Congressional hearing Transcript: The Drug Enforcement Administration's Role in Combating the Opioid Epidemic | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-02271 | 5/11/2016 | DEA Distributor Conference Presentation, Indianapolis IN | N/A | N/A | | | | | | | | | |
| P-02272 | 5/10/2016 | DEA Trends and Update Distributor Conference Presentation. Distributor Conference, Indianapolis, IN | N/A | N/A | | | | | | | | | |
| P-02273 | 9/1/2017 | Centers for Disease Control and Prevention "International Overdose Awareness Day - August 31, 2017" | N/A | N/A | | | | | | | | | |
| P-02278 | 8/12/2009 | Ohio Dept. of Health "Epidemic of Prescription Drug Overdose in Ohio" | N/A | N/A | | | | | | | | | |
| P-02279 | 12/1/2003 | HDMA Voluntary Guidelines | N/A | N/A | | | | | | | | | |
| P-02283 | 4/29/2014 | CDC Washington: Examining the Growing Problems of Prescription Drug and Heroin Abuse, Ctrs. For Disease Control and Prevention | N/A | N/A | | | | | | | | | |
| P-02284 | 8/31/2016 | Letter from Vivek H. Murthy, Surgeon General, Tide RX (Aug. 2016) | N/A | N/A | | | | | | | | | |
| P-02285 | N/A | 21 U.S.C. §802(10-11) | N/A | N/A | | | | | | | | | |
| P-02286 | N/A | 21 U.S.C. §822(a)(1-2) | N/A | N/A | | | | | | | | | |
| P-02287 | 10/17/2017 | Nick Miroff, From Teddy Roosevelt to Trump: How Drug Companies Triggered an Opioid Crisis a Century Ago, The Washington Post | N/A | N/A | | | | | | | | | |
| P-02288 | 12/19/2006 | Email: Pharmacy Fraud & Abuse Compliance Manual | CAH_MDL2804_00842869 | CAH_MDL2804_00842919 | | | | | | | | | |
| P-02289 | 10/22/2013 | Thomas W. Prevoznik, Office of Diversion Control, Distributor Initiative presentation | N/A | N/A | | | | | | | | | |
| P-02290 | 6/1/2020 | U.S. Dept. of Justice, Drug Diversion Administration, Diversion Control Division website | N/A | N/A | | | | | | | | | |
| P-02291 | 10/14/2009 | U.S. Dept. of Justice DEA, Diversion Control Division website, Pharmaceutical Industry Conference (Oct 14 & 15, 2009), Suggested Questions a Distributor should ask prior to shipping controlled substances, Drug Enforcement Administration | N/A | N/A | | | | | | | | | |
| P-02292 | 10/3/2010 | Richard Widup, Jr., Kathleen H. Dooley, Esq., Pharmaceutical Production Diversion: Beyond the PDMA, Purdue Pharma and McGuireWoods LLC | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------|--------------------|--|--|--|--|--|--|--|--|--|
| P-02293 | 9/21/2017 | CVS Health Unveils New PBM, Pharmacy Efforts to Curb Opioid Abuse | N/A | N/A | | | | | | | | | |
| P-02294 | 8/31/2010 | Walgreens fiscal year 2010 SEC Form 10-K | N/A | N/A | | | | | | | | | |
| P-02295 | 10/28/2010 | Omnicare Faces Federal Probe, Wall Street Journal | N/A | N/A | | | | | | | | | |
| P-02296 | 5/11/2012 | Settlement Agreement between DEA and Omnicare - \$50M | N/A | N/A | | | | | | | | | |
| P-02297 | 5/13/2020 | Omnicare Inc agrees to pay over \$15M to resolve allegations it improperly dispensed narcotics at long-term care facilities | N/A | N/A | | | | | | | | | |
| P-02298 | 4/18/2014 | Rx Integrity Market 25 Presentation - Controlled Substance Trends | WAGMDL00673006 | WAGMDL00673030 | | | | | | | | | |
| P-02299 | 11/3/2014 | Rx Integrity Market 3 Presentation - Controlled Substance Trends | WAGMDL00018177 | WAGMDL00018207 | | | | | | | | | |
| P-02300 | 3/31/2011 | POM 1311 (2011-04-08 to 2014-10-23) | WMT_IN_AG_00000066 | WMT_IN_AG_00000069 | | | | | | | | | |
| P-02301 | 11/7/2017 | Are Business Tactics at Some Pharmacies Risking Your Health? | N/A | N/A | | | | | | | | | |
| P-02302 | 1/31/2020 | How Chaos at Chain Pharmacies Is Putting Patients at Risk, The New York Times, Gabler, Ellen | N/A | N/A | | | | | | | | | |
| P-02303 | 12/15/2016 | Pharmacies Miss Half of Dangerous Drug Combinations, The Chicago Tribune | N/A | N/A | | | | | | | | | |
| P-02304 | 6/5/2013 | NABP, Performance Metrics and Quotas in the Practice of Pharmacy (Resolution 109-7-13) | N/A | N/A | | | | | | | | | |
| P-02305 | 8/8/2019 | Distributors, pharmacies and manufacturers respond to previously unreleased DEA data about opioid sales, The Washington Post | N/A | N/A | | | | | | | | | |
| P-02306 | 8/31/2019 | Walgreens Board Report on Oversight of Risk Related to Opioids | N/A | N/A | | | | | | | | | |
| P-02307 | 1/7/2009 | Walmart Settles Drug Records Accusation, The Daily Herald | N/A | N/A | | | | | | | | | |
| P-02308 | 8/1/2019 | Pharmacies Across Ohio Received Large Amounts of Painkillers as Opioid Epidemic Ramped Up | N/A | N/A | | | | | | | | | |
| P-02309 | N/A | Rite Aid, Pharmacy, Health Information | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-02310 | 6/19/2017 | DOJ, DEA, Docket No. 15-26, [FR Doc. No. 2017-13158], Decision and Order | N/A | N/A | | | | | | | | | |
| P-02311 | 9/26/2018 | Oklahoma State Board of Pharmacy Minutes | N/A | N/A | | | | | | | | | |
| P-02312 | 6/7/2011 | 16 Charged in 'pill mill' pipeline, The Columbus Dispatch | N/A | N/A | | | | | | | | | |
| P-02313 | 7/16/2015 | Leader of Ohio pill-mill trafficking scheme sentenced, Star Beacon | N/A | N/A | | | | | | | | | |
| P-02314 | 10/31/2017 | C. William Swank Program in Rural-Urban Policy, Taking Measure of Ohio's Opioid Crisis, The Ohio State University | N/A | N/A | | | | | | | | | |
| P-02315 | 4/30/2020 | Years of Life Lost due to Opioid Overdose in Ohio, Temporal and Geographic Patterns of Excess Mortality | N/A | N/A | | | | | | | | | |
| P-02316 | 5/25/2017 | Testimony of Dr. Thomas P. Gilson, Chief Medical Examiner of Cuyahoga County, Hearing of the U.S. Permanent Subcommittee on Investigations, of the Senate Committee on Homeland Security and Government Affairs, Subject, Public Health Emergency Stemming from Opiate/Opioid Crisis | N/A | N/A | | | | | | | | | |
| P-02317 | 10/22/2019 | Ohio Program seeks to reunite families of addicts | N/A | N/A | | | | | | | | | |
| P-02318 | 4/14/2020 | Portrait of Warren, Ohio - a microcosm of the Rust Belt struggle | N/A | N/A | | | | | | | | | |
| P-02319 | 2020 | Public Children Services Association of Ohio | N/A | N/A | | | | | | | | | |
| P-02320 | 4/16/2018 | What The Opioid Crisis Is Costing The Mahoning Valley | N/A | N/A | | | | | | | | | |
| P-02321 | N/A | Neonatal Abstinence Syndrome Project, OPQC, Ohio Perinatal Quality Collaborative | N/A | N/A | | | | | | | | | |
| P-02322 | 9/25/2014 | Walmart, Your Career as a Walmart Pharmacist; https://youtu.be/9VD12IXOzfs | N/A | N/A | | | | | | | | | |
| P-02323 | 7/9/2012 | States Take on 'Tourists' Trafficking Painkillers | N/A | N/A | | | | | | | | | |
| P-02792 | 9/1/2012 | Drug Trends Long Island, New York September 2012 | CVS-MDLT1-000114359 | CVS-MDLT1-000114469 | | | | | | | | | |
| P-02843 | 2/28/2011 | Herald-Tribune Article, A Healthy Dose of Shaming | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|---------------|---------------|--|--|--|--|--|--|--|--|--|
| P-02847 | N/A | Title 21 United States Code Controlled Substances Act Subchapter 1 Control and Enforcement Part A - Introductory Provisions (2) the illegal importation, manufacture, distribution, and possession and improper use of controlled substances have a substantial and detrimental effect on the health and general welfare of the american people | N/A | N/A | | | | | | | | | |
| P-02851 | 12/1/2003 | United States General Accounting Office- PRESCRIPTION DRUGS OxyContin Abuse and Diversion and Efforts to Address the Problem GAO-04-110 | N/A | N/A | | | | | | | | | |
| P-02864 | 8/1/2017 | Prescription Opioid Overdose Data, Key Data, Prescription Opioid Map, Prescription Opioid Graph | N/A | N/A | | | | | | | | | |
| P-02865 | 1/10/2018 | Drug Overdose Mortality by State | N/A | N/A | | | | | | | | | |
| P-02877 | 1/1/2016 | Public Law 114-145- April 19, 2016, Ensuring Patient Access and Effective Drug Enforcement Act of 2016 | N/A | N/A | | | | | | | | | |
| P-02912 | 5/23/2020 | Article, Drug Distributor Employees Emailed a Parody song about 'pillbillies' documents show, The Washington Post | N/A | N/A | | | | | | | | | |
| P-02968 | 3/20/2018 | Pre-Hearing Written Statement Acting Administrator DEA, R. Patterson | N/A | N/A | | | | | | | | | |
| P-02969 | 9/00/2019 | Review of the DEA's Regulatory and Enforcement Efforts to Control the Diversion of Opioids | N/A | N/A | | | | | | | | | |
| P-03376 | 6/11/2013 | SDF Press Release re WAG settlement of \$80 million with MOT & Addendum attached | N/A | N/A | | | | | | | | | |
| P-04500 | Fall 2016 | Fall 2016, The Crime Scene Newsletter of the Lake County Crime Laboratory | LAKE000001976 | LAKE000001983 | | | | | | | | | |
| P-04501 | 2016 | Lake County Sheriff's Office Jail Treatment Program, Year in Review 2016 | LAKE000002371 | LAKE000002386 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------|---------------|--|--|--|--|--|--|--|--|--|
| P-04502 | 2017 | Lake County Sheriff's Office Jail Treatment Program, Year in Review 2017 | LAKE000002387 | LAKE000002402 | | | | | | | | | |
| P-04503 | 2018 | Lake County Sheriff's Office Jail Treatment Program, Year in Review 2018 | LAKE000002403 | LAKE000002418 | | | | | | | | | |
| P-04504 | 8/19/2014 | Ohio Office of Criminal Justice Services letter | LAKE000004500 | LAKE000004502 | | | | | | | | | |
| P-04505 | 2014 | OSAM Surveillance of Drug Abuse Trends in the State of Ohio January-June 2014 | LAKE000009106 | LAKE000009280 | | | | | | | | | |
| P-04506 | 5/23/2019 | State of Ohio Board of Pharmacy letter | LAKE000047018 | LAKE000047019 | | | | | | | | | |
| P-04507 | 2014 | Lake County Sheriff's Office Jail Treatment Program Year in Review 2014 | LAKE000339021 | LAKE000339036 | | | | | | | | | |
| P-04508 | 8/20/2014 | Narcan email from Jail Administrator | LAKE000348296 | LAKE000348298 | | | | | | | | | |
| P-04509 | 4/12/2017 | Opiate Recovery Program Lake County Common Pleas Court Report | LAKE000367604 | LAKE000367656 | | | | | | | | | |
| P-04510 | 9/1/2017 | email regarding Law Enforcement Diversion Program Application - Lake County Sheriff's Office | LAKE001210642 | LAKE001210674 | | | | | | | | | |
| P-04511 | 10/1/2018 | Lake County ADAMHS Board County Hub Program to Combat Opioid Addiction - Initial Report, October 2018 | LAKE002430159 | LAKE002430176 | | | | | | | | | |
| P-04512 | 2017-2018 | QRT Hub Report December 2017-December 2018 | LAKE002433131 | LAKE002433132 | | | | | | | | | |
| P-04513 | 8/17/2017 | Program Narrative for the Lake County Quick Response Team | LAKE002433259 | LAKE002433269 | | | | | | | | | |
| P-04514 | 9/18/2019 | Heroin Task Force data sheets | LAKE002434347 | LAKE002434349 | | | | | | | | | |
| P-04515 | 8/5/2015 | Lake County Sheriff's Office post | LAKE002434880 | LAKE002434881 | | | | | | | | | |
| P-04516 | 12/28/2017 | Operation Resolve flyer | LAKE002724727 | LAKE002724728 | | | | | | | | | |
| P-04517 | 9/21/2017 | Vote for Issue 3 November 7th flyer | LAKE002732838 | LAKE002732840 | | | | | | | | | |
| P-04518 | 12/1/2019 | Lake County ADAMHS Board County Hub Program to Combat Opioid Addiction, December 2019 | LAKE002732972 | LAKE002732997 | | | | | | | | | |
| P-04519 | 2015 | Lake County Unintentional Drug Overdose Deaths/Poisonings 2015 | LAKE002733249 | LAKE002733253 | | | | | | | | | |
| P-04520 | 9/21/2017 | On November 7th Vote for Issue 3 flyer | LAKE002733745 | LAKE002733746 | | | | | | | | | |
| P-04521 | 10/12/2017 | On November 7th Vote for Issue 3 flyers | LAKE002733773 | LAKE002733775 | | | | | | | | | |
| P-04522 | 9/11/2017 | On November 7th Vote for Issue 3 flyers | LAKE002733780 | LAKE002733783 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------|---------------|--|--|--|--|--|--|--|--|--|
| P-04523 | 9/12/2017 | On November 7th Vote for Issue 3 flyers | LAKE002733812 | LAKE002733814 | | | | | | | | | |
| P-04524 | 9/4/2017 | Ohio foster care crisis due to opioid epidemic article | LAKE002733889 | LAKE002733892 | | | | | | | | | |
| P-04525 | 2/1/2018 | Lake County Job and Family Services Newsletter | LAKE002734269 | LAKE002734276 | | | | | | | | | |
| P-04526 | 11/15/2017 | PCSAO, Factors Impacting Placement Costs: What Drives Placements, Strategies to Control Costs, and Future Challenges | LAKE002736801 | LAKE002736846 | | | | | | | | | |
| P-04527 | 9/1/2017 | When Addiction Hits Close To Home article | LAKE002747621 | LAKE002747624 | | | | | | | | | |
| P-04528 | 8/12/2010 | Lake County Opiate Task Force meeting notes | LAKE002819096 | LAKE002819099 | | | | | | | | | |
| P-04529 | 9/29/2017 | Lake County Client Data spreadsheet | LAKE002860096 | LAKE002860096 | | | | | | | | | |
| P-04530 | N/A | Heroin Task Force spreadsheet | LAKE002860097 | LAKE002860097 | | | | | | | | | |
| P-04531 | 5/27/2015 | Ohio Department of Health, 2013 Drug Overdose Data: General Findings | LAKE004014041 | LAKE004014047 | | | | | | | | | |
| P-04532 | 2008 | OSAM-O-GRAM, Dateline: Ohio | LAKE005097288 | LAKE005097289 | | | | | | | | | |
| P-04533 | N/A | Lake County General Health District, Lake County Drug-related Overdose Deaths: 2013 to 2017 | LAKE005126103 | LAKE005126129 | | | | | | | | | |
| P-04534 | N/A | On November 7th Vote for Issue 3 flyer | LAKE005143905 | LAKE005143906 | | | | | | | | | |
| P-04536 | 9/5/2017 | Other victims of opioid crisis article | LAKE005143912 | LAKE005143913 | | | | | | | | | |
| P-04537 | 6/16/2017 | Process begins to put children services levy on ballot | LAKE005143914 | LAKE005143914 | | | | | | | | | |
| P-04538 | 11/29/2012 | Board of County Commissioners Resolution | LAKE005703396 | LAKE005703397 | | | | | | | | | |
| P-04539 | 6/20/2019 | CVSHealth, Important Update - Opioid Utilization Management Strategy | LAKE005705045 | LAKE005705046 | | | | | | | | | |
| P-04540 | 2017 | Trumbull County Mental Health and Recovery Board presentation | TRUM000004169 | TRUM000004169 | | | | | | | | | |
| P-04541 | 2017-2020 | Trumbull County Opiate Action Plan 2017-2020 | TRUM000004193 | TRUM000004201 | | | | | | | | | |
| P-04542 | 6/18/2020 | The Opiate Crisis Impact On Families and Children presentation | TRUM000002997 | TRUM000003038 | | | | | | | | | |
| P-04543 | 2018 | Ohio Department of Mental Health and Addiction Services, Community Plan Update for SFY 2018, Trumbull County Mental Health and Recovery Board | TRUM000003198 | TRUM000003218 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------|---------------|--|--|--|--|--|--|--|--|--|
| P-04544 | 2018 | Trumbull County Mental Health and Recovery Board All Clients data | TRUM000003261 | TRUM000003261 | | | | | | | | | |
| P-04545 | 2019 | Trumbull County Mental Health and Recovery Board All Clients data | TRUM000003269 | TRUM000003269 | | | | | | | | | |
| P-04546 | 2017-2019 | Trumbull County Opiate Action Plan 2017-2019 | TRUM000003271 | TRUM000003278 | | | | | | | | | |
| P-04547 | 2/21/2017 | Trumbull County Citizens Budget Review Committee Minutes Compilation | TRUM000316735 | TRUM000316769 | | | | | | | | | |
| P-04548 | N/A | Fentanyl and Related Drugs Like Carfentanil as well as Cocaine Drive Increase in Overdose Deaths | TRUM001033148 | TRUM001033157 | | | | | | | | | |
| P-04549 | 2013 | OSAM Surveillance of Drug Abuse Trends in the State of Ohio January-June 2013 | TRUM001518308 | TRUM001518474 | | | | | | | | | |
| P-04550 | 11/19/2015 | Trumbull County Educational Service Center "Informed Parents + Healthy Kids = A Healthy Community" flyer | TRUM001719606 | TRUM001719608 | | | | | | | | | |
| P-04551 | 2017 | PCSAO, The Opioid Epidemic's Impact on Children Services in Ohio presentation | TRUM002037061 | TRUM002037078 | | | | | | | | | |
| P-04552 | 2015 | Judicial Symposium on Addiction & Child Welfare, County Data Packet | TRUM002084411 | TRUM002084453 | | | | | | | | | |
| P-04553 | N/A | Franklin Search Warrant | TRUM002465730 | TRUM002465770 | | | | | | | | | |
| P-04554 | 2017-2019 | Trumbull County Opiate Action Plan 2017-2019 | TRUM002588250 | TRUM002588257 | | | | | | | | | |
| P-04555 | N/A | Stuck in Trumbull County Opiate & Heroin Epidemic presentation | TRUM003210711 | TRUM003210712 | | | | | | | | | |
| P-04556 | 9/12/2019 | TAG Drug Task Force letter to Sheriff Paul Monroe | TRUM003210714 | TRUM003210720 | | | | | | | | | |
| P-04557 | 11/16/2017 | email regarding list (TAG accomplishments and stats) | TRUM003214947 | TRUM003214947 | | | | | | | | | |
| P-04558 | 9/4/2020 | TAG Drug Tips Spreadsheet | TRUM003636871 | TRUM003637383 | | | | | | | | | |
| P-04559 | N/A | TAG investigation documents | TRUM003637384 | TRUM003637424 | | | | | | | | | |
| P-04560 | N/A | TAG investigation documents | TRUM003920350 | TRUM003920597 | | | | | | | | | |
| P-04561 | 2017 | TCSO 2017 | TRUM004098782 | TRUM004098783 | | | | | | | | | |
| P-04562 | 5/11/2015 | Looking For A Way Out, Addiction Treatment And Education Resources In Trumbull County | TRUM004589807 | TRUM004589818 | | | | | | | | | |
| P-04563 | 2019 | 2019 ED Encounters and Emergency Response due to Drug Overdoses | TRUM004589936 | TRUM004589937 | | | | | | | | | |
| P-04564 | 2017 | 2017 ED Encounters and Emergency Response due to Drug Overdoses | TRUM004590054 | TRUM004590054 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------|---------------|--|--|--|--|--|--|--|--|--|
| P-04565 | 2018 | 2018 ED Encounters and Emergency Response due to Drug Overdoses | TRUM004590055 | TRUM004590056 | | | | | | | | | |
| P-04566 | 10/28/2016 | Project Dawn | TRUM004592431 | TRUM004592431 | | | | | | | | | |
| P-04567 | 3/1/2016 | Looking For A Way Out, A Guide to Addiction Treatment And Education Resources In Trumbull County | TRUM004592643 | TRUM004592656 | | | | | | | | | |
| P-04568 | 4/18/2017 | Resolution: Responding to Ohio's Opiate Epidemic | TRUM004592699 | TRUM004592699 | | | | | | | | | |
| P-04569 | 2017 | SFY 2017 Strategic Prevention Framework Partnership for Success Sub-Recipients Grant Application | TRUM004592870 | TRUM004592911 | | | | | | | | | |
| P-04570 | 2014 | ASAP Opiate Task Force Activities | TRUM004593734 | TRUM004593735 | | | | | | | | | |
| P-04571 | 2019 | Trumbull County Mental Health and Recovery Board presentation | TRUM004594950 | TRUM004594956 | | | | | | | | | |
| P-04572 | 4/16/2019 | Trumbull County Mental Health and Recovery Board Meeting Agenda | TRUM004595250 | TRUM004595302 | | | | | | | | | |
| P-04573 | 2018 | 2018 ED Encounters and Emergency Response due to Drug Overdoses | TRUM004596750 | TRUM004596762 | | | | | | | | | |
| P-04574 | 6/6/2019 | 2018-2019 Trumbull County Community Health Assessment | TRUM004613388 | TRUM004613650 | | | | | | | | | |
| P-04575 | 2010 | Violence and Injury Prevention Program 2010 Ohio Drug Overdose Data; General Findings | TRUM004648686 | TRUM004648689 | | | | | | | | | |
| P-04576 | 7/1/2011 | Ohio Department of Alcohol & Drug Addiction Services, Ohio's Opiate Epidemic | TRUM004648886 | TRUM004648887 | | | | | | | | | |
| P-04577 | 2016 | ASAP 2016 Drug Summit: From Addiction to Recovery presentation | TRUM004679842 | TRUM004679848 | | | | | | | | | |
| P-04578 | 2014 | Trumbull County Mental Health and Recovery Board presentation | TRUM004687179 | TRUM004687181 | | | | | | | | | |
| P-04579 | 2017 | Trumbull County Mental Health and Recovery Board presentation | TRUM004687182 | TRUM004687188 | | | | | | | | | |
| P-04580 | 2012 | Opiate Epidemic: Trumbull County presentation | TRUM004687310 | TRUM004687319 | | | | | | | | | |
| P-04581 | 2012 | Opiate Epidemic: Trumbull County presentation | TRUM004687320 | TRUM004687328 | | | | | | | | | |
| P-04582 | 2017 | Opiate Epidemic: Trumbull County presentation | TRUM004687382 | TRUM004687390 | | | | | | | | | |
| P-04583 | 2016 | Trumbull County Mental Health and Recovery Board presentation | TRUM004687402 | TRUM004687408 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--|---|--|--|--|--|--|--|--|--|--|
| P-04584 | N/A | The Opiate Epidemic presentation | TRUM004687409 | TRUM004687415 | | | | | | | | | |
| P-04585 | 3/15/2018 | Statement of Need (Compass) | TRUM004694257 | TRUM004694259 | | | | | | | | | |
| P-04586 | N/A | OSAM Trends in Pharmaceutical Opioid Abuse in Ohio | TRUM004708197 | TRUM004708198 | | | | | | | | | |
| P-04587 | N/A | Pharmaceutical Opioid Abuse: A Pathway to Heroin Addiction | TRUM004708211 | TRUM004708211 | | | | | | | | | |
| P-04588 | 3/1/2014 | 2012 Ohio Drug Overdose Deaths | TRUM004709497 | TRUM004709501 | | | | | | | | | |
| P-04589 | 8/16/2016 | Trumbull County Children Services Board, Board Meeting | TRUM004768692 | TRUM004768695 | | | | | | | | | |
| P-04590 | 2018 | Ohio Start Pilot Program Application | TRUM004772778 | TRUM004772782 | | | | | | | | | |
| P-04591 | 2019 | Ohio Sobriety, Treatment, and Reducing Trauma (START) Program: Practice Manual | TRUM004772976 | TRUM004773039 | | | | | | | | | |
| P-04592 | 2018 | Trumbull County Children Services Annual Report | TRUM004773317 | TRUM004773321 | | | | | | | | | |
| P-04593 | 3/17/2019 | TCCS SUD Programming | TRUM004794041 | TRUM004794041 | | | | | | | | | |
| P-04594 | 2016 | Trumbull County Children Services Annual Report | TRUM004794753 | TRUM004794757 | | | | | | | | | |
| P-04595 | 2016-17 | New Strategies to Fight the Opiate and Fentanyl Crisis in Ohio (2016-17) | TRUM004875667 | TRUM004875677 | | | | | | | | | |
| P-04596 | N/A | Officer Safety Alert | TRUM004882664 | TRUM004882665 | | | | | | | | | |
| P-04597 | 5/18/2015 | State of Ohio Board of Pharmacy letter | TRUM004890053 | TRUM004890168 | | | | | | | | | |
| P-04598 | 2017-2021 | Trumbull County Opiate Action Plan 2017-2021 | TRUM004984281 | TRUM004984301 | | | | | | | | | |
| P-06048 | 8/6/2014 | Email Practice Standards Team 080614 Attachment Professional Practice Standards Group, Resource Plan PPT | CVS-MDLT3-000030960 | CVS-MDLT3-000030969 | | | | | | | | | |
| P-06060 | 1/1/2013 | Prescriber Algorithm, Evolution and Enhancements, January 2013 | CVS-MDLT3-000033969 CVS-MDLT3-000034325 | CVS-MDLT3-000034325.0011 CVS-MDLT3-000034380 | | | | | | | | | |
| P-06067 | 10/26/2010 | Affirmance of Suspension Order for East Main Street Pharmacy | N/A | N/A | | | | | | | | | |
| P-06076 | 12/19/2018 | Report "Red Flags and Warning Signs Ignored: Opioid Distribution and Enforcement Concerns in West Virginia," prepared by the House Energy and Commerce Committee | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-06078 | 6/1/2018 | Follow the Money Report on Pharmaceutical Manufacturer Payments and Opioids Prescribing | N/A | N/A | | | | | | | | | |
| P-06097 | 5/10/2007 | Purdue Frederick Company Inc. Violation Tracker | N/A | N/A | | | | | | | | | |
| P-06116 | N/A | CFR Section 1301.74 | N/A | N/A | | | | | | | | | |
| P-06118 | 10/8/2014 | Email MAQ Attachment maq deck (chain)3_13_14 PPT | CVS-MDLT3-000073635 | CVS-MDLT3-000073648 | | | | | | | | | |
| P-06123 | 12/12/1995 | FDA Approval Oxy NDA | N/A | N/A | | | | | | | | | |
| P-06272 | 1/1/2013 | Pharmacy Professional Practice Team PPT | CVS-MDLT3-000076065 | CVS-MDLT3-000076086 | | | | | | | | | |
| P-06325 | 2/21/2021 | Overview of Programs | CVS-MDLT3-000076315 | CVS-MDLT3-000076317 | | | | | | | | | |
| P-06329 | 2013 | Analysis of New stores entering the CSDP in 2013 | CVS-MDLT3-000078701 | CVS-MDLT3-000078703 | | | | | | | | | |
| P-06344 | 12/1/2014 | CVS Form re Dr. George Blatti | CVS-NYAG-000021960 | CVS-NYAG-000021961 | | | | | | | | | |
| P-06400 | 2006 | FY2006 RAR Store Bonus Program Summary | Rite_Aid_OMDL_0060638 | Rite_Aid_OMDL_0060645 | | | | | | | | | |
| P-06402 | 2007 | FY2007 RAR Store Bonus Program Summary | Rite_Aid_OMDL_0060671 | Rite_Aid_OMDL_0060681 | | | | | | | | | |
| P-06407 | 2008 | FY2008 RAR Store Bonus Program Summary | Rite_Aid_OMDL_0060684 | Rite_Aid_OMDL_0060695 | | | | | | | | | |
| P-06442 | 2015 | FY2015 Store Bonus Program Guide | Rite_Aid_OMDL_0035161 | Rite_Aid_OMDL_0035168 | | | | | | | | | |
| P-06447 | 11/21/2016 | Procedures For Validation & Dispensing Of High Alert Controlled Substances | Rite_Aid_OMDL_0044309 | Rite_Aid_OMDL_0044317 | | | | | | | | | |
| P-06448 | 2016 | FY2016 Store Bonus Program Guide | Rite_Aid_OMDL_0035282 | Rite_Aid_OMDL_0035289 | | | | | | | | | |
| P-06452 | 2017 | FY2017 Store Bonus Program Guide | Rite_Aid_ONY_000001 | Rite_Aid_ONY_000008 | | | | | | | | | |
| P-06457 | 7/9/2018 | FW: Phase II CS Documentation Feedback; Attachments Store feedback from Phase II of CS Documentation Pilot; Phase II CS Documentation Feedback; 2018.6.25_Controlled Substance Therapy Review Checklist_Final_Vers | CVS-MDLT3-000083267 | CVS-MDLT3-000083272 | | | | | | | | | |
| P-06464 | 6/4/2019 | News article, Federal Agents Execute Search Warrants at Several Rite Aid Pharmacies | N/A | N/A | | | | | | | | | |
| P-06468 | 4/19/2013 | Professional Practice 3 Year Roadmap June 2013 | CVS-MDLT3-000085478 | CVS-MDLT3-000085493 | | | | | | | | | |
| P-06491 | 5/15/2011 | Drug Topics, Rite Aid offers 15-minute Rx guarantee | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-06503 | 9/27/2017 | FW: can you send Tara the newest version of the role play guide? we need today for the RM presentation- thankyou Attachments Narrator_v8_8_22_17 (Final); 2017.8.25_RxC Profile for RLC PPT | CVS-MDLT3-000089278 | CVS-MDLT3-000089301 | | | | | | | | | |
| P-06506 | 6/11/2013 | Quarter 2 Stores Entering Controlled Substance Dispensing Program; Tier1_flagging_6_12_13fv | CVS-MDLT3-000089566 | CVS-MDLT3-000089568 | | | | | | | | | |
| P-06510 | 4/17/2018 | Email Documentation pilot outline Attachments 2018.4.5_Opioid Therapy Review for Prescribers; 2018.4.17_Controlled Substance Therapy Review Checklist; 2018.4.17_Controlled Substance Therapy Review Checklist_all patients; 2018.4.17_Documentation timeline PPT | CVS-MDLT3-000090825 | CVS-MDLT3-000090830 | | | | | | | | | |
| P-06511 | 5/3/2018 | 2018_3_28 Pharmacy Professional Services Overview_Chris Cox_v1 | CVS-MDLT3-000090869 | CVS-MDLT3-000090914 | | | | | | | | | |
| P-06535 | 12/8/2014 | FW: Cocktail Attachment Publication1 (2); Publication1 | CVS-MDLT3-000094963 | CVS-MDLT3-00009495 | | | | | | | | | |
| P-06554 | 1/17/2020 | RE: HUB communication pilot Attachment Meghan R2F-DUR | CVS-MDLT3-000096404 | CVS-MDLT3-000096413 | | | | | | | | | |
| P-06558 | 7/10/2013 | Email Allied Pain Treatment - Dr. Thomas Ranieri - Offices raided and closed yesterday!!!! | CVS-MDLT3-000100951 | CVS-MDLT3-000100952 | | | | | | | | | |
| P-06560 | 1/14/2015 | Email Privileged and confidential ***Please open the attachment to view report*** Attachment Memo To: Pharmacist Team From: Professional Practices Subject: Controlled Substances Maximum Allowable Ordering Quantity, Store #4606 | CVS-MDLT3-000100955 | CVS-MDLT3-000100956 | | | | | | | | | |
| P-06562 | 8/12/2015 | Email Privileged and confidential ***Please open the attachment to view report*** Attachment Memo To: Pharmacist Team From: Professional Practices Subject: Controlled Substances Maximum Allowable Ordering Quantity, Store #4606 | CVS-MDLT3-000100958 | CVS-MDLT3-000100963 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------------------|--------------------------------|--|--|--|--|--|--|--|--|--|
| P-06566 | 12/1/2014 | RE: pain management doctor | CVS-MDLT3-000100987 | CVS-MDLT3-000100987 | | | | | | | | | |
| P-06576 | 1/9/2019 | 2019_1_9 MME Program Overview | CVS-MDLT3-000111119 | CVS-MDLT3-000111157 | | | | | | | | | |
| P-06595 | 6/11/2013 | FW: Revised AVP communication w/ File Attachment Memo to Senior Vice Presidents and Area Vice Presidents | CVS-MDLT3-000115384 | CVS-MDLT3-000115387 | | | | | | | | | |
| P-06609 | 7/20/2018 | OH - Mandatory Review of OARRS; HUB_Pharmacist Mandatory OARRS Querying Criteria & Mandatory Use Compliance Reports | CVS-MDLT3-000115453 | CVS-MDLT3-000115455 | | | | | | | | | |
| P-06612 | 1/24/2020 | RE: RPHAI red flag alerts Attachment 2020_1_24_Rules for Red Flags (003) | CVS-MDLT3-000122348 | CVS-MDLT3-000122351 | | | | | | | | | |
| P-06620 | 6/8/2016 | RE: WLM Regarding Store Level Blanket Policies Attachment Memo To: All Pharmacy Supervisors; Contact: Professional Practice Team; Subject: Store Level "Blanket" Policies Concerning Controlled Substances | CVS-MDLT3-000123571 | CVS-MDLT3-000123574 | | | | | | | | | |
| P-06625 | 2/25/2016 | US Patent Application Publication US20160055315A1 | CVS-MDLT3-000132431 | CVS-MDLT3-000132440 | | | | | | | | | |
| P-06635 | 3/3/2014 | Year-End Review - 2013 (Finalized), Michelle Travassos | CVS-MDLT3-000139629 | CVS-MDLT3-000139638 | | | | | | | | | |
| P-06672 | 8/31/2020 | 2020 Mid-Year Performance Check-In for Michelle L. Travassos | CVS-MDLT3-000139673 | CVS-MDLT3-000139681 | | | | | | | | | |
| P-06689 | 2018 | 2018 Summer Performance Check-In for Tara L. Hartman | CVS-MDLT3-000139723 | CVS-MDLT3-000139723 | | | | | | | | | |
| P-06700 | 1/24/2006 | CVS/Pharmacy Employment Offer Terms and Conditions | CVS-MDLT3-000140042 | CVS-MDLT3-000140042 | | | | | | | | | |
| P-06709 | 1/17/2013 | FW: Prescriber CS Paper | CVS-NYAG-000059684 | CVS-NYAG-000059693 | | | | | | | | | |
| P-06710 | 7/9/2016 | Metrics reports | GE_TL00011878 GE_TL00011878 | GE_TL00012022 GE_TL00012025 | | | | | | | | | |
| P-06712 | 2000 | Annual Performance Review - FY0 for Emily K. Mooney | GE_TL00015154 | GE_TL00015164 | | | | | | | | | |
| P-06714 | 2011 | Performance Appraisal - FY11 for Emily K. Mooney | GE_TL00015205 | GE_TL00015208 | | | | | | | | | |
| P-06721 | 9/12/2020 | Emily K. Mooney, Pharmacy Team Leader, Success Dialogue | GE_TL00015265 | GE_TL00015270 | | | | | | | | | |
| P-06775 | 10/21/2008 | PowerPoint titled, "Giant Eagle Pharmacy Welcome Workshop" | HBC_MDL00191099 | HBC_MDL00191106 | | | | | | | | | |
| P-06906 | N/A | Kristie Provost Gorman LinkedIn profile | N/A | N/A | | | | | | | | | |
| P-06908 | 10/8/2012 | FW: IMS C2 Analytics Capabilities | WAGMDL01167526 | WAGMDL01167527 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-06911 | 11/19/2012 | Email Prescriber Dashboard Top 100 NJ and PA only Attachment Prescriber Dashboard Top 100 NJ and PA only | WAGMDL01132742 | WAGMDL01132755 | | | | | | | | | |
| P-06919 | 10/17/2012 | RE: Communication pieces | WAGMDL01132835 | WAGMDL01132836 | | | | | | | | | |
| P-06934 | 1/3/2017 | FW: Pharmacy Operations Compliance Risk Assessment Attachment Pharmacy Operations Risk Assessment 12292016 | WAGMDL01133205 | WAGMDL01133209 | | | | | | | | | |
| P-06938 | 10/23/2012 | Tableau Benefits - gathered from pilot by Loss Prevention | WAGMDL01134494 | WAGMDL01134496 | | | | | | | | | |
| P-06949 | 4/3/2013 | Email Ray Stukel Project Update Attachment Ray Stukel Project Update | WAGMDL01167459 | WAGMDL01167460 | | | | | | | | | |
| P-06950 | 3/20/2013 | Email Status update Attachment Ray Stukel Project Update | WAGMDL01167462 | WAGMDL01167463 | | | | | | | | | |
| P-06954 | 3/6/2013 | Email Ray Stukel Project Update Attachment Ray Stukel Project Update | WAGMDL01167464 | WAGMDL01167465 | | | | | | | | | |
| P-06960 | 2/20/2013 | Email Ray Stukel Project Update Attachment Ray Stukel Project Update | WAGMDL01167474 | WAGMDL01167475 | | | | | | | | | |
| P-06961 | 2/5/2013 | Email Ray Stukel Project Update Attachment Ray Stukel Project Update | WAGMDL01167476 | WAGMDL01167477 | | | | | | | | | |
| P-06980 | 1/9/2013 | Email Ray Stukel Project Update Attachment Ray Stukel Project Update | WAGMDL01167478 | WAGMDL01167479 | | | | | | | | | |
| P-06983 | 12/11/2012 | Email Ray Stukel Project Update Attachment Ray Stukel Project Update | WAGMDL01167485 | WAGMDL01167486 | | | | | | | | | |
| P-06985 | 11/14/2012 | Email Ray Stukel Project Update Attachment Ray Stukel Project Update | WAGMDL01167498 | WAGMDL01167499 | | | | | | | | | |
| P-06988 | 12/31/2012 | FW: Final Version of Audit Committee Materials Attachments Item 3 (a) LP Update; Item 3 (b) Asset Protection Update | WAGMDL01174154 | WAGMDL01174161.0002 | | | | | | | | | |
| P-06996 | 1/18/2013 | Email Executive Report: Top 500 Potential Risk Stores - Oxycodone - 3 months ending Dec 2012 Attachment Oxycodone Store Potential Risk Overview | WAGMDL01176297 | WAGMDL01176298 | | | | | | | | | |
| P-06999 | 10/25/2012 | Email Prescriber Index Attachment Prescriber Index Approach_v2 | WAGMDL01176493 | WAGMDL01176496 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|--------------------|--------------------|--|--|--|--|--|--|--|--|--|
| P-07006 | 8/13/2012 | Email Updated Report July 2012: Exec Summary Top 100 - Oxy Potential Risk Store Index Attachment Store Potential Risk Index - end July 2012 - Exec Top 100 | WAGMDL01176503 | WAGMDL01176504 | | | | | | | | | |
| P-07013 | 2/1/2017 | POM 1311 (2017-02-17 to 2017-03-01) | WMT_IN_AG_00000104 | WMT_IN_AG_00000110 | | | | | | | | | |
| P-07022 | 3/1/2017 | POM 1311 (2017-03-29 to 2017-06-23) | WMT_IN_AG_00000118 | WMT_IN_AG_00000124 | | | | | | | | | |
| P-07023 | 8/1/2012 | POM 1316 (2013-08-29 to 2015-08-13) | WMT_IN_AG_00000132 | WMT_IN_AG_00000134 | | | | | | | | | |
| P-07029 | 4/1/2016 | POM 1316 (2016-08-25 to 2018-02-16) | WMT_IN_AG_00000141 | WMT_IN_AG_00000143 | | | | | | | | | |
| P-07035 | 1/1/2018 | POM 1316 (2018-02-16 to current) | WMT_IN_AG_00000144 | WMT_IN_AG_00000146 | | | | | | | | | |
| P-07036 | 12/31/2013 | Compliance Focus Areas_1.2.14 | WMT_MDL_000030223 | WMT_MDL_000030223 | | | | | | | | | |
| P-07083 | N/A | PART 1301 — REGISTRATION OF MANUFACTURERS, DISTRIBUTORS, AND DISPENSERS OF CONTROLLED SUBSTANCES SECURITY REQUIREMENTS §1301.71 Security requirements generally | N/A | N/A | | | | | | | | | |
| P-07087 | 3/31/2009 | POM-Forged, Fraudulent or Altered Prescription Procedures | WMT_MDL_000067646 | WMT_MDL_000067653 | | | | | | | | | |
| P-07095 | 2/1/2010 | POM 1316 - Prescription Monitoring Programs v1 eff 2-22-2010 to 3-28-2011 | WMT_MDL_000069138 | WMT_MDL_000069139 | | | | | | | | | |
| P-07096 | 3/1/2011 | POM 1316 - Prescription Monitoring Programs v2.1 eff 1-28-2012 to 8-31-2012 | WMT_MDL_000069142 | WMT_MDL_000069144 | | | | | | | | | |
| P-07139 | 11/8/2005 | POM 1703 - Forged or Fraudulent Prescription Procedures v10.1 eff 11-9-2005 to 8-17-2007 | WMT_MDL_000069188 | WMT_MDL_000069192 | | | | | | | | | |
| P-07148 | 8/16/2007 | POM 1703 - Forged or Fraudulent Prescription Procedures v11.1 eff 8-17-2007 to 8-20-2017 | WMT_MDL_000069193 | WMT_MDL_000069198 | | | | | | | | | |
| P-07157 | 4/1/2009 | POM 1703 - Forged or Fraudulent Prescription Procedures v14.1 eff 7-17-2009 to 2-4-2010 | WMT_MDL_000069205 | WMT_MDL_000069213 | | | | | | | | | |
| P-07173 | 3/1/2011 | POM 1703 - Forged or Fraudulent Prescription Procedures v17.1 eff 3-28-2011 to 3-29-2011 | WMT_MDL_000069237 | WMT_MDL_000069245 | | | | | | | | | |
| P-07174 | 8/13/2010 | Application for Job 36156 | WMT_MDL_000079032 | WMT_MDL_000079043 | | | | | | | | | |
| P-07381 | 2/2/2011 | Common signs of diversion in POM 1703 and 1311 | WMT_MDL_000080248 | WMT_MDL_000080248 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-07754 | 9/3/2010 | FW: CVS #0219-BC5289055-Decision | CAH_MDL2804_01448800 | CAH_MDL2804_01448802 | | | | | | | | | |
| P-07767 | N/A | Overdose Deaths Involving Opioids, United States, 2000 - 2015 chart | N/A | N/A | | | | | | | | | |
| P-07797 | 9/12/2012 | DEA Revokes Two CVS Retailers' Ability To Sell Controlled Substances | WMT_MDL_000086284 | WMT_MDL_000086285 | | | | | | | | | |
| P-07798 | 2/27/2012 | Re: [RxNews] Feds: CVS failed to ensure legitimate Rx's | WMT_MDL_000086832 | WMT_MDL_000086833 | | | | | | | | | |
| P-07799 | 3/21/2014 | CVS Final Order Federal Register | WMT_MDL_000093429 | WMT_MDL_000093463 | | | | | | | | | |
| P-07833 | 2/25/2008 | MAPM Orientation H&W Feb08 | WMT_MDL_000350653 | WMT_MDL_000350656 | | | | | | | | | |
| P-07843 | 7/8/2014 | Connexus Workflow August 30, 2012 | WMT_MDL_000376862 | WMT_MDL_000376863 | | | | | | | | | |
| P-07846 | 5/19/2011 | DEA_MOA_Webinar_Walmart 030411 | WMT_MDL_000448286 | WMT_MDL_000448287 | | | | | | | | | |
| P-07907 | 1/4/2018 | Opioid Stewardship Video. January 2018 (final) | WMT_MDL_000466679 | WMT_MDL_000466681 | | | | | | | | | |
| P-07908 | 11/25/2014 | Fwd: Controls from a local DR | WMT_MDL_000536546 | WMT_MDL_000536547 | | | | | | | | | |
| P-07932 | 11/14/2014 | Survey | WMT_MDL_000661952 | WMT_MDL_000661981 | | | | | | | | | |
| P-07966 | 2/6/2015 | Filling C2 electronic prescriptions and refusal to fill web forms | WMT_MDL_000677718 | WMT_MDL_000677720 | | | | | | | | | |
| P-07967 | 1/26/2013 | RE: Friendly Reminder -- Action Requested: NACDS DEA WG -- Code of Conduct Survey; NACDS CS Principles Survey and Response | WMT_MDL_000891159 | WMT_MDL_000891180 | | | | | | | | | |
| P-07974 | 3/7/2016 | Brad Nelson, 2016 Evaluation | WMT_MDL_000913791 | WMT_MDL_000913797 | | | | | | | | | |
| P-08022 | 1/16/2014 | RE: Oklahoma | WMT_MDL_001005971 | WMT_MDL_001005972 | | | | | | | | | |
| P-08037 | 2/24/2017 | RE: Tech Disqualification | WMT_MDL_001017453 | WMT_MDL_001017458 | | | | | | | | | |
| P-08045 | 7/9/2020 | Opioid overdoses are skyrocketing as Covid-19 sweeps across US an old epidemic returns | N/A | N/A | | | | | | | | | |
| P-08048 | 1/14/2014 | RE: Prescriber concern | WMT_MDL_001182767 | WMT_MDL_001182768 | | | | | | | | | |
| P-08068 | 7/4/2016 | FW: DEA AND DR COCKTAILS | WMT_MDL_001203322 | WMT_MDL_001203324 | | | | | | | | | |
| P-08069 | 7/15/2013 | RE: Pharmacist professional judgment | WMT_MDL_001203706 | WMT_MDL_001203708 | | | | | | | | | |
| P-08071 | N/A | Compilation of Annual Performance Evaluations for Lori Militello | WMT_MDL_001217493 | WMT_MDL_001217513 | | | | | | | | | |
| P-08075 | 3/6/2017 | CONFIDENTIAL GENERAL RELEASE AND SEPARATION AGREEMENT for Brad Nelson | WMT_MDL_001217518 | WMT_MDL_001217527 | | | | | | | | | |
| P-08076 | 2/27/2017 | Annual Performance Evaluations for Brad Nelson for FY2012-2017 | WMT_MDL_001217533 | WMT_MDL_001217566 | | | | | | | | | |
| P-08077 | N/A | Brad Nelson Salary History - excerpt | WMT_MDL_001217567 | WMT_MDL_001217567 | | | | | | | | | |
| P-08078 | 1/6/2017 | POM 1311 (2017-01-06 to 2017-01-09) | WMT_NH_AG_00000089 | WMT_NH_AG_00000095 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-08080 | 6/23/2017 | POM 1311 (2017-06-23 to current) | WMT_NH_AG_00000124 | WMT_NH_AG_00000130 | | | | | | | | | |
| P-08088 | 4/26/2018 | Opioid Stewardship Video Script | WMT_NH_AG_00000975 | WMT_NH_AG_00000980 | | | | | | | | | |
| P-08093 | N/A | Title 21 CFR 1304.04 Maintenance of records and inventories | N/A | N/A | | | | | | | | | |
| P-08160 | 5/9/2019 | Two North Texas Doctors, One Nurse, Sentenced to Prison for Federal Drug Trafficking Violations | N/A | N/A | | | | | | | | | |
| P-08162 | 11/11/2016 | McKinney Doctor connected to two more deaths; 8 total | N/A | N/A | | | | | | | | | |
| P-08163 | N/A | Title 21 CFR 1306.04 Purpose of issue of prescription | N/A | N/A | | | | | | | | | |
| P-08164 | N/A | Title 21 CFR 1306.06 Persons entitled to fill prescriptions | N/A | N/A | | | | | | | | | |
| P-08166 | 10/12/2012 | Holiday CVS, L.L.C., d/b/a CVS/Pharmacy Nos. 219 and 5195; Decision and Order | N/A | N/A | | | | | | | | | |
| P-08169 | 2009 | 2009 Pharmacist Incentive Plan | CVS-MDLT1-000060968 | CVS-MDLT1-000060974 | | | | | | | | | |
| P-08170 | 10/13/2010 | Non-Prosecution Agreement between USAO-CDCA and USAO-NV and CVS Pharmacy | N/A | N/A | | | | | | | | | |
| P-08171 | 3/1/2011 | March 2011 Bi-Annual Compliance Training, Pharmacist and Intern Version, Course #800131 | CVS-DR22-000004752 | CVS-DR22-000004811 | | | | | | | | | |
| P-08174 | 10/1/2011 | October 2011 Bi-Annual Compliance Training, Pharmacist & Grad Intern Version, Course #800131 | CVS-DR22-000004446 | CVS-DR22-000004549 | | | | | | | | | |
| P-08178 | 2011 | 2011 Pharmacist Incentive Plan | CVS-FLAG-000045634 | CVS-FLAG-000045670 | | | | | | | | | |
| P-08179 | 12/1/2011 | Prescription Monitoring Program (PMP), RxConnect, Self-Paced Training Guide | CVS-NYAG-000036512 | CVS-NYAG-000036525 | | | | | | | | | |
| P-08182 | 1/10/2011 | High Quantity Stores 682971 | WAGFLDEA00000846 | WAGFLDEA00000851 | | | | | | | | | |
| P-08183 | 2/15/2005 | Handling Suspicious Drug Orders | WAGFLDEA00001854 | WAGFLDEA00001855 | | | | | | | | | |
| P-08185 | 3/1/2012 | March 2012 Bi-Annual Compliance Training, Pharmacist & Grad Intern Version, Course #800131 | CVS-DR22-000003848 | CVS-DR22-000003951 | | | | | | | | | |
| P-08186 | 4/1/2013 | Controlled Substance Monitoring Program, Quarter Two 2013 Education Program | CVS-MDLT3-000084776 | CVS-MDLT3-000084828 | | | | | | | | | |
| P-08187 | 6/5/2015 | Our Communities, Our Responsibility, CVS Pharmacy PPT | CVS-DR22-000001412 | CVS-DR22-000001412 | | | | | | | | | |
| P-08189 | 2/11/2013 | Corresponding Responsibility Exercise: Pharmacist Required Review Pre-work | CVS-NYAG-000031887 | CVS-NYAG-000031887 | | | | | | | | | |
| P-08203 | 4/3/2013 | Email Refusing MD Scripts | CVS-MDLT3-000100682 | CVS-MDLT3-000100682 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|--------------------------------------|--------------------------------------|--|--|--|--|--|--|--|--|--|
| P-08204 | 6/19/2017 | Memo To: All Pharmacist Contact: Your Pharmacy Supervisor Subject: Dispensing Controlled Substances and Refusal to Fill | CVS-FLAG-000057113 | CVS-FLAG-000057115 | | | | | | | | | |
| P-08205 | 10/1/2015 | ROPP-47561 Federal Guidelines for Controlled Substances | CVS-NYAG-000026631 | CVS-NYAG-000026644 | | | | | | | | | |
| P-08206 | 12/4/2014 | Email Privileged and Confidential: James Dambrogio Prescriber Interview Materials Attachments | CVS-MDLT3-000113463 | CVS-MDLT3-000113488 | | | | | | | | | |
| P-08211 | 1/2/2013 | PAIN CARE FORUM_directory | PPLP003985564 | PPLP003985575 | | | | | | | | | |
| P-08214 | 3/19/2007 | Email Rite Aid | CHI_001255680 | CHI_001255680 | | | | | | | | | |
| P-08221 | 12/2/2014 | ROPP-0001 Professional Standards | CVS-NYAG-000010802 | CVS-NYAG-000010813 | | | | | | | | | |
| P-08222 | 12/4/2014 | Dambrogio James Prescriber Notes | CVS-MDLT3-000000095 | CVS-MDLT3-000000097 | | | | | | | | | |
| P-08226 | 3/28/2014 | FW: Target Trainings for "User Guide" Attachments RxConnect Prescription Monitoring Program (PMP) Web Access; Cocktail_Revised; CVS_RefusaltoFill_ConversationG uide_Final; Red_Flag_Check; PMP Web Access Job Aid v5 | CVS-MDLT3-000109780 | CVS-MDLT3-000109791 | | | | | | | | | |
| P-08234 | 5/8/2014 | FW: Target Trainings for "User Guide" Attachments RxConnect Prescription Monitoring Program (PMP) Web Access; Cocktail_Revised; CVS_RefusaltoFill_ConversationG uide_Final; Red_Flag_Check; PMP Web Access Job Aid v5 | CVS-MDLT3-000025965 | CVS-MDLT3-000025969 | | | | | | | | | |
| P-08240 | 9/1/2014 | Our Communities, Our Responsibility, CVS Pharmacy PPT | CVS-DR22-000001423 | CVS-DR22-000001423 | | | | | | | | | |
| P-08244 | 9/9/2014 | CVS Think Customer, Deliver Growth PPT | CVS-DR22-000001465 | CVS-DR22-000001465 | | | | | | | | | |
| P-08249 | 9/11/2007 | DEA's Office of Diversion Control 13th Pharmaceutical Industry Conference | CAH_MDL_PRIORPROD_DEA07_ 01185382 | CAH_MDL_PRIORPROD_DEA07_ 01185426 | | | | | | | | | |
| P-08251 | 1/1/2015 | January/February 2015 Bi-Annual Training: Pharmacist/Grad Intern Version Course #800142 | CVS-DR22-000001695 | CVS-DR22-000001855 | | | | | | | | | |
| P-08252 | 3/30/2015 | 2015 Pharmacist Incentive Plan | CVS-FLAG-000013566 | CVS-FLAG-000013574 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-08253 | 8/1/2015 | Bi-Annual Training Pharmacist/Grad Intern Version Course #800142 | CVS-FLAG-000053306 | CVS-FLAG-000053385 | | | | | | | | | |
| P-08254 | 3/13/2015 | FW: patient communication training Attachment CVS_RefusaltoFill_ConversationGuide_Final - 1-3-1 version | CVS-MDLT3-000128985 | CVS-MDLT3-000128988 | | | | | | | | | |
| P-08258 | 10/28/2015 | FW: Ohio Update - Ohio Automated Rx Reporting System (OARRS) Attachment John Kasich OARRS communication 10-2015 | CVS-MDLT3-000091474 | CVS-MDLT3-000091477 | | | | | | | | | |
| P-08259 | 11/1/2016 | CVS Health Pharmacy Professional Practice, Corresponding Responsibility Review PPT | CVS-NYAG-000033662 | CVS-NYAG-000033714 | | | | | | | | | |
| P-08260 | 1/1/2015 | Rx Connect User Guide | CVS-MDLT3-000006278 | CVS-MDLT3-000006381 | | | | | | | | | |
| P-08268 | 9/23/2015 | ROPP-0062 Prescription Drug Monitoring Program | CVS-NYAG-000010773 | CVS-NYAG-000010776 | | | | | | | | | |
| P-08281 | 2016 | CVS Health 2016 Public Policy Principles | N/A | N/A | | | | | | | | | |
| P-08282 | 12/1/2016 | CVS Health The Importance of Patient Notes Corresponding Responsibility Newsletter | CVS-NYAG-000033640 | CVS-NYAG-000033641 | | | | | | | | | |
| P-08283 | 4/29/2016 | 2016 Staff Pharmacist Incentive Plan | CVS-FLAG-000013619 | CVS-FLAG-000013626 | | | | | | | | | |
| P-08286 | 1/12/2016 | ROPP-047561 Federal Regulations and CVS Guidelines for Controlled Substances | CVS-NYAG-000026686 | CVS-NYAG-000026700 | | | | | | | | | |
| P-08287 | 1/4/2016 | Re: State Board question? | CVS-MDLT3-000100685 | CVS-MDLT3-000100685 | | | | | | | | | |
| P-08288 | 2/1/2016 | CVS Health To Make Overdose-Reversing Drug Available Without A Prescription At All CVS Pharmacy Locations Across Ohio | CVS-FLAG-000057323 | CVS-FLAG-000057325 | | | | | | | | | |
| P-08289 | 4/13/2016 | CVS Health 2016 Q1 What is "Corresponding Responsibility"? | CVS-NYAG-000033638 | CVS-NYAG-000033639 | | | | | | | | | |
| P-08290 | 5/10/2015 | ROPP-0061 Guidelines for Dispensing Controlled Substances | CVS-NYAG-000010652 | CVS-NYAG-000010654 | | | | | | | | | |
| P-08291 | 9/26/2016 | ROPP-0061 Guidelines for Dispensing Controlled Substances | CVS-NYAG-000010655 | CVS-NYAG-000010659 | | | | | | | | | |
| P-08292 | 9/27/2015 | ROPP-047561 Federal Regulations and CVS Guidelines for Controlled Substances | CVS-NYAG-000026721 | CVS-NYAG-000026737 | | | | | | | | | |
| P-08293 | 3/9/2017 | State Specific Guidance | CVS-MDLT3-000075836 | CVS-MDLT3-000075838 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|----------------------|---------------------------|--|--|--|--|--|--|--|--|--|
| P-08295 | 4/13/2017 | FW: Final Review Materials Attachments 2016 Pharmacy Manager RPH Review Guide; 2016 Pharmacy Supervisor Annual RPH Review Guide; 2017 Draft of Sign Off; 2017 Final Draft RPH Review WLM (feb 1) | CVS-MDLT3-000006994 | CVS-MDLT3-000007007 | | | | | | | | | |
| P-08296 | 6/5/2017 | 2017 Staff Pharmacist Incentive Plan | CVS-FLAG-000013644 | CVS-FLAG-000013650 | | | | | | | | | |
| P-08302 | 9/17/2015 | Re: TIME SENSITIVE REQUEST - NACDS Policy Council | ABDCMDL00273963 | ABDCMDL00273964 | | | | | | | | | |
| P-08306 | 5/17/2018 | FW: Content Round Up- Corresponding Responsibility Training Attachments Materials for CR Training; 2018.4.18_Rapid Task Analysis Template PPT; 202670_Intro_to_Morphine_ME q_FINAL (1) PPT; Grad_Intern_Professional Practice PPT; Guidelines for Dispensing Controlled Substances Policy; Pharmacy Professional Practice Emerging Leader Program PPT | CVS-MDLT1B-000016872 | CVS-MDLT1B-000016966.0008 | | | | | | | | | |
| P-08310 | 4/27/2017 | CVS Health Report Examines Public Perceptions of Opioid Epidemic, Drug Disposal Ahead of National Prescription Drug Take Back Day | CVS-FLAG-000057331 | CVS-FLAG-000057333 | | | | | | | | | |
| P-08311 | 6/12/2017 | FW: 2017-6 Emerging Leader Program for EL's Attachment 2017-6 Emerging Leader Program for EL's PPT | CVS-MDLT3-000029911 | CVS-MDLT3-000029960 | | | | | | | | | |
| P-08312 | 6/19/2017 | 2016 Review of Corresponding Responsibility | CVS-NYAG-000033642 | CVS-NYAG-000033643 | | | | | | | | | |
| P-08313 | 6/19/2017 | Workload, Workload Item Name, Dispensing CS and Refusal to Fill | CVS-NYAG-000033648 | CVS-NYAG-000033651 | | | | | | | | | |
| P-08316 | 6/19/2017 | Dispensing CS and Refusal to Fill | CVS-NYAG-000033644 | CVS-NYAG-000033647 | | | | | | | | | |
| P-08318 | 6/19/2017 | Would you fill for this patient? Training Material | CVS-NYAG-000033636 | CVS-NYAG-000033637 | | | | | | | | | |
| P-08319 | 6/20/2017 | To: All Pharmacy Supervisors Contact: Professional Practice Team Subject: Store Level "Blanket" Policies Concerning Controlled Substances | CVS-NYAG-000033715 | CVS-NYAG-000033716 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-08320 | 6/7/2017 | CVS Pharmacy Now Using Time Delay Safes in Ohio for Controlled Substances to Combat Opioid Epidemic, Reduce Robbery Incidents | CVS-FLAG-000057341 | CVS-FLAG-000057343 | | | | | | | | | |
| P-08321 | 9/1/2017 | ROPP-0062 Prescription Drug Monitoring Program | CVS-NYAG-000010781 | CVS-NYAG-000010784 | | | | | | | | | |
| P-08322 | 6/17/2019 | Using Opioids Appropriately in the Community Pharmacy Setting, Volume 2016, Course No. 243, Self-Study Course #160243 | CVS-FLAG-000057043 | CVS-FLAG-000057058 | | | | | | | | | |
| P-08323 | 4/18/2018 | Email Ohio disposal press release (CVS Health Expands Safe Drug Disposal at CVS Pharmacy Locations in Ohio to Help Combat Opioid Abuse) | CVS-MDLT3-000069811 | CVS-MDLT3-000069814 | | | | | | | | | |
| P-08324 | 4/19/2018 | CVS Health Expands Safe Drug Disposal at CVS Pharmacy Locations in Ohio to Help Combat Opioid Abuse | CVS-FLAG-000057316 | CVS-FLAG-000057319 | | | | | | | | | |
| P-08326 | 5/22/2018 | ROPP-047561 Federal Regulations and CVS Pharmacy Guidelines for Controlled Substances | CVS-NYAG-000026899 | CVS-NYAG-000026919 | | | | | | | | | |
| P-08334 | 43291 | ROPP-0061 Guidelines for Dispensing Controlled Substances | CVS-NYAG-000010665 | CVS-NYAG-000010665 | | | | | | | | | |
| P-08335 | 43593 | 2018 Staff Pharmacist Incentive Plan | CVS-FLAG-000020148 | CVS-FLAG-000020154 | | | | | | | | | |
| P-08336 | 2016 | Corresponding Responsibility Newsletter, Quarter 2 2016 | CVS-NYAG-000036548 | CVS-NYAG-000036550 | | | | | | | | | |
| P-08337 | 43760 | Review of Corresponding Responsibility Form | CVS-NYAG-000036560 | CVS-NYAG-000036560 | | | | | | | | | |
| P-08338 | 43522 | Community Responsibility Scorecard (CRS) 2019 PPT | CVS-INDAG-00017097 | CVS-INDAG-00017121 | | | | | | | | | |
| P-08339 | 2018 | 2018 CVS Pharmacist Annual Review - Answer Key | CVS-NYAG-000035121 | CVS-NYAG-000035123 | | | | | | | | | |
| P-08343 | 2/24/2012 | Declaration of Joseph Rannazzisi | N/A | N/A | | | | | | | | | |
| P-08344 | 3/28/2015 | Birmingham Pharmacy Diversion Awareness Conference: DEA Perspective: Pharmaceutical Use & Abuse | N/A | N/A | | | | | | | | | |
| P-08345 | 8/19/2019 | In re Nat'l Prescription Opiate Litig., No. 1:17-MD-2804, 2019 WL 3917575 | N/A | N/A | | | | | | | | | |
| P-08346 | 2019 | CVS Rhode Island Settlement 2019 | N/A | N/A | | | | | | | | | |
| P-08347 | 6/18/2019 | 2017 Retail Leadership Conference PPT | CVS-NYAG-000035197 | CVS-NYAG-000035314 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-08348 | 7/9/2019 | Rx Connect Prescription Monitoring Program Guide | CVS-NYAG-000036504 | CVS-NYAG-000036505 | | | | | | | | | |
| P-08349 | 7/9/2019 | Subject: Prescription Monitoring Program- Mandatory Registration | CVS-NYAG-000036502 | CVS-NYAG-000036502 | | | | | | | | | |
| P-08350 | 7/9/2019 | Corresponding Responsibility: Your Professional Obligation Course #206071 | CVS-NYAG-000036401 | CVS-NYAG-000036471 | | | | | | | | | |
| P-08351 | 7/9/2019 | CVS Pharmacist Training Module PPT | CVS-NYAG-000036472 | CVS-NYAG-000036501 | | | | | | | | | |
| P-08356 | 1/1/2020 | Pharmacy Basics LearnRX RxConnect Workbook | CVS-MDLT3-000109828 | CVS-MDLT3-000109885 | | | | | | | | | |
| P-08366 | N/A | OARRS Rules for Pharmacists (OAC 4729-5-20) | N/A | N/A | | | | | | | | | |
| P-08371 | N/A | When to Check OARRS - Pocket Card - Prescribers and Pharmacists | N/A | N/A | | | | | | | | | |
| P-08373 | 1/3/2017 | USPTO - Patent assignment 040870/0339. Detection of Abusive Prescribing of Controlled Substances | N/A | N/A | | | | | | | | | |
| P-08374 | 3/28/2017 | Mimms vs. CVS Pharmacy; 1:15-cv-00970 USDC Southern District of Indiana - Trial Transcript | N/A | N/A | | | | | | | | | |
| P-08376 | N/A | List of Programs and Individuals Interviewed by Harrington | N/A | N/A | | | | | | | | | |
| P-08377 | 10/15/2012 | "Holiday CVS Final Order Reveals Gross Negligence by Two CVS Pharmacies in Stanford, Florida," DEA press release | N/A | N/A | | | | | | | | | |
| P-08378 | 4/24/2012 | Prescription Drug Monitoring Websites, ROPP-0062 | CVS-DR22-000001318 | CVS-DR22-000001320 | | | | | | | | | |
| P-08389 | 1/21/2015 | 800141_Bi-annual Course tech and Tech Trainee_final | CVS-DR22-000001557 | CVS-DR22-000001694 | | | | | | | | | |
| P-08395 | 2014 | RxConnect Operational Prescriber Validation Policy and Procedures | CVS-INDAG-00014211 | CVS-INDAG-00014219 | | | | | | | | | |
| P-08396 | 9/22/2017 | Filling/Dispensing Prescriptions, ROPP-045491 | CVS-MDLT1B-000002011 | CVS-MDLT1B-000002035 | | | | | | | | | |
| P-08397 | 3/22/2013 | Email more pmp communications Attachments OH - Prospective Drug Administrative Review Communication June 2012 revised(KV) | CVS-MDLT1B-000009185 | CVS-MDLT1B-000009209 | | | | | | | | | |
| P-08398 | 10/21/2016 | 201603 Store Algorithm Results; 201603 Tier 1 and 2 Store Algorithm - 20161021 | CVS-MDLT1B-000018433 | CVS-MDLT1B-000018434 | | | | | | | | | |
| P-08399 | 2/3/2016 | 5480074--Veres Frank 2 3 16--694069 | CVS-MDLT3-000000110 | CVS-MDLT3-000000110 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|-------------------------|--|--|--|--|--|--|--|--|--|
| P-08400 | 6/8/2020 | Veres F 1 03 | CVS-MDLT3-000000235 | CVS-MDLT3-000000237 | | | | | | | | | |
| P-08401 | 6/6/2018 | RE: Red Flag Pilot Attachment Controlled Substance Review | CVS-MDLT3-000002017 | CVS-MDLT3-000002019 | | | | | | | | | |
| P-08402 | 4/23/2015 | FW: Red Flags Charter Attachment Controlled Substance Mgt - Project Charter | CVS-MDLT3-000005486 | CVS-MDLT3-000005516 | | | | | | | | | |
| P-08403 | 4/25/2016 | Email Quarterly Newsletter on Corresponding Responsibility | CVS-MDLT3-000005638 | CVS-MDLT3-000005638 | | | | | | | | | |
| P-08404 | 12/12/2016 | RE: EED Message | CVS-MDLT3-000009347 | CVS-MDLT3-000009348 | | | | | | | | | |
| P-08405 | 2/27/2014 | FW: Quarter 1 Stores Entering Controlled Substance Dispensing Program-Update Attachment LP Store Review, Store number 4606; RLPD CS Visit CVS 4606 (2- 14-14) | CVS-MDLT3-000028128 | CVS-MDLT3-000028131 | | | | | | | | | |
| P-08406 | 7/18/2013 | FW: Update to CSM LP Reviews for Accountability Meeting - July Attachments LP Store Review, Store 4606 | CVS-MDLT3-000029184 | CVS-MDLT3-000029190 | | | | | | | | | |
| P-08407 | 8/12/2014 | Email For CS Monitoring Process Review Attachments CSM Process Flow Update 8.1.14; Controlled Substance Monitoring Program SOP DRAFT 8.12.14 (clean); Controlled Substance Monitoring Program SOP DRAFT 8.12.14 (tracked changes); FW: Updates to the CSDP for the SOP | CVS-MDLT3-000029235 | CVS-MDLT3-000029245 | | | | | | | | | |
| P-08408 | 3/21/2014 | FW: Store 4606 - controlled substance dispensing program follow-up Q1 | CVS-MDLT3-000029571 | CVS-MDLT3-000029571 | | | | | | | | | |
| P-08409 | 5/4/2020 | CVS Store Information, Store 4606 | CVS-MDLT3-000030227 | CVS-MDLT3-000030227 | | | | | | | | | |
| P-08410 | 3/25/2019 | RE: Emerging Leader Deck Attachment Professional Practices Emerging Leader March 2019 | CVS-MDLT3-000004241 | CVS-MDLT3-000004277.001 | | | | | | | | | |
| P-08411 | 1/22/2015 | RE: Cocktail fill - document for annual RPh review 2015; Cocktail_Dispensing_Document | CVS-MDLT3-000087243 | CVS-MDLT3-000087246 | | | | | | | | | |
| P-08412 | 1/24/2015 | RE: Cocktail fill - document for annual RPh review 2015; Cocktail_Dispensing_Document | CVS-MDLT3-000087250 | CVS-MDLT3-000087253 | | | | | | | | | |
| P-08413 | 1/29/2015 | RE: Cocktail fill - document for annual RPh review 2015; OpioidsReprint_HR | CVS-MDLT3-000000785 | CVS-MDLT3-000000789 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-08414 | 2/19/2015 | RE: Cocktail fill - document for annual RPH review 2015; Cocktail_Revised_2_18_15_final | CVS-MDLT3-000089927 | CVS-MDLT3-000089930 | | | | | | | | | |
| P-08415 | 4/17/2017 | RPPC Annual Planning next steps; 4-11-17 RPPC 3 Year Roadmap_Davis - Professional Services | CVS-MDLT3-000080178 | CVS-MDLT3-000080218 | | | | | | | | | |
| P-08416 | 5/31/2013 | Framework for Corresponding Responsibility; NACDS CORRESPONDING RESPONSIBILITY DOC vFINAL | CVS-MDLT3-000102863 | CVS-MDLT3-000102872 | | | | | | | | | |
| P-08417 | 11/18/2014 | Regulatory Review Questions to Remove | CVS-MDLT3-000007042 | CVS-MDLT3-000007042 | | | | | | | | | |
| P-08418 | 4/9/2015 | EL presentation; 2015-4 Emerging Leader | CVS-MDLT3-000068984 | CVS-MDLT3-000069023 | | | | | | | | | |
| P-08419 | 11/5/2014 | RE: Weekly Conference Call notes for 11/6/14 | CVS-MDLT3-000143069 | CVS-MDLT3-000143078 | | | | | | | | | |
| P-08420 | 9/17/2018 | APhA Visit: Dry Run; APhA Onsite Visit Deck 92018 v4 | CVS-MDLT3-000144323 | CVS-MDLT3-000144379 | | | | | | | | | |
| P-08421 | 9/23/2016 | NACDS Strategic Comms Update: Chicago Tribune Update; GPhA Statement; AP on PhRMA/Opioids | CVS-MDLT3-000126603 | CVS-MDLT3-000126604 | | | | | | | | | |
| P-08422 | 10/24/2013 | Action Requested: Phy Ops_Care DEA WG: Response Documents for NABP "Time Sensitive"; Clean Phy Ops -- Draft NABP Response Document DEA Industry Barriers docx tuesday; DEA Red Flags - Patient And Physician Conduct | CVS-MDLT3-000030675 | CVS-MDLT3-000030681 | | | | | | | | | |
| P-08423 | 4/23/2013 | PMP policy; PDMP Policy - QB PB KS PG Comments - 2_12_13 (2)(3)(4) | CVS-MDLT3-000026380 | CVS-MDLT3-000026384 | | | | | | | | | |
| P-08424 | 9/14/2016 | PMP Update Pwpt; Prescription Monitoring Program Update | CVS-MDLT3-000088096 | CVS-MDLT3-000088106 | | | | | | | | | |
| P-08425 | 9/20/2017 | FW: NACDS Policy Council Call - September 22 @ 11:00 a.m. EDT; PDMP | CVS-MDLT3-000097419 | CVS-MDLT3-000097424 | | | | | | | | | |
| P-08426 | 12/23/2019 | RE: Update Project Trackers; _Kahra Professional Practice Project Slides_12-20-19_Updated_NH Edits | CVS-MDLT3-000091173 | CVS-MDLT3-000091198 | | | | | | | | | |
| P-08427 | 1/22/2020 | 2020 Goals_ (MT) v3 (003) | CVS-MDLT3-000111283 | CVS-MDLT3-000111285 | | | | | | | | | |
| P-08428 | 5/14/2013 | Metric Definitions | CVS-MDLT3-000086002 | CVS-MDLT3-000086004 | | | | | | | | | |
| P-08429 | 7/30/2013 | RE: Red Flags Scope Items | CVS-MDLT3-000026794 | CVS-MDLT3-000026796 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-08430 | 11/14/2019 | RE: RTF Job Aid and Communication Ideas; Refusal to Fill Training Division Meeting November nh comments | CVS-MDLT3-000008144 | CVS-MDLT3-000008165 | | | | | | | | | |
| P-08431 | 4/24/2017 | 2017 2 9_Q 131 Q1 2017; Corresponding Responsibility Review of Reporting Forged Prescriptions | CVS-MDLT3-000077194 | CVS-MDLT3-000077195 | | | | | | | | | |
| P-08432 | 1/26/2001 | RE: ME CVSPharmEd CE Program | PNY000425002 | PNY000425004 | | | | | | | | | |
| P-08433 | 7/1/2014 | Overview of Purdue Programs for CVS Meeting July 1 2014 - CVS | CVS-MDLT3-000127314 | CVS-MDLT3-000127339 | | | | | | | | | |
| P-08434 | 1/14/2013 | FW: President's Update--January 11, 2013 | CVS-MDLT3-000094636 | CVS-MDLT3-000094637 | | | | | | | | | |
| P-08435 | 2/10/2013 | NACDS CS Working Group | CVS-MDLT3-000076292 | CVS-MDLT3-000076301 | | | | | | | | | |
| P-08436 | 2/10/2013 | NACDS DEA Working Group Update | CVS-MDLT3-000127100 | CVS-MDLT3-000127110 | | | | | | | | | |
| P-08437 | 2/15/2013 | DEA WG Follow-Up - Potential Areas of Consensus; 2.12.13 - Areas of Consensus; Working Group Summary 2.12.13 | CVS-MDLT3-000140372 | CVS-MDLT3-000140381 | | | | | | | | | |
| P-08438 | 2/21/2013 | FW: Strawman for pharmacist professional judgment framework; NACDS Working Group Draft 021813 v2 | CVS-MDLT3-000085393 | CVS-MDLT3-000085397 | | | | | | | | | |
| P-08439 | 6/14/2013 | RE: Action Required: NACDS DEA Subcommittee: Draft Framework Document; NACDS Document Edits | CVS-MDLT3-000086107 | CVS-MDLT3-000086117 | | | | | | | | | |
| P-08440 | 12/13/2013 | Updated DEA Workgroup Email; HDMA 20081113_icg | CVS-MDLT1-000129303 | CVS-MDLT1-000129318 | | | | | | | | | |
| P-08441 | 5/22/2017 | FW: NACDS Policy Council - National PDMP/Opioid Recommendations | CVS-MDLT3-000088568 | CVS-MDLT3-000088569 | | | | | | | | | |
| P-08442 | 5/26/2017 | FW: UPDATED Pre-Read for June 1 Executive Committee Meeting-- Potential Positions of NACDS to Address Opioid Abuse; Policy Council Recs to the EC on Opioid | CVS-MDLT3-000093480 | CVS-MDLT3-000093491 | | | | | | | | | |
| P-08443 | 6/2/2017 | FW: Action Requested of Co-Chairs: Follow-Up DEA Subcommittee - Chair Correspondence; Policy Council Recs to the EC on Opioid | CVS-MDLT3-000093504 | CVS-MDLT3-000093515 | | | | | | | | | |
| P-08444 | 10/9/2017 | RE: Connecting With You Regarding Our Work on the Opioid Industry Group | CVS-MDLT3-000095356 | CVS-MDLT3-000095359 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-08445 | 6/21/2019 | Opioid Policy Document Comments; New Opioid Policies Discussion PC June 2019 CVS Comment | CVS-MDLT3-000094287 | CVS-MDLT3-000094300 | | | | | | | | | |
| P-08446 | 10/1/2019 | FW: DEA Subcommittee; Survey_Nationwide PDMP Recommendation; DOJ Discussion Points_PDMP - For Review | CVS-MDLT3-000095972 | CVS-MDLT3-000095977 | | | | | | | | | |
| P-08448 | 4/24/2020 | 4_24_2020_Weekly Status Report | CVS-MDLT3-000111886 | CVS-MDLT3-000111899 | | | | | | | | | |
| P-08449 | 6/27/2014 | Program Review Slides | CVS-MDLT3-000094953 | CVS-MDLT3-000094962 | | | | | | | | | |
| P-08450 | 1/9/2014 | RE: 2014.1.7_2014 Professional Practices Planning and Goals_v2; Updated Prescriber Slides | CVS-NYAG-000042745 | CVS-NYAG-000042747 | | | | | | | | | |
| P-08451 | 7/24/2015 | FW: Most recent Naughty Doctor Report; Q4 2014 THRU JUNE 2015 FOR ANNE | CVS-NYAG-000042060 | CVS-NYAG-000042061 | | | | | | | | | |
| P-08452 | 8/13/2015 | RE: Prescriber Controlled Substance Monitoring | CVS-NYAG-000042067 | CVS-NYAG-000042068 | | | | | | | | | |
| P-08453 | 4/18/2016 | FW: Up to date List of Physicians from Misc Media Reports as of April 15, 2016 | CVS-MDLT3-000068572 | CVS-MDLT3-000068573 | | | | | | | | | |
| P-08454 | 8/26/2016 | FW: Meeting Slides/Birthday Cake!; Professional Services August 2016 Engagement Meeting | CVS-MDLT3-000068382 | CVS-MDLT3-000068445 | | | | | | | | | |
| P-08455 | 4/20/2015 | 4540316--Blatti, George Prescriber Notes 07.17.14--391746 | CVS-NYAG-000021965 | CVS-NYAG-000021966 | | | | | | | | | |
| P-08456 | 10/30/2019 | Rockville Centre doctor indicted for allegedly selling opioid and amphetamine prescriptions - DOJ press release | N/A | N/A | | | | | | | | | |
| P-08457 | 3/4/2021 | New York doctor charged with murder in 5 opioid deaths - CBS News (public) | N/A | N/A | | | | | | | | | |
| P-08458 | 7/22/2014 | Harrington letter to Blatti, George 7/10/2014 | CVS-NYAG-000037435 | CVS-NYAG-000037435 | | | | | | | | | |
| P-08459 | 7/17/2014 | Blatti G 01 - Grimes and Harrington interview with Dr. George Blatti | CVS-NYAG-000038884 | CVS-NYAG-000038886 | | | | | | | | | |
| P-08460 | 5/19/2016 | RE: red flag dr info | CVS-NYAG-000042403 | CVS-NYAG-000042404 | | | | | | | | | |
| P-08462 | 5/11/2017 | prescriber archer db report 5.11.17 | CVS-MDLT3-000081783 | CVS-MDLT3-000081784 | | | | | | | | | |
| P-08463 | 10/15/2019 | Follow-up Items from Prescriber Team Touch Base; Access Database Export 10.4.2019; Controlled_Substance_Monitoring_Prescriber_Program_SOP2018; DRAFT Interview Notes | CVS-MDLT3-000121323 | CVS-MDLT3-000121333 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-08464 | 5/17/2007 | Presentence Report | LAKE003001658 | LAKE003001670 | | | | | | | | | |
| P-08465 | 3/16/2012 | 1627915--Pharmacist panel 3162012 Store 4351--56342 | CVS-MDLT3-000030199 | CVS-MDLT3-000030200 | | | | | | | | | |
| P-08466 | 2012 | Store Statistics for SOM Order Review; Store #4351 | CVS-MDLT3-000000367 | CVS-MDLT3-000000368 | | | | | | | | | |
| P-08467 | 10/29/2014 | shady md | CVS-MDLT3-000100942 | CVS-MDLT3-000100942 | | | | | | | | | |
| P-08468 | 2/25/2015 | 4598043--Demangone D 2 4 15_InitialOutreachLetter1-- 405946 | CVS-MDLT1B-000001616 | CVS-MDLT1B-000001616 | | | | | | | | | |
| P-08469 | 9/21/2018 | Notice of Central Prescriber Block for DR. D. Demangone (Walmart/Sam's Club) | WMT_MDL_000286297 | WMT_MDL_000286298 | | | | | | | | | |
| P-08470 | 4/23/2015 | 4562197--Prescriber Outreach_Tracking--395092 | CVS-MDLT1B-000001586 | CVS-MDLT1B-000001586 | | | | | | | | | |
| P-08471 | 4/7/2015 | Q3 2014 Tier 1_2 Prescribers | CVS-MDLT3-000000044 | CVS-MDLT3-000000044 | | | | | | | | | |
| P-08472 | N/A | Access Database Export 10.4.2019 | CVS-MDLT3-000000066 | CVS-MDLT3-000000066 | | | | | | | | | |
| P-08474 | 3/9/2015 | 4598043--Demangone Prescriber Slide--405949 | CVS-MDLT1B-000001613 | CVS-MDLT1B-000001615 | | | | | | | | | |
| P-08480 | 6/15/2020 | 2015-12-63043 TCF | CVS-MDLT3-000010797 | CVS-MDLT3-000010802 | | | | | | | | | |
| P-08482 | 9/10/2012 | Separate questions on hydrocodone - Federal C2s | WAGMDL00075673 | WAGMDL00075673 | | | | | | | | | |
| P-08483 | 7/2/2012 | Discussion of ceiling limits - updated with x for review (slides 4+); Controlled Substance Order Review Business Logic (6/22/2012) | WAGMDL00077015 | WAGMDL00077023 | | | | | | | | | |
| P-08484 | 12/23/2015 | 5480074--Frank Veres Ethics Line Case--694066 | CVS-MDLT3-000000098 | CVS-MDLT3-000000099 | | | | | | | | | |
| P-08488 | 6/8/2020 | Veres F 1 07 | CVS-MDLT3-000000242 | CVS-MDLT3-000000242 | | | | | | | | | |
| P-08489 | 6/8/2020 | Veres F 1 10 | CVS-MDLT3-000000248 | CVS-MDLT3-000000249 | | | | | | | | | |
| P-08493 | 6/8/2020 | Veres F 2 01 | CVS-MDLT3-000000252 | CVS-MDLT3-000000252 | | | | | | | | | |
| P-08494 | 2/10/2016 | RE: Interview w/Dr. Frank Veres; 3304CVS_location; Frank Veres Ethics Line Case; Maps_SurroundingCVS; Veres CS Analysis; Veres National Prescriber Tableau Dashboard v5; Veres Prescriber Slide; Veres_12ScriptAlg; Veres_40ScriptAlg; Veres_article | CVS-MDLT3-000026085 | CVS-MDLT3-000026101 | | | | | | | | | |
| P-08495 | 2/10/2016 | Veres F 1 02 | CVS-MDLT3-000000233 | CVS-MDLT3-000000234 | | | | | | | | | |
| P-08496 | 1/5/2016 | DEA | CVS-MDLT3-000100716 | CVS-MDLT3-000100716 | | | | | | | | | |
| P-08497 | 12/12/2016 | RE: MEDIC Inquiry--Zachary Veres | CVS-MDLT3-000129178 | CVS-MDLT3-000129181 | | | | | | | | | |
| P-08499 | 12/9/2016 | RE: MEDIC Inquiry--Zachary Veres | CVS-MDLT3-000129170 | CVS-MDLT3-000129173 | | | | | | | | | |
| P-08500 | 4/14/2017 | 5480074--Veres Frank DO Prescriber Notes 2 10 16 (2)-- 1425805 | CVS-MDLT3-000000116 | CVS-MDLT3-000000117 | | | | | | | | | |
| P-08501 | 3/20/2018 | 8007398--Veres Frank 3.16.18-- 1509750 | CVS-MDLT3-000000118 | CVS-MDLT3-000000118 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-08503 | 8/15/2018 | Prescriber Outreach Tracking 6.29.18 SM | CVS-MDLT3-000035710 | CVS-MDLT3-000035711 | | | | | | | | | |
| P-08504 | 4/10/2013 | FW: April 9th; 4_16 Wave of Stores going to ABC; CII_Amerisource; CII_ANDA | WAGMDL00095929 | WAGMDL00095937 | | | | | | | | | |
| P-08505 | 2/10/2016 | 5480074--Veres Prescriber Slide--694072 | CVS-MDLT3-000000107 | CVS-MDLT3-000000108 | | | | | | | | | |
| P-08506 | 7/3/2013 | 2008 Sales & Execution; Field User Guide Toolkit | CVS-DR22-000030803 | CVS-DR22-000030856 | | | | | | | | | |
| P-08507 | 8/20/2019 | Pharmacy Supervisor Position Description | CVS-FLAG-000045718 | CVS-FLAG-000045730 | | | | | | | | | |
| P-08508 | 10/11/2012 | FW: Walgreens Stores - Oxycodone Usage | WAGMDL00101696 | WAGMDL00101699 | | | | | | | | | |
| P-08509 | 3/13/2013 | FW: Walgreens Threshold Limits | WAGMDL00102642 | WAGMDL00102644 | | | | | | | | | |
| P-08510 | 11/23/2016 | Mills.Steven.Resume | WAGMDL00104075 | WAGMDL00104077 | | | | | | | | | |
| P-08511 | 10/8/2012 | RE: Daily SOM Report | WAGMDL00107485 | WAGMDL00107488 | | | | | | | | | |
| P-08512 | 9/25/2012 | FW: Daily SOM Report | WAGMDL00119536 | WAGMDL00119538 | | | | | | | | | |
| P-08513 | 4/19/2013 | Status Format; Status 02.14.13 | WAGMDL00245768 | WAGMDL00245769 | | | | | | | | | |
| P-08514 | 2/10/2014 | CVS Form 10-k for 2013 | N/A | N/A | | | | | | | | | |
| P-08515 | 2/5/2013 | FW: Walgreen Co. | WAGMDL00246239 | WAGMDL00246241 | | | | | | | | | |
| P-08516 | 7/29/2020 | QA_FAQs | CVS-MDLT3-000006588 | CVS-MDLT3-000006589 | | | | | | | | | |
| P-08517 | N/A | McKinsey PPT for Purdue | MCK-MAAG-0201384 | Composite | | | | | | | | | |
| P-08518 | 4/1/2020 | Opioid Treatments for Chronic Pain - Agency for Healthcare Research and Quality (AHRQ) | N/A | N/A | | | | | | | | | |
| P-08520 | 2/2/2021 | Issue brief: Reports of increases in opioid- and other drug-related overdose and other concerns during COVID pandemic | N/A | N/A | | | | | | | | | |
| P-08521 | 2/16/2021 | Prop Letter to AMA RE: AMA's Opposition to Dose & Duration Guidance for Opioid Prescribing | N/A | N/A | | | | | | | | | |
| P-08522 | 5/29/2020 | AMA Covid-19 Update - video | N/A | N/A | | | | | | | | | |
| P-08559 | 2/25/2013 | Fwd: OXYCONTIN CO-PAY support cards-Action required by Steve (Attachment is Non-Responsive) | PPLPC004000348272 | PPLPC004000348273 | | | | | | | | | |
| P-08562 | 7/1/2016 | Email Meeting Summary: Rite Aid (6/29/16) | PPLPC024000981992 | PPLPC024000981994 | | | | | | | | | |
| P-08617 | 2/5/2013 | FW: Suspicious Order; What makes an order suspicious? | WAGMDL00303305 | WAGMDL00303307 | | | | | | | | | |
| P-08619 | 6/19/2013 | DCs Suspicious Order Monitoring Policy and Procedure | WAGMDL00316771 | WAGMDL00316785 | | | | | | | | | |
| P-08620 | 2/8/2012 | Suspicious Order Monitoring Process | WAGMDL00325129 | WAGMDL00325130 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------------|--------------------------|--|--|--|--|--|--|--|--|--|
| P-08624 | 8/7/2012 | FW: NACDS Pharmacy Operations Committee -- Action Requested: DEA Interim Solution; Developing Interim Solution (2) final draft 8_6_12 | WAGMDL00331103 | WAGMDL00331110 | | | | | | | | | |
| P-08626 | 3/1/2013 | Perrysburg CIII-CV - meeting notes. | WAGMDL00358471 | WAGMDL00358473 | | | | | | | | | |
| P-08655 | 10/27/1999 | RE: Walgreens CE Programs Oct 25th @ 26th | PPLPC024000008341 | PPLPC024000008342 | | | | | | | | | |
| P-08656 | 1/17/2000 | Tampa District - Walgreens' request for money | PPLPC024000010714 | PPLPC024000010716 | | | | | | | | | |
| P-08657 | 6/20/2001 | The Use of Opioids for Chronic and Acute Pain | PPLPC022000010323 | PPLPC022000010323 | | | | | | | | | |
| P-08658 | 2011 | CVS Patient and Pharmacist Educational Services | INSYS-MDL-000422516 | INSYS-MDL-000422525 | | | | | | | | | |
| P-08659 | 4/5/2012 | FW: CCP Exhibit; CVS -Endo Opana ER Exhibit - CareCheck Plus 03 08 201 | ENDO-OPIOID_MDL-06157727 | ENDO-OPIOID_MDL-06157748 | | | | | | | | | |
| P-08660 | 5/10/2001 | Walgreens Meeting April 25, 2001 | PKY180267742 | PKY180267745 | | | | | | | | | |
| P-08661 | 11/6/2012 | RE: Tactical Plan; DRAFT Business Plan Presentation- Opana ER (11-6-12) | ENDO-CHI_LIT-00214077 | ENDO-CHI_LIT-00214085 | | | | | | | | | |
| P-08662 | 5/11/2001 | CVS Pharmacy - from Seid | PDD1701046870 | PDD1701046870 | | | | | | | | | |
| P-08663 | 6/30/2001 | Letter to CVS Pharmacists | PDD1501726314 | PDD1501726314 | | | | | | | | | |
| P-08664 | 8/24/2001 | Request for CE EDUCATIONAL GRANT1 | PPLPC008000019584 | PPLPC008000019588 | | | | | | | | | |
| P-08674 | 2013 | John Aivazis Year-End Review - 2013 | CVS-MDLT3-000154655 | CVS-MDLT3-000154656 | | | | | | | | | |
| P-08675 | 10/30/2014 | Email No Subject Attachments 2014 Medication Management - Key Performance Measures; Store Reports; FS mCE Service Diagnostic 'Hot Spot' Report; WeCARE Scorecard | CVS-MDLT3-000145997 | CVS-MDLT3-000146018 | | | | | | | | | |
| P-08676 | 2/10/2015 | Email 4327 visit with Attachments Community Responsibility Scorecard; 2016 myPatientCare Outcomes; S mCE Service Diagnostic 'Hot Spot' Report | CVS-MDLT3-000147732 | CVS-MDLT3-000147767 | | | | | | | | | |
| P-08677 | 8/3/2015 | Email 4351 visit with Attachments Community Responsibility Scorecard; 2016 myPatientCare Outcomes; S mCE Service Diagnostic 'Hot Spot' Report | CVS-MDLT3-000151102 | CVS-MDLT3-000151136 | | | | | | | | | |
| P-08678 | 10/24/2016 | FW: visit folder Attachments October 10th - November 4th myStore Health Checklist; October 2016 myStore Health Cycle Training Tracker; myStore Health | CVS-MDLT3-000153376 | CVS-MDLT3-000153429 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-08679 | 12/17/2012 | Email Flow Charts for CSM Attachments Store, Pharmacist, and Distribution Center, Controlled Substance Monitoring Process | CVS-MDLT3-000085034 | CVS-MDLT3-000085055 | | | | | | | | | |
| P-08680 | 3/1/2018 | Re: Store CS Algorithm Flagging Criteria Attachment Store Algorithm Flagging Criteria | CVS-MDLT3-000025980 | CVS-MDLT3-000025981 | | | | | | | | | |
| P-08681 | 3/17/2014 | Email Outlier Stores Entering Controlled Substance Dispensing Programs Attachments | CVS-MDLT3-000028136 | CVS-MDLT3-000028143 | | | | | | | | | |
| P-08682 | 4/10/2014 | Email Store #4351. Privileged and Confidential- prepared at the Direction of Counsel Attachment 4351 controlled drug dispensing | CVS-MDLT3-000030224 | CVS-MDLT3-000030225 | | | | | | | | | |
| P-08683 | 7/16/2013 | Email LP Store Reviews- Privileged and Confidential Attachments | CVS-MDLT3-000114296 | CVS-MDLT3-000114298 | | | | | | | | | |
| P-08768 | 10/7/2010 | Email re New BSR - control drug IRR changes; BIDForm- V3 | CVS-MDLT1-000034172 | CVS-MDLT1-000034177 | | | | | | | | | |
| P-08778 | 4/29/2009 | (11626397)_(1)_1.14.08 Letter to DEA w_ Attachments (2) | CAH_MDL2804_01376788 | CAH_MDL2804_01376809 | | | | | | | | | |
| P-08801 | 6/27/2007 | Email from Michael Mapes (DEA) to Dwayne Pinon (Walgreens in house counsel) | WAGMDL00387635 | WAGMDL00387637 | | | | | | | | | |
| P-08802 | 7/28/2006 | Letter D. Pinon (Walgreens) to B. Dobric (DEA) | WAGMDL00387642 | WAGMDL00387650 | | | | | | | | | |
| P-08803 | 3/26/2008 | Dwayne Pinon (WAG in house counsel) email to Dallas DEA | WAGMDL00387651 | WAGMDL00387652 | | | | | | | | | |
| P-08804 | 6/11/2013 | Appendix B | WAGMDL00387653 | WAGMDL00387707 | | | | | | | | | |
| P-08805 | 6/11/2013 | Appendix | WAGMDL00387975 | WAGMDL00387982 | | | | | | | | | |
| P-08807 | 4/3/2007 | DEA Suspicious Controlled Drug Report | WAGMDL00400357 | WAGMDL00400357 | | | | | | | | | |
| P-08808 | 10/12/2018 | 20130328 - Knowing Your Customer - Suspicious Orders Reporting | WAGMDL00400361 | WAGMDL00400364 | | | | | | | | | |
| P-08809 | 11/18/2013 | Tramadol products classification; DI035P_items with drug_class_all_ndc_match | WAGMDL00436800 | WAGMDL00436802 | | | | | | | | | |
| P-08811 | 2/15/2013 | RE: Weekly PMO Status of Top 20 SC projects; Weekly PMO Status - Thursday Update 2-14-2013 | WAGMDL00477975 | WAGMDL00477989 | | | | | | | | | |
| P-08876 | 11/16/2015 | Emails regarding Update on Hatch-Whitehouse - confidential | CAH_MDL2804_02467634 | CAH_MDL2804_02467634 | | | | | | | | | |
| P-08877 | 8/22/2015 | Fwd: Feedback from DEA/DOJ on S. 483 | CAH_MDL2804_02471084 | CAH_MDL2804_02471088 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-08878 | 8/21/2015 | RE: Update on S. 483 - feedback requested | CAH_MDL2804_02471125 | CAH_MDL2804_02471126 | | | | | | | | | |
| P-08937 | 7/15/2014 | RE: Alliance: HR 4709 Sign On Letter to Speaker Boehner - Deadline tomorrow at 3p | CVS-MDLT1-000093512 | CVS-MDLT1-000093513 | | | | | | | | | |
| P-08938 | 7/10/2014 | Alliance: Draft Letter to ONDCP | CVS-MDLT1-000093536 | CVS-MDLT1-000093538 | | | | | | | | | |
| P-08949 | 1/12/2007 | Email from Morteliti to Gardner re DEA Compliance Survey Blank | CVS-MDLT1-000034435 | CVS-MDLT1-000034441 | | | | | | | | | |
| P-08950 | 3/21/2011 | Letter to Frank Devlin, CVS Corporation from Gary Glotz | CVS-MDLT1-000105407 | CVS-MDLT1-000105428 | | | | | | | | | |
| P-08952 | 3/17/2008 | Letter to Amy Brown, CVS from Gary Glotz | CVS-MDLT1-000109193 | CVS-MDLT1-000109197 | | | | | | | | | |
| P-08953 | 6/24/2009 | CVS Knoxville Distribution Center | CVS-MDLT1-000124350 | CVS-MDLT1-000124458 | | | | | | | | | |
| P-08954 | 5/12/2015 | x_Settlement Agreement_Signed | CVS-MDLT1-000060796 | CVS-MDLT1-000060804 | | | | | | | | | |
| P-08955 | 2/12/2016 | CVS-Maryland Settlement 2-12-16 | CVS-MDLT1-000060805 | CVS-MDLT1-000060811 | | | | | | | | | |
| P-08956 | 7/5/2017 | CVS - Settlement Agreement FINAL Executed with Attach A | CVS-MDLT1-000060856 | CVS-MDLT1-000060871 | | | | | | | | | |
| P-08957 | 1/15/2014 | FW: SOM Presentation 1-16-14 | CVS-MDLT1-000078060 | CVS-MDLT1-000078069 | | | | | | | | | |
| P-08959 | 1/16/2014 | Keys to an Effective SOM System SOM Presentation | CVS-MDLT1-000078101 | CVS-MDLT1-000078109 | | | | | | | | | |
| P-08960 | 2/19/2014 | Alliance to Prevent the Abuse of Medicines - Legislative Concepts - Comments Due by Wednesday February 26th at 3p; Legislative Concepts HIGHLIGHTED CHANGES Working Draft 2 19 14 | CVS-MDLT1-000079145 | CVS-MDLT1-000079153 | | | | | | | | | |
| P-08965 | 7/15/2014 | FW: Alliance: HR 4709 Sign On Letter to Speaker Boehner - Deadline tomorrow at 3p | CVS-MDLT1-000093530 | CVS-MDLT1-000093532 | | | | | | | | | |
| P-08966 | 8/26/2009 | DEA Suspicious Order Item Limits - Phase II | WAGMDL00492067 | WAGMDL00492069 | | | | | | | | | |
| P-08968 | 5/1/2012 | Functional Requirements & (Macro) Design, DEA Suspicious Ordering - Phase IV, Project Number W0003956 | WAGMDL00492562 | WAGMDL00492579 | | | | | | | | | |
| P-08993 | 2/15/2016 | FW: 9461 Roxicodone | WAGNYNS00001674 | WAGNYNS00001675 | | | | | | | | | |
| P-08994 | 2/6/2017 | FW: Policy Council - Updates & Clarifications; RxIMPACT msg 01 24 2017; DEA 2016-28966; DEA EPCS IFR March 2010 Fr copy | WAGNYNS00005513 | WAGNYNS00005654 | | | | | | | | | |
| P-09000 | 9/19/2013 | Controlled Substance Order (CSO) Override Form & Ceiling Limits Tool | WAGNYNS00015484 | WAGNYNS00015485 | | | | | | | | | |
| P-09001 | 1/6/2020 | Control Data_NY | WAGNYNS00016301 | WAGNYNS00016301 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-09004 | 3/9/2018 | Email DEA Red Flag Document | WAGNYNS00017983 | WAGNYNS00017983 | | | | | | | | | |
| P-09005 | 6/1/2012 | Focus on Compliance - June 2012 - Summary Data; Focus on Compliance - June 2012 - All Response Data with Stores | WAGNYNS00022707 | WAGNYNS00022708 | | | | | | | | | |
| P-09013 | 10/11/2013 | Pharmacist GFD Review Coaching Opportunities, Pharmaceutical Integrity Team PPT | WAGNYNS00031874 | WAGNYNS00031896 | | | | | | | | | |
| P-09015 | 5/12/2014 | Good Faith Dispensing PPT | WAGNYNS00031920 | WAGNYNS00031943 | | | | | | | | | |
| P-09016 | 2/7/2013 | Umbley Red Flags_CS Dispensing | WAGNYNS00032002 | WAGNYNS00032004 | | | | | | | | | |
| P-09018 | 8/22/2013 | Email GFD Flowchart Attachment Visio-GFD Decision Tree | WAGNYNS00032416 | WAGNYNS00032418 | | | | | | | | | |
| P-09020 | N/A | Cocktails from RPh coaching examples | WAGNYNS00048875 | WAGNYNS00048876 | | | | | | | | | |
| P-09021 | N/A | Opioid Index Data | WAGNYNS00048877 | WAGNYNS00048877 | | | | | | | | | |
| P-09038 | 2/5/2012 | Fw: Executive Committee Call -- Follow-up Materials | CVS-MDLT1-000102930 | CVS-MDLT1-000102933 | | | | | | | | | |
| P-09039 | 1/15/2014 | Alliance to Prevent the Abuse of Medicines - Revised ONDCP Slide Deck | CVS-MDLT1-000103494 | CVS-MDLT1-000103508 | | | | | | | | | |
| P-09040 | 6/20/2014 | Alliance: Trust for America's Health Agenda and Attendees | CVS-MDLT1-000103561 | CVS-MDLT1-000103627 | | | | | | | | | |
| P-09057 | 4/23/2012 | 2011 September Cmts OARRS | WAGMDL00580455 | WAGMDL00580488 | | | | | | | | | |
| P-09058 | 4/10/2018 | NACDS Slate of nominations BoD 3-26-18 | WAGMDL00593951 | WAGMDL00593981 | | | | | | | | | |
| P-09059 | 5/13/2016 | NACDS Policy Council | WAGMDL00605718 | WAGMDL00605721 | | | | | | | | | |
| P-09060 | 5/23/2012 | RE: URGENT/Manchin Amendment/Potential Call to Greg Wasson | WAGMDL00614056 | WAGMDL00614059 | | | | | | | | | |
| P-09061 | 5/23/2012 | Fw: URGENT/Manchin Amendment/Potential Call to Greg Wasson | WAGMDL00614060 | WAGMDL00614063 | | | | | | | | | |
| P-09062 | 4/26/2014 | Exec Com minutes Apr 26 2014 | CVS-MDLT1-000106756 | CVS-MDLT1-000106763 | | | | | | | | | |
| P-09065 | 6/23/2008 | DEA Suspicious Order Reporting - Proposal for defining "suspicious orders" in the Walgreen distribution system | WAGMDL00624503 | WAGMDL00624509 | | | | | | | | | |
| P-09066 | 8/13/2015 | Agenda Minutes Consent Calendar 8-23-15 | WAGMDL00633964 | WAGMDL00634070 | | | | | | | | | |
| P-09067 | 5/1/2012 | RE: Document for Policy Council Call - DEA Issues - Tuesday May 1 @ 1:15 p.m.; Drug Diversion - PDUFA | WAGMDL00638068 | WAGMDL00638072 | | | | | | | | | |
| P-09069 | 5/31/2012 | Fw: Cardinal Health News Alert - Fla Situation and Other Pharma Article of Interest | WAGMDL00642582 | WAGMDL00642587 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------------------|----------------------------------|--|--|--|--|--|--|--|--|--|
| P-09104 | 4/11/2013 | Transferring Controlled Substances | WAGMDL00700161 | WAGMDL00700161 | | | | | | | | | |
| P-09105 | 10/1/2012 | Re: OXYCODONE no longer being ordered via PDQ | WAGMDL00705318 | WAGMDL00705320 | | | | | | | | | |
| P-09112 | 8/16/2005 | Internet Presentation with AmerisourceBergen | US-DEA-00000147 | US-DEA-00000164 | | | | | | | | | |
| P-09114 | 8/23/2005 | Meeting with Cardinal Health, Inc. Concerning Internet Pharmacies | US-DEA-00000352 | US-DEA-00000366 | | | | | | | | | |
| P-09115 | 12/6/2005 | Conference Call with. Mr John. Gilbert, Legal Counsel, representing the McKesson Corporation | US-DEA-00000369 | US-DEA-00000370 | | | | | | | | | |
| P-09116 | 1/3/2006 | Meeting between Office of Diversion Control (OD) and McKesson Corp. | US-DEA-00000371 | US-DEA-00000373 | | | | | | | | | |
| P-09125 | 6/1/2011 | HDMA Letter to follow-up on December 7, 2010 Meeting between DEA and HDMA regarding prevention of diversion | ABDCMDL00284385 | ABDCMDL00284408 | | | | | | | | | |
| P-09128 | 5/27/2006 | 1. Other Stuff | WAGMDL00709507 | WAGMDL00709558 | | | | | | | | | |
| P-09129 | 8/22/2013 | Fw: Analyst Report | WAGMDL00746694 | WAGMDL00746711 | | | | | | | | | |
| P-09153 | 10/7/2013 | Authentication of Prescription Order Policy | WAGMDL00749381 | WAGMDL00749407 | | | | | | | | | |
| P-09158 | 10/25/2013 | FW: FDA hydrocodone rescheduling recommendation | CVS-MDLT1-000121577 | CVS-MDLT1-000121578 | | | | | | | | | |
| P-09159 | 5/11/2011 | Re: VAWD Question; RX Questionable Order Qty | WAGMDL00751821 | WAGMDL00751823 | | | | | | | | | |
| P-09173 | 3/9/2006 | DEA Audit Recap Perrysburg 3/2/2006 | WAGMDL00757762 | WAGMDL00757773 | | | | | | | | | |
| P-09175 | 9/25/2014 | Inventory Controls Doc 1A - Suspicious Ordering Monitoring Program | WAGMDL00757776 | WAGMDL00757784 | | | | | | | | | |
| P-09176 | 12/11/2006 | vawd store questionable qty | WAGMDL00757788 | WAGMDL00757788 | | | | | | | | | |
| P-09206 | 3/15/2018 | RE: NACDS/Walgreens Intro: Ohio Regulation Coordination | HDA_MDL_000094993 | HDA_MDL_000094994 | | | | | | | | | |
| P-09245 | 1/18/2011 | 1/18/2011 Email Parvu to Spink re HDMA invoice (CVS Membership dues) | CVS-MDLT1-000099537 | CVS-MDLT1-000099540 | | | | | | | | | |
| P-09248 | 11/14/2012 | Letter from Gray to Farrell re 2013 Invoice (CVS Membership dues) | CVS-MDLT1000099569 | CVS-MDLT1000099570 | | | | | | | | | |
| P-09261 | 2/12/2008 | HDMA DEA Suspicious Orders Best Practices Powerpoint presentation | HDA_MDL_000213058 | HDA_MDL_000213077 | | | | | | | | | |
| P-09307 | 2/16/1990 | DEA Diversion Investigators Manual | CAH_MDL_PRIORPROD_DEA07_01176247 | CAH_MDL_PRIORPROD_DEA07_01176558 | | | | | | | | | |
| P-09311 | 11/27/1995 | DEA Compliance Manual | CAH_MDL_PRIORPROD_DEA07_01178834 | CAH_MDL_PRIORPROD_DEA07_01179179 | | | | | | | | | |
| P-09320 | 11/17/1997 | Duplicate DEA Compliance Manual | CAH_MDL_PRIORPROD_DEA07_01383895 | CAH_MDL_PRIORPROD_DEA07_01384238 | | | | | | | | | |

| | | | | | | | | | | | | | | |
|---------|------------|---|----------------------------------|----------------------------------|--|--|--|--|--|--|--|--|--|--|
| P-09359 | 10/17/2008 | Letter from DEA to John Gray | CAH_MDL_PRIORPROD_DEA12_00000825 | CAH_MDL_PRIORPROD_DEA12_00000825 | | | | | | | | | | |
| P-09360 | N/A | HDMA SOM Industry Compliance Guidelines | CAH_MDL_PRIORPROD_DEA12_00000826 | CAH_MDL_PRIORPROD_DEA12_00000840 | | | | | | | | | | |
| P-09385 | 3/1/2007 | 09. Memorandum by Linden Barber, Legal Guidance on Reporting Suspicious Orders | CAH_MDL_PRIORPROD_DEA12_00010978 | CAH_MDL_PRIORPROD_DEA12_00010979 | | | | | | | | | | |
| P-09399 | 2/10/2012 | Declaration of Joseph Rannazzisi in Cardinal Health v Holder | CAH_MDL_PRIORPROD_DEA12_00014479 | CAH_MDL_PRIORPROD_DEA12_00014512 | | | | | | | | | | |
| P-09510 | 2/26/2016 | Giant Eagle Common Carrier Policy, Customer Auth, Crisis Operations | HBC_MDL00004341 | HBC_MDL00004514 | | | | | | | | | | |
| P-09511 | 3/21/2016 | Monthly narcotic audit and PIC (change in Pharmacy team Leader) Inventory | HBC_MDL00004635 | HBC_MDL00004650 | | | | | | | | | | |
| P-09512 | 7/26/2017 | FW: Giant Eagle Training Materials | HBC_MDL00006939 | HBC_MDL00007136 | | | | | | | | | | |
| P-09513 | 7/7/2016 | cash patients | HBC_MDL00029892 | HBC_MDL00029892 | | | | | | | | | | |
| P-09514 | 3/26/2015 | April Team Leader Call | HBC_MDL00032483 | HBC_MDL00032515 | | | | | | | | | | |
| P-09515 | 6/3/2013 | Controlled Substance Manual_Nancy | HBC_MDL00032601 | HBC_MDL00032652 | | | | | | | | | | |
| P-09516 | 2/18/2013 | Steps Required to Correctly Perform Monthly Narcotic Audits | HBC_MDL00032826 | HBC_MDL00032829 | | | | | | | | | | |
| P-09517 | 2/16/2017 | SOM Policy Procedure_v5 | HBC_MDL00045915 | HBC_MDL00045918 | | | | | | | | | | |
| P-09518 | 1/23/2017 | Drug Control Program Update for 1/25 | HBC_MDL00046025 | HBC_MDL00046033 | | | | | | | | | | |
| P-09519 | 4/23/2018 | Giant Eagle Suspicious Order Monitoring Program | HBC_MDL00051908 | HBC_MDL00051908 | | | | | | | | | | |
| P-09520 | 2/13/2014 | 2014-02 Audit Cmte Rx Slides v1 | HBC_MDL00052136 | HBC_MDL00052136 | | | | | | | | | | |
| P-09521 | 1/29/2017 | FW: Hot Topics -Weekly Summary - WE 1/28/17 | HBC_MDL00058943 | HBC_MDL00058966 | | | | | | | | | | |
| P-09522 | 4/13/2017 | 4th Quarter CQI slide | HBC_MDL00059580 | HBC_MDL00059581 | | | | | | | | | | |
| P-09523 | 8/26/2016 | Controlled Substance Research | HBC_MDL00059779 | HBC_MDL00059781 | | | | | | | | | | |
| P-09524 | 8/24/2016 | Controlled Substance Research | HBC_MDL00060766 | HBC_MDL00060768 | | | | | | | | | | |
| P-09525 | 8/13/2017 | Weekly Notes | HBC_MDL00063628 | HBC_MDL00063710 | | | | | | | | | | |
| P-09526 | 8/25/2014 | monthly team leader call /please print agenda and attachemnts for call/reminder | HBC_MDL00063993 | HBC_MDL00064007 | | | | | | | | | | |
| P-09527 | 8/22/2015 | RE: Thrifty White Notes | HBC_MDL00069558 | HBC_MDL00069561 | | | | | | | | | | |
| P-09528 | 1/19/2015 | TL Master Training Deck and Design | HBC_MDL00078497 | HBC_MDL00078501 | | | | | | | | | | |
| P-09529 | 4/9/2015 | All polices for VAWD reflected as of 5:00pm today | HBC_MDL00078594 | HBC_MDL00078668 | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-----------------|-----------------|--|--|--|--|--|--|--|--|--|
| P-09530 | 12/11/2015 | FW: It's OK to Say No. You Might Just Save a Life. State of Ohio Board of Pharmacy Announces New OARRS Rules for Pharmacists | HBC_MDL00080620 | HBC_MDL00080625 | | | | | | | | | |
| P-09531 | 9/28/2016 | RE: Annual meetings | HBC_MDL00091025 | HBC_MDL00091123 | | | | | | | | | |
| P-09532 | 9/20/2012 | Regulatory and Compliance Policies and Procedures List | HBC_MDL00092129 | HBC_MDL00092132 | | | | | | | | | |
| P-09533 | 1/29/2016 | RE: buprenorphine | HBC_MDL00124656 | HBC_MDL00124657 | | | | | | | | | |
| P-09534 | 8/26/2016 | Controlled Substance Research Steps_Jason | HBC_MDL00126914 | HBC_MDL00126915 | | | | | | | | | |
| P-09535 | 10/2/2013 | Controlled Substance Dispensing Guideline_v2 | HBC_MDL00126950 | HBC_MDL00126953 | | | | | | | | | |
| P-09537 | 12/5/2014 | FW: DSCSA Documents | HBC_MDL00133435 | HBC_MDL00133463 | | | | | | | | | |
| P-09539 | 2/28/2016 | Weekly Notes | HBC_MDL00167041 | HBC_MDL00167064 | | | | | | | | | |
| P-09543 | 8/18/2011 | FW: Controlled drug procedures | HBC_MDL00180816 | HBC_MDL00180824 | | | | | | | | | |
| P-09544 | 1/12/2017 | PharmTechBonus_Adjusted Final-2017 | HBC_MDL00191116 | HBC_MDL00191119 | | | | | | | | | |
| P-09545 | 4/3/2013 | Rx Bonus Plan 2013 | HBC_MDL00191120 | HBC_MDL00191121 | | | | | | | | | |
| P-09546 | 1/23/2014 | Rx Bonus Plan 2014 | HBC_MDL00191122 | HBC_MDL00191124 | | | | | | | | | |
| P-09547 | 9/17/2015 | Rx Bonus Plan 2016 | HBC_MDL00191125 | HBC_MDL00191126 | | | | | | | | | |
| P-09550 | 8/27/2014 | Rx Bonus Plan 2015 | HBC_MDL00191127 | HBC_MDL00191128 | | | | | | | | | |
| P-09555 | 10/29/2011 | Rx Bonus Plan 2012 | HBC_MDL00191129 | HBC_MDL00191130 | | | | | | | | | |
| P-09564 | 12/20/2017 | Rx Bonus Plan 2018 | HBC_MDL00191151 | HBC_MDL00191152 | | | | | | | | | |
| P-09570 | 7/25/2016 | Rx Bonus Plan 2017 | HBC_MDL00191153 | HBC_MDL00191154 | | | | | | | | | |
| P-09576 | 2/1/2020 | Rx Bonus Plan 2020 | HBC_MDL00191155 | HBC_MDL00191157 | | | | | | | | | |
| P-09577 | 8/9/2017 | Rx Tech Bonus_FY18 | HBC_MDL00191169 | HBC_MDL00191171 | | | | | | | | | |
| P-09579 | 10/19/2018 | Rx Tech Bonus_FY19 (Final) | HBC_MDL00191172 | HBC_MDL00191174 | | | | | | | | | |
| P-09582 | 8/1/2019 | Rx Tech Bonus_FY20 | HBC_MDL00191175 | HBC_MDL00191177 | | | | | | | | | |
| P-09583 | 9/16/2019 | Rx Bonus Plan 2019 | HBC_MDL00191181 | HBC_MDL00191183 | | | | | | | | | |
| P-09584 | 1/14/2014 | Controlled Substances Filling Prescriptions | HBC_MDL00191477 | HBC_MDL00191477 | | | | | | | | | |
| P-09585 | 9/11/2015 | 10-019 Incident Reporting Policy-9-11-15. | HBC_MDL00191684 | HBC_MDL00191686 | | | | | | | | | |
| P-09586 | 3/23/2006 | Monthly Schedule II Audit | HBC_MDL00192400 | HBC_MDL00192402 | | | | | | | | | |
| P-09587 | 7/18/2016 | Drug Utilization Review (DUR) & Counseling Standard | HBC_MDL00192518 | HBC_MDL00192520 | | | | | | | | | |
| P-09588 | 9/21/2018 | Summit County Oct 2009-May 2018 | HBC_MDL00002099 | HBC_MDL00002099 | | | | | | | | | |
| P-09596 | 9/21/2018 | Cuyahoga County Oct 2009-May 2018 | HBC_MDL00002100 | HBC_MDL00002100 | | | | | | | | | |
| P-09597 | 8/1/2015 | Pharmacy Administration as of August 2015 | HBC_MDL00002191 | HBC_MDL00002191 | | | | | | | | | |
| P-09598 | 11/13/2014 | Pharmacy Operations Organizational Chart as of January 2015 | HBC_MDL00002216 | HBC_MDL00002216 | | | | | | | | | |
| P-09606 | 2/13/2015 | Pharmacy organizational chart as of January 2015 | HBC_MDL00002219 | HBC_MDL00002219 | | | | | | | | | |
| P-09607 | 6/1/2015 | Pharmacy Operations Organizational Chart as of June 2015 | HBC_MDL00002222 | HBC_MDL00002222 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-09611 | 5/31/2014 | 20140530_Daily_HBC_Controls | HBC_MDL00002244 | HBC_MDL00002244 | | | | | | | | | |
| P-09612 | 12/31/2013 | 20131229_Daily_HBC_Controls | HBC_MDL00002246 | HBC_MDL00002246 | | | | | | | | | |
| P-09615 | 8/29/2014 | 20140828_Daily_HBC_Controls_W7 | HBC_MDL00002332 | HBC_MDL00002332 | | | | | | | | | |
| P-09616 | 12/17/2009 | Presentation: How to Keep (or Lose) Your DEA Registration | CAH_MDL2804_00889528 | CAH_MDL2804_00889540 | | | | | | | | | |
| P-09618 | 3/31/2014 | 20140330_Daily_HBC_Controls | HBC_MDL00002336 | HBC_MDL00002336 | | | | | | | | | |
| P-09619 | 10/31/2013 | 20131030_Daily_HBC_Controls | HBC_MDL00002348 | HBC_MDL00002348 | | | | | | | | | |
| P-09620 | 6/30/2014 | 20140629_Daily_HBC_Controls | HBC_MDL00002437 | HBC_MDL00002437 | | | | | | | | | |
| P-09621 | 1/31/2014 | 20140130_Daily_HBC_Controls | HBC_MDL00002459 | HBC_MDL00002459 | | | | | | | | | |
| P-09622 | 4/30/2014 | 20140429_Daily_HBC_Controls | HBC_MDL00002627 | HBC_MDL00002627 | | | | | | | | | |
| P-09625 | 11/13/2008 | HDMA Industry Compliance Guidelines | CAH_MDL2804_00988432 | CAH_MDL2804_00988472 | | | | | | | | | |
| P-09626 | 11/30/2013 | 20131129_Daily_HBC_Controls | HBC_MDL00002646 | HBC_MDL00002646 | | | | | | | | | |
| P-09627 | 9/30/2014 | 20140929_Daily_HBC_Controls_W7 | HBC_MDL00002700 | HBC_MDL00002700 | | | | | | | | | |
| P-09628 | 2/28/2014 | 20140227_Daily_HBC_Controls | HBC_MDL00002837 | HBC_MDL00002837 | | | | | | | | | |
| P-09632 | 7/31/2014 | 20140730_Daily_HBC_Controls_W7 | HBC_MDL00002843 | HBC_MDL00002843 | | | | | | | | | |
| P-09633 | 10/29/2016 | 20161028_Daily_HBC_Controls_W7 | HBC_MDL00003126 | HBC_MDL00003126 | | | | | | | | | |
| P-09634 | 6/6/2016 | 30-010 - Inventory Control - Suspicious Order Policy FINALx | HBC_MDL00004209 | HBC_MDL00004210 | | | | | | | | | |
| P-09635 | 11/13/2015 | Central Signer Procedures | HBC_MDL00004656 | HBC_MDL00004657 | | | | | | | | | |
| P-09637 | 11/16/2015 | SOM and Controlled drug monitoring | HBC_MDL00004996 | HBC_MDL00004998 | | | | | | | | | |
| P-09639 | 9/28/2015 | Control Blocking Policy and Procedure | HBC_MDL00005466 | HBC_MDL00005467 | | | | | | | | | |
| P-09640 | 11/20/2015 | RE: Existing SOM Related Processes/reports | HBC_MDL00005810 | HBC_MDL00005811 | | | | | | | | | |
| P-09642 | 10/24/2017 | RE: Control Limits | HBC_MDL00009648 | HBC_MDL00009649 | | | | | | | | | |
| P-09643 | 12/5/2016 | Drug Control Program: Weekly Team Meeting | HBC_MDL00010088 | HBC_MDL00010105 | | | | | | | | | |
| P-09646 | 1/20/2017 | CII Thresholds: Expand Pilot 1/24 | HBC_MDL00015121 | HBC_MDL00015124 | | | | | | | | | |
| P-09647 | 11/4/2014 | Pharmacy Quarterly Meeting | HBC_MDL00015549 | HBC_MDL00015608 | | | | | | | | | |
| P-09650 | 11/13/2015 | Notes for Purdue Order Monitoring Systemx | HBC_MDL00028405 | HBC_MDL00028407 | | | | | | | | | |
| P-09651 | 12/2/2015 | Order Monitoring System Policy and procedures | HBC_MDL00028717 | HBC_MDL00028721 | | | | | | | | | |
| P-09652 | 12/15/2015 | FW: DEA Questionnaire | HBC_MDL00029194 | HBC_MDL00029198 | | | | | | | | | |
| P-09653 | 4/14/2016 | RE: USL Questionnaire | HBC_MDL00030064 | HBC_MDL00030069 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-09654 | 3/20/2018 | Rhodes - Distributor Questionnaire and supporting docs | HBC_MDL00030616 | HBC_MDL00030622 | | | | | | | | | |
| P-09655 | 7/7/2013 | Copy of Narcotic Audit Chain Discrepancies Summary_07-01-13.xls | HBC_MDL00032853 | HBC_MDL00032853 | | | | | | | | | |
| P-09656 | 11/4/2013 | Copy of Narcotic Audit Chain Discrepancies Summary_October 2013.xls | HBC_MDL00032878 | HBC_MDL00032878 | | | | | | | | | |
| P-09657 | 6/3/2014 | Pharmacy AOP Follow-Up | HBC_MDL00034114 | HBC_MDL00034149 | | | | | | | | | |
| P-09658 | 10/8/2015 | FW: Giant Eagle First Amendment | HBC_MDL00035614 | HBC_MDL00035624 | | | | | | | | | |
| P-09659 | 1/10/2014 | RE: Daily HBC Suspicious Purchasing Report - 01/09/14 | HBC_MDL00039223 | HBC_MDL00039223 | | | | | | | | | |
| P-09660 | 1/9/2013 | Narcotic Audit Application | HBC_MDL00041837 | HBC_MDL00041850 | | | | | | | | | |
| P-09661 | 9/16/2015 | Thrifty White Controlled Substance Policies | HBC_MDL00042149 | HBC_MDL00042226 | | | | | | | | | |
| P-09662 | 10/8/2012 | Wags- Admin Motion | CAH_MDL2804_01431069 | CAH_MDL2804_01431124 | | | | | | | | | |
| P-09665 | 1/27/2017 | SOM Process - High Level | HBC_MDL00046143 | HBC_MDL00046145 | | | | | | | | | |
| P-09667 | 11/21/2016 | RE: Suspicious Order Monitoring (SOM) | HBC_MDL00046220 | HBC_MDL00046228 | | | | | | | | | |
| P-09669 | 8/7/2014 | Inventory Control Doc | HBC_MDL00052107 | HBC_MDL00052110 | | | | | | | | | |
| P-09670 | 8/31/2015 | FW: Thank You email from Sr. Category Manager Bob McClune to | HBC_MDL00055709 | HBC_MDL00055788 | | | | | | | | | |
| P-09671 | 12/3/2015 | Order Monitoring System Policy and procedures | HBC_MDL00056199 | HBC_MDL00056203 | | | | | | | | | |
| P-09672 | 1/15/2016 | FW: Daily HBC Suspicious Purchasing Report - 01/14/16 | HBC_MDL00057182 | HBC_MDL00057186 | | | | | | | | | |
| P-09673 | 9/23/2015 | RE: Daily HBC Suspicious Purchasing Report - 09/20/15 | HBC_MDL00058099 | HBC_MDL00058100 | | | | | | | | | |
| P-09674 | 8/11/2015 | RE: Procedural Inconsistency | HBC_MDL00063991 | HBC_MDL00063992 | | | | | | | | | |
| P-09675 | 5/1/2012 | FW: 2012 Anda Supply Chain Symposium | HBC_MDL00064379 | HBC_MDL00064441 | | | | | | | | | |
| P-09677 | 3/7/2013 | 2013.03.02 All Inclusive Notes | HBC_MDL00068314 | HBC_MDL00068314 | | | | | | | | | |
| P-09678 | 8/20/2015 | FW: Thrifty White Notes | HBC_MDL00069566 | HBC_MDL00069571 | | | | | | | | | |
| P-09679 | 8/12/2015 | Email FW: VAWD Physical Inspection Preparation | HBC_MDL00076207 | HBC_MDL00076218 | | | | | | | | | |
| P-09681 | 1/21/2016 | DEA notification of suspicious order | HBC_MDL00078018 | HBC_MDL00078020 | | | | | | | | | |
| P-09682 | 4/20/2015 | April Team Leader Call-update | HBC_MDL00078437 | HBC_MDL00078469 | | | | | | | | | |
| P-09684 | 7/22/2013 | GIANT EAGLE CSMP 7/22 | HBC_MDL00079213 | HBC_MDL00079214 | | | | | | | | | |
| P-09685 | 7/17/2013 | Giant Eagle CSMP 07.17.13 | HBC_MDL00079386 | HBC_MDL00079387 | | | | | | | | | |
| P-09686 | 7/18/2013 | Giant Eagle CSMP | HBC_MDL00079491 | HBC_MDL00079492 | | | | | | | | | |
| P-09688 | 7/16/2013 | Giant Eagle CSMP 07.16.13 | HBC_MDL00079510 | HBC_MDL00079511 | | | | | | | | | |
| P-09689 | 10/24/2013 | OARRS HBC Demand Letter | HBC_MDL00081290 | HBC_MDL00081293 | | | | | | | | | |
| P-09690 | 9/21/2016 | Control Substance Monitoring Report - NOT Finalized | HBC_MDL00086620 | HBC_MDL00086621 | | | | | | | | | |
| P-09693 | 8/23/2016 | Emailing: Order_item_Blocking_5 Dec_13x, Suspicious Reporting.sql | HBC_MDL00086642 | HBC_MDL00086644 | | | | | | | | | |
| P-09694 | 1/30/2012 | RE: HBC phone number | HBC_MDL00090001 | HBC_MDL00090004 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-09695 | 7/9/2014 | FW: RX4031 | HBC_MDL00090010 | HBC_MDL00090011 | | | | | | | | | |
| P-09696 | 7/14/2011 | Giant Eagle warehouse (HBC Service Company) Delivery Change | HBC_MDL00090362 | HBC_MDL00090364 | | | | | | | | | |
| P-09697 | 11/16/2015 | RE: Access to Data Warehouse | HBC_MDL00092010 | HBC_MDL00092011 | | | | | | | | | |
| P-09698 | 11/25/2013 | FW: Daily HBC Suspicious Purchasing Report - 11/13/13 | HBC_MDL00094599 | HBC_MDL00094600 | | | | | | | | | |
| P-10039 | 3/30/2015 | CVS Controlled Substance & DEA List Chemical Order Monitoring Dress; DOC-047162 | CVS-MDLT1-000000001 | CVS-MDLT1-000000005 | | | | | | | | | |
| P-10040 | 6/23/2014 | SOM work instructions DC | CVS-MDLT1-000000298 | CVS-MDLT1-000000303 | | | | | | | | | |
| P-10041 | 8/9/2013 | RE: SOM training | CVS-MDLT1-000000397 | CVS-MDLT1-000000397 | | | | | | | | | |
| P-10042 | 11/21/2013 | Email Closing Meeting; Attachments Letter to Mr. Gillen November 21, 2013; Definition of Metrics for SOM analysis; SOM SOP v 3; Stopped orders; NEJM abusive prescribing cvs data | CVS-MDLT1-000000409 | CVS-MDLT1-000000420 | | | | | | | | | |
| P-10043 | 11/25/2013 | Re: Closing meeting | CVS-MDLT1-000000421 | CVS-MDLT1-000000422 | | | | | | | | | |
| P-10044 | 8/22/2014 | Re: Breaking News: DEA rules to reschedule Hydrocodone | CVS-MDLT1-000000437 | CVS-MDLT1-000000438 | | | | | | | | | |
| P-10045 | 1/9/2014 | FW: 2013 Logistics Planning Initiatives | CVS-MDLT1-000000459 | CVS-MDLT1-000000459 | | | | | | | | | |
| P-10046 | 1/8/2014 | Suspicious Orders eBook Part 2 | CVS-MDLT1-000002173 | CVS-MDLT1-000002194 | | | | | | | | | |
| P-10047 | 8/24/2014 | Hydrocodone Rescheduling | CVS-MDLT1-000000717 | CVS-MDLT1-000001054 | | | | | | | | | |
| P-10048 | 2/17/2014 | Dean_Logistics Planning 021714 | CVS-MDLT1-000002296 | CVS-MDLT1-000002309 | | | | | | | | | |
| P-10049 | 9/29/2014 | Email: Hydrocodone - DC Return Process | CVS-MDLT1-000001069 | CVS-MDLT1-000001074 | | | | | | | | | |
| P-10050 | 8/6/2013 | SOM work instructions | CVS-MDLT1-000003020 | CVS-MDLT1-000003025 | | | | | | | | | |
| P-10052 | 8/26/2014 | RE: DEA to Publish Final Rule Rescheduling Hydrocodone Combination Products | CVS-MDLT1-000003065 | CVS-MDLT1-000003066 | | | | | | | | | |
| P-10053 | 8/21/2014 | DEA to Publish Final Rule Rescheduling Hydrocodone Combination Products | CVS-MDLT1-000003069 | CVS-MDLT1-000003071 | | | | | | | | | |
| P-10054 | 8/22/2014 | RE: BREAKING NEWS: DEA issues final rule on the rescheduling of HCPs | CVS-MDLT1-000003076 | CVS-MDLT1-000003077 | | | | | | | | | |
| P-10055 | 8/15/2018 | Email Control IRR dated 12/23/12 stores | CVS-MDLT1-000003166 | CVS-MDLT1-000003169 | | | | | | | | | |
| P-10056 | 5/6/2011 | DEA SOP 06-19-22 | CVS-MDLT1-000003177 | CVS-MDLT1-000003242 | | | | | | | | | |
| P-10057 | 2/7/2014 | Irregular Order - Logistics Communication | CVS-MDLT1-000003346 | CVS-MDLT1-000003347 | | | | | | | | | |
| P-10058 | 2/10/2013 | Irregular Order - Logistics Communication | CVS-MDLT1-000003348 | CVS-MDLT1-000003349 | | | | | | | | | |
| P-10059 | 3/14/2014 | FW: Controlled Substance Documents | CVS-MDLT1-000003749 | CVS-MDLT1-000003781 | | | | | | | | | |
| P-10060 | 9/12/2018 | PRODUCTION_Shipment_Data_Extract_20180912 | CVS-MDLT1-000003782 | CVS-MDLT1-000003782 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10061 | 9/12/2018 | PRODUCTION_Shipment_Data_Store_Detail_20180912 | CVS-MDLT1-000007362 | CVS-MDLT1-000007364 | | | | | | | | | |
| P-10062 | 9/29/2013 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000010918 | CVS-MDLT1-000011219 | | | | | | | | | |
| P-10063 | 1/2/2013 | Chart: Control IRR_12 31 12 | CVS-MDLT1-000007621 | CVS-MDLT1-000007766 | | | | | | | | | |
| P-10064 | 12/31/2015 | Signed LOA CVS INDIANA (2) | CVS-MDLT1-000008014 | CVS-MDLT1-000008015 | | | | | | | | | |
| P-10065 | 1/26/2016 | Indy SOM letter | CVS-MDLT1-000008016 | CVS-MDLT1-000008018 | | | | | | | | | |
| P-10066 | 9/7/2012 | Required Headcount to Complete IRR SOM Process | CVS-MDLT1-000008248 | CVS-MDLT1-000008249 | | | | | | | | | |
| P-10070 | 8/9/2013 | DEA Regulatory Inspection 2013 | CVS-MDLT1-000008389 | CVS-MDLT1-000008395 | | | | | | | | | |
| P-10071 | 3/11/2011 | CVS Distributor Standard Operating Procedures | CVS-MDLT1-000008413 | CVS-MDLT1-000008482 | | | | | | | | | |
| P-10072 | 12/10/2013 | Email: Control/PSE IRR date 12/9/13 store 4101; Store 6813 IN | CVS-MDLT1-000008483 | CVS-MDLT1-000008487 | | | | | | | | | |
| P-10073 | 2/7/2014 | Email re: Control PSE IRR | CVS-MDLT1-000008496 | CVS-MDLT1-000008499 | | | | | | | | | |
| P-10074 | 3/21/2012 | DEA SOP 11-08-11 | CVS-MDLT1-000008506 | CVS-MDLT1-000008571 | | | | | | | | | |
| P-10075 | 9/5/2013 | DEA SOP 09-05-13 | CVS-MDLT1-000008572 | CVS-MDLT1-000008635 | | | | | | | | | |
| P-10076 | 5/3/2011 | DEA SOP 05-03-11 | CVS-MDLT1-000008898 | CVS-MDLT1-000008963 | | | | | | | | | |
| P-10077 | 8/26/2010 | DEA SOP 08-25-10 | CVS-MDLT1-000008964 | CVS-MDLT1-000009032 | | | | | | | | | |
| P-10078 | 11/29/2010 | DEA SOP 11-29-10 | CVS-MDLT1-000009033 | CVS-MDLT1-000009100 | | | | | | | | | |
| P-10079 | 8/19/2009 | DEA SOP 8-18-09 | CVS-MDLT1-000009167 | CVS-MDLT1-000009237 | | | | | | | | | |
| P-10080 | 6/10/2013 | Email SOM | CVS-MDLT1-000009678 | CVS-MDLT1-000009678 | | | | | | | | | |
| P-10081 | 6/11/2013 | Email FW: Kelly Baker | CVS-MDLT1-000009683 | CVS-MDLT1-000009683 | | | | | | | | | |
| P-10082 | 7/2/2012 | IRR PSE CONTROL RECAP (5) | CVS-MDLT1-000009689 | CVS-MDLT1-000009798 | | | | | | | | | |
| P-10083 | 10/11/2012 | Loss Prevention Analyst - Job Description / Work Instruction; Revised PSE Control Drug SOP - 2; Work Instruction - Loss Prevention Analyst | CVS-MDLT1-000009810 | CVS-MDLT1-000009818 | | | | | | | | | |
| P-10086 | 8/29/2013 | FW: The Pharma Compliance Group - Follow up to NACDS Meeting | CVS-MDLT1-000009821 | CVS-MDLT1-000009847 | | | | | | | | | |
| P-10087 | 3/13/2013 | Training for Archer - SOM | CVS-MDLT1-000009848 | CVS-MDLT1-000009855 | | | | | | | | | |
| P-10088 | 8/22/2014 | Distribution Center Loss Prevention Procedures - CVS DEA Distributor SOP[1] | CVS-MDLT1-000010125 | CVS-MDLT1-000010179 | | | | | | | | | |
| P-10089 | 11/21/2013 | FW: Closing meeting SecureMail; Letter to Mr. Gillen November 21, 2013; Definition of Metrics for SOM analysis; SOM SOP v 3; NEJM abusive prescribing cvs data | CVS-MDLT1-000010201 | CVS-MDLT1-000010212 | | | | | | | | | |
| P-10094 | 7/11/2014 | Email SOM Due Diligence SOP 022414v1 | CVS-MDLT1-000010213 | CVS-MDLT1-000010218 | | | | | | | | | |
| P-10095 | 8/27/2010 | RE: DEA day 3 | CVS-MDLT1-000010223 | CVS-MDLT1-000010224 | | | | | | | | | |
| P-10096 | 3/26/2014 | IRR Control_PSE RECAP for 2014 (version 1) | CVS-MDLT1-000010235 | CVS-MDLT1-000010267 | | | | | | | | | |
| P-10097 | 2/6/2014 | IRR Control_PSE RECAP for 2013 | CVS-MDLT1-000010268 | CVS-MDLT1-000010521 | | | | | | | | | |
| P-10098 | 8/5/2013 | DEA Notice of Inspection; DEA Visit Regulatory Visit Notes | CVS-MDLT1-000010522 | CVS-MDLT1-000010532 | | | | | | | | | |

| | | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|--|
| P-10099 | 2/10/2016 | DEA Pharmacist's Manual | HBC_MDL00126694 | HBC_MDL00126779 | | | | | | | | | | |
| P-10100 | 8/24/2010 | Results of DEA Inspection | CVS-MDLT1-000010542 | CVS-MDLT1-000010543 | | | | | | | | | | |
| P-10101 | 9/27/2006 | DEA Letter | CVS-MDLT1-000010552 | CVS-MDLT1-000010555 | | | | | | | | | | |
| P-10102 | 8/29/2013 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000010672 | CVS-MDLT1-000010757 | | | | | | | | | | |
| P-10103 | 12/28/2012 | Spreadsheet: Item Review Report | CVS-MDLT1-000011359 | CVS-MDLT1-000011442 | | | | | | | | | | |
| P-10104 | 12/26/2011 | IRR bullet points | CVS-MDLT1-000012286 | CVS-MDLT1-000012298 | | | | | | | | | | |
| P-10105 | 8/18/2013 | SOM update | CVS-MDLT1-000012363 | CVS-MDLT1-000012363 | | | | | | | | | | |
| P-10106 | 1/14/2014 | SOM Communications from DEA | CVS-MDLT1-000013534 | CVS-MDLT1-000013537 | | | | | | | | | | |
| P-10107 | 9/2/2015 | RE: Vault / Refrigeration | HBC_MDL00127457 | HBC_MDL00127460 | | | | | | | | | | |
| P-10108 | 8/26/2014 | SOM Due Diligence questions | CVS-MDLT1-000014197 | CVS-MDLT1-000014199 | | | | | | | | | | |
| P-10109 | 6/10/2013 | Email SOM Team | CVS-MDLT1-000014750 | CVS-MDLT1-000014750 | | | | | | | | | | |
| P-10110 | 3/14/2014 | RX Abuse Epidemic Pres-Customer Version 2-4-14 - FINALx | CVS-MDLT1-000015499 | CVS-MDLT1-000015531 | | | | | | | | | | |
| P-10111 | 7/18/2011 | Email: re: DEA License | CVS-MDLT1-000017100 | CVS-MDLT1-000017101 | | | | | | | | | | |
| P-10112 | 3/14/2014 | RE: Nightly Front Store Order Files | CVS-MDLT1-000017246 | CVS-MDLT1-000017246 | | | | | | | | | | |
| P-10113 | 9/27/2013 | Email RE: SOM | CVS-MDLT1-000017250 | CVS-MDLT1-000017250 | | | | | | | | | | |
| P-10114 | 11/13/2013 | RE: request 26725 | CVS-MDLT1-000017255 | CVS-MDLT1-000017258 | | | | | | | | | | |
| P-10115 | 8/19/2013 | FW: SOM update | CVS-MDLT1-000018729 | CVS-MDLT1-000018730 | | | | | | | | | | |
| P-10116 | 2/3/2011 | 2011 Logistics Initiatives | CVS-MDLT1-000018910 | CVS-MDLT1-000018945 | | | | | | | | | | |
| P-10117 | 8/23/2012 | 800133_Automated DC Compliance Training_July 2012 | CVS-MDLT1-000019005 | CVS-MDLT1-000019059 | | | | | | | | | | |
| P-10118 | 6/8/2012 | FW: Top 10 Report Review | CVS-MDLT1-000019491 | CVS-MDLT1-000019680 | | | | | | | | | | |
| P-10119 | 9/25/2014 | EMAILS SENT 4-28 and 8-28 VAWD accreditation package | HBC_MDL00128238 | HBC_MDL00128260 | | | | | | | | | | |
| P-10120 | 5/31/2012 | RE: Control/ PSE IRR dated 5/30/12 | CVS-MDLT1-000019682 | CVS-MDLT1-000019683 | | | | | | | | | | |
| P-10121 | 6/2/2015 | RX-001 CVS DC Controlled Drug | CVS-MDLT1-000019722 | CVS-MDLT1-000019786 | | | | | | | | | | |
| P-10122 | 9/15/2014 | Logistics Planning 091514 | CVS-MDLT1-000019834 | CVS-MDLT1-000019838 | | | | | | | | | | |
| P-10123 | 3/14/2012 | IRR PSE CONTROL RECAP | CVS-MDLT1-000020379 | CVS-MDLT1-000020421 | | | | | | | | | | |
| P-10124 | 3/27/2012 | Item Review Report | CVS-MDLT1-000012194 | CVS-MDLT1-000012275 | | | | | | | | | | |
| P-10125 | 3/26/2012 | Work Instruction - Loss Prevention Analyst | CVS-MDLT1-000020425 | CVS-MDLT1-000020433 | | | | | | | | | | |
| P-10126 | 8/26/2011 | DEA SOP 03-11-11 | CVS-MDLT1-000021017 | CVS-MDLT1-000021083 | | | | | | | | | | |
| P-10127 | 10/3/2013 | Email Fw: SOM Positions | CVS-MDLT1-000022055 | CVS-MDLT1-000022061 | | | | | | | | | | |
| P-10128 | 5/15/2014 | DEA closing audit | CVS-MDLT1-000022230 | CVS-MDLT1-000022231 | | | | | | | | | | |
| P-10129 | 11/15/2013 | RE: Closing audit | CVS-MDLT1-000022277 | CVS-MDLT1-000022277 | | | | | | | | | | |
| P-10130 | 11/14/2013 | Closing audit | CVS-MDLT1-000022284 | CVS-MDLT1-000022284 | | | | | | | | | | |
| P-10131 | 5/8/2013 | Email Staff Meeting Update - Logistics Planning | CVS-MDLT1-000022896 | CVS-MDLT1-000022899 | | | | | | | | | | |
| P-10132 | 3/8/2013 | SOM GPS Goal | CVS-MDLT1-000022922 | CVS-MDLT1-000022922 | | | | | | | | | | |
| P-10133 | 3/29/2011 | FW: Attachments for SOM Meeting - possible changes to Report BIP006A | CVS-MDLT1-000024494 | CVS-MDLT1-000024510 | | | | | | | | | | |
| P-10134 | 7/21/2009 | RE Pharmacy controllable substance location.rtf | HBC_MDL00128697 | HBC_MDL00128697 | | | | | | | | | | |
| P-10135 | 3/21/2011 | RE: SOM Modifications | CVS-MDLT1-000024523 | CVS-MDLT1-000024524 | | | | | | | | | | |
| P-10136 | 11/21/2011 | Control Drug IRR Implementation.rtf | CVS-MDLT1-000024538 | CVS-MDLT1-000024552 | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10137 | 2/6/2012 | Revised PSE Control Drug SOP (7) (2) | CVS-MDLT1-000024620 | CVS-MDLT1-000024625 | | | | | | | | | |
| P-10138 | 1/3/2012 | Revised PSE Control Drug SOP (6) (2) | CVS-MDLT1-000024632 | CVS-MDLT1-000024639 | | | | | | | | | |
| P-10141 | 10/18/2010 | Posted DEA SOP | CVS-MDLT1-000024807 | CVS-MDLT1-000024941 | | | | | | | | | |
| P-10142 | 10/2/2012 | Revised PSE Control Drug SOP - 2 | CVS-MDLT1-000025017 | CVS-MDLT1-000025021 | | | | | | | | | |
| P-10143 | 1/23/2013 | Stop Order_Order Resumption - 01 21 13 | CVS-MDLT1-000025127 | CVS-MDLT1-000025131 | | | | | | | | | |
| P-10144 | 1/3/2008 | Email New RX DEA SOP; CVS 7th draft - November, 2007 | CVS-MDLT1-000025204 | CVS-MDLT1-000025259 | | | | | | | | | |
| P-10145 | 10/27/2009 | FW reporting.rtf | HBC_MDL00128698 | HBC_MDL00128698 | | | | | | | | | |
| P-10146 | 1/23/2013 | FW: Stop Order_Order Resumption - 01 10 13x | CVS-MDLT1-000025365 | CVS-MDLT1-000025369 | | | | | | | | | |
| P-10147 | 11/23/2016 | Master Agreement - SupplyLogix - Amendment 1 - Eff 9.30.14 | HBC_MDL00132477 | HBC_MDL00132479 | | | | | | | | | |
| P-10148 | 7/28/2014 | SOM SOP v 3 | CVS-MDLT1-000025546 | CVS-MDLT1-000025551 | | | | | | | | | |
| P-10149 | 2/4/2013 | Updated CVS SOM Data Request - 4 FEB 2013 | CVS-MDLT1-000028141 | CVS-MDLT1-000028147 | | | | | | | | | |
| P-10150 | 11/16/2014 | Suspicious Order Monitoring Summary | HBC_MDL00132616 | HBC_MDL00132616 | | | | | | | | | |
| P-10151 | 7/16/2013 | FW: Archer SOM User Acceptance Testing | CVS-MDLT1-000028615 | CVS-MDLT1-000028617 | | | | | | | | | |
| P-10152 | 7/18/2013 | RE: Archer SOM - UAT COMPLETE | CVS-MDLT1-000029478 | CVS-MDLT1-000029479 | | | | | | | | | |
| P-10153 | 4/29/2011 | Logistics Business Support Requests - 2011-04-28 | CVS-MDLT1-000029864 | CVS-MDLT1-000029866 | | | | | | | | | |
| P-10154 | 1/7/2013 | Email: Attorney Client Privilege - Stop Order_Order Resumption - 01.07.13 | CVS-MDLT1-000028390 | CVS-MDLT1-000028393 | | | | | | | | | |
| P-10155 | 11/27/2012 | Email SOM Meeting - 11/27 | CVS-MDLT1-000029867 | CVS-MDLT1-000029870 | | | | | | | | | |
| P-10156 | 5/25/2011 | FW: Logistics Business Support Requests - 2011-04-28 | CVS-MDLT1-000029877 | CVS-MDLT1-000029880 | | | | | | | | | |
| P-10157 | 11/28/2012 | Required Headcount to Complete IRR SOM Process 11-27-12 | CVS-MDLT1-000029883 | CVS-MDLT1-000029884 | | | | | | | | | |
| P-10158 | 6/11/2014 | Project Update 061614 | CVS-MDLT1-000030176 | CVS-MDLT1-000030177 | | | | | | | | | |
| P-10159 | 4/1/2013 | Proposal 2013 04 01- Preliminary SOM Size Tests | CVS-MDLT1-000030208 | CVS-MDLT1-000030219 | | | | | | | | | |
| P-10160 | 7/1/2013 | SOM Process SO 070113 | CVS-MDLT1-000030237 | CVS-MDLT1-000030241 | | | | | | | | | |
| P-10161 | 3/8/2013 | SOM Due Diligence SOP 3 5 13 (2) | CVS-MDLT1-000030353 | CVS-MDLT1-000030358 | | | | | | | | | |
| P-10162 | 2/26/2013 | SOM Due Diligence SOP | CVS-MDLT1-000030452 | CVS-MDLT1-000030456 | | | | | | | | | |
| P-10163 | 6/10/2013 | Email FW: IS High level milestones and Risks | CVS-MDLT1-000030472 | CVS-MDLT1-000030473 | | | | | | | | | |
| P-10164 | 2/7/2013 | Irregular Order - Logistics Communication 1 8 13; Irregular Order - DC Communication Indianapolis IRR dated 11-18-12 store 7045 | CVS-MDLT1-000030478 | CVS-MDLT1-000030490 | | | | | | | | | |
| P-10165 | 12/5/2013 | 2401 | HBC_MDL00132815 | HBC_MDL00132816 | | | | | | | | | |
| P-10166 | 10/13/2014 | FW: Items for NABP | HBC_MDL00132908 | HBC_MDL00132924 | | | | | | | | | |
| P-10167 | 9/23/2010 | IDC ORG CHART 09_21_10. | CVS-MDLT1-000030733 | CVS-MDLT1-000030733 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10169 | 7/1/2009 | Wholesale Supply Agreement | CVS-MDLT1-000030817 | CVS-MDLT1-000030891 | | | | | | | | | |
| P-10170 | 1/1/2004 | Wholesale Supply Agreement | CVS-MDLT1-000030892 | CVS-MDLT1-000030970 | | | | | | | | | |
| P-10171 | 7/26/2012 | RE: Ratio Calculation | CVS-MDLT1-000031518 | CVS-MDLT1-000031863 | | | | | | | | | |
| P-10172 | 3/30/2011 | SOM - Reporting | CVS-MDLT1-000033126 | CVS-MDLT1-000033187 | | | | | | | | | |
| P-10173 | 10/10/2012 | Justification (2) | CVS-MDLT1-000033498 | CVS-MDLT1-000033499 | | | | | | | | | |
| P-10174 | 10/10/2012 | Justification | CVS-MDLT1-000033573 | CVS-MDLT1-000033573 | | | | | | | | | |
| P-10175 | 10/8/2012 | FW: Conference Call Notes - 10 5 12 | CVS-MDLT1-000033579 | CVS-MDLT1-000033581 | | | | | | | | | |
| P-10176 | 4/4/2013 | Email: Attorney Client Privilege - SOM SOP's; Stop Order_Order Resumption - 03 28 13 | CVS-MDLT1-000030545 | CVS-MDLT1-000030552 | | | | | | | | | |
| P-10177 | 10/14/2010 | FW: New BSR - Control Drug IRR Changes | CVS-MDLT1-000034168 | CVS-MDLT1-000034171 | | | | | | | | | |
| P-10178 | 5/16/2011 | Email: Control Drug IRR with Control Drug IRR | CVS-MDLT1-000034182 | CVS-MDLT1-000034183 | | | | | | | | | |
| P-10179 | 5/19/2009 | FW: Updated DEA SOP | CVS-MDLT1-000034234 | CVS-MDLT1-000034300 | | | | | | | | | |
| P-10180 | 9/18/2008 | FW: Control Work Instructions | CVS-MDLT1-000034374 | CVS-MDLT1-000034414 | | | | | | | | | |
| P-10181 | 8/16/2012 | Email: Privileged and Confidential: Updated SOM cutoffs | CVS-MDLT1-000033808 | CVS-MDLT1-000033911 | | | | | | | | | |
| P-10182 | 5/1/2007 | CVS-1st Draft | CVS-MDLT1-000034450 | CVS-MDLT1-000034501 | | | | | | | | | |
| P-10183 | 1/13/2014 | Email: 4189_30JAN2014_HYDRO_NSYSR | CVS-MDLT1-000059484 | CVS-MDLT1-000059485 | | | | | | | | | |
| P-10184 | 6/3/2014 | Project Update 060614 | CVS-MDLT1-000039934 | CVS-MDLT1-000039936 | | | | | | | | | |
| P-10185 | 7/9/2013 | RE: Archer SOM | CVS-MDLT1-000051586 | CVS-MDLT1-000051588 | | | | | | | | | |
| P-10186 | 5/8/2013 | RE: DEA Letter | CVS-MDLT1-000055266 | CVS-MDLT1-000055268 | | | | | | | | | |
| P-10187 | 4/26/2013 | RE: Order Flagging Reasons | CVS-MDLT1-000055291 | CVS-MDLT1-000055294 | | | | | | | | | |
| P-10188 | 3/3/2014 | SOM Due Diligence SOP 022414v1 | CVS-MDLT1-000055298 | CVS-MDLT1-000055302 | | | | | | | | | |
| P-10189 | 7/25/2018 | January 9, 2014 BOD Minutes | CVS-MDLT1-000055303 | CVS-MDLT1-000055352 | | | | | | | | | |
| P-10190 | 7/20/2012 | Email: Test BIP006A Report | CVS-MDLT1-000064377 | CVS-MDLT1-000065247 | | | | | | | | | |
| P-10191 | 11/11/2012 | RE: Recap progress made | CVS-MDLT1-000055834 | CVS-MDLT1-000055835 | | | | | | | | | |
| P-10192 | 7/2/2010 | Email: BIP006A, CNTRL_DRUG_SOM_RPT_SCORE 0.65 | CVS-MDLT1-000088410 | CVS-MDLT1-000088515 | | | | | | | | | |
| P-10193 | 4/9/2012 | Spreadsheet of Suspicious Orders | CVS-MDLT1-000056057 | CVS-MDLT1-000056938 | | | | | | | | | |
| P-10194 | 5/5/2015 | RE: McKesson DEA Investigation Outcome | HBC_MDL00133464 | HBC_MDL00133465 | | | | | | | | | |
| P-10195 | 5/16/2011 | Control Drug Suspicious Order Monitoring | CVS-MDLT1-000057736 | CVS-MDLT1-000057738 | | | | | | | | | |
| P-10196 | 8/26/2014 | SOM Due Diligence questions | CVS-MDLT1-000057741 | CVS-MDLT1-000057743 | | | | | | | | | |
| P-10198 | 8/25/2010 | Control Drug IRR SOP | CVS-MDLT1-000057751 | CVS-MDLT1-000057754 | | | | | | | | | |
| P-10199 | 3/14/2011 | RE: IRR/SOM Retunement BSR_LOG_61148 | CVS-MDLT1-000057759 | CVS-MDLT1-000057759 | | | | | | | | | |
| P-10200 | 7/23/2013 | RE: SOM to WN | CVS-MDLT1-000057777 | CVS-MDLT1-000057777 | | | | | | | | | |
| P-10201 | 5/20/2013 | RE: July Issue - Logistics Insider | CVS-MDLT1-000057783 | CVS-MDLT1-000057784 | | | | | | | | | |
| P-10202 | 1/24/2013 | Email on Various Projects | CVS-MDLT1-000057796 | CVS-MDLT1-000057797 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10203 | 11/26/2012 | SOM System End State Solution | CVS-MDLT1-000058034 | CVS-MDLT1-000058037 | | | | | | | | | |
| P-10204 | 1/23/2011 | CVS Item Review Report - Control Drugs, see 1031-1032, 1036 | CVS-MDLT1-000101022 | CVS-MDLT1-000101057 | | | | | | | | | |
| P-10205 | 11/20/2013 | SOM SOP | CVS-MDLT1-000058093 | CVS-MDLT1-000058093 | | | | | | | | | |
| P-10206 | 3/25/2013 | Project Update 032613 | CVS-MDLT1-000058175 | CVS-MDLT1-000058177 | | | | | | | | | |
| P-10207 | 2/3/2014 | RE: SOM Go Live | CVS-MDLT1-000059258 | CVS-MDLT1-000059258 | | | | | | | | | |
| P-10208 | 10/25/2018 | Settlement Agreement CVS-Calera- All Signatures Included (00468466) | CVS-MDLT1-000060812 | CVS-MDLT1-000060821 | | | | | | | | | |
| P-10209 | 3/28/2013 | CVS Oklahoma Settlement Agreement - signed | CVS-MDLT1-000060822 | CVS-MDLT1-000060829 | | | | | | | | | |
| P-10210 | 10/25/2018 | CVS entered into a settlement agreement with the USAO for the District of Connecticut for \$600,000.00 | CVS-MDLT1-000060830 | CVS-MDLT1-000060838 | | | | | | | | | |
| P-10211 | 6/15/2018 | CVS signed agreement | CVS-MDLT1-000060839 | CVS-MDLT1-000060846 | | | | | | | | | |
| P-10212 | 8/7/2015 | CVS Settlement Agreement | CVS-MDLT1-000060847 | CVS-MDLT1-000060855 | | | | | | | | | |
| P-10213 | 6/30/2016 | CVS Fully Executed Settlement Agreement w Attachments | CVS-MDLT1-000060872 | CVS-MDLT1-000060906 | | | | | | | | | |
| P-10214 | 9/2/2014 | CVS Settlement agreement with the USAO for the Southern District of Texas for \$1,912,500.00 | CVS-MDLT1-000060907 | CVS-MDLT1-000060914 | | | | | | | | | |
| P-10215 | 12/18/2015 | Stipulated Agreement - Fully Executed | CVS-MDLT1-000060915 | CVS-MDLT1-000060921 | | | | | | | | | |
| P-10216 | 11/10/2009 | Logistics Update 11-9-2009 | CVS-MDLT1-000061097 | CVS-MDLT1-000061097 | | | | | | | | | |
| P-10217 | 8/16/2009 | Regulatory update 8-19-2009 | CVS-MDLT1-000061121 | CVS-MDLT1-000061128 | | | | | | | | | |
| P-10218 | 9/2/2010 | FW: Indianapolis DEA Visit | CVS-MDLT1-000061132 | CVS-MDLT1-000061134 | | | | | | | | | |
| P-10219 | 2/9/2011 | FW: The CVS Retunement | CVS-MDLT1-000061141 | CVS-MDLT1-000061154 | | | | | | | | | |
| P-10220 | 8/27/2010 | DEA Speaking Points IRR | CVS-MDLT1-000061190 | CVS-MDLT1-000061203 | | | | | | | | | |
| P-10221 | 4/16/2018 | DEA Regulatory Inspection 2013 | CVS-MDLT1-000061229 | CVS-MDLT1-000061236 | | | | | | | | | |
| P-10222 | 8/7/2013 | DEA Visit 8-5-13 | CVS-MDLT1-000061606 | CVS-MDLT1-000061607 | | | | | | | | | |
| P-10223 | 8/28/2007 | CVS 3rd draft Distribution Centers Controlled Drug - DEA Standard Operating Procedures Manual | CVS-MDLT1-000061732 | CVS-MDLT1-000061787 | | | | | | | | | |
| P-10224 | 9/21/2007 | CVS 5th draft Distribution Centers Controlled Drug - DEA Standard Operating Procedures Manual | CVS-MDLT1-000062277 | CVS-MDLT1-000062330 | | | | | | | | | |
| P-10225 | 2/5/2009 | Final DEA SOP | CVS-MDLT1-000062393 | CVS-MDLT1-000062464 | | | | | | | | | |
| P-10228 | 4/13/2009 | RX DEA SOP 4-1-09 | CVS-MDLT1-000062954 | CVS-MDLT1-000063020 | | | | | | | | | |
| P-10229 | 5/18/2009 | RX DEA SOP 5-18-09 | CVS-MDLT1-000063021 | CVS-MDLT1-000063085 | | | | | | | | | |
| P-10231 | 9/1/2010 | FW: DEA Speaking Points | CVS-MDLT1-000064114 | CVS-MDLT1-000064127 | | | | | | | | | |
| P-10232 | 6/20/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 6 19 12 | CVS-MDLT1-000112646 | CVS-MDLT1-000112647 | | | | | | | | | |
| P-10233 | 6/6/2008 | DEA SOP 2008 | CVS-MDLT1-000066035 | CVS-MDLT1-000066105 | | | | | | | | | |
| P-10235 | 12/8/2009 | DEA SOP 12-8-09 | CVS-MDLT1-000066379 | CVS-MDLT1-000066444 | | | | | | | | | |
| P-10236 | 4/3/2009 | Email FW: Updated DEA SOP | CVS-MDLT1-000066574 | CVS-MDLT1-000066641 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10237 | 6/14/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 6 13 12 | CVS-MDLT1-000112659 | CVS-MDLT1-000112667 | | | | | | | | | |
| P-10238 | 8/22/2014 | CVS Caremark Daily News: Friday, August 22, 2014 | CVS-MDLT1-000066939 | CVS-MDLT1-000066955 | | | | | | | | | |
| P-10239 | 10/6/2010 | FW: VAWD items; CVS Indianapolis Review Report | CVS-MDLT1-000066963 | CVS-MDLT1-000066976 | | | | | | | | | |
| P-10240 | 4/10/2015 | FW: HBC VAWD Application and Documents, Part 2 | HBC_MDL00133670 | HBC_MDL00133673 | | | | | | | | | |
| P-10241 | 10/22/2018 | VIPERx PDMMR - Supplemental | CVS-MDLT1-000067863 | CVS-MDLT1-000067921 | | | | | | | | | |
| P-10244 | 2/4/2011 | High Priority October 21-January 22 | CVS-MDLT1-000074450 | CVS-MDLT1-000074454 | | | | | | | | | |
| P-10245 | 9/1/2010 | FW: DEA Speaking Points | CVS-MDLT1-000075299 | CVS-MDLT1-000075312 | | | | | | | | | |
| P-10246 | 6/25/2012 | Email: LP Analyst Time Study | CVS-MDLT1-000112668 | CVS-MDLT1-000112669 | | | | | | | | | |
| P-10247 | 10/12/2010 | Email RE: VBDC question | CVS-MDLT1-000075542 | CVS-MDLT1-000075547 | | | | | | | | | |
| P-10248 | 2/15/2011 | Email IRR PPoint DEA Presentation follow up | CVS-MDLT1-000075564 | CVS-MDLT1-000075564 | | | | | | | | | |
| P-10249 | 8/12/2013 | FW: Irregular Order - DC Communication Knoxville IRR dated 08-11-13 store 4376 Privileged & Confidential | CVS-MDLT1-000076095 | CVS-MDLT1-000076096 | | | | | | | | | |
| P-10250 | 3/5/2014 | FW: Nicastro GPS | CVS-MDLT1-000076100 | CVS-MDLT1-000076107 | | | | | | | | | |
| P-10251 | 7/17/2013 | FW: Archer SOM | CVS-MDLT1-000076114 | CVS-MDLT1-000076117 | | | | | | | | | |
| P-10252 | 9/19/2013 | SOM Process - 05 07 13 | CVS-MDLT1-000076118 | CVS-MDLT1-000076123 | | | | | | | | | |
| P-10253 | 11/21/2013 | DEA letter | CVS-MDLT1-000076127 | CVS-MDLT1-000076134 | | | | | | | | | |
| P-10254 | 11/25/2013 | CVS Store # 06880 & 6757 | CVS-MDLT1-000076135 | CVS-MDLT1-000076135 | | | | | | | | | |
| P-10255 | 11/21/2013 | FW: SOM Process - 05 07 13 | CVS-MDLT1-000076136 | CVS-MDLT1-000076141 | | | | | | | | | |
| P-10256 | 11/19/2013 | Attorney Privileged and confidential | CVS-MDLT1-000076142 | CVS-MDLT1-000076145 | | | | | | | | | |
| P-10257 | 3/20/2014 | FW: List of store numbers | CVS-MDLT1-000076146 | CVS-MDLT1-000076148 | | | | | | | | | |
| P-10259 | 1/5/2011 | Email FW: DEA Response Letter | CVS-MDLT1-000076236 | CVS-MDLT1-000076238 | | | | | | | | | |
| P-10260 | 8/24/2010 | RE: DEA Audit Indy | CVS-MDLT1-000076281 | CVS-MDLT1-000076281 | | | | | | | | | |
| P-10262 | 9/2/2010 | Email re: Indianapolis DEA Visit | CVS-MDLT1-000076283 | CVS-MDLT1-000076285 | | | | | | | | | |
| P-10263 | 7/5/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 7 3 12 | CVS-MDLT1-000112672 | CVS-MDLT1-000112673 | | | | | | | | | |
| P-10264 | 4/15/2011 | PSE or Controls (CSA) | CVS-MDLT1-000076286 | CVS-MDLT1-000076352 | | | | | | | | | |
| P-10265 | 2/4/2011 | Email 2011 Logistics Initiatives | CVS-MDLT1-000076353 | CVS-MDLT1-000076389 | | | | | | | | | |
| P-10266 | 7/16/2013 | RE: Archer SOM User Acceptance Testing | CVS-MDLT1-000077910 | CVS-MDLT1-000077911 | | | | | | | | | |
| P-10267 | 7/10/2013 | FW: Archer SOM | CVS-MDLT1-000077942 | CVS-MDLT1-000077945 | | | | | | | | | |
| P-10268 | 7/9/2013 | RE: Archer SOM | CVS-MDLT1-000077946 | CVS-MDLT1-000077948 | | | | | | | | | |
| P-10269 | 7/23/2013 | RE: Interaction SD3873373 has been opened for you | CVS-MDLT1-000077953 | CVS-MDLT1-000077954 | | | | | | | | | |
| P-10270 | 7/17/2013 | RE: Archer SOM User Acceptance Testing | CVS-MDLT1-000077973 | CVS-MDLT1-000077974 | | | | | | | | | |
| P-10271 | 1/15/2014 | SOM Presentation 1-16-14 | CVS-MDLT1-000078028 | CVS-MDLT1-000078037 | | | | | | | | | |
| P-10272 | 12/13/2012 | Flagged Orders | CVS-MDLT1-000078045 | CVS-MDLT1-000078047 | | | | | | | | | |
| P-10273 | 7/16/2013 | FW: Archer SOM | CVS-MDLT1-000078116 | CVS-MDLT1-000078119 | | | | | | | | | |
| P-10274 | 7/9/2013 | Re: Archer SOM | CVS-MDLT1-000078127 | CVS-MDLT1-000078129 | | | | | | | | | |
| P-10275 | 2/3/2014 | 1446_02FEB2014_BUPRE_HCL | CVS-MDLT1-000079901 | CVS-MDLT1-000080199 | | | | | | | | | |
| P-10276 | 4/3/2008 | Email: DEA SOP | CVS-MDLT1-000081210 | CVS-MDLT1-000081280 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10277 | 12/11/2009 | FW: RX DEA SOP | CVS-MDLT1-000081281 | CVS-MDLT1-000081346 | | | | | | | | | |
| P-10278 | 1/4/2013 | Control / PSE IRR dated 1/3/13 | CVS-MDLT1-000081372 | CVS-MDLT1-000081373 | | | | | | | | | |
| P-10279 | 1/11/2014 | Fyi. FW: Daily HBC Suspicious Purchasing Report - 01/09/14 | HBC_MDL00134729 | HBC_MDL00134729 | | | | | | | | | |
| P-10280 | 12/26/2013 | IRR SOM REVIEW PROCESS | CVS-MDLT1-000082312 | CVS-MDLT1-000082313 | | | | | | | | | |
| P-10281 | 10/31/2012 | RE: Today's IRR | CVS-MDLT1-000083056 | CVS-MDLT1-000083058 | | | | | | | | | |
| P-10282 | 1/15/2014 | FW: Qualitest SOM | HBC_MDL00134936 | HBC_MDL00134940 | | | | | | | | | |
| P-10283 | 9/24/2009 | DEA compliance (3) (3) (2) | CVS-MDLT1-000083340 | CVS-MDLT1-000083343 | | | | | | | | | |
| P-10284 | 11/14/2009 | SOM DRAFT | CVS-MDLT1-000083348 | CVS-MDLT1-000083351 | | | | | | | | | |
| P-10285 | 9/15/2010 | FW: Control Drug IRR Implementation | CVS-MDLT1-000083367 | CVS-MDLT1-000083380 | | | | | | | | | |
| P-10286 | 6/28/2011 | PSE Control Drug SOP (3) | CVS-MDLT1-000083551 | CVS-MDLT1-000083556 | | | | | | | | | |
| P-10287 | 7/10/2012 | FW: Attorney/Client Privileged Information | CVS-MDLT1-000083855 | CVS-MDLT1-000083857 | | | | | | | | | |
| P-10288 | 10/8/2012 | Conference Call Notes - 10 5 12 | CVS-MDLT1-000083880 | CVS-MDLT1-000083882 | | | | | | | | | |
| P-10289 | 1/28/2011 | RE: IRR Narratives | CVS-MDLT1-000083966 | CVS-MDLT1-000083971 | | | | | | | | | |
| P-10290 | 11/5/2009 | RE: November 10 2009 Meeting | CVS-MDLT1-000087889 | CVS-MDLT1-000087890 | | | | | | | | | |
| P-10291 | 3/12/2012 | Emailing: DEA Speaking Points IRR | CVS-MDLT1-000088134 | CVS-MDLT1-000088146 | | | | | | | | | |
| P-10292 | 9/9/2013 | RE: Controls at HBC | HBC_MDL00135022 | HBC_MDL00135024 | | | | | | | | | |
| P-10293 | 10/25/2013 | Anda/GE Demo Meeting Minutes 131016 | HBC_MDL00135030 | HBC_MDL00135037 | | | | | | | | | |
| P-10296 | 7/26/2010 | important IRR question | CVS-MDLT1-000088734 | CVS-MDLT1-000088737 | | | | | | | | | |
| P-10297 | 8/26/2010 | DEA SOP 08-25-10 | CVS-MDLT1-000088956 | CVS-MDLT1-000089025 | | | | | | | | | |
| P-10298 | 5/22/2014 | Re: CSMP Report: Follow-Up with Account Manager | HBC_MDL00135101 | HBC_MDL00135103 | | | | | | | | | |
| P-10299 | 8/23/2010 | RE: DEA SOP | CVS-MDLT1-000089188 | CVS-MDLT1-000089189 | | | | | | | | | |
| P-10301 | 2/1/2012 | DEA SOP 11-15-10 | CVS-MDLT1-000089315 | CVS-MDLT1-000089379 | | | | | | | | | |
| P-10302 | 11/29/2007 | RE: New RX DEA SOP | CVS-MDLT1-000089768 | CVS-MDLT1-000089770 | | | | | | | | | |
| P-10303 | 1/22/2008 | CVS - November, 2007.fn.draft | CVS-MDLT1-000090029 | CVS-MDLT1-000090098 | | | | | | | | | |
| P-10304 | 8/26/2008 | RE: | CVS-MDLT1-000090382 | CVS-MDLT1-000090452 | | | | | | | | | |
| P-10305 | 2/24/2009 | RX DEA SOP 2-20-09 | CVS-MDLT1-000090581 | CVS-MDLT1-000090649 | | | | | | | | | |
| P-10306 | 6/15/2009 | RE: DEA SOP | CVS-MDLT1-000090853 | CVS-MDLT1-000090854 | | | | | | | | | |
| P-10307 | 2/21/2008 | DEA Letters - SOMs | CVS-MDLT1-000091508 | CVS-MDLT1-000091518 | | | | | | | | | |
| P-10308 | 7/2/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 7 2 12 | CVS-MDLT1-000112674 | CVS-MDLT1-000112675 | | | | | | | | | |
| P-10309 | 1/22/2014 | FW: Wholesale Distributor Questionnaire | HBC_MDL00135570 | HBC_MDL00135574 | | | | | | | | | |
| P-10310 | 6/25/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 6 22 12 | CVS-MDLT1-000112684 | CVS-MDLT1-000112685 | | | | | | | | | |
| P-10311 | 11/15/2013 | RE: I don't see any new test results on sharepoint ? | CVS-MDLT1-000092932 | CVS-MDLT1-000092932 | | | | | | | | | |
| P-10312 | 5/16/2014 | DEA visit Closing recap 051514 | CVS-MDLT1-000093961 | CVS-MDLT1-000093962 | | | | | | | | | |
| P-10313 | 11/14/2018 | CVS entered into a settlement agreement with the DOJ and DEA for \$50,000.00 | CVS-MDLT1-000099702 | CVS-MDLT1-000099704 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10315 | 9/17/2013 | RE: I've had some pretty catastrophic news today so I may not at my best. I may be cashing in some sick time or vacation in the next few days. I'm cutting out a little early today. | CVS-MDLT1-000099708 | CVS-MDLT1-000099709 | | | | | | | | | |
| P-10316 | 9/8/2014 | Distributor SOM Questions | CVS-MDLT1-000100054 | CVS-MDLT1-000100180 | | | | | | | | | |
| P-10317 | 8/18/2013 | Dean_Logistics Planning 081713 | CVS-MDLT1-000100353 | CVS-MDLT1-000100367 | | | | | | | | | |
| P-10318 | 2/8/2012 | FW: Control Drug IRR important info part 2 | CVS-MDLT1-000100370 | CVS-MDLT1-000100371 | | | | | | | | | |
| P-10320 | 12/14/2010 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000100763 | CVS-MDLT1-000100774 | | | | | | | | | |
| P-10321 | 11/30/2010 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000100775 | CVS-MDLT1-000100850 | | | | | | | | | |
| P-10322 | 2/20/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000100851 | CVS-MDLT1-000100864 | | | | | | | | | |
| P-10326 | 1/25/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000100984 | CVS-MDLT1-000101021 | | | | | | | | | |
| P-10328 | 1/11/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000101074 | CVS-MDLT1-000101091 | | | | | | | | | |
| P-10329 | 1/4/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000101092 | CVS-MDLT1-000101099 | | | | | | | | | |
| P-10333 | 3/8/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000101165 | CVS-MDLT1-000101173 | | | | | | | | | |
| P-10334 | 3/1/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000101174 | CVS-MDLT1-000101196 | | | | | | | | | |
| P-10335 | 2/21/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000101197 | CVS-MDLT1-000101215 | | | | | | | | | |
| P-10337 | 3/29/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000101371 | CVS-MDLT1-000101427 | | | | | | | | | |
| P-10341 | 9/16/2013 | FW: Control and PSE IRR reports | CVS-MDLT1-000102845 | CVS-MDLT1-000102846 | | | | | | | | | |
| P-10342 | 9/17/2013 | RE: I've had some pretty catastrophic news today so I may not at my best. I may be cashing in some sick time or vacation in the next few days. I'm cutting out a little early today | CVS-MDLT1-000103068 | CVS-MDLT1-000103068 | | | | | | | | | |
| P-10343 | 1/22/2013 | Importance of Incorporating OV Orders | CVS-MDLT1-000103327 | CVS-MDLT1-000103328 | | | | | | | | | |
| P-10344 | 9/19/2013 | RE: Controls at HBC | HBC_MDL00135579 | HBC_MDL00135580 | | | | | | | | | |
| P-10345 | 1/18/2013 | Monday Meeting w/Tom P | CVS-MDLT1-000103329 | CVS-MDLT1-000103329 | | | | | | | | | |
| P-10346 | 6/17/2014 | SOM Risk Analysis | CVS-MDLT1-000103342 | CVS-MDLT1-000103343 | | | | | | | | | |
| P-10347 | 7/13/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 7 13 12 | CVS-MDLT1-000112686 | CVS-MDLT1-000112687 | | | | | | | | | |
| P-10348 | 9/11/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 9 10 12 | CVS-MDLT1-000112692 | CVS-MDLT1-000112693 | | | | | | | | | |
| P-10349 | 12/12/2012 | Status Report Docs | CVS-MDLT1-000103373 | CVS-MDLT1-000103380 | | | | | | | | | |
| P-10350 | 11/13/2013 | RE: No Policy Council Call this Week - Please Read Email | CVS-MDLT1-000103475 | CVS-MDLT1-000103476 | | | | | | | | | |

| | | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|--|
| P-10351 | 10/29/2010 | Agenda / Updates for Monday's staff meeting | CVS-MDLT1-000103859 | CVS-MDLT1-000103872 | | | | | | | | | | |
| P-10352 | 1/4/2016 | FW: LOA | CVS-MDLT1-000104850 | CVS-MDLT1-000104852 | | | | | | | | | | |
| P-10353 | 10/12/2010 | 10/12/10 Control Drug IRR | CVS-MDLT1-000104883 | CVS-MDLT1-000104883 | | | | | | | | | | |
| P-10354 | 10/13/2010 | LP Analyst | CVS-MDLT1-000104894 | CVS-MDLT1-000104897 | | | | | | | | | | |
| P-10355 | 8/21/2013 | Engagement Letter to Matthew Murphy to confirm CVS has engaged Pharma Compliance Group | CVS-MDLT1-000104917 | CVS-MDLT1-000104921 | | | | | | | | | | |
| P-10356 | 12/21/2011 | DEA - PSE Review 3rd 2011 | CVS-MDLT1-000105713 | CVS-MDLT1-000105721 | | | | | | | | | | |
| P-10357 | 5/1/2014 | SOM DEA train - legal | CVS-MDLT1-000106514 | CVS-MDLT1-000106561 | | | | | | | | | | |
| P-10358 | 1/6/2012 | FW: CVS / BuzzeoPDMA - SOM PSE Maintenance Proposal | CVS-MDLT1-000106598 | CVS-MDLT1-000106601 | | | | | | | | | | |
| P-10359 | 11/10/2010 | RE: RX Control-Change Max Store Order | CVS-MDLT1-000108797 | CVS-MDLT1-000108800 | | | | | | | | | | |
| P-10360 | 9/13/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 9 12 12 | CVS-MDLT1-000112694 | CVS-MDLT1-000112695 | | | | | | | | | | |
| P-10361 | 3/23/2007 | CVS Consulting Proposal March 2007 | CVS-MDLT1-000109198 | CVS-MDLT1-000109202 | | | | | | | | | | |
| P-10363 | 1/28/2011 | RE: IRR Narratives | CVS-MDLT1-000109843 | CVS-MDLT1-000109848 | | | | | | | | | | |
| P-10365 | 3/26/2012 | Letter on IRR SOM process Flow, Loss Prevention Analyst; IRR SOM Process Flow.vsd | CVS-MDLT1-000109870 | CVS-MDLT1-000109878 | | | | | | | | | | |
| P-10366 | 4/18/2014 | Re: 35 missing tote | HBC_MDL00135668 | HBC_MDL00135670 | | | | | | | | | | |
| P-10367 | 9/12/2012 | FW: Maximum Cutoffs on IRR 9/11/12 | CVS-MDLT1-000109941 | CVS-MDLT1-000109941 | | | | | | | | | | |
| P-10368 | 10/15/2012 | CVS SOM proposal 11OCT12 (2) | CVS-MDLT1-000109962 | CVS-MDLT1-000109978 | | | | | | | | | | |
| P-10369 | 9/12/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 9 11 12 | CVS-MDLT1-000112696 | CVS-MDLT1-000112697 | | | | | | | | | | |
| P-10370 | 10/6/2010 | Control Drug IRR Issue recap | CVS-MDLT1-000110260 | CVS-MDLT1-000110260 | | | | | | | | | | |
| P-10371 | 2/24/2010 | RE: Adjustment to the CVS SOM | CVS-MDLT1-000110434 | CVS-MDLT1-000110436 | | | | | | | | | | |
| P-10372 | 3/10/2010 | RE: Adjustment to the CVS SOM | CVS-MDLT1-000110439 | CVS-MDLT1-000111185 | | | | | | | | | | |
| P-10373 | 7/14/2014 | CSOS Meeting Minutes and Notes | HBC_MDL00136052 | HBC_MDL00136089 | | | | | | | | | | |
| P-10374 | 3/5/2010 | FW: Adjustment to the CVS SOM | CVS-MDLT1-000111260 | CVS-MDLT1-000111308 | | | | | | | | | | |
| P-10375 | 12/13/2013 | Compliance Issues HBC Whse | HBC_MDL00136141 | HBC_MDL00136213 | | | | | | | | | | |
| P-10376 | 4/4/2013 | RE: recent example of generic launch? | CVS-MDLT1-000111877 | CVS-MDLT1-000111879 | | | | | | | | | | |
| P-10377 | 12/19/2012 | CVS Caremark / BuzzeoPDMA - SOM Statistical Model Development | CVS-MDLT1-000111913 | CVS-MDLT1-000111917 | | | | | | | | | | |
| P-10378 | 11/15/2013 | FW: Closing audit | CVS-MDLT1-000111940 | CVS-MDLT1-000111941 | | | | | | | | | | |
| P-10379 | 1/27/2011 | FW: IRR Narratives | CVS-MDLT1-000112597 | CVS-MDLT1-000112600 | | | | | | | | | | |
| P-10381 | 6/26/2013 | Giant Eagle CSMP - 06/26/2013 | HBC_MDL00136237 | HBC_MDL00136238 | | | | | | | | | | |
| P-10382 | 11/12/2013 | MCK email with ppt attachment CSMP | HBC_MDL00136653 | HBC_MDL00136654 | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10385 | 7/13/2012 | Letter on LP Analyst Time Study | CVS-MDLT1-000112680 | CVS-MDLT1-000112683 | | | | | | | | | |
| P-10387 | 1/19/2011 | FW: Completed PSE Policy & Procedure Template | CVS-MDLT1-000113943 | CVS-MDLT1-000113949 | | | | | | | | | |
| P-10388 | 7/11/2012 | Project Plan - 5 1 12 | CVS-MDLT1-000114320 | CVS-MDLT1-000114329 | | | | | | | | | |
| P-10389 | 9/22/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 9 21 12 | CVS-MDLT1-000112700 | CVS-MDLT1-000112701 | | | | | | | | | |
| P-10390 | 2/9/2011 | CVS Retunement | CVS-MDLT1-000114641 | CVS-MDLT1-000114652 | | | | | | | | | |
| P-10391 | 1/3/2008 | Letter from DEA with handwritten notes | CVS-MDLT1-000115464 | CVS-MDLT1-000115467 | | | | | | | | | |
| P-10392 | 3/17/2015 | SOM Business Requirements Document | CVS-MDLT1-000115820 | CVS-MDLT1-000115883 | | | | | | | | | |
| P-10393 | 4/9/2010 | DEA SOP compliance | CVS-MDLT1-000118291 | CVS-MDLT1-000118295 | | | | | | | | | |
| P-10394 | 11/8/2013 | RE: request 26725 | CVS-MDLT1-000118312 | CVS-MDLT1-000118314 | | | | | | | | | |
| P-10395 | 7/18/2013 | RE: Resume-Kelly Baker | CVS-MDLT1-000118897 | CVS-MDLT1-000118898 | | | | | | | | | |
| P-10396 | 7/17/2013 | FW: Resume-Kelly Baker | CVS-MDLT1-000118931 | CVS-MDLT1-000118934 | | | | | | | | | |
| P-10397 | 9/12/2013 | FW: Irregular Order - Logistics Communication 09 9 13 | CVS-MDLT1-000119704 | CVS-MDLT1-000119705 | | | | | | | | | |
| P-10398 | 9/17/2013 | RE: I CC'd you a few of the reports we send out just FYI so we can speak to it next week | CVS-MDLT1-000119935 | CVS-MDLT1-000119935 | | | | | | | | | |
| P-10399 | 10/11/2013 | FW: Kelly Baker | CVS-MDLT1-000119938 | CVS-MDLT1-000119938 | | | | | | | | | |
| P-10400 | 6/10/2013 | PSE Reports Committee | CVS-MDLT1-000119953 | CVS-MDLT1-000119953 | | | | | | | | | |
| P-10401 | 9/24/2009 | FW: DEA compliance (3) (3) (2) | CVS-MDLT1-000120422 | CVS-MDLT1-000120422 | | | | | | | | | |
| P-10402 | 1/5/2019 | Year End Review - 2014, Craig Schiavo | CVS-MDLT1-000120573 | CVS-MDLT1-000120579 | | | | | | | | | |
| P-10403 | 1/5/2019 | Schiavo 2013b | CVS-MDLT1-000120580 | CVS-MDLT1-000120588 | | | | | | | | | |
| P-10404 | 1/5/2019 | Schiavo 2013 | CVS-MDLT1-000120589 | CVS-MDLT1-000120595 | | | | | | | | | |
| P-10405 | 1/5/2019 | Schiavo 2012b | CVS-MDLT1-000120596 | CVS-MDLT1-000120606 | | | | | | | | | |
| P-10406 | 1/19/2019 | Baker 2013 | CVS-MDLT1-000121559 | CVS-MDLT1-000121560 | | | | | | | | | |
| P-10407 | 2/11/2019 | Descriptive Overview Document: CegeDim Dendrite Suspicious Order Monitoring (SOM) Model | CVS-MDLT1-000123386 | CVS-MDLT1-000123392 | | | | | | | | | |
| P-10408 | 9/26/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 9 25 12 | CVS-MDLT1-000112704 | CVS-MDLT1-000112705 | | | | | | | | | |
| P-10409 | 9/27/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 9 26 12 | CVS-MDLT1-000112706 | CVS-MDLT1-000112707 | | | | | | | | | |
| P-10410 | 9/27/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 9 27 12 | CVS-MDLT1-000112708 | CVS-MDLT1-000112709 | | | | | | | | | |
| P-10411 | 10/2/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 10 1 12 | CVS-MDLT1-000112710 | CVS-MDLT1-000112711 | | | | | | | | | |
| P-10425 | 11/11/2013 | Fw: Controlled Substance Suspicious Monitoring | HBC_MDL00136771 | HBC_MDL00136772 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-10428 | 1/6/2014 | RE: Ohio State Board of Pharmacy - Nov. 2013 - Change to OARRS Report - "80 MED" threshold scoring system | HBC_MDL00137199 | HBC_MDL00137202 | | | | | | | | | |
| P-10439 | 10/1/2014 | FW: Narcs found in tote | HBC_MDL00137363 | HBC_MDL00137364 | | | | | | | | | |
| P-10445 | 1/23/2014 | Re: VAWD | HBC_MDL00140166 | HBC_MDL00140204 | | | | | | | | | |
| P-10450 | 5/21/2013 | CSMP Questionnaire - Complete Responses | HBC_MDL00144314 | HBC_MDL00144322 | | | | | | | | | |
| P-10453 | 5/9/2014 | FW: Purdue Meeting Request | HBC_MDL00154218 | HBC_MDL00154219 | | | | | | | | | |
| P-10455 | 8/22/2013 | FW: CVS News Story | HBC_MDL00154265 | HBC_MDL00154266 | | | | | | | | | |
| P-10456 | 6/24/2016 | RE: CSOS into Warehouse | HBC_MDL00169369 | HBC_MDL00169373 | | | | | | | | | |
| P-10457 | 8/28/2015 | RE: 30-010 - Inventory Control - Suspicious Order Policy FINALx | HBC_MDL00169466 | HBC_MDL00169466 | | | | | | | | | |
| P-10458 | 8/28/2015 | 30-010 - Inventory Control - Suspicious Order Policy FINALx | HBC_MDL00169475 | HBC_MDL00169477 | | | | | | | | | |
| P-10461 | 12/18/2013 | RE: Hydrocodone APAP Elixir/ Tab Conv Progr status | HBC_MDL00171642 | HBC_MDL00171645 | | | | | | | | | |
| P-10463 | 7/30/2013 | RE: Oxycodone Threshold | HBC_MDL00174163 | HBC_MDL00174163 | | | | | | | | | |
| P-10472 | 10/18/2013 | Email of DEA THRESHOLD WARNING REPORT_8164 | HBC_MDL00174476 | HBC_MDL00174477 | | | | | | | | | |
| P-10475 | 7/1/2008 | RE: Vicodin quota ???????????? | HBC_MDL00179373 | HBC_MDL00179374 | | | | | | | | | |
| P-10477 | 4/7/2014 | RE: VAWD status meeting 4-7 project plan | HBC_MDL00180061 | HBC_MDL00180088 | | | | | | | | | |
| P-10478 | 3/29/2015 | RE: Buzzeo recommendations discussion notes 3-24 | HBC_MDL00181482 | HBC_MDL00181511 | | | | | | | | | |
| P-10479 | 3/16/2015 | RE: VAWD - Compliance Gaps | HBC_MDL00181521 | HBC_MDL00181555 | | | | | | | | | |
| P-10480 | 11/4/2009 | HBC PHARMACY OPERATIONS AND PROCEDURES COVER master (2) | HBC_MDL00189099 | HBC_MDL00189107 | | | | | | | | | |
| P-10481 | 3/1/2019 | Cuyahoga County Oct 2009-May 2018v2 | HBC_MDL00189212 | HBC_MDL00189212 | | | | | | | | | |
| P-10482 | 3/1/2019 | Summit County Oct 2009-May 2018v2 | HBC_MDL00189213 | HBC_MDL00189213 | | | | | | | | | |
| P-10484 | 5/23/2012 | Email: Attorney Client Privilege - LP Analyst Time Study 5 22 12 | CVS-MDLT1-000113868 | CVS-MDLT1-000113874 | | | | | | | | | |
| P-10485 | 5/30/2012 | Emailing: Attorney Client Privilege - LP Analyst Time Study 5 25 12, Attorney Client Privilege - LP Analyst Time Study 5 29 12, Attorney Client Privilege - LP Analyst Time Study 5 24 12 | CVS-MDLT1-000116595 | CVS-MDLT1-000116613 | | | | | | | | | |
| P-10486 | 5/13/2015 | DOJ Press Release - MD Florida; United States Reaches \$22 Million Settlement Agreement with CVS for Unlawful Distribution of Controlled Substances | CAH_MDL2804_01493477 | CAH_MDL2804_01493478 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10487 | 8/21/2014 | Hydrocodone Federal Register C3 to C2 with parent email | CVS-MDLT1-000002086 | CVS-MDLT1-000002172 | | | | | | | | | |
| P-10488 | 8/6/2013 | Email re: SOM Huddle Materials | CVS-MDLT1-000003026 | CVS-MDLT1-000003032 | | | | | | | | | |
| P-10489 | 6/6/2013 | Email RE: Kelly Baker Compliance Modules | CVS-MDLT1-000007767 | CVS-MDLT1-000007767 | | | | | | | | | |
| P-10490 | 1/10/2013 | Access to MicroStrategy | CVS-MDLT1-000009637 | CVS-MDLT1-000009640 | | | | | | | | | |
| P-10491 | 2/19/2013 | Irregular Order - DC Communication Orlando IRR dated 2-18-13 store 633 | CVS-MDLT1-000009646 | CVS-MDLT1-000009667 | | | | | | | | | |
| P-10493 | 8/30/2012 | IRR - Control Drugs | CVS-MDLT1-000011949 | CVS-MDLT1-000012191 | | | | | | | | | |
| P-10494 | 4/16/2013 | Email requesting any docs provided by the DEA during or after last 2 regulatory visits | CVS-MDLT1-000012372 | CVS-MDLT1-000012372 | | | | | | | | | |
| P-10495 | 8/18/2013 | email - SOM update, future SOM manager sounds like the perfect candidate, works closely with DEA | CVS-MDLT1-000017268 | CVS-MDLT1-000017269 | | | | | | | | | |
| P-10496 | 2/28/2014 | email - DEA publishes proposal to reschedule Hydrocodone | CVS-MDLT1-000018577 | CVS-MDLT1-000018579 | | | | | | | | | |
| P-10497 | 3/17/2014 | email - SOM Director job posting | CVS-MDLT1-000018961 | CVS-MDLT1-000018963 | | | | | | | | | |
| P-10498 | 11/8/2012 | Email FW: The CVS Retunement Attorney Client Privilege | CVS-MDLT1-000022040 | CVS-MDLT1-000022054 | | | | | | | | | |
| P-10499 | 1/13/2014 | Email with D Vanelli's 2014 goals | CVS-MDLT1-000022672 | CVS-MDLT1-000022676 | | | | | | | | | |
| P-10500 | 5/13/2013 | email - FDA role in making recommendation for hydrocodone rescheduling | CVS-MDLT1-000022736 | CVS-MDLT1-000022737 | | | | | | | | | |
| P-10501 | 11/4/2013 | email - new algo re suspicious orders and contacting DEA | CVS-MDLT1-000023972 | CVS-MDLT1-000023972 | | | | | | | | | |
| P-10502 | 9/6/2013 | email - SOM Transition Justification | CVS-MDLT1-000026026 | CVS-MDLT1-000026027 | | | | | | | | | |
| P-10503 | 8/1/2013 | training for Archer SOM Application | CVS-MDLT1-000029026 | CVS-MDLT1-000029032 | | | | | | | | | |
| P-10504 | 7/18/2013 | Archer SOM - UAT COMPLETE | CVS-MDLT1-000029417 | CVS-MDLT1-000029418 | | | | | | | | | |
| P-10505 | 3/8/2013 | Archer CS Monitoring - SOM Testing and Approval | CVS-MDLT1-000030493 | CVS-MDLT1-000030494 | | | | | | | | | |
| P-10506 | 2/9/2004 | CVS and CAH letter of agreement | CVS-MDLT1-000030783 | CVS-MDLT1-000030793 | | | | | | | | | |
| P-10508 | 6/2/2004 | 2nd Amendment to Wholesale Supply Agreement between CVS and CAH | CVS-MDLT1-000030797 | CVS-MDLT1-000030809 | | | | | | | | | |
| P-10510 | 5/26/2004 | 1st Amendment to Wholesale Supply Agreement between CAH and CVS | CVS-MDLT1-000030971 | CVS-MDLT1-000030994 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10511 | 7/1/2007 | Wholesale Supply Agreement Between CAH and CVS | CVS-MDLT1-000030995 | CVS-MDLT1-000031063 | | | | | | | | | |
| P-10512 | 10/5/2012 | Pharmacy/DC Ordering Process c/c recap | CVS-MDLT1-000033495 | CVS-MDLT1-000033497 | | | | | | | | | |
| P-10514 | 10/15/2013 | CVS logistics DC SOM | CVS-MDLT1-000039904 | CVS-MDLT1-000039907 | | | | | | | | | |
| P-10515 | 1/10/2008 | Modification to Indirect Contracts: CVSCARE06, CVSRETL06, CVSMK07 | CVS-MDLT1-000055458 | CVS-MDLT1-000055460 | | | | | | | | | |
| P-10516 | 4/24/2012 | Guidelines for Dispensing Controlled Substances | CVS-MDLT1-000055548 | CVS-MDLT1-000055550 | | | | | | | | | |
| P-10517 | 8/9/2013 | SOM Consultant starts Monday, former DEA Investigator, Tony Sheller | CVS-MDLT1-000057776 | CVS-MDLT1-000057776 | | | | | | | | | |
| P-10518 | 2006 | 2006 Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000060975 | CVS-MDLT1-000060979 | | | | | | | | | |
| P-10519 | 2012 | 2012 Pharmacist Incentive Plan | CVS-MDLT1-000060980 | CVS-MDLT1-000060988 | | | | | | | | | |
| P-10521 | 7/1/2013 | email re Archer SOM | CVS-MDLT1-000077929 | CVS-MDLT1-000077932 | | | | | | | | | |
| P-10522 | 7/17/2013 | email re Archer SOM - Identifier? | CVS-MDLT1-000077975 | CVS-MDLT1-000077975 | | | | | | | | | |
| P-10523 | 6/19/2014 | email re concerns over launching two more DC's and workload being too great | CVS-MDLT1-000078048 | CVS-MDLT1-000078048 | | | | | | | | | |
| P-10524 | 4/25/2013 | email re Enacted CS Storage and Handling Exemption language 2-6-13; HDMA State Controlled Substance Chart | CVS-MDLT1-000078049 | CVS-MDLT1-000078057 | | | | | | | | | |
| P-10525 | 7/23/2013 | email re SOM Due Diligence has stopped for the day | CVS-MDLT1-000078112 | CVS-MDLT1-000078113 | | | | | | | | | |
| P-10526 | 7/15/2013 | email re Archer SOM User Acceptance Testing | CVS-MDLT1-000078120 | CVS-MDLT1-000078122 | | | | | | | | | |
| P-10527 | 4/30/2014 | Email: No Policy Council Call this Week - Please See Important Information | CVS-MDLT1-000078938 | CVS-MDLT1-000078948 | | | | | | | | | |
| P-10529 | 6/10/2014 | Email: NACDS Policy Council - Information | CVS-MDLT1-000079106 | CVS-MDLT1-000079125 | | | | | | | | | |
| P-10530 | 1/8/2013 | Email: Control / PSE IRR 1/7/13 | CVS-MDLT1-000081362 | CVS-MDLT1-000081363 | | | | | | | | | |
| P-10531 | 11/29/2012 | Email re: Privileged and Confidential - SOM Process Documentation. Attachments: Opportunities doc, SOM Plan, SOM Process | CVS-MDLT1-000083064 | CVS-MDLT1-000083304 | | | | | | | | | |
| P-10532 | 1/9/2013 | Status Meeting - Requested Documentation | CVS-MDLT1-000092649 | CVS-MDLT1-000092657 | | | | | | | | | |
| P-10533 | 12/4/2012 | RE: Confidential Attorney-Client Privileged Communication | CVS-MDLT1-000092933 | CVS-MDLT1-000093206 | | | | | | | | | |
| P-10534 | 1/31/2014 | RE: 4189_30JAN2014_HYDRO_NSYSR | CVS-MDLT1-000093498 | CVS-MDLT1-000093502 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-10535 | 11/19/2013 | Email FW: Attorney Client Privileged and confidential. Attachments: DEA letter November 2013 | CVS-MDLT1-000100265 | CVS-MDLT1-000100268 | | | | | | | | | |
| P-10536 | 9/16/2013 | Email - Control and PSE IRR reports | CVS-MDLT1-000102843 | CVS-MDLT1-000102844 | | | | | | | | | |
| P-10537 | 6/19/2014 | Email re: SOM Team | CVS-MDLT1-000103344 | CVS-MDLT1-000103372 | | | | | | | | | |
| P-10538 | 8/30/2012 | Email DEA CS Monitoring with DEA letter from 12.27.07 attached | CVS-MDLT1-000103381 | CVS-MDLT1-000103385 | | | | | | | | | |
| P-10539 | 6/17/2014 | Email: SOM Risk Analysis | CVS-MDLT1-000103386 | CVS-MDLT1-000103387 | | | | | | | | | |
| P-10540 | 6/24/2014 | Email: Updated - SOM Risk Analysis | CVS-MDLT1-000103388 | CVS-MDLT1-000103389 | | | | | | | | | |
| P-10541 | 2006 | 2006 Management Incentive Plan | CVS-MDLT1-000104836 | CVS-MDLT1-000104842 | | | | | | | | | |
| P-10542 | N/A | Consulting service agreements with CVS and Buzzo/Dendrite/Cegedim | CVS-MDLT1-000105585 | CVS-MDLT1-000105596 | | | | | | | | | |
| P-10543 | 11/27/2012 | Email FW: Privileged and Confidential: AGI Proposal | CVS-MDLT1-000106664 | CVS-MDLT1-000106673 | | | | | | | | | |
| P-10544 | 4/6/2007 | Email: CVS Attachment III April 2007 | CVS-MDLT1-000109203 | CVS-MDLT1-000109206 | | | | | | | | | |
| P-10545 | 11/2/2012 | Email: SOM Report Attorney Client Privilege with attached CVS SOM Revised Coefficients | CVS-MDLT1-000109623 | CVS-MDLT1-000109625 | | | | | | | | | |
| P-10546 | 12/20/2012 | Email re: Attorney Client Privilege - Store Metrics Report | CVS-MDLT1-000109775 | CVS-MDLT1-000109775 | | | | | | | | | |
| P-10547 | 5/9/2012 | Email: IRR Recap....Privileged and Confidential/Attorney Client Privilege with IRR PSE CONTROL RECAP | CVS-MDLT1-000110414 | CVS-MDLT1-000110415 | | | | | | | | | |
| P-10548 | 11/5/2012 | Email: CVS SOM proposal 11 OCT 12 with attachment | CVS-MDLT1-000111926 | CVS-MDLT1-000111935 | | | | | | | | | |
| P-10549 | 8/23/2012 | Email re: Attorney Client Privilege - LP Analyst Time Study | CVS-MDLT1-000112595 | CVS-MDLT1-000112596 | | | | | | | | | |
| P-10550 | 6/21/2012 | Email re: Attorney Client Privilege - LP Analyst Time Study | CVS-MDLT1-000112644 | CVS-MDLT1-000112645 | | | | | | | | | |
| P-10551 | 6/19/2012 | Email re: Attorney Client Privilege - LP Analyst Time Study | CVS-MDLT1-000112648 | CVS-MDLT1-000112656 | | | | | | | | | |
| P-10552 | 6/18/2012 | Email re: Attorney Client Privilege - LP Analyst Time Study | CVS-MDLT1-000112657 | CVS-MDLT1-000112658 | | | | | | | | | |
| P-10553 | 7/6/2012 | Email re: Attorney Client Privilege - LP Analyst Time Study | CVS-MDLT1-000112676 | CVS-MDLT1-000112677 | | | | | | | | | |
| P-10554 | 7/19/2012 | Email re: Attorney Client Privilege - LP Analyst Time Study | CVS-MDLT1-000112690 | CVS-MDLT1-000112691 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------------|---------------------------|--|--|--|--|--|--|--|--|--|
| P-10555 | 9/10/2012 | Email re: Attorney Client Privilege - LP Analyst Time Study | CVS-MDLT1-000112698 | CVS-MDLT1-000112699 | | | | | | | | | |
| P-10556 | 9/25/2012 | Email re: Attorney Client Privilege - LP Analyst Time Study | CVS-MDLT1-000112702 | CVS-MDLT1-000112703 | | | | | | | | | |
| P-10557 | 12/23/2012 | Email: Revised proposal with CVS SOM Proposal edited 23DEC12 attached | CVS-MDLT1-000112818 | CVS-MDLT1-000112833 | | | | | | | | | |
| P-10558 | 1/11/2013 | Email: Statement of Work | CVS-MDLT1-000114026 | CVS-MDLT1-000114041 | | | | | | | | | |
| P-10559 | 4/29/2014 | Rannazzisi Home Files Redwell #2 Pt 2 | DEA_Rannazzisi-00000387 | DEA_Rannazzisi-00000593 | | | | | | | | | |
| P-10561 | 4/23/2012 | SIGNED ARPAIO DECLARATION | DEA_Rannazzisi-00006053 | DEA_Rannazzisi-00006100 | | | | | | | | | |
| P-10562 | 12/27/2012 | Emailing: Active ingredient grouping 31AUG12 | CVS-MDLT1-000114330 | CVS-MDLT1-000114331 | | | | | | | | | |
| P-10563 | 10/15/2013 | Email: IRR txt file data dump | CVS-MDLT1-000114677 | CVS-MDLT1-000114677 | | | | | | | | | |
| P-10564 | 5/3/2012 | Email re: Prepared at the request of legal counsel subject to attorney client privilege | CVS-MDLT1-000117715 | CVS-MDLT1-000117718 | | | | | | | | | |
| P-10568 | 7/8/2013 | Email: IRR for Sunday not posted | CVS-MDLT1-000119606 | CVS-MDLT1-000119606 | | | | | | | | | |
| P-10569 | 9/10/2013 | Email: Sat IRR | CVS-MDLT1-000119952 | CVS-MDLT1-000119952 | | | | | | | | | |
| P-10570 | 1/3/2013 | Email: Kelly Baker is new IRR Specialist | CVS-MDLT1-000120406 | CVS-MDLT1-000120406 | | | | | | | | | |
| P-10571 | 1/23/2013 | email RE: Attorney Client Privilege - 2843 | CVS-MDLT1-000120571 | CVS-MDLT1-000120572 | | | | | | | | | |
| P-10572 | 12/31/2018 | Craig Schiavo Monthly Salary 8/10/12 - 10/10/14 | CVS-MDLT1-000120607 | CVS-MDLT1-000120625 | | | | | | | | | |
| P-10573 | 12/31/2018 | Aaron Burtner Weekly/Biweekly pay 7/02/10 - 7/12/13 | CVS-MDLT1-000120639 | CVS-MDLT1-000120656 | | | | | | | | | |
| P-10574 | 1/4/2019 | Kelly Baker Biweekly pay 12/28/12 - 11/15/13 | CVS-MDLT1-000121561 | CVS-MDLT1-000121564 | | | | | | | | | |
| P-10575 | 6/10/2013 | Re: this week | CVS-MDLT1-000122062 | CVS-MDLT1-000122063 | | | | | | | | | |
| P-10576 | 7/2/2014 | RE: SOM verbiage; SOM Training | CVS-MDLT1-000019849 | CVS-MDLT1-000019987 | | | | | | | | | |
| P-11144 | 10/8/2015 | FW: Consultant Retained by MNK for SOM and Other Matters: BuzzzoPDMA Services Brochures | HBC_MDL00028251 | HBC_MDL00028272 | | | | | | | | | |
| P-11296 | 5/6/2009 | Hydrocodone and Oxycodone commitment ltr for Quote - Walmart | PAR_OPIOID_MDL_0000400253 | PAR_OPIOID_MDL_0000400256 | | | | | | | | | |
| P-11298 | 3/29/2016 | Email re Giant Eagle/BuzzzoPDMA: SOM Service Proposal | HBC_MDL00028498 | HBC_MDL00028500 | | | | | | | | | |
| P-11308 | 1/22/2008 | HDMA 1984 Suspicious Orders monitoring System | HDA_MDL_000150967 | HDA_MDL_000150996 | | | | | | | | | |
| P-11574 | 11/1/2011 | Policy Impact - Prescription Painkiller Overdoses | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------------|-------------------------|--|--|--|--|--|--|--|--|--|
| P-11724 | 2018 | Senate Homeland Security and Gov. Affairs Comm., 116th Cong., Report on Fueling an Epidemic Report Two: Exposing the Financial Ties Between Opioid Manufacturers and Third Party Advocacy Groups (2018) | N/A | N/A | | | | | | | | | |
| P-11880 | 12/15/2016 | Chicago Tribune: Pharmacies miss more than half of dangerous drug combinations | CVS-MDLT3-000161846 | CVS-MDLT3-000161861 | | | | | | | | | |
| P-11918 | 3/14/2014 | Email, Nicole Harrington(CVS) to Dean Vanelli, re Controlled Substance Documents, which she received from Donald Walker (McKesson) | CVS-MDLT1-000003716 | CVS-MDLT1-000003748 | | | | | | | | | |
| P-12504 | 6/20/2014 | RE: FYE16 SOM - Prioritization_scoring_model v3 Finalized.xlsx | WMT_MDL_001219246 | WMT_MDL_001219247 | | | | | | | | | |
| P-12506 | 11/12/2015 | RE: Store #742 Suspicious Order Remediation | WMT_MDL_000790494 | WMT_MDL_000790502 | | | | | | | | | |
| P-12536 | 12/9/2014 | RE: DC 6001 Suspicious Order Monitoring - | WMT_CN_000008113 | WMT_CN_000008114 | | | | | | | | | |
| P-12564 | 9/11/2017 | RE: SOM - Weekly Sync | WMT_IQVIA_MDL_000006593 | WMT_IQVIA_MDL_000006595 | | | | | | | | | |
| P-12566 | 11/19/2012 | Over 20 Report 11.19.12 | WMT_MA_000000176 | WMT_MA_000000177 | | | | | | | | | |
| P-12578 | 12/31/2012 | Over 20 Report 2012.xlsx | WMT_MA_000000535 | WMT_MA_000000535 | | | | | | | | | |
| P-12586 | 2/24/2014 | [No Subject] | WMT_MA_000001358 | WMT_MA_000001358 | | | | | | | | | |
| P-12587 | 6/18/2014 | RE: SOM ask for FYE 16 | WMT_MA_000001718 | WMT_MA_000001719 | | | | | | | | | |
| P-12588 | 2/18/2014 | Reddwerks Order Alerts | WMT_MA_000001797 | WMT_MA_000001799 | | | | | | | | | |
| P-12602 | 2/4/2014 | FW: 6045 Order Alert Process | WMT_MA_000001930 | WMT_MA_000001933 | | | | | | | | | |
| P-12605 | 6/18/2014 | RE: SOM ask for FYE 16 | WMT_MA_000004861 | WMT_MA_000004863 | | | | | | | | | |
| P-12606 | 4/13/2016 | 4.14.16 HW Compliance Focus Areas Deck | WMT_MA_000005765 | WMT_MA_000005780 | | | | | | | | | |
| P-12625 | 8/3/2016 | Compliance Focus Areas_080416 (2) | WMT_MA_000006172 | WMT_MA_000006188 | | | | | | | | | |
| P-12653 | 7/1/2018 | WMT_MA_000009221 HIGHLY CONFIDENTIAL_Nationwide Block List.xlsx | WMT_MA_000009221 | WMT_MA_000009221 | | | | | | | | | |
| P-12717 | 8/13/2014 | Email Bi-Mart CSMP Call Attachments Data Norms PDF; RX Abuse Epidemic Pres- Customer Version 2-4-14 - FINAL PPT; CSMP Call Data_Bi Mart_8-14-14 | MCKMDL00407448 | MCKMDL00407480 | | | | | | | | | |
| P-12719 | 7/5/2016 | Buzzee/WM SOM Kick Off | WMT_MDL_000001012 | WMT_MDL_000001013 | | | | | | | | | |
| P-12740 | 10/14/2015 | Archer Spreadsheet 10.5 to 10.9 | WMT_MDL_000005733 | WMT_MDL_000005734 | | | | | | | | | |
| P-12765 | 11/26/2014 | Re: Suspicious Order Monitoring Update - 11/26 | WMT_MDL_000008081 | WMT_MDL_000008082 | | | | | | | | | |
| P-12768 | 8/22/2014 | Health and Wellness Weekly Update | WMT_MDL_000008155 | WMT_MDL_000008156 | | | | | | | | | |
| P-12779 | 11/19/2014 | FW: SOM Presentation | WMT_MDL_000008220 | WMT_MDL_000008225 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-12812 | 7/25/2014 | Review SOM Process Document | WMT_MDL_000008376 | WMT_MDL_000008382 | | | | | | | | | |
| P-12827 | 6/6/2014 | SOM ISD ask - updated slide | WMT_MDL_000008423 | WMT_MDL_000008424 | | | | | | | | | |
| P-12837 | 8/25/2014 | FW: SOM Contract | WMT_MDL_000008427 | WMT_MDL_000008447 | | | | | | | | | |
| P-12838 | 12/18/2014 | FW: RFP - Suspicious Order Monitoring | WMT_MDL_000008598 | WMT_MDL_000008610 | | | | | | | | | |
| P-12871 | 11/19/2014 | Suspicious Order Monitoring Process for Controlled Substances | WMT_MDL_000008629 | WMT_MDL_000008630 | | | | | | | | | |
| P-12872 | 11/3/2014 | 3. Controlled Substances Update_Nov 2014 | WMT_MDL_000009645 | WMT_MDL_000009652 | | | | | | | | | |
| P-12887 | 10/3/2013 | Reddwerks Meeting Recap.docx | WMT_MDL_000010343 | WMT_MDL_000010345 | | | | | | | | | |
| P-12904 | 11/14/2014 | SOM Program Notes - LOA Handoff.docx | WMT_MDL_000010372 | WMT_MDL_000010373 | | | | | | | | | |
| P-12907 | 11/20/2015 | The HDMA document | MCKMDL00561303 | MCKMDL00561306 | | | | | | | | | |
| P-12964 | 9/10/2014 | Weekly Status Meeting Minutes | WMT_MDL_000016240 | WMT_MDL_000016243 | | | | | | | | | |
| P-13002 | 5/16/2014 | Re: Walmart / Reddwerks Call Notes and Action Items | WMT_MDL_000018846 | WMT_MDL_000018848 | | | | | | | | | |
| P-13006 | 3/31/2011 | RE: Rite Aid CSMP 03.31.11 | MCKMDL00646634 | MCKMDL00646635 | | | | | | | | | |
| P-13030 | 6/11/2014 | RE: Weekly RR State Compliance LOE review and prioritization meeting` | WMT_MDL_000018961 | WMT_MDL_000018964 | | | | | | | | | |
| P-13031 | 11/6/2014 | RE: Executive Summary for October Scorecard | WMT_MDL_000019048 | WMT_MDL_000019051 | | | | | | | | | |
| P-13033 | 6/11/2014 | FW: Weekly RR State Compliance LOE review and prioritization meeting` | WMT_MDL_000019546 | WMT_MDL_000019548 | | | | | | | | | |
| P-13036 | 3/13/2014 | SOM | WMT_MDL_000019565 | WMT_MDL_000019566 | | | | | | | | | |
| P-13044 | 2/6/2015 | RE: Suspicious Order Monitoring Update - 2/5 | WMT_MDL_000020427 | WMT_MDL_000020428 | | | | | | | | | |
| P-13051 | 6/4/2014 | Focus Area slide 6.5.2014 | WMT_MDL_000020710 | WMT_MDL_000020711 | | | | | | | | | |
| P-13062 | 10/14/2013 | RE: Meeting Notes - Please Review | WMT_MDL_000020719 | WMT_MDL_000020721 | | | | | | | | | |
| P-13077 | 3/26/2014 | Timeline Slide | WMT_MDL_000028320 | WMT_MDL_000028321 | | | | | | | | | |
| P-13084 | 11/13/2013 | SOMP GANTT 11.11.13 | WMT_MDL_000028322 | WMT_MDL_000028322 | | | | | | | | | |
| P-13097 | 9/10/2014 | 11-Sep | WMT_MDL_000028420 | WMT_MDL_000028420 | | | | | | | | | |
| P-13130 | 9/16/2014 | SOM Notes for Atlanta | WMT_MDL_000028633 | WMT_MDL_000028633 | | | | | | | | | |
| P-13142 | 1/28/2014 | SOMP - Execution stage | WMT_MDL_000028730 | WMT_MDL_000028731 | | | | | | | | | |
| P-13143 | 7/11/2014 | Re: SOM - Reddwerks update | WMT_MDL_000028771 | WMT_MDL_000028773 | | | | | | | | | |
| P-13205 | 3/13/2014 | SOM slides for GM Meeting | WMT_MDL_000028782 | WMT_MDL_000028783 | | | | | | | | | |
| P-13206 | 3/13/2014 | SOM slides for GM Meeting | WMT_MDL_000031348 | WMT_MDL_000031349 | | | | | | | | | |
| P-13222 | 3/12/2010 | Updated: Walmart Dendrite Conf. Call -Mon. March 29 @ 10:00 Eastern / 9:00 Central | WMT_MDL_000032897 | WMT_MDL_000032914 | | | | | | | | | |
| P-13225 | 8/26/2013 | Next Steps - Aug 23.docx | WMT_MDL_000041973 | WMT_MDL_000041976 | | | | | | | | | |
| P-13241 | 3/7/2013 | FW: Book1.xls | WMT_MDL_000042765 | WMT_MDL_000042767 | | | | | | | | | |
| P-13287 | 8/31/2017 | Report | WMT_MDL_000043080 | WMT_MDL_000043080 | | | | | | | | | |
| P-13298 | 8/5/2015 | Monthly Reports; Safety Truths worksheet; July APM Business Recap DC 6001-6045; 405-1 July 6045 | WMT_MDL_000043186 | WMT_MDL_000043191 | | | | | | | | | |
| P-13403 | 4/3/2015 | 405-1 March.xls 6045 | WMT_MDL_000043229 | WMT_MDL_000043230 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-13404 | 2/15/2018 | Controlled Substances Dispensed Report | WMT_MDL_000043312 | WMT_MDL_000043312 | | | | | | | | | |
| P-13405 | 11/9/2018 | Red Flag orders | WMT_MDL_000071579 | WMT_MDL_000071579 | | | | | | | | | |
| P-13406 | 6/5/2014 | FW: ISD/systems meeting | WMT_MDL_000046577 | WMT_MDL_000046585 | | | | | | | | | |
| P-13407 | 6/26/2014 | FY16 Compliance IT asks | WMT_MDL_000046628 | WMT_MDL_000046641 | | | | | | | | | |
| P-13408 | 6/12/2014 | FW: SOM ISD Request Form | WMT_MDL_000047821 | WMT_MDL_000047825 | | | | | | | | | |
| P-13409 | 6/18/2014 | FW: SOM ask for FYE 16 - Hard Limits and Vendor Data | WMT_MDL_000047830 | WMT_MDL_000047835 | | | | | | | | | |
| P-13415 | 8/28/2014 | FW: REVISED: FYE 2016 Project Summary AUG 2014 FINAL | WMT_MDL_000048012 | WMT_MDL_000048088 | | | | | | | | | |
| P-13418 | 7/22/2014 | FW: SOM ISD Request Form | WMT_MDL_000048110 | WMT_MDL_000048113 | | | | | | | | | |
| P-13452 | 7/22/2014 | FW: SOM ISD Request Form | WMT_MDL_000048174 | WMT_MDL_000048177 | | | | | | | | | |
| P-13544 | 6/18/2014 | FW: SOM ask for FYE 16 - Hard Limits and Vendor Data | WMT_MDL_000049273 | WMT_MDL_000049278 | | | | | | | | | |
| P-13640 | 11/4/2015 | 11.05.15 HW Compliance Focus Areas Deck | WMT_MDL_000050079 | WMT_MDL_000050122 | | | | | | | | | |
| P-13679 | 9/16/2014 | Attorney Client Privilege: Compliance Oversight Meeting Materials September 18 2:00-4:00, Clarence Archer Conference Room | WMT_MDL_000052195 | WMT_MDL_000052274 | | | | | | | | | |
| P-13725 | 6/26/2014 | FY16 Compliance IT asks | WMT_MDL_000052313 | WMT_MDL_000052326 | | | | | | | | | |
| P-13739 | 9/24/2012 | Significant Compliance Issues | WMT_MDL_000052363 | WMT_MDL_000052364 | | | | | | | | | |
| P-13795 | 11/5/2014 | 11/6/14 HW Compliance Focus Areas deck | WMT_MDL_000053313 | WMT_MDL_000053340 | | | | | | | | | |
| P-13796 | 7/14/2014 | RE: Suspicious Order Monitoring | WMT_MDL_000054706 | WMT_MDL_000054707 | | | | | | | | | |
| P-13797 | 12/22/2018 | Report | WMT_MDL_000055626 | WMT_MDL_000055626 | | | | | | | | | |
| P-13798 | 10/20/2015 | NACDS Invoice | WMT_MDL_000059064 | WMT_MDL_000059064 | | | | | | | | | |
| P-13799 | 3/10/2014 | RE: SOMP threshold - Next steps & effort estimates | WMT_MDL_000060327 | WMT_MDL_000060328 | | | | | | | | | |
| P-13801 | 1/23/2014 | RE: Analysis documents_Logistics Compliance | WMT_MDL_000062539 | WMT_MDL_000062541 | | | | | | | | | |
| P-14051 | 1/15/2016 | RE: Daily HBC Suspicious Purchasing Report - 01/14/16 | HBC_MDL00057872 | HBC_MDL00057874 | | | | | | | | | |
| P-14052 | 8/24/2016 | ***Forged Oxycodone script*** | HBC_MDL00060356 | HBC_MDL00060356 | | | | | | | | | |
| P-14053 | 9/6/2016 | FW: Lighthouse Medical | HBC_MDL00060999 | HBC_MDL00060999 | | | | | | | | | |
| P-14054 | 9/6/2016 | RE: Lighthouse Medical | HBC_MDL00061009 | HBC_MDL00061010 | | | | | | | | | |
| P-14055 | 11/13/2015 | Biography | HBC_MDL00080575 | HBC_MDL00080575 | | | | | | | | | |
| P-14056 | 1/15/2016 | FW: Daily HBC Suspicious Purchasing Report - 01/14/16 | HBC_MDL00091954 | HBC_MDL00091956 | | | | | | | | | |
| P-14156 | 2/21/2012 | FW: Update on Cardinal/ CVS problem | DC00056871 | DC00056872 | | | | | | | | | |
| P-14170 | 9/11/2015 | RE: Health & Wellness Compliance Oversight Committee Materials Request - Due September 11, 2015. | WMT_MDL_000062542 | WMT_MDL_000062550 | | | | | | | | | |
| P-14223 | 11/13/2013 | SOMP - Focus Area deck | WMT_MDL_000062675 | WMT_MDL_000062676 | | | | | | | | | |
| P-14224 | 6/25/2014 | Re: DEA Questionnaire | WMT_MDL_000063573 | WMT_MDL_000063574 | | | | | | | | | |
| P-14225 | 11/21/2013 | RE: ABC order limits | WMT_MDL_000063588 | WMT_MDL_000063589 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-14226 | 9/19/2013 | Suspicious Order Monitoring Advisory Panel | WMT_MDL_000064290 | WMT_MDL_000064300 | | | | | | | | | |
| P-14235 | 9/13/2013 | Suspicious Order Monitoring Program - Strategy Deck | WMT_MDL_000064316 | WMT_MDL_000064323 | | | | | | | | | |
| P-14317 | 10/8/2013 | Suspicious Order Monitoring - Program Documents | WMT_MDL_000064329 | WMT_MDL_000064341 | | | | | | | | | |
| P-14330 | 9/3/2013 | Suspicious Order Monitoring Program - 4:00 meeting | WMT_MDL_000064428 | WMT_MDL_000064434 | | | | | | | | | |
| P-14344 | 1/3/2018 | McKesson Calls.one (On 1-3-2018).one | WMT_MDL_000067459 | WMT_MDL_000067464 | | | | | | | | | |
| P-14348 | 6/1/2018 | POM 1317 - CS Prescriptions Written by Out of State Prescribers v5 eff 6-14-2018 to current (1-9-2018) | WMT_MDL_000069165 | WMT_MDL_000069166 | | | | | | | | | |
| P-14349 | 5/20/2011 | Week 17 Health & Wellness Leadership Weekly | WMT_MDL_000078980 | WMT_MDL_000079011 | | | | | | | | | |
| P-14350 | 7/19/2012 | Version 2 of CII tool kit and PMP wire posting | WMT_MDL_000083583 | WMT_MDL_000083596 | | | | | | | | | |
| P-14351 | 6/4/2015 | 6.4.15 HW Compliance Focus Areas Deck | WMT_MDL_000095513 | WMT_MDL_000095547 | | | | | | | | | |
| P-14352 | 9/11/2014 | Re: Per your call | WMT_MDL_000100195 | WMT_MDL_000100196 | | | | | | | | | |
| P-14355 | 12/31/2019 | WAG TCS Pharmacy Renewal Work Order Signature Version | TCS00027465 | TCS00027586 | | | | | | | | | |
| P-14356 | 10/4/2019 | Walgreens - Quality Engineering for Pharmacy Transformation Program; WBA Rx Renewal - TCS Proposal vDraft vShare | TCS00000893 | TCS00000926 | | | | | | | | | |
| P-14357 | 12/20/2019 | Re: UX research readout session - FEEDBACK; | TCS00027120 | TCS00027208 | | | | | | | | | |
| P-14358 | 11/12/2019 | Latosha notes#1 | TCS00000493 | TCS00000558 | | | | | | | | | |
| P-14359 | 2/29/2020 | walgreens contextual inquiry bannockburn | TCS00027825 | TCS00027827 | | | | | | | | | |
| P-14360 | 2/29/2020 | highland park pharmacist interview | TCS00027828 | TCS00027829 | | | | | | | | | |
| P-14361 | 2/29/2020 | pharmacy manager interview | TCS00027832 | TCS00027833 | | | | | | | | | |
| P-14362 | 11/13/2019 | Justin notes#1 | TCS00000453 | TCS00000492 | | | | | | | | | |
| P-14363 | 1/2/2020 | Re: UX research readout session - FEEDBACK | TCS00027058 | TCS00027119 | | | | | | | | | |
| P-14364 | 1/3/2020 | Re: UX research readout session - FEEDBACK | TCS00027209 | TCS00027274 | | | | | | | | | |
| P-14365 | 1/16/2020 | RE: Discussion on Updated Personas and Research Findings | TCS00027587 | TCS00027589 | | | | | | | | | |
| P-14366 | 3/2/2020 | Justin Chats | TCS00028141 | TCS00028145 | | | | | | | | | |
| P-14367 | 1/22/2020 | Justin Chats | TCS00028290 | TCS00028487 | | | | | | | | | |
| P-14368 | 1/17/2020 | Re: Research Report Concerns | TCS00028547 | TCS00028548 | | | | | | | | | |
| P-14369 | 1/23/2020 | Re: Discussion on Updated Personas and Research Findings | TCS00028573 | TCS00028577 | | | | | | | | | |
| P-14370 | 1/27/2020 | Discussion on Updated Personas and Research Findings (Session 2) | TCS00025912 | TCS00025969 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-14371 | 1/27/2020 | RE: Discussion on Updated Personas and Research Findings | TCS00027625 | TCS00027633 | | | | | | | | | |
| P-14372 | 11/10/2014 | SOM Update for Phyllis | WMT_MDL_000100534 | WMT_MDL_000100534 | | | | | | | | | |
| P-14373 | 4/3/2015 | RE: Logistics SOM Deck | WMT_MDL_000100550 | WMT_MDL_000100551 | | | | | | | | | |
| P-14374 | 10/12/2010 | VAWD Documents | WMT_MDL_000102695 | WMT_MDL_000102703 | | | | | | | | | |
| P-14375 | 8/28/2015 | RE: SOM process gap | WMT_MDL_000102750 | WMT_MDL_000102750 | | | | | | | | | |
| P-14376 | 10/8/2013 | Meeting Notes - Please Review | WMT_MDL_000102919 | WMT_MDL_000102920 | | | | | | | | | |
| P-14377 | 10/13/2014 | RE: CVS SOM | WMT_MDL_000103123 | WMT_MDL_000103125 | | | | | | | | | |
| P-14378 | 9/4/2013 | Investigation Info | WMT_MDL_000103312 | WMT_MDL_000103315 | | | | | | | | | |
| P-14379 | 5/1/2012 | Drug Diversion and Pharmacy Compliance | WMT_MDL_000104479 | WMT_MDL_000104485 | | | | | | | | | |
| P-14380 | 7/19/2012 | Version 2 of CII tool kit and PMP wire posting | WMT_MDL_000122334 | WMT_MDL_000122347 | | | | | | | | | |
| P-14381 | 10/4/2012 | Actavis acknowledgment | WMT_MDL_000127457 | WMT_MDL_000127459 | | | | | | | | | |
| P-14382 | 1/19/2010 | FW: Dendrite Compliance Solutions (BuzzeoPDMA) | WMT_MDL_000129912 | WMT_MDL_000129934 | | | | | | | | | |
| P-14385 | 1/26/2010 | RE: Dendrite Compliance Solutions (BuzzeoPDMA) | WMT_MDL_000130500 | WMT_MDL_000130501 | | | | | | | | | |
| P-14386 | 11/14/2014 | SOM GANTT Chart | WMT_MDL_000137141 | WMT_MDL_000137142 | | | | | | | | | |
| P-14387 | 6/13/2014 | SOM JQ review | WMT_MDL_000137450 | WMT_MDL_000137453 | | | | | | | | | |
| P-14388 | 9/16/2014 | RE: Updated SOM Policy - DRAFT - DO NOT DISTRIBUTE | WMT_MDL_000138216 | WMT_MDL_000138216 | | | | | | | | | |
| P-14389 | 1/27/2015 | RE: DEA Fines - SOM | WMT_MDL_000139587 | WMT_MDL_000139587 | | | | | | | | | |
| P-14390 | 3/16/2016 | RE: Buzzeo | WMT_MDL_000139617 | WMT_MDL_000139617 | | | | | | | | | |
| P-14391 | 9/17/2015 | RE: BuzzeoPDMA SOM Services Proposal / Project ID 28098 - Walmart - 62128 - Drug Tracking | WMT_MDL_000139839 | WMT_MDL_000139843 | | | | | | | | | |
| P-14392 | 9/4/2013 | Charter doc | WMT_MDL_000141679 | WMT_MDL_000141680 | | | | | | | | | |
| P-14393 | 7/18/2013 | RE: H&W Business Review | WMT_MDL_000142043 | WMT_MDL_000142044 | | | | | | | | | |
| P-14394 | 10/11/2013 | RE: Focus Areas | WMT_MDL_000142694 | WMT_MDL_000142697 | | | | | | | | | |
| P-14395 | 11/13/2013 | Spotlight Deck | WMT_MDL_000142698 | WMT_MDL_000142699 | | | | | | | | | |
| P-14396 | 2/17/2011 | RE: Walmart Stores East, LP - Bentonville AR - 5th P&P Review Report (Corp + site) | WMT_MDL_000143080 | WMT_MDL_000143087 | | | | | | | | | |
| P-14397 | 10/13/2011 | Project Shelby PPT | WMT_MDL_000143221 | WMT_MDL_000143223 | | | | | | | | | |
| P-14398 | 1/20/2010 | RE: Dendrite Compliance Solutions (BuzzeoPDMA) | WMT_MDL_000145322 | WMT_MDL_000145323 | | | | | | | | | |
| P-14399 | 2/24/2010 | Walmart Dendrite Conf. Call Tues. March 9 @ 12:00 Eastern / 11:00 Central | WMT_MDL_000145325 | WMT_MDL_000145336 | | | | | | | | | |
| P-14400 | 7/17/2012 | FW: Suspicious Order Monitoring (SOM) program - Site Review Services | WMT_MDL_000148326 | WMT_MDL_000148329 | | | | | | | | | |
| P-14401 | 1/15/2010 | Dendrite Compliance Solutions (BuzzeoPDMA) | WMT_MDL_000156555 | WMT_MDL_000156577 | | | | | | | | | |
| P-14402 | 10/15/2013 | FW: Meeting Notes - Please Review | WMT_MDL_000167146 | WMT_MDL_000167153 | | | | | | | | | |
| P-14403 | 10/21/2013 | RE: Meeting Notes - Please Review | WMT_MDL_000167197 | WMT_MDL_000167199 | | | | | | | | | |
| P-14404 | 10/24/2007 | RE: Letter from Pharmacy Operations | WMT_MDL_000168928 | WMT_MDL_000168930 | | | | | | | | | |
| P-14405 | 10/11/2013 | RE: Focus Areas | WMT_MDL_000171848 | WMT_MDL_000171851 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-14406 | 3/7/2011 | FW: Walmart Stores Ease, LP - Bentonville, AR - 6th P&P Review Report | WMT_MDL_000172473 | WMT_MDL_000172477 | | | | | | | | | |
| P-14407 | 11/3/2014 | HDMA SOM Industry Guide | WMT_MDL_000172819 | WMT_MDL_000172834 | | | | | | | | | |
| P-14408 | 1/15/2010 | Dendrite Compliance Solutions (BuzzeoPDMA) | WMT_MDL_000175510 | WMT_MDL_000175532 | | | | | | | | | |
| P-14409 | 4/16/2014 | Brad's comments for the Boot camp. | WMT_MDL_000183617 | WMT_MDL_000183618 | | | | | | | | | |
| P-14410 | 2/15/2012 | FW: Google Alert - Oxycodone | WMT_MDL_000186540 | WMT_MDL_000186540 | | | | | | | | | |
| P-14411 | 3/14/2014 | RE: SOM data | WMT_MDL_000195072 | WMT_MDL_000195079 | | | | | | | | | |
| P-14412 | 5/13/2016 | Health & Wellness Info | WMT_MDL_000195376 | WMT_MDL_000195388 | | | | | | | | | |
| P-14413 | 9/26/2014 | FW: Walmart Stores East, LP, Bentonville, AR - 1st Corporate P&P Review Report | WMT_MDL_000195449 | WMT_MDL_000195564 | | | | | | | | | |
| P-14414 | 11/20/2014 | RE: Suspicious Order Monitoring Process for Controlled Substances | WMT_MDL_000196333 | WMT_MDL_000196334 | | | | | | | | | |
| P-14415 | 9/2/2011 | First Revision | WMT_MDL_000197481 | WMT_MDL_000197481 | | | | | | | | | |
| P-14416 | 10/8/2014 | The Pharmacist Manual | WMT_MDL_000197700 | WMT_MDL_000197785 | | | | | | | | | |
| P-14417 | 6/12/2014 | FW: SOM ISD Request Form | WMT_MDL_000198047 | WMT_MDL_000198050 | | | | | | | | | |
| P-14418 | 6/18/2014 | FW: SOM ask for FYE 16 | WMT_MDL_000198051 | WMT_MDL_000198054 | | | | | | | | | |
| P-14419 | 9/4/2014 | RE: Walmart Stores East, LP, Bentonville, AR - 1st Corporate P&P Review Report | WMT_MDL_000198254 | WMT_MDL_000198257 | | | | | | | | | |
| P-14420 | 9/4/2014 | Re: Walmart Stores East, LP, Bentonville, AR - 1st Corporate P&P Review Report | WMT_MDL_000198403 | WMT_MDL_000198407 | | | | | | | | | |
| P-14421 | 7/14/2014 | RE: SOM role | WMT_MDL_000198501 | WMT_MDL_000198501 | | | | | | | | | |
| P-14422 | 4/29/2014 | FW: Walmart Stores East, LP, Bentonville, AR - 1st Corporate P&P Review Report | WMT_MDL_000198556 | WMT_MDL_000198573 | | | | | | | | | |
| P-14423 | 7/30/2010 | RE: GAO Review of DEA's Diversion Control Program | WMT_MDL_000200334 | WMT_MDL_000200336 | | | | | | | | | |
| P-14424 | 9/17/2014 | Zydus Oxycodone Compliance Questionnaire | WMT_MDL_000216703 | WMT_MDL_000216708 | | | | | | | | | |
| P-14425 | 7/12/2010 | Walmart Pharmacy Controlled Substances Ordering System (CSOS) | WMT_MDL_000217318 | WMT_MDL_000217329 | | | | | | | | | |
| P-14426 | 10/18/2013 | FW: Meeting Notes - Please Review | WMT_MDL_000217431 | WMT_MDL_000217439 | | | | | | | | | |
| P-14427 | 12/18/2014 | FW: Pharmacy Logistics (Debrief 12-17-14) | WMT_MDL_000217509 | WMT_MDL_000217511 | | | | | | | | | |
| P-14428 | 2/21/2012 | FW: Thinking of you!! | WMT_MDL_000218459 | WMT_MDL_000218462 | | | | | | | | | |
| P-14429 | 9/8/2014 | RE: Health and Wellness Weekly Update | WMT_MDL_000218970 | WMT_MDL_000218971 | | | | | | | | | |
| P-14430 | 10/1/2014 | RE: Safety | WMT_MDL_000222079 | WMT_MDL_000222080 | | | | | | | | | |
| P-14431 | 4/24/2008 | Controlled Substance Monitoring Program | WMT_MDL_000223238 | WMT_MDL_000223243 | | | | | | | | | |
| P-14432 | 8/3/2010 | RE: GAO Review of DEA's Diversion Control Program | WMT_MDL_000235712 | WMT_MDL_000235715 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-14433 | 3/11/2014 | UPDATE - SOM Mgr JQ | WMT_MDL_000237520 | WMT_MDL_000237521 | | | | | | | | | |
| P-14434 | 7/24/2014 | SOM - DC processes | WMT_MDL_000239954 | WMT_MDL_000239954 | | | | | | | | | |
| P-14435 | 6/13/2014 | SOM JQ review | WMT_MDL_000240130 | WMT_MDL_000240133 | | | | | | | | | |
| P-14436 | 5/29/2014 | FW: 5/29/14 HW Compliance Focus Areas | WMT_MDL_000247345 | WMT_MDL_000247373 | | | | | | | | | |
| P-14440 | 5/26/2017 | FW: Controlled Substances Ratings Pilot Kickoff | WMT_MDL_000265985 | WMT_MDL_000265990 | | | | | | | | | |
| P-14442 | 10/20/2011 | RE: Compliance projects- fy 13 | WMT_MDL_000284363 | WMT_MDL_000284365 | | | | | | | | | |
| P-14446 | 4/13/2018 | Notice of Central Prescriber Block for Dr. Veres AV2944519 (Sam's & Walmart) | WMT_MDL_000286249 | WMT_MDL_000286250 | | | | | | | | | |
| P-14447 | 7/3/2018 | Notice of Central Prescriber Block for DR. Kousa (Sam's Club/Walmart) | WMT_MDL_000286277 | WMT_MDL_000286278 | | | | | | | | | |
| P-14448 | 7/25/2017 | Notice of Central Prescriber Block | WMT_MDL_000286291 | WMT_MDL_000286292 | | | | | | | | | |
| P-14449 | 4/13/2017 | Notice of Central Prescriber Block | WMT_MDL_000286295 | WMT_MDL_000286296 | | | | | | | | | |
| P-14450 | 7/17/2015 | RE: POM 1311 Updates | WMT_MDL_000289035 | WMT_MDL_000289035 | | | | | | | | | |
| P-14451 | 12/12/2013 | FW: c2_red_flags | WMT_MDL_000291357 | WMT_MDL_000291363 | | | | | | | | | |
| P-14452 | 9/24/2014 | RE: Pharmacy DC Crawfordsville IN | WMT_MDL_000294828 | WMT_MDL_000294831 | | | | | | | | | |
| P-14453 | 9/18/2014 | RE: Pharmacy DC Crawfordsville IN | WMT_MDL_000294832 | WMT_MDL_000294833 | | | | | | | | | |
| P-14454 | 9/24/2014 | Re: Pharmacy DC Crawfordsville IN | WMT_MDL_000294834 | WMT_MDL_000294837 | | | | | | | | | |
| P-14455 | 11/5/2014 | FW: Updated FY16 BOD Objectives | WMT_MDL_000294966 | WMT_MDL_000294966 | | | | | | | | | |
| P-14456 | 12/24/2012 | RE: Suspicious Order Monitoring Survey for Controlled Substances - KVK-Tech - Pharmacies/Chains | WMT_MDL_000295535 | WMT_MDL_000295536 | | | | | | | | | |
| P-14457 | 11/25/2014 | FW: Suspicious Order Monitoring Update | WMT_MDL_000296843 | WMT_MDL_000296844 | | | | | | | | | |
| P-14458 | 12/9/2014 | RE: Suspicious Order Monitoring Update - 12/10 | WMT_MDL_000297250 | WMT_MDL_000297252 | | | | | | | | | |
| P-14459 | 3/26/2013 | Connexus Workflow August 30, 2012 | WMT_MDL_000300674 | WMT_MDL_000300675 | | | | | | | | | |
| P-14461 | 7/17/2017 | 071717 Assessment 1 Request Store 1863 Eastlake, OH | WMT_MDL_000303844 | WMT_MDL_000303865 | | | | | | | | | |
| P-14462 | 10/1/2014 | DEA at DC6028 Summary | WMT_MDL_000307891 | WMT_MDL_000307892 | | | | | | | | | |
| P-14463 | 3/14/2014 | RE: SOM data | WMT_MDL_000319134 | WMT_MDL_000319138 | | | | | | | | | |
| P-14464 | 1/23/2014 | RE: Qualitest SOM Response | WMT_MDL_000319153 | WMT_MDL_000319155 | | | | | | | | | |
| P-14465 | 6/4/2014 | FW: Suspicious Orders | WMT_MDL_000319329 | WMT_MDL_000319334 | | | | | | | | | |
| P-14466 | 3/20/2014 | FW: SOM Manager JQ - REVISED | WMT_MDL_000320368 | WMT_MDL_000320369 | | | | | | | | | |
| P-14467 | 3/26/2013 | RE: supplier questions | WMT_MDL_000341512 | WMT_MDL_000341512 | | | | | | | | | |
| P-14468 | 3/26/2013 | RE: supplier questions | WMT_MDL_000342792 | WMT_MDL_000342793 | | | | | | | | | |
| P-14470 | 7/23/2014 | RE: Server space | WMT_MDL_000348353 | WMT_MDL_000348354 | | | | | | | | | |
| P-14473 | 10/30/2013 | RE: NACDS in the News Daily: 10/28/13 | WMT_MDL_000363260 | WMT_MDL_000363265 | | | | | | | | | |
| P-14474 | 9/22/2020 | 1857; 2006 | WMT_MDL_000365375 | WMT_MDL_000365375 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-14475 | 9/22/2020 | 1857; DEA 2004-2007 | WMT_MDL_000365453 | WMT_MDL_000365453 | | | | | | | | | |
| P-14476 | 1/6/2016 | FW: CALL TO ACTION // Board of Director Deliverables due 12:00 pm on Friday, January 8 | WMT_MDL_000366658 | WMT_MDL_000366662 | | | | | | | | | |
| P-14477 | 11/25/2015 | Cindy Strategy Template -- Practice Compliance | WMT_MDL_000366728 | WMT_MDL_000366729 | | | | | | | | | |
| P-14478 | 6/27/2014 | Weekly Update 6.27.2014 | WMT_MDL_000368230 | WMT_MDL_000368231 | | | | | | | | | |
| P-14482 | 4/5/2017 | RE: Procedures | WMT_MDL_000368833 | WMT_MDL_000368833 | | | | | | | | | |
| P-14483 | 12/21/2015 | FW: please take a look | WMT_MDL_000369621 | WMT_MDL_000369622 | | | | | | | | | |
| P-14484 | 12/9/2014 | Greg's FYE 15 Eval.docx | WMT_MDL_000370925 | WMT_MDL_000370932 | | | | | | | | | |
| P-14485 | 10/31/2014 | Investigation Thresholds | WMT_MDL_000377103 | WMT_MDL_000377103 | | | | | | | | | |
| P-14486 | 12/19/2014 | FW: DC 6028 DEA RECAP | WMT_MDL_000384461 | WMT_MDL_000384463 | | | | | | | | | |
| P-14487 | 4/14/2015 | Dr. Prommersberger RTF's for 2014 | WMT_MDL_000385691 | WMT_MDL_000385691 | | | | | | | | | |
| P-14488 | 7/7/2014 | Follow up items - May Oversight session | WMT_MDL_000388087 | WMT_MDL_000388087 | | | | | | | | | |
| P-14489 | 7/21/2012 | RE: CII Limits | WMT_MDL_000390273 | WMT_MDL_000390273 | | | | | | | | | |
| P-14490 | 11/20/2014 | Language for SOM Process in QPC | WMT_MDL_000396747 | WMT_MDL_000396747 | | | | | | | | | |
| P-14492 | 2/1/2018 | SOM_Data1330_METHADONE HYDROCHLORIDE_02.01.18.xlsx | WMT_MDL_000415760 | WMT_MDL_000415760 | | | | | | | | | |
| P-14499 | | WMT_MDL_000416563 HIGHLY CONFIDENTIAL Track 3 SOM2_OH.xlsx | WMT_MDL_000416563 | WMT_MDL_000416563 | | | | | | | | | |
| P-14500 | 8/29/2007 | RX Associates.doc | WMT_MDL_000422302 | WMT_MDL_000422303 | | | | | | | | | |
| P-14501 | 2/21/2012 | RE: Thinking of you!! | WMT_MDL_000425327 | WMT_MDL_000425331 | | | | | | | | | |
| P-14502 | 9/18/2014 | RE: DC 6028 DEA RECAP | WMT_MDL_000427428 | WMT_MDL_000427430 | | | | | | | | | |
| P-14503 | 10/22/2018 | FW: PCSM training on Opioid Stewardship feedback | WMT_MDL_000437964 | WMT_MDL_000437965 | | | | | | | | | |
| P-14504 | 7/1/2014 | RE: Refusal to Fill | WMT_MDL_000439980 | WMT_MDL_000439981 | | | | | | | | | |
| P-14505 | 11/13/2013 | Focus Area & Spotlight Deck | WMT_MDL_000448283 | WMT_MDL_000448285 | | | | | | | | | |
| P-14506 | 7/29/2013 | RE: Refusal to Fill follow up | WMT_MDL_000455591 | WMT_MDL_000455593 | | | | | | | | | |
| P-14507 | 11/27/2019 | Notice of Central Prescriber Block for DR. ESCOBAR (Walmart/Sam's Club) | WMT_MDL_000457129 | WMT_MDL_000457130 | | | | | | | | | |
| P-14508 | 2/3/2020 | Notice of Central Prescriber Block for DR. KIM (Sam's Club/Walmart) | WMT_MDL_000457135 | WMT_MDL_000457136 | | | | | | | | | |
| P-14509 | 9/16/2013 | FW: Health and Wellness Compliance Scorecard - August FY14 | WMT_MDL_000462428 | WMT_MDL_000462432 | | | | | | | | | |
| P-14510 | 8/22/2013 | FW: CVS Cuts off Docs who prescribe too many narcotics | WMT_MDL_000463386 | WMT_MDL_000463387 | | | | | | | | | |
| P-14511 | 9/27/2013 | SOMP Systems.docx | WMT_MDL_000472666 | WMT_MDL_000472668 | | | | | | | | | |
| P-14512 | 6/25/2015 | Rx Practice Risk Assessment | WMT_MDL_000472669 | WMT_MDL_000472670 | | | | | | | | | |
| P-14513 | 7/7/2014 | Fwd: FYE%2016%20HW%20Compliance%20Technology%20Projects | WMT_MDL_000475078 | WMT_MDL_000475080 | | | | | | | | | |
| P-14514 | 10/30/2014 | HW Practice Compliance FY15-FY16 Goals (3) | WMT_MDL_000475178 | WMT_MDL_000475179 | | | | | | | | | |
| P-14515 | 8/1/2014 | Reddwerks | WMT_MDL_000475225 | WMT_MDL_000475241 | | | | | | | | | |
| P-14516 | 11/9/2012 | RE: A thought.... | WMT_MDL_000480037 | WMT_MDL_000480045 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-14518 | 3/14/2013 | Compliance Focus Areas_3.14.13 | WMT_MDL_000493546 | WMT_MDL_000493593 | | | | | | | | | |
| P-14519 | 3/22/2018 | FW: Overdose Score | WMT_MDL_000497628 | WMT_MDL_000497669 | | | | | | | | | |
| P-14520 | 12/5/2018 | Ways of Working - Documents for Presentation Today | WMT_MDL_000500697 | WMT_MDL_000500706 | | | | | | | | | |
| P-14521 | 11/13/2013 | 11/14/13 Compliance Focus Areas Deck | WMT_MDL_000503039 | WMT_MDL_000503096 | | | | | | | | | |
| P-14522 | 8/7/2015 | RE: Board Objectives | WMT_MDL_000509835 | WMT_MDL_000509836 | | | | | | | | | |
| P-14523 | 2/5/2015 | RE: Please Review: Suspicious Order Monitoring Update - 2/4 | WMT_MDL_000509843 | WMT_MDL_000509844 | | | | | | | | | |
| P-14524 | 9/6/2011 | DEA Risk Assessment 11-19-07 (2) | WMT_MDL_000510716 | WMT_MDL_000510717 | | | | | | | | | |
| P-14525 | 10/9/2014 | October IT Portfolio Projects Report | WMT_MDL_000511386 | WMT_MDL_000511388 | | | | | | | | | |
| P-14526 | 12/18/2014 | FYE 15 Systems Projects - Tracker.xls | WMT_MDL_000514553 | WMT_MDL_000514554 | | | | | | | | | |
| P-14527 | 6/10/2014 | FW: SOM ISD Request Form | WMT_MDL_000518857 | WMT_MDL_000518860 | | | | | | | | | |
| P-14528 | 10/22/2013 | CCTV & CSRA update v.3.pdf - Adobe Acrobat Professional | WMT_MDL_000519179 | WMT_MDL_000519208 | | | | | | | | | |
| P-14529 | 8/16/2013 | 1st cut at Phyllis' edits | WMT_MDL_000519243 | WMT_MDL_000519262 | | | | | | | | | |
| P-14530 | 4/17/2014 | Suspicious Orders.xlsx | WMT_MDL_000520238 | WMT_MDL_000520242 | | | | | | | | | |
| P-14531 | 9/13/2013 | Suspicious Order Monitoring Program - Strategy Deck | WMT_MDL_000520465 | WMT_MDL_000520472 | | | | | | | | | |
| P-14532 | 7/16/2014 | SOM data examples | WMT_MDL_000520492 | WMT_MDL_000520497 | | | | | | | | | |
| P-14533 | 9/26/2014 | RE: Good morning... | WMT_MDL_000522577 | WMT_MDL_000522578 | | | | | | | | | |
| P-14534 | 7/10/2014 | Awareness: Projected FY15 Carry-Over and FY16 ISD Technology Asks | WMT_MDL_000522865 | WMT_MDL_000522946 | | | | | | | | | |
| P-14535 | 9/17/2013 | Suspicious Order Monitoring Program - Work Group Meeting | WMT_MDL_000523547 | WMT_MDL_000523558 | | | | | | | | | |
| P-14536 | 10/15/2013 | Process flow | WMT_MDL_000524864 | WMT_MDL_000524875 | | | | | | | | | |
| P-14537 | 3/20/2014 | FW: SOM Manager JQ - REVISED | WMT_MDL_000528200 | WMT_MDL_000528201 | | | | | | | | | |
| P-14538 | 1/7/2019 | PPT Presentations | WMT_MDL_000529907 | WMT_MDL_000529912 | | | | | | | | | |
| P-14539 | 2/6/2015 | RE: Filling C2--dr under investigation | WMT_MDL_000537448 | WMT_MDL_000537451 | | | | | | | | | |
| P-14540 | 11/12/2015 | RE: Refusal to Fill-store 20 | WMT_MDL_000699182 | WMT_MDL_000699183 | | | | | | | | | |
| P-14541 | 7/13/2017 | Blocked Prescribers | WMT_MDL_000720867 | WMT_MDL_000721002 | | | | | | | | | |
| P-14542 | 11/19/2013 | FW: Final ASPL presentation | WMT_MDL_000724340 | WMT_MDL_000724393 | | | | | | | | | |
| P-14543 | 3/13/2017 | FW: Regarding Mark Flores, blocked provider | WMT_MDL_000798161 | WMT_MDL_000798162 | | | | | | | | | |
| P-14544 | 3/18/2017 | RE: Store #2689 Suspicious Order Remediation | WMT_MDL_000874693 | WMT_MDL_000874699 | | | | | | | | | |
| P-14545 | 6/4/2014 | FW: 042814 Stores #2555, New Castle, DE and #5436, Wilmington, DE-Over 20 Drug Orders | WMT_MDL_000899322 | WMT_MDL_000899327 | | | | | | | | | |
| P-14552 | 12/5/2015 | RE: Dr. Falzuddin Shareef | WMT_MDL_000956439 | WMT_MDL_000956440 | | | | | | | | | |
| P-14553 | 6/25/2015 | Re: Krew from Kentucky | WMT_MDL_000958453 | WMT_MDL_000958455 | | | | | | | | | |
| P-14554 | 3/3/2015 | RE: We need your feedback - c2 drug substance | WMT_MDL_000958740 | WMT_MDL_000958741 | | | | | | | | | |
| P-14559 | 6/5/2015 | RE: Doctor Question | WMT_MDL_001074132 | WMT_MDL_001074133 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-14560 | 3/16/2015 | RE: Dr. Walter Wallingford, MD | WMT_MDL_001091465 | WMT_MDL_001091466 | | | | | | | | | |
| P-14561 | 1/8/2015 | FW: Refusal to Fill | WMT_MDL_001091599 | WMT_MDL_001091600 | | | | | | | | | |
| P-14562 | 10/23/2015 | FW: 3207 FL Final response, supportive documents - signed statement | WMT_MDL_001119744 | WMT_MDL_001119764 | | | | | | | | | |
| P-14563 | 12/19/2013 | RE: toyota Assistance | WMT_MDL_001136326 | WMT_MDL_001136327 | | | | | | | | | |
| P-14564 | 9/25/2013 | RE: Pain clinic info | WMT_MDL_001139294 | WMT_MDL_001139296 | | | | | | | | | |
| P-14565 | 12/12/2013 | RE: CII Utilization Review | WMT_MDL_001140342 | WMT_MDL_001140343 | | | | | | | | | |
| P-14566 | 12/12/2016 | FW: md under investigation | WMT_MDL_001172561 | WMT_MDL_001172564 | | | | | | | | | |
| P-14567 | 4/11/2018 | Re: Refusal to fill | WMT_MDL_001173319 | WMT_MDL_001173321 | | | | | | | | | |
| P-14568 | 2/7/2014 | RE: MD investigation... | WMT_MDL_001182765 | WMT_MDL_001182766 | | | | | | | | | |
| P-14571 | 8/17/2016 | RE: Store 2391 Control Prescriptions | WMT_MDL_001186425 | WMT_MDL_001186426 | | | | | | | | | |
| P-14575 | 3/27/2013 | FW: Dea inquiry | WMT_MDL_001188785 | WMT_MDL_001188789 | | | | | | | | | |
| P-14579 | 8/17/2012 | Oxy 30mg | WMT_MDL_001212932 | WMT_MDL_001212932 | | | | | | | | | |
| P-14580 | 10/23/2013 | FW: Focus Areas - 4th Thursday of the Month Leadership Meeting | WMT_MDL_001213572 | WMT_MDL_001213611 | | | | | | | | | |
| P-14581 | 3/16/2010 | Re: TQ Deck from today | WMT_MDL_001217664 | WMT_MDL_001217681 | | | | | | | | | |
| P-14582 | 2014 | OARRS Opioid Utilization 2013-2014 | ODM_035343 | ODM_035343 | | | | | | | | | |
| P-14584 | 9/4/2015 | U.S. Compliance: Systems portfolio report - 09/04/15 | WMT_MDL_001217727 | WMT_MDL_001217728 | | | | | | | | | |
| P-14585 | 3/19/2014 | HW Compliance Presentation | WMT_MDL_001217733 | WMT_MDL_001217733 | | | | | | | | | |
| P-14587 | 9/28/2012 | RE: CII utilization review | WMT_MDL_001245057 | WMT_MDL_001245058 | | | | | | | | | |
| P-14598 | 7/17/2014 | H&W Portfolio Monthly Status Update | WMT_MDL_001247881 | WMT_MDL_001247882 | | | | | | | | | |
| P-14599 | 8/2/2012 | 1935 Controlled drug Review-- Pennsylvania | WMT_MDL_001250249 | WMT_MDL_001250252 | | | | | | | | | |
| P-14605 | 2/21/2017 | Exhibit B - Prescriber Central Block Process_2.21.17.docx | WMT_MDL_001256127 | WMT_MDL_001256129 | | | | | | | | | |
| P-14609 | 5/11/2015 | RE: Controlled substance webinar | WMT_MDL_001256270 | WMT_MDL_001256272 | | | | | | | | | |
| P-14612 | 8/14/2018 | RE: Pharmacy Safety Metrics | WMT_MDL_001260921 | WMT_MDL_001260921 | | | | | | | | | |
| P-14615 | 2/29/2012 | Information we Discussed | WMT_MDL_001263276 | WMT_MDL_001263277 | | | | | | | | | |
| P-14616 | 5/27/2019 | Dispensing Volume Feedback and Analytics | WMT_MDL_001266857 | WMT_MDL_001266859 | | | | | | | | | |
| P-14617 | 9/6/2016 | FW: CVS Settles w/ MA AG Over PMP | WMT_MDL_001268057 | WMT_MDL_001268062 | | | | | | | | | |
| P-14618 | 4/16/2012 | RE: 1711 Forged or Fraudulent Rx 4-12 | WMT_MDL_001278583 | WMT_MDL_001278584 | | | | | | | | | |
| P-14619 | 6/5/2018 | RE: Centrally blocked prescribers | WMT_MDL_001284293 | WMT_MDL_001284294 | | | | | | | | | |
| P-14620 | 8/29/2012 | Email re Over 20 Report 8.29.12 | WMT_NM_AG_000000131 | WMT_NM_AG_000000131 | | | | | | | | | |
| P-14622 | 8/22/2014 | PCG_Qualitest_GiantEagle_Asses s | ENDO_HSGAC_0007616 | ENDO_HSGAC_0007639 | | | | | | | | | |
| P-14623 | 1/9/2014 | 20140108_Daily_HBC_Controls.xl sx | HBC_MDL00002303 | HBC_MDL00002303 | | | | | | | | | |
| P-14624 | 1/10/2014 | 20140109_Daily_HBC_Controls.xl sx | HBC_MDL00002309 | HBC_MDL00002309 | | | | | | | | | |
| P-14625 | 5/11/2016 | 20160510_Daily_HBC_Controls_ W7.xlsx | HBC_MDL00008497 | HBC_MDL00008498 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-14626 | 6/14/2016 | 20160613_Daily_HBC_Controls_W7.xlsx | HBC_MDL00008725 | HBC_MDL00008726 | | | | | | | | | |
| P-14627 | 12/17/2015 | Code of Conduct | HBC_MDL00043238 | HBC_MDL00043284 | | | | | | | | | |
| P-14628 | 3/26/2017 | Giant Eagle Suspicious Order Monitoring Program.docx | HBC_MDL00043413 | HBC_MDL00043415 | | | | | | | | | |
| P-14629 | 7/23/2013 | Surescripts_CSAR_deck_072313_final | HBC_MDL00052111 | HBC_MDL00052123 | | | | | | | | | |
| P-14630 | 1/15/2016 | FW: Daily HBC Suspicious Purchasing Report - 01/14/16 | HBC_MDL00057971 | HBC_MDL00057973 | | | | | | | | | |
| P-14631 | 9/2/2016 | Rx Bonus Plan 2017 | HBC_MDL00191162 | HBC_MDL00191163 | | | | | | | | | |
| P-14632 | 2/1/2020 | Rx Bonus Plan 2020 | HBC_MDL00191164 | HBC_MDL00191166 | | | | | | | | | |
| P-14633 | 12/9/2015 | Rx Bonus Plan 2016 | HBC_MDL00191167 | HBC_MDL00191168 | | | | | | | | | |
| P-14634 | 12/20/2017 | Rx Bonus Plan 2018 | HBC_MDL00191178 | HBC_MDL00191179 | | | | | | | | | |
| P-14635 | 7/25/2012 | FW: Over 20 Report.xlsx 072512 | WMT_NM_AG_000000227 | WMT_NM_AG_000000228 | | | | | | | | | |
| P-14636 | 9/19/2013 | FW: Over 20 Report 9.18.13 | WMT_NM_AG_000006869 | WMT_NM_AG_000006871 | | | | | | | | | |
| P-14638 | 3/6/2013 | FW: Over 20 Report 03/06/2013 | WMT_NV_000000718 | WMT_NV_000000719 | | | | | | | | | |
| P-14647 | 2/22/2012 | Practice Compliance Org Chart | WMT_MDL_000012773 | WMT_MDL_000012773 | | | | | | | | | |
| P-14648 | 3/4/2015 | Practice Compliance Org Chart | WMT_MDL_000012726 | WMT_MDL_000012728 | | | | | | | | | |
| P-14649 | 1/23/2008 | Org Chart | WMT_MDL_000012772 | WMT_MDL_000012772 | | | | | | | | | |
| P-14650 | 8/1/2017 | HW Compliance Org Chart | WMT_MDL_000067568 | WMT_MDL_000067568 | | | | | | | | | |
| P-14651 | 2/17/2014 | Practice Compliance Org Chart | WMT_MDL_000012753 | WMT_MDL_000012753 | | | | | | | | | |
| P-14653 | 7/24/2007 | 2007 Product Concept Doc Improve Pharmacy Central Fill | WMT_MDL_000426712 | WMT_MDL_000426732 | | | | | | | | | |
| P-14656 | 10/2/2018 | Red Flag Resource Powerpoint | WMT_MDL_000500115 | WMT_MDL_000500116 | | | | | | | | | |
| P-14667 | 7/9/1996 | Walmart Pharmacy CE - New Trends in the Use of Opioids in Pain Management | PKY180257493 | PKY180257493 | | | | | | | | | |
| P-14671 | 7/9/1996 | Walmart Pharmacy Services - 1996 Symposium Information Sheet | PKY180794346 | PKY180794354 | | | | | | | | | |
| P-14672 | 9/15/2002 | Copy of the Chain Pharmacist Practice memo from the National Association of Chain Drug Stores: Special Issue: Prescription Drug Misuse and Abuse | PKY181864224 | PKY181864229 | | | | | | | | | |
| P-14673 | 6/5/2012 | RE: Opportunity for Walmart to partner with manufacturer to reduce Oxycontin abuse - no cost to Walmart - RESPONSE REQUESTED | PPLPC004000325236 | PPLPC004000325241 | | | | | | | | | |
| P-14674 | 1/30/2013 | Re: Walmart not Dispensing 80mg | PPLPC004000346133 | PPLPC004000346134 | | | | | | | | | |
| P-14678 | 1/13/2003 | email re: RE: 1/14/2003 Walmart | PPLPC008000028695 | PPLPC008000028696 | | | | | | | | | |
| P-14680 | 4/29/2016 | Email regarding Weekly Highlights P/E 4/29/16 | PPLPC019001271323 | PPLPC019001271342 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-14688 | 9/24/2001 | Re: Follow Up to NACDS Pharmacy and Technology Conference | PPLPC008000020592 | PPLPC008000020595 | | | | | | | | | |
| P-14690 | 6/2/2000 | FW:Pharmacy Support | PDD8801136088 | PDD8801136089 | | | | | | | | | |
| P-14691 | N/A | Living Our Vision | PDD8801366607 | PDD8801366664 | | | | | | | | | |
| P-14692 | N/A | Use of Opioids in Chronic Non Cancer Pain | PKY180293682 | PKY180293697 | | | | | | | | | |
| P-14693 | 4/12/2001 | RE: Walgreens CE programs for 6/19/01 and 6/20/01 | PKY181985212 | PKY181985213 | | | | | | | | | |
| P-14695 | 4/18/2011 | Pain Management for the Primary Care Provider: A daylong course in the diagnosis, treatment, and legal issues surrounding the treatment of pain | PPLP003469655 | PPLP003469655 | | | | | | | | | |
| P-14696 | 10/24/2001 | National Accounts 2001 | PPLPC008000021189 | PPLPC008000021190 | | | | | | | | | |
| P-14697 | 10/21/1999 | FW: Walgreens Program | PPLPC012000007168 | PPLPC012000007168 | | | | | | | | | |
| P-14698 | 4/6/2011 | HAD_Activities_2011_04_06_v2 | PPLPC021000370693 | PPLPC021000370702 | | | | | | | | | |
| P-14699 | 6/21/2011 | ionEDGE_OL_Listing_2011_Jun-21 | PPLPC021000386842 | PPLPC021000386842 | | | | | | | | | |
| P-14700 | 3/5/2000 | Walgreens RPH Invitation2 | PPLPC024000012812 | PPLPC024000012813 | | | | | | | | | |
| P-14701 | 4/3/2000 | Walgreens CEU Program | PPLPC024000014422 | PPLPC024000014423 | | | | | | | | | |
| P-14703 | 12/12/2011 | Online Certified Education for Pharmacists from RxSchool | PPLPC024000596538 | PPLPC024000596540 | | | | | | | | | |
| P-14704 | 11/1/1999 | RE: Walgreens CE Programs Oct 25th @ 26th | PPLPC025000005258 | PPLPC025000005259 | | | | | | | | | |
| P-14705 | 11/4/1999 | End of Month Report - October 1999 | PPLPC028000008080 | PPLPC028000008083 | | | | | | | | | |
| P-14706 | 6/23/2000 | FW: A COMPLETE Value-Added Program | PPLPC029000019201 | PPLPC029000019203 | | | | | | | | | |
| P-14708 | 2/6/2004 | Re: Jennifer Bolen, JD | PPLPC046000007359 | PPLPC046000007360 | | | | | | | | | |
| P-14709 | 9/19/2012 | MDL-07 Pain Law Survey - Group 4 (Bolen) | PPLPC048000051384 | PPLPC048000051391 | | | | | | | | | |
| P-14710 | 12/27/1988 | Edmund Choroski RPH LTR 12-27-1988 - Searchable (2)_Redacted | US-DEA-00025683 | US-DEA-00025683 | | | | | | | | | |
| P-14711 | 6/30/2011 | WALMART_ MOA_03 17 2011 | US-DEA-00006101 | US-DEA-00006107 | | | | | | | | | |
| P-14738 | 8/20/2011 | Email FL FOC - Recap of Meeting with DEA (Forbes) | WAGFLDEA000001168 | WAGFLDEA000001173 | | | | | | | | | |
| P-14739 | 4/9/2013 | RE: Walgreens Woodland Data - Red Stores Attachment Walgreens Woodland DC_Mar 2013 | WAGMDL00407671 | WAGMDL00407674 | | | | | | | | | |
| P-14743 | 12/2/2013 | FW: Letter to Outlier Physicians Attachment GFD Outlier Letter #1v1HL | WAGMDL00407179 | WAGMDL00407184 | | | | | | | | | |
| P-14744 | 1/16/2013 | Re: Executive Committee Meeting -- January 17, 2013 -- Chairman's Script Attachment | WAGMDL00502664 | WAGMDL00502668 | | | | | | | | | |
| P-14745 | 1/8/2014 | Fwd: Targeted drugs for GFD | WAGMDL00704540 | WAGMDL00704540 | | | | | | | | | |
| P-14746 | 5/1/2013 | New Rx Integrity Update May 2013 PPT | WAGMDL00655767 | WAGMDL00655785 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-14748 | 1/9/2014 | Email Controlled substance information Attachments Rx Integrity and Controlled Substance Dispensing; | WAGMDL00704532 | WAGMDL00704539 | | | | | | | | | |
| P-14749 | 3/20/2014 | Re: DEA questions Costco's record keeping for hydrocodone pills Attachment purpose_disclaimer | WAGMDL00705156 | WAGMDL00705160 | | | | | | | | | |
| P-14750 | 6/11/2013 | Settlement and Memorandum of Agreement, Department of Justice and Walgreens Co. | WAGMDL00286197 | WAGMDL00286209 | | | | | | | | | |
| P-14751 | 3/22/2013 | DEA strategy meeting 3 22 13 | WAGMDL00667587 | WAGMDL00667588 | | | | | | | | | |
| P-14752 | 6/11/2013 | RE: Article: Walgreen Florida Facility Barred From Shipping Oxycodone | PPLPC029000522318 | PPLPC029000522320 | | | | | | | | | |
| P-14753 | 12/7/2012 | FW: Executive Summary Attachment AAPM executive summary final | WAGMDL00704665 | WAGMDL00704674 | | | | | | | | | |
| P-14754 | 11/9/1998 | Walgreen and Purdue Agree to the Following | PKY181268638 | PKY181268643 | | | | | | | | | |
| P-14756 | 11/26/2012 | Email Pharmacy Manufacturer and Wholesaler Communication Plan Attachments Agenda- Pharmacy Manufacturer and Wholesaler Communication Plan; Copy of Frank's and Jeff's Contact List-Talking Points 12-2012 (2); Copy of J Berkowitz Contact List-Talking Points 12-2012 (3); Branded Pharmaceutical Manufacturers FAQs RE: Direct Purchase Agreements with Branded Pharmaceutical Manufacturers; Wholesaler FAQs-direct 11-2013--JP; ABDC RFP Letter 12-2012; Mfr RFP letter 12-2012; CAH RFP Letter 12-2012 | WAGMDL00485568 | WAGMDL00485581 | | | | | | | | | |
| P-14758 | 9/26/2012 | Email Article in WSJ | WAGMDL00528261 | WAGMDL00528263 | | | | | | | | | |
| P-14761 | 1/30/2015 | FW: Store Feedback on ABC | WAGMDL00486353 | WAGMDL00486355 | | | | | | | | | |
| P-14766 | 2/26/2013 | Re: Perrysburg CIII-CV - follow up | WAGMDL00358466 | WAGMDL00358467 | | | | | | | | | |
| P-14767 | 9/19/2012 | RE: Jupiter Email | WAGMDL00308159 | WAGMDL00308160 | | | | | | | | | |
| P-14768 | 10/8/2012 | FW: Jupiter - PB MDG Shift By Date Attachment C2 GA 10-8-12 | WAGMDL00308088 | WAGMDL00308090 | | | | | | | | | |
| P-14769 | 2/20/2013 | FW: Perrysburg CIII-CV - follow up | WAGMDL00357495 | WAGMDL00357497 | | | | | | | | | |
| P-14774 | 3/4/2011 | Re: Fw: INC000002834005 <Store #3836 WIC#682971, ordered qty 148> | WAGFLDEA00000908 | WAGFLDEA00000911 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------------------|----------------------------------|--|--|--|--|--|--|--|--|--|
| P-14776 | 5/5/2011 | Re: Fw: Oxycontin question | WAGFLDEA00001039 | WAGFLDEA00001046 | | | | | | | | | |
| P-14777 | 5/16/2011 | Re: Fw: CII Order | WAGFLDEA00001049 | WAGFLDEA00001059 | | | | | | | | | |
| P-14778 | 1/9/2012 | Email Woodland CIII - CV Expansion Attachment Perryburg_CII_costsavings | WAGMDL00541656 | WAGMDL00541657 | | | | | | | | | |
| P-14781 | 4/6/2012 | Email Talking Points on Current Field Activity | WAGMDL00317111 | WAGMDL00317112 | | | | | | | | | |
| P-14782 | 9/18/2012 | Email USA Drug / FL DEA Issue: 9/18 update | WAGMDL00667931 | WAGMDL00667934 | | | | | | | | | |
| P-14783 | 9/27/2012 | FW: ANDA backup C2 call summary | WAGMDL00541577 | WAGMDL00541579 | | | | | | | | | |
| P-14784 | 11/2/2012 | Florida DBPR Notice of Violation to Walgreens | WAGMDL00426289 | WAGMDL00426293 | | | | | | | | | |
| P-14785 | 2/7/2013 | RE: Questions for Walgreens Store | WAGMDL00132065 WAGMDL00132065 | WAGMDL00132068 WAGMDL00132101 | | | | | | | | | |
| P-14786 | 2/21/2013 | Re: CSOS to stores for Walgreens Follow-up Meeting | WAGMDL00524763 | WAGMDL00524771 | | | | | | | | | |
| P-14787 | 4/3/2013 | FW: Walgreens Schedule Recap | WAGMDL00303003 | WAGMDL00303005 | | | | | | | | | |
| P-14791 | 6/11/2013 | Email WALGREENS / DEA END-OF-DAY MEDIA COVERAGE UPDATE -- 06/11/2013 | WAGMDL00407509 | WAGMDL00407511 | | | | | | | | | |
| P-15017 | 5/10/2012 | Email re SOM Project | CVS-MDLT1-000128001 | CVS-MDLT1-000128004 | | | | | | | | | |
| P-15018 | 7/6/2005 | Consulting Services Agreement Attachment XI | IQVIA-CVS-000000008 | IQVIA-CVS-000000009 | | | | | | | | | |
| P-15019 | 1/9/2012 | CVS / BuzzeeoPDMA - SOM PSE Maintenance Proposal | IQVIA-CVS-000000128 | IQVIA-CVS-000000129 | | | | | | | | | |
| P-15020 | 4/1/2009 | Email re CVS Elements used by SOM Model | IQVIA-CVS-000000275 | IQVIA-CVS-000000278 | | | | | | | | | |
| P-15021 | 6/28/2009 | Email re SOMs Calculation | IQVIA-CVS-000000303 | IQVIA-CVS-000000305 | | | | | | | | | |
| P-15022 | 6/30/2009 | Email re SOM Calculation Results | IQVIA-CVS-000000466 | IQVIA-CVS-000000468 | | | | | | | | | |
| P-15024 | 2/15/2010 | Email re Adjustment to the CVS SOM | IQVIA-CVS-000000484 | IQVIA-CVS-000000484 | | | | | | | | | |
| P-15025 | 7/29/2009 | Email SOM Report | IQVIA-CVS-000001328 | IQVIA-CVS-000001328 | | | | | | | | | |
| P-15026 | 6/10/2009 | Email re CVS Knoxville | IQVIA-CVS-000001602 | IQVIA-CVS-000001631 | | | | | | | | | |
| P-15027 | 9/29/2010 | Email re milligram Conversion for CS SOM Retunement | IQVIA-CVS-000000653 | IQVIA-CVS-000000654 | | | | | | | | | |
| P-15028 | 2/4/2013 | Email re Hydro Shift to RPH only | CVS-MDLT1-000128881 | CVS-MDLT1-000128882 | | | | | | | | | |
| P-15029 | 3/8/2013 | Email re Commented Version of Dream List | CVS-MDLT1-000127548 | CVS-MDLT1-000127552 | | | | | | | | | |
| P-15030 | 6/30/2010 | Email re SOM Update | IQVIA-CVS-000000493 | IQVIA-CVS-000000493 | | | | | | | | | |
| P-15031 | 4/12/2012 | Email Attaching Eval of Suspicious Orders and DEA National Forensic Lab Information System NFLIS | CVS-MDLT1-000124986 | CVS-MDLT1-0001245039 | | | | | | | | | |
| P-15033 | 4/3/2014 | Email re AROCS Reporting DC SOP | CVS-MDLT1-000022355 | CVS-MDLT1-000022361 | | | | | | | | | |
| P-15034 | 11/25/2009 | Email re Updated DEA SOP | CVS-MDLT1-000087905 | CVS-MDLT1-000087971 | | | | | | | | | |
| P-15035 | 8/30/2010 | Email re Info on Previous Data/SOM retunement | CVS-MDLT1-000111395 | CVS-MDLT1-000111396 | | | | | | | | | |
| P-15036 | 5/16/2011 | Email re Control Drug IRR Doc | CVS-MDLT1-000111539 | CVS-MDLT1-000111540 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-15037 | 9/17/2015 | Walgreens Good Faith Dispensing Email and Policies | WAGMDL00001237 | WAGMDL00001251 | | | | | | | | | |
| P-15038 | 5/24/2016 | TD GFD Policy with out PMP printing | WAGMDL00001150 | WAGMDL00001156 | | | | | | | | | |
| P-15050 | 11/30/2004 | Controlled Drug Policy | WAGFLDEA00000020 | WAGFLDEA00000020 | | | | | | | | | |
| P-15051 | 2012 | DEA Reference Tools | WAGFLDEA000000157 | WAGFLDEA000000157 | | | | | | | | | |
| P-15052 | 5/1/2011 | Dispensing Prescription Drugs Policy | WAGFLDEA000000161 | WAGFLDEA000000161 | | | | | | | | | |
| P-15053 | 10/27/2011 | Walgreens Good Faith Dispensing PPT Your Responsibilities - Training Module | WAGFLDEA000000184 | WAGFLDEA000000205 | | | | | | | | | |
| P-15054 | 11/8/2011 | Controlled Substance Prescriptions & Good Faith Dispensing | WAGFLDEA000000206 | WAGFLDEA000000207 | | | | | | | | | |
| P-15056 | 8/29/2007 | Preventing Diversion of Controlled Substances | WAGFLDEA000000271 | WAGFLDEA000000271 | | | | | | | | | |
| P-15057 | 3/2/2011 | Refilling Prescriptions | WAGFLDEA000000276 | WAGFLDEA000000276 | | | | | | | | | |
| P-15058 | 6/27/2007 | Theft or Diversion of Prescription Drugs by Walgreens Family of Companies Employees | WAGFLDEA000000328 | WAGFLDEA000000328 | | | | | | | | | |
| P-15060 | 11/4/2011 | Action Required: Control Substance Powerpoint from Wednesday | WAGFLDEA000000477 | WAGFLDEA000000507 | | | | | | | | | |
| P-15061 | N/A | Guidelines for Appropriate Dispensing of Oxycodone | WAGFLDEA000000658 | WAGFLDEA000000658 | | | | | | | | | |
| P-15062 | N/A | Target Drug Good Faith Dispensing Checklist | WAGMDL000000360 | WAGMDL000000360 | | | | | | | | | |
| P-15064 | 5/15/2017 | Target Drug Good Faith Dispensing Policy | WAGMDL0000003569 | WAGMDL0000003578 | | | | | | | | | |
| P-15066 | 5/11/2016 | Controlled Substance Prescriptions & Good Faith Dispensing Policy | WAGMDL0000003934 | WAGMDL0000003941 | | | | | | | | | |
| P-15068 | 5/1/2017 | Controlled Substance Prescriptions & Good Faith Dispensing Policy; Target Drug Good Faith Dispensing Checklist, Steps for the Technician to Complete; Target Drug Good Faith Dispensing Policy | WAGMDL0000005358 | WAGMDL0000005373 | | | | | | | | | |
| P-15071 | 3/6/2018 | Target Drug Good Faith Dispensing Checklist, Steps for the Technician to Complete | WAGMDL0000005573 | WAGMDL0000005577 | | | | | | | | | |
| P-15073 | 6/25/2016 | Target Drug Good Faith Dispensing Policy | WAGMDL0000007207 | WAGMDL0000007218 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-15074 | 2/21/2014 | Controlled Substance Prescriptions and Good Faith Dispensing Policy (2/21/2014); Controlled Substance Prescriptions and Good Faith Dispensing Policy (8/1/2013); Controlled Substance Prescriptions and Good Faith Dispensing Policy (6/11/2012); Controlled Substance Prescriptions and Good Faith Dispensing Policy (8/11/2011); Controlled Substance Prescriptions and Good Faith Dispensing Policy (6/20/2011); Good Faith Practices and Fraudulent Prescriptions (3/28/2007); Good Faith Practices and Fraudulent Prescriptions; Target Drug Good Faith Dispensing Policy (6/1/2016); Target Drug Good Faith Dispensing Policy (9/1/2013) | WAGMDL00008070 | WAGMDL00008132 | | | | | | | | | |
| P-15083 | 6/18/2013 | RE: GLMS Report | WMT_MDL_000182793 | WMT_MDL_000183114 | | | | | | | | | |
| P-15084 | 2/6/2018 | Target Drug Good Faith Dispensing Checklist, Steps for the Technician to Complete | WAGMDL00009436 | WAGMDL00009439 | | | | | | | | | |
| P-15085 | 9/9/2015 | RE: Monthly DM webinars; Good Faith Dispensing DM Webinar | WAGMDL00037613 | WAGMDL00037624 | | | | | | | | | |
| P-15086 | 8/3/2017 | Blocked Prescribers Project | WMT_MDL_000204841 | WMT_MDL_000204844 | | | | | | | | | |
| P-15087 | 1/8/2013 | Target Drug Good Faith Dispensing Policy; Target Drug Good Faith Dispensing REDLINE | WAGMDL00043333 | WAGMDL00043338 | | | | | | | | | |
| P-15088 | 4/10/2018 | Re: H&W Proactive Dashboards | WMT_MDL_000281261 | WMT_MDL_000281261 | | | | | | | | | |
| P-15090 | 9/3/2018 | Good Faith Dispensing redline draft; GFD "Call to Prescriber" Template; Target Drug Good Faith Dispensing Policy | WAGMDL00049466 | WAGMDL00049476 | | | | | | | | | |
| P-15092 | 2012 | Good Faith Dispensing of Controlled Substances - Policy Acknowledgement | WAGMDL00049534 | WAGMDL00049546 | | | | | | | | | |
| P-15093 | 8/1/2013 | Controlled Substance Prescriptions & Good Faith Dispensing | WAGMDL00054578 | WAGMDL00054586 | | | | | | | | | |
| P-15094 | 6/6/2014 | Market 4 RX integrity Presentation PPT | WAGMDL00060045 | WAGMDL00060082 | | | | | | | | | |
| P-15095 | 5/9/2014 | Market 13 RX integrity Presentation PPT | WAGMDL00060207 | WAGMDL00060246 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-15096 | 9/12/2016 | DM Walk July - August Monthly Compliance Walkx | WAGMDL00065344 | WAGMDL00065353 | | | | | | | | | |
| P-15097 | 11/9/2012 | Draft Target Drug Good Faith Dispensing Policy | WAGMDL00066712 | WAGMDL00066721 | | | | | | | | | |
| P-15101 | N/A | Current Fill Process Chart | WAGMDL00121783 | WAGMDL00121787 | | | | | | | | | |
| P-15105 | 11/12/2015 | Prescription Drug Monitoring Program PPT | WAGMDL00269423 | WAGMDL00269437 | | | | | | | | | |
| P-15106 | 6/1/2016 | Target Drug Good Faith Dispensing Policy | WAGMDL00289031 | WAGMDL00289035 | | | | | | | | | |
| P-15107 | 11/1/2012 | November 2012 Target Drug Good Faith Dispensing Policy | WAGMDL00289036 | WAGMDL00289039 | | | | | | | | | |
| P-15108 | 9/23/2013 | Target Drug Good Faith Dispensing Policy | WAGMDL00289040 | WAGMDL00289044 | | | | | | | | | |
| P-15109 | 10/2/2017 | Target Drug Good Faith Dispensing Policy | WAGMDL00289045 | WAGMDL00289049 | | | | | | | | | |
| P-15110 | 2013 | 2013 National Target Drug Good Faith Dispensing Policy Final; National Target Drug Good Faith Dispensing Policy; Target Drug Good Faith Dispensing Policy (2012) | WAGMDL00289331 | WAGMDL00289453 | | | | | | | | | |
| P-15113 | 12/19/2016 | Preventing Theft or Loss of Controlled Substances | WAGMDL00294318 | WAGMDL00294319 | | | | | | | | | |
| P-15114 | N/A | Good Faith Dispensing (GFD), District Leader Roles and Responsibilities | WAGMDL00302782 | WAGMDL00302784 | | | | | | | | | |
| P-15115 | N/A | Good Faith Dispensing - Compliance Checklist | WAGMDL00303117 | WAGMDL00303118 | | | | | | | | | |
| P-15116 | N/A | Good Faith Dispensing (GFD) Compass Communication edit 3 | WAGMDL00303281 | WAGMDL00303297 | | | | | | | | | |
| P-15117 | 1/14/2013 | Good Faith Dispensing Policy review | WAGMDL00303383 | WAGMDL00303407 | | | | | | | | | |
| P-15118 | N/A | Pharmacy Manager letter TD GFD | WAGMDL00304139 | WAGMDL00304144 | | | | | | | | | |
| P-15119 | 2/9/2005 | Good Faith Practices (2/9/2005); Good Faith Practices (3/24/2003); Good Faith Practices (4/3/2003); Good Faith Practices (1/6/2003); Good Faith Practices (6/14/2004); Good Faith Practices/Fraudulent Prescriptions (2/26/2006); Good Faith Practices (8/1/1998); Good Faith Practices (11/15/2005) | WAGMDL00335010 | WAGMDL00335025 | | | | | | | | | |
| P-15121 | 12/9/2016 | Up to date List of Physicians from Misc Media Reports as of December 9 2016 | WMT_MDL_000370131 | WMT_MDL_000370132 | | | | | | | | | |
| P-15123 | 2/10/2015 | RE: Ohio OARRS Reporting | WMT_MDL_000393081 | WMT_MDL_000393082 | | | | | | | | | |
| P-15125 | N/A | Preventing Filling of Prescriptions for Prescribers with Inactive DEA Registrations | WAGMDL00387991 | WAGMDL00387994 | | | | | | | | | |

| | | | | | | | | | | | | | | |
|---------|------------|---|----------------|----------------|--|--|--|--|--|--|--|--|--|--|
| P-15126 | 10/17/2013 | Walgreens Pharmacy and Health Care Code of Conduct and General Training | WAGMDL00444056 | WAGMDL00444058 | | | | | | | | | | |
| P-15129 | N/A | Good Faith Dispensing (GFD) Training FAQs | WAGMDL00491159 | WAGMDL00491159 | | | | | | | | | | |
| P-15131 | N/A | RX Integrity Calculating total dosage for opioids | WAGMDL00491170 | WAGMDL00491170 | | | | | | | | | | |
| P-15132 | N/A | Calculating MME equivalents | WAGMDL00491178 | WAGMDL00491178 | | | | | | | | | | |
| P-15133 | N/A | Target Drug Good Faith Dispensing FAQ | WAGMDL00491179 | WAGMDL00491179 | | | | | | | | | | |
| P-15161 | 11/11/2015 | DUR Pharmacy Operations Filling Prescriptions | WAGMDL00492959 | WAGMDL00492959 | | | | | | | | | | |
| P-15162 | N/A | Drug Utilization review DUR policies and standard operating procedures | WAGMDL00492960 | WAGMDL00492960 | | | | | | | | | | |
| P-15166 | N/A | Filling Instructions | WAGMDL00492965 | WAGMDL00492965 | | | | | | | | | | |
| P-15169 | 5/1/2011 | Pharmacist Training Program Trainer's Guide | WAGMDL00520675 | WAGMDL00520731 | | | | | | | | | | |
| P-15170 | N/A | Target Drug Good Faith Dispensing Policy Store manager LD report | WAGMDL00656588 | WAGMDL00656594 | | | | | | | | | | |
| P-15171 | 4/17/2012 | Routine and periodic training on CS and GFD | WAGMDL00657563 | WAGMDL00657566 | | | | | | | | | | |
| P-15172 | N/A | Target Drug (TD) Good Faith Dispensing (GFD) FAQ | WAGMDL00657585 | WAGMDL00657590 | | | | | | | | | | |
| P-15173 | 2013 | 2013 DEA Subpoenas | WAGMDL00657806 | WAGMDL00657828 | | | | | | | | | | |
| P-15174 | 6/1/2003 | Good Faith Practices | WAGMDL00670946 | WAGMDL00670947 | | | | | | | | | | |
| P-15175 | 6/18/2004 | Good Faith Practices | WAGMDL00670948 | WAGMDL00670949 | | | | | | | | | | |
| P-15176 | 6/26/2006 | Good Faith Practices | WAGMDL00670950 | WAGMDL00670951 | | | | | | | | | | |
| P-15177 | 2/24/2003 | Good Faith Practices | WAGMDL00670954 | WAGMDL00670955 | | | | | | | | | | |
| P-15178 | 11/15/2005 | Good Faith Practices | WAGMDL00670963 | WAGMDL00670964 | | | | | | | | | | |
| P-15179 | 2/1/2014 | Best Practices for Filling Controlled Substance Prescriptions and Providing Good Customer Service | WAGMDL00675061 | WAGMDL00675074 | | | | | | | | | | |
| P-15181 | 2013 | 2013 Targeted Drug Good Faith Dispensing Policy & Procedures | WAGMDL00698364 | WAGMDL00698366 | | | | | | | | | | |
| P-15183 | N/A | Pharmacy Losses Dashboard: HRxD | WAGMDL00736117 | WAGMDL00736118 | | | | | | | | | | |
| P-15184 | 6/1/2017 | Accepting New Verbal Prescriptions; Dispensing Prescription Drug Policy (1/10/2017) | WAGMDL00737720 | WAGMDL00737770 | | | | | | | | | | |
| P-15187 | N/A | Schedule II Narcotic Dispensing Guidelines v3 | WAGMDL00746791 | WAGMDL00746805 | | | | | | | | | | |
| P-15188 | 2012 | Controlled Substance Prescriptions and Good Faith Dispensing Policy REDLINE | WAGMDL00767022 | WAGMDL00767027 | | | | | | | | | | |
| P-15189 | 2012 | Controlled Substance Prescriptions and Good Faith Dispensing Policy | WAGMDL00767028 | WAGMDL00767030 | | | | | | | | | | |
| P-15190 | 2012 | Controlled Substance Prescriptions and Good Faith Dispensing Policy | WAGMDL00767031 | WAGMDL00767033 | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-15191 | N/A | Target Drug Good Faith Dispensing - Prescriber Office Visit Checklist | WAGMDL00774701 | WAGMDL00774706 | | | | | | | | | |
| P-15192 | 10/1/2016 | Walgreens SOP Fraudulent Prescriptions | WAGMDL00778614 | WAGMDL00778615 | | | | | | | | | |
| P-15196 | 6/1/2019 | Pharmacy Manager development program screenshots; Code of Conduct and Business Ethics; DEA Pharmacist Manual; FAQ changes in this years program; Chapter 5 Executes with Excellence, Maintains Pharmacy Expertise, Manages Time Effectively; Chapter 6 Communicates with Credibility; Chapter 4 Builds Talent; Clues to the Queues - Best Practices on Managing Exception Queues; Chapter 10 Builds and Sustains Relationships; Chapter 7. Acts with Professional Integrity, Solves Problems, Focuses on Quality; Chapter. 8 Leads Change; Chapter 9. Advocates customer focus, counsels patients effectively | WAGMDL00779574 | WAGMDL00779831 | | | | | | | | | |
| P-15199 | 3/27/2014 | DC 6045 Over 20 Report 03.27.14 | WMT_MDL_000415840 | WMT_MDL_000415841 | | | | | | | | | |
| P-15225 | 5/6/2011 | Walgreens Pharmacy and Health Care Code of Conduct and General Training | WAGMDL00801267 | WAGMDL00801270 | | | | | | | | | |
| P-15226 | 5/3/2012 | DEA Reference Tools | WAGMDL00801297 | WAGMDL00801297 | | | | | | | | | |
| P-15227 | 11/8/2011 | Controlled Substance Prescriptions & Good Faith Dispensing | WAGMDL00801346 | WAGMDL00801347 | | | | | | | | | |
| P-15230 | 8/29/2007 | Preventing Diversion of Controlled Substances | WAGMDL00801411 | WAGMDL00801411 | | | | | | | | | |
| P-15231 | 3/2/2011 | Refilling Prescriptions | WAGMDL00801416 | WAGMDL00801416 | | | | | | | | | |
| P-15234 | 5/1/2011 | Walgreens Pharmacy and Health Care Code of Conduct Policy | WAGMDL00801487 | WAGMDL00801487 | | | | | | | | | |
| P-15241 | 8/1/1998 | Accepting and Filling New Prescriptions | WAGMDL00801504 | WAGMDL00801507 | | | | | | | | | |
| P-15244 | 9/7/2004 | Accepting and Filling the Prescription Procedure 5 | WAGMDL00801513 | WAGMDL00801515 | | | | | | | | | |
| P-15249 | 12/4/2002 | Deleting Prescriptions with Stale Dates | WAGMDL00801523 | WAGMDL00801523 | | | | | | | | | |
| P-15272 | 10/15/1997 | Refilling Prescriptions Policy | WAGMDL00801582 | WAGMDL00801583 | | | | | | | | | |
| P-15287 | 6/10/2014 | Email RAD 10610 Snapshot; Attachment Copy of Rite Aid 10610 Pharm Snapshot_ap comments 06 09 14 | WAGNYS00046862 | WAGNYS00046863 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-15288 | 4/18/2011 | Email Follow Up - Pain Week; Attachment Pain Presentation 4.11.11; Pain Presentation 4.11.11 | PPLPC024000543773 | PPLPC024000543774 | | | | | | | | | |
| P-15289 | 4/28/2015 | Email Updated Slides; Attachments Rx Integrity District Manager Training PPT; Pharmacy Inventory | WAGMDL00004704 | WAGMDL00004757 | | | | | | | | | |
| P-15290 | 6/10/2016 | Email C2 Tote Audit; Attachment DMAIC Storyboard DEFINE C2 tote audit PPT | WAGMDL00094053 | WAGMDL00094067 | | | | | | | | | |
| P-15291 | 8/16/2012 | RE: Controlled Substance Order Quantity Override Form | WAGMDL00107470 | WAGMDL00107472 | | | | | | | | | |
| P-15292 | 8/9/2012 | FW: Controlled Substance Order Quantity Override Form | WAGMDL00107532 | WAGMDL00107533 | | | | | | | | | |
| P-15293 | 4/19/2013 | RE: Top 500 Potential Risk Stores Oxycodone - 3 months ending February 2013 *UPDATED TOP 100* | WAGMDL00245776 | WAGMDL00245780 | | | | | | | | | |
| P-15294 | 5/13/2016 | Re: ABC Meeting; Attachment WAG - Partial Controls Discussion Document 5.9.16 PPT | WAGMDL00283633 | WAGMDL00283641 | | | | | | | | | |
| P-15295 | 3/8/2013 | Email notes from last Friday's DEA strategy meeting; Attachment DEA Strategy meeting 3.1.13 | WAGMDL00302948 | WAGMDL00302950 | | | | | | | | | |
| P-15296 | 5/5/2014 | RE: GFD Document Requests; Attachments Dir Rx Integrity Goals; Goal_Details_Nick_Leners | WAGMDL00305702 | WAGMDL00305736 | | | | | | | | | |
| P-15297 | 1/14/2013 | RE: Process Flow Documents Attachments DEA Controlled Substance Reporting; Decision Process Flow Chart for Ceiling Violation; Good Faith Dispensing Policy Review; Suspicious Order Monitoring Program Policy and Procedures for the Rx Integrity Team; Controlled Substance Reporting KPI Screen Shots; RXS Investigate Straw Man | WAGMDL00311317 | WAGMDL00311341 | | | | | | | | | |
| P-15298 | 11/12/2012 | Email RXS Investigation of Stores Attachment What Should the RXS Investigate | WAGMDL00311366 | WAGMDL00311367 | | | | | | | | | |
| P-15299 | 1/7/2013 | Email Re-look at store walk and 5 minute meeting notes re: GFD | WAGMDL00314402 | WAGMDL00314402 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-15300 | 1/14/2013 | Report Re: Suspicious Order Reporting Query - WALGREENS CORPORATION Distribution Center - DEA #RW0294493 | DEA-T3CC-00014231 | DEA-T3CC-00014231 | | | | | | | | | |
| P-15301 | 10/24/2012 | Email SOM Attachment Controlled Substance Order and SOM procedures | WAGMDL00317049 | WAGMDL00317050 | | | | | | | | | |
| P-15303 | 6/5/2012 | Email Controlled Substance Order Quantity Override Process Attachment Process for Ordering Specific Manufacturers | WAGMDL00371319 | WAGMDL00371322 | | | | | | | | | |
| P-15304 | 4/15/2013 | NACDS DEA documents | WAGMDL00897784 | WAGMDL00897810 | | | | | | | | | |
| P-15305 | 10/4/2012 | FL DM Good Faith Dispensing Training PPT | WAGMDL00389171 | WAGMDL00389186 | | | | | | | | | |
| P-15306 | 1/18/2012 | RE: Confirmed: RxOps Meeting Attachments 01 - How much do you know about RxHWT; RxOps - RxHWT Strategy Workshop; 03 - RxHWT Roadmap - 01-18-2011 | WAGMDL00484976 | WAGMDL00485028 | | | | | | | | | |
| P-15307 | 2/28/2017 | Email Green Belt Project Introduction Attachments Project Kickoff Meeting - TDGFD Process Time Reduction PPT; TDGFD Charter V4 | WAGMDL00573578 | WAGMDL00573605 | | | | | | | | | |
| P-15308 | 7/26/2010 | PBM 101 Presentation - July 2012 PPT; Pharmacy Workload | WAGMDL00591279 | WAGMDL00591444 | | | | | | | | | |
| P-15309 | 3/1/2013 | DEA Market Meeting Update March 2013 PPT | WAGMDL00674641 | WAGMDL00674667 | | | | | | | | | |
| P-15310 | 5/16/2017 | Email Training material per DEA subpoena - FW: TIME UPDATE: Please deliver invitation to Grad Intern: Graduate Intern Orientation Meeting Attachments PHIG Orientation 2015 w-ap update PPT; | WAGMDL00674947 | WAGMDL00675047 | | | | | | | | | |
| P-15313 | 7/8/2013 | Retail Pharmacy Kick Off PPT | WAGMDL00741752 | WAGMDL00742113 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-15314 | 6/11/2012 | Email Materials for Today's Controlled Substance Action Plan Videoconference Attachments Controlled Substance Action Plan; FOC Survey - June 2012; Focus on Compliance June 2012; FOC Pain Management - Job Aid; Controlled Substance Prescriptions & Good Faith Dispensing Policy; FOC Pain Management - Job Aid; Controlled Substance Prescriptions & Good Faith Dispensing Policy | WAGMDL00742641 | WAGMDL00742671 | | | | | | | | | |
| P-15315 | 12/12/2012 | Email Schedule II narcotic dispensing policy Attachments Schedule II Narcotic Dispensing Guidelines v3; Official Prescriber Sanction Letter; Prescriber Sanction Pilot; Prescriber Scorecard | WAGMDL00745731 | WAGMDL00745745 | | | | | | | | | |
| P-15317 | 2011 | MOA between Walgreen Co and DEA re Store 06094 | WAGMDL00757802 | WAGMDL00757808 | | | | | | | | | |
| P-15318 | 1/1/2013 | GFD Milwaukee Jan 13 PPT | WAGMDL00779140 | WAGMDL00779174 | | | | | | | | | |
| P-15319 | 1/8/2013 | Prescriber Index 01-08-13 all drugs through December | WAGMDL00790888 | WAGMDL00790888 | | | | | | | | | |
| P-15320 | N/A | Controlled substances sold from store 10518 from 6/10/2012 to 5/16/2014 | WAGMDL00790914 | WAGMDL00790914 | | | | | | | | | |
| P-15321 | 10/3/2013 | FW: Overdue Legal PPL (DEADLINE 10/10) | WAGMDL00793450 | WAGMDL00793467 | | | | | | | | | |
| P-15322 | 9/4/2013 | Email Good Faith Dispensing #3314 | WAGMDL00798142 | WAGMDL00798142 | | | | | | | | | |
| P-15323 | 2/23/2013 | FW: Controlled Substance Compass Project due 02-27 | WAGMDL00798209 | WAGMDL00798210 | | | | | | | | | |
| P-15324 | 4/17/2012 | Fw: #3310: Tue, Apr 17 | WAGMDL00798644 | WAGMDL00798645 | | | | | | | | | |
| P-15331 | 3/15/2017 | FW: #4159: Wed, Mar 14 | WAGMDL00809643 | WAGMDL00809644 | | | | | | | | | |
| P-15333 | 12/30/2007 | Walgreens Pharmacy Code of Conduct | WAGMDL00815828 | WAGMDL00815834 | | | | | | | | | |
| P-15334 | 1/2/2013 | FW: UPDATES | WAGMDL00819840 | WAGMDL00819841 | | | | | | | | | |
| P-15335 | 7/14/2009 | Re: Fw: c2 order pattern | WAGMDL00819852 | WAGMDL00819854 | | | | | | | | | |
| P-15336 | 1/9/2012 | Fw: DEA Reporting - Revised Attachment DEA Controlled Substance Project - Report Design V3 | WAGMDL00820291 | WAGMDL00820296 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-----------------|-----------------|--|--|--|--|--|--|--|--|--|
| P-15337 | 12/22/2011 | Re: Fw: Review Controlled Substance Order Report 4N1 - 1411 Lake Cook Attachments DEA Controlled Substance Project - Report Design V2; 2011-12-21 - Meeting Minutes, DEA Controlled Substance - Dashboard Design Concepts | WAGMDL00820304 | WAGMDL00820312 | | | | | | | | | |
| P-15339 | 1/26/2016 | Email Action: Upskilling initiative Attachments DM(V2) Summit Slide pptx 1 25 16 PPT ; Phase 1V2 Facilitator Guide; Phase 1V2P Participant Guide; TimelinePhase1and 2 Plan PPT | WAGMDL00834231 | WAGMDL00834328 | | | | | | | | | |
| P-15340 | 6/18/2012 | Email Conference call Attachments Notes June 11; ICE Roll-out Agenda | WAGMDL00838936 | WAGMDL00839128 | | | | | | | | | |
| P-15341 | 6/1/2012 | Re: #5206: Thu, May 31 | WAGMDL00839567 | WAGMDL00839568 | | | | | | | | | |
| P-15342 | 4/21/2011 | Email drug diversion training | WAGMDL00839611 | WAGMDL00839611 | | | | | | | | | |
| P-15343 | N/A | Prescriber Index 02-19-13 all drugs through January UNDER CONSTRUCTION | WAGNYNS00032015 | WAGNYNS00032015 | | | | | | | | | |
| P-15344 | 2/12/2013 | RE: Drug Reports | WAGNYNS00033436 | WAGNYNS00033440 | | | | | | | | | |
| P-15346 | 2/25/2013 | Prescriber Index 02-19-13 all drugs through January UNDER CONSTRUCTION | WAGNYNS00042909 | WAGNYNS00042909 | | | | | | | | | |
| P-15348 | 7/10/2012 | RE: PDQ Order Analysis Attachment CII PDQ 6-26-2012 | WAGPADC00001649 | WAGPADC00001651 | | | | | | | | | |
| P-15349 | 7/5/2012 | FW: PDQ Order Analysis Attachment CII PDQ 6-26-2012 | WAGPADC00001729 | WAGPADC00001731 | | | | | | | | | |
| P-15350 | 5/2/2012 | FW: c2data request Attachment CII PDQ Orders | WAGPADC00003016 | WAGPADC00003017 | | | | | | | | | |
| P-15352 | 1/9/2013 | Pharmacist Index 01-09-13 | WAGPADC00013014 | WAGPADC00013014 | | | | | | | | | |
| P-15353 | 2/19/2013 | Pharmacist Index 02-19-13 UNDER CONSTRUCTION | WAGPADC00013015 | WAGPADC00013015 | | | | | | | | | |
| P-15354 | 9/28/2012 | Email FOC Attachment FOC Survey - June 2012_vf | WAGMDL00113816 | WAGMDL00113820 | | | | | | | | | |
| P-15355 | 2/5/2013 | Controlled Substance Order Monitoring System PPT Version 2 | WAGMDL00675532 | WAGMDL00675568 | | | | | | | | | |
| P-15356 | 3/31/2013 | Fwd: National TD GFD Powerpoint Update Attachments National TD GFD Powerpoint EPD Final PPT; National TD GFD Powerpoint EPD Final | WAGMDL00744592 | WAGMDL00744624 | | | | | | | | | |
| P-15357 | 4/15/2013 | RE: Oxycodone 30mg override | WAGMDL00698309 | WAGMDL00698309 | | | | | | | | | |
| P-15358 | 6/12/2013 | RE: CII Orders | WAGMDL00698445 | WAGMDL00698445 | | | | | | | | | |
| P-15360 | 6/12/2013 | Re: CII order | WAGMDL00687021 | WAGMDL00687021 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-15361 | 6/12/2013 | RE: Oxy/Apap | WAGMDL00697774 | WAGMDL00697776 | | | | | | | | | |
| P-15362 | 7/1/2013 | FW: Controlled Substance Order Quantity Override Form | WAGMDL00698296 | WAGMDL00698297 | | | | | | | | | |
| P-15363 | 8/12/2013 | FW: Percocet | WAGMDL00698150 | WAGMDL00698150 | | | | | | | | | |
| P-15364 | 8/22/2013 | Re: Percocet 5/325 | WAGMDL00698196 | WAGMDL00698196 | | | | | | | | | |
| P-15367 | N/A | Historial IRR Tracker | CVS-BAL-000014033 | CVS-BAL-000014033 | | | | | | | | | |
| P-15368 | 9/19/2014 | FW: Hydro; Hydro Inventory 9.18.14 | CVS-MDLT1-000003073 | CVS-MDLT1-000003075 | | | | | | | | | |
| P-15375 | 12/31/2012 | IRR - BIP006A | CVS-MDLT1-000011221 | CVS-MDLT1-000011358 | | | | | | | | | |
| P-15377 | 6/13/2012 | Email re Review of Top 10 Report and Download | CVS-MDLT1-000019096 | CVS-MDLT1-000019490 | | | | | | | | | |
| P-15392 | 1/31/2012 | IRR - BIP006A | CVS-MDLT1-000102023 | CVS-MDLT1-000102119 | | | | | | | | | |
| P-15396 | 11/1/2011 | IRR - BIP006A | CVS-MDLT1-000102503 | CVS-MDLT1-000102557 | | | | | | | | | |
| P-15403 | 5/29/2011 | IRR - BIP006A | CVS-MDLT1-000102738 | CVS-MDLT1-000102802 | | | | | | | | | |
| P-15474 | 12/13/2013 | Report of Investigation re CVS Indiana | US-DEA-00027457 | US-DEA-00027491 | | | | | | | | | |
| P-15475 | 6/10/2008 | Email from Robert Williams to Frank Devlin re Official Agreement | IQVIA-CVS-000000624 | IQVIA-CVS-000000624 | | | | | | | | | |
| P-15476 | 11/11/2008 | Cegedim Dendrite Buzzeo Proposal for Regulatory Compliance Audits | CVS-MDLT1-000125252 | CVS-MDLT1-000125255 | | | | | | | | | |
| P-15477 | 5/23/2009 | Buzzeo Compliance Audit of CVS Knoxville DC | IQVIA-CVS-000001938 | IQVIA-CVS-000001956 | | | | | | | | | |
| P-15478 | 6/30/2009 | Email re SOM Calculation Results | IQVIA-CVS-000001868 | IQVIA-CVS-000001870 | | | | | | | | | |
| P-15479 | 7/13/2009 | Email from Greg Brantley to Sean Humphries attaching DEA Action Plan | CVS-MDLT1-000091774 | CVS-MDLT1-000091775 | | | | | | | | | |
| P-15480 | 9/24/2009 | Email re DEA Compliance Disregard as in Testing Stage | CVS-MDLT1-000087900 | CVS-MDLT1-000087900 | | | | | | | | | |
| P-15481 | 10/22/2009 | Email Matthew Bachofen to Mortelliti re Conference Call Recap | CVS-MDLT1-000087882 | CVS-MDLT1-000087884 | | | | | | | | | |
| P-15482 | 10/22/2009 | Email exchange re SOM project | CVS-MDLT1-000110431 | CVS-MDLT1-000110433 | | | | | | | | | |
| P-15483 | 1/26/2010 | Email from Matt Laskoski to Mortelliti re Viper Dispensing | CVS-MDLT1-000088532 | CVS-MDLT1-000088534 | | | | | | | | | |
| P-15484 | 3/11/2010 | Email exchange re Eliminating orders. Changing the score | CVS-MDLT1-000111309 | CVS-MDLT1-000111311 | | | | | | | | | |
| P-15485 | 8/20/2010 | Email re DEA Inspection Email to Devlin | CVS-MDLT1-000126294 | CVS-MDLT1-000126295 | | | | | | | | | |
| P-15486 | 9/29/2010 | Email exchange re progress of the milligram conversion for controls in SOM retunement | CVS-MDLT1-000111448 | CVS-MDLT1-000111449 | | | | | | | | | |
| P-15489 | 10/2/2010 | Email re Active Ingredient Retunement | CVS-MDLT1-000111460 | CVS-MDLT1-000111461 | | | | | | | | | |
| P-15490 | 10/13/2010 | Email from Mortelliti explaining IRR | CVS-NYAG-000012063 | CVS-NYAG-000012065 | | | | | | | | | |
| P-15491 | 2/24/2011 | FW: Regulatory Review Report | CVS-MDLT1-000124882 | CVS-MDLT1-000124898 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-15492 | 3/18/2011 | Email Exchanges re Retunement moving SOM to Knoxville DC | CVS-MDLT1-000111464 | CVS-MDLT1-000111466 | | | | | | | | | |
| P-15493 | 4/1/2011 | Email Exchanges re returned SOMs | CVS-MDLT1-000111469 | CVS-MDLT1-000111470 | | | | | | | | | |
| P-15494 | 6/10/2011 | Email exchanges from Ellen Demetris re Retunement Clarification | CVS-MDLT1-000111609 | CVS-MDLT1-000111696 | | | | | | | | | |
| P-15496 | 7/19/2012 | Email re SOM Sample Data and Language for Agreement | CVS-MDLT1-000127092 | CVS-MDLT1-000127097 | | | | | | | | | |
| P-15497 | 8/8/2012 | Draft Indianapolis Report | CVS-MDLT1-000124276 | CVS-MDLT1-000124276 | | | | | | | | | |
| P-15498 | 9/4/2012 | IRR SOM Project Team Accomplishments | CVS-MDLT1-000120520 | CVS-MDLT1-000120520 | | | | | | | | | |
| P-15499 | 12/19/2012 | 800131_Biannual_Pharmacist_Grad Intern_September 2012 | CVS-NYAG-000031237 | CVS-NYAG-000031365 | | | | | | | | | |
| P-15500 | 10/30/2012 | Today's IRR | CVS-MDLT1-000120255 | CVS-MDLT1-000120257 | | | | | | | | | |
| P-15501 | 7/31/2011 | GPS Midyear Review | CVS-MDLT1-000120425 | CVS-MDLT1-000120429 | | | | | | | | | |
| P-15502 | 1/24/2013 | Store Report Template | CVS-MDLT1-000120568 | CVS-MDLT1-000120570 | | | | | | | | | |
| P-15503 | 7/6/2005 | BuzzeoPDMA, Inc. and CVS Consulting Agreement Attachment III | CVS-MDLT1-000121597 | CVS-MDLT1-000121599 | | | | | | | | | |
| P-15504 | 7/6/2005 | BuzzeoPDMA, Inc. and CVS Consulting Agreement Attachment V | CVS-MDLT1-000121600 | CVS-MDLT1-000121602 | | | | | | | | | |
| P-15505 | 7/6/2010 | BuzzeoPDMA, Inc. and CVS Consulting Agreement Attachment XIII | CVS-MDLT1-000121603 | CVS-MDLT1-000121605 | | | | | | | | | |
| P-15506 | 7/6/2005 | BuzzeoPDMA, Inc. and CVS Consulting Agreement | CVS-MDLT1-000121606 | CVS-MDLT1-000121611 | | | | | | | | | |
| P-15507 | 1/10/2014 | SOM Process Flow; RX Investigative Protocol; | CVS-MDLT1-000122064 | CVS-MDLT1-000122067 | | | | | | | | | |
| P-15508 | 1/28/2009 | Dendrite International Inc. and CVS Consulting Agreement Attachment VII | CVS-MDLT1-000122364 | CVS-MDLT1-000122366 | | | | | | | | | |
| P-15509 | 7/6/2005 | BuzzeoPDMA, Inc. and CVS Consulting Services Agreement | CVS-MDLT1-000122367 | CVS-MDLT1-000122372 | | | | | | | | | |
| P-15510 | 12/17/2010 | Cegedim Inc. and CVS Consulting Agreement Attachment XIV | CVS-MDLT1-000122373 | CVS-MDLT1-000122374 | | | | | | | | | |
| P-15511 | 2/14/2013 | Email re Order entry Data | CVS-MDLT1-000123230 | CVS-MDLT1-000123231 | | | | | | | | | |
| P-15512 | 11/18/2018 | Draft email re Indianapolis DC visit | CVS-MDLT1-000123233 | CVS-MDLT1-000123237 | | | | | | | | | |
| P-15513 | 3/13/2012 | Conference Call Follow up; DEA Project and IRR SOM | CVS-MDLT1-000123242 | CVS-MDLT1-000123246 | | | | | | | | | |
| P-15514 | 4/6/2012 | Evaluation of Suspicious Orders Monitoring System for CVS Caremark by the Drug & Chemical Advisory Group, LLC | CVS-MDLT1-000124181 | CVS-MDLT1-000124234 | | | | | | | | | |
| P-15515 | 4/14/2009 | Cegedim, CVS La Habra Distribution Center, Executive Summary | CVS-MDLT1-000125040 | CVS-MDLT1-000125072 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-15518 | 4/6/2012 | Draft Evaluation of SOMS System for CVS | CVS-MDLT1-000125358 | CVS-MDLT1-000125375 | | | | | | | | | |
| P-15519 | 4/11/2012 | Hotlist | CVS-MDLT1-000125546 | CVS-MDLT1-000125547 | | | | | | | | | |
| P-15520 | 3/23/2012 | Hotlist | CVS-MDLT1-000125550 | CVS-MDLT1-000125551 | | | | | | | | | |
| P-15521 | 3/16/2012 | Top 10 Project | CVS-MDLT1-000125558 | CVS-MDLT1-000125559 | | | | | | | | | |
| P-15522 | 3/16/2012 | Top 10 Project | CVS-MDLT1-000125560 | CVS-MDLT1-000125561 | | | | | | | | | |
| P-15523 | 9/3/2009 | DEA Audit Review August | CVS-MDLT1-000125975 | CVS-MDLT1-000125978 | | | | | | | | | |
| P-15524 | 2/11/2011 | DEA Visit Recap | CVS-MDLT1-000126144 | CVS-MDLT1-000126144 | | | | | | | | | |
| P-15525 | 9/16/2013 | SOM SOP V3 | CVS-MDLT1-000126553 | CVS-MDLT1-000126557 | | | | | | | | | |
| P-15526 | 8/7/2013 | FW: Indianapolis DC DEA Visit - Day #2 Recap | CVS-MDLT1-000126917 | CVS-MDLT1-000126918 | | | | | | | | | |
| P-15527 | 9/26/2013 | SOM Action Log_092613; SOM plan_092613 | CVS-MDLT1-000127264 | CVS-MDLT1-000127270 | | | | | | | | | |
| P-15528 | 2/17/2014 | SOM Deployment Activities; SOM Output Issues Log; SOM_Agenda | CVS-MDLT1-000127409 | CVS-MDLT1-000127412 | | | | | | | | | |
| P-15529 | 5/29/2014 | SOM Opportunities List 052914 | CVS-MDLT1-000127461 | CVS-MDLT1-000127467 | | | | | | | | | |
| P-15530 | 12/19/2012 | SOM Action Log 121212, SOM Plan 121812 | CVS-MDLT1-000127483 | CVS-MDLT1-000127487 | | | | | | | | | |
| P-15531 | 12/15/2012 | DC SOM | CVS-MDLT1-000127500 | CVS-MDLT1-000127503 | | | | | | | | | |
| P-15532 | 8/5/2019 | Consulting Services Agreement Attachment IX | IQVIA-CVS-000000001 | IQVIA-CVS-000000002 | | | | | | | | | |
| P-15533 | 6/3/2008 | Consulting Services Agreement Attachment V | IQVIA-CVS-000000003 | IQVIA-CVS-000000005 | | | | | | | | | |
| P-15534 | 8/5/2019 | Consulting Services Agreement Attachment XVI | IQVIA-CVS-000000006 | IQVIA-CVS-000000007 | | | | | | | | | |
| P-15535 | 8/5/2019 | Consulting Services Agreement Attachment VIII | IQVIA-CVS-000000010 | IQVIA-CVS-000000011 | | | | | | | | | |
| P-15536 | 8/5/2019 | Consulting Services Agreement Attachment XII | IQVIA-CVS-000000012 | IQVIA-CVS-000000013 | | | | | | | | | |
| P-15537 | 8/5/2019 | Consulting Services Agreement Attachment VII | IQVIA-CVS-000000014 | IQVIA-CVS-000000016 | | | | | | | | | |
| P-15538 | 8/5/2019 | Consulting Services Agreement Attachment VI | IQVIA-CVS-000000020 | IQVIA-CVS-000000022 | | | | | | | | | |
| P-15539 | 8/5/2019 | Customer Services Agreement (BuzzeoPDMA Services) | IQVIA-CVS-000000025 | IQVIA-CVS-000000031 | | | | | | | | | |
| P-15540 | 8/5/2019 | Consulting Services Agreement Attachment XIII | IQVIA-CVS-000000032 | IQVIA-CVS-000000034 | | | | | | | | | |
| P-15546 | 8/2/2011 | Ltr re State of Work to Letter Agreement Dated April 4, 2011 | IQVIA-CVS-000000074 | IQVIA-CVS-000000078 | | | | | | | | | |
| P-15547 | 8/5/2019 | Consulting Services Agreement Attachment II | IQVIA-CVS-000000079 | IQVIA-CVS-000000079 | | | | | | | | | |
| P-15549 | 1/3/2012 | Questions on the new IRR/SOM system | IQVIA-CVS-000000130 | IQVIA-CVS-000000133 | | | | | | | | | |
| P-15550 | 1/11/2010 | Shipping PSE to Puerto Rico | IQVIA-CVS-000000490 | IQVIA-CVS-000000492 | | | | | | | | | |
| P-15551 | 6/24/2010 | CVS/Cegedim Dendrite - SOM Maintenance Program Proposal | IQVIA-CVS-000000495 | IQVIA-CVS-000000495 | | | | | | | | | |
| P-15552 | 11/20/2009 | re PSE and RX SOM Draft SOPs | IQVIA-CVS-000000571 | IQVIA-CVS-000000572 | | | | | | | | | |
| P-15553 | 11/24/2009 | PSE and RX SOM Draft SOPs | IQVIA-CVS-000000589 | IQVIA-CVS-000000590 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-15555 | 11/16/2009 | Suspicious Order Monitoring Policy Draft | IQVIA-CVS-000000600 | IQVIA-CVS-000000606 | | | | | | | | | |
| P-15556 | 8/30/2010 | Re: Info on previous data/SOM retunement | IQVIA-CVS-000000656 | IQVIA-CVS-000000659 | | | | | | | | | |
| P-15557 | 7/26/2010 | Re SOM Update | IQVIA-CVS-000000666 | IQVIA-CVS-000000668 | | | | | | | | | |
| P-15558 | 7/29/2009 | Mortelliti re SOM | IQVIA-CVS-000001067 | IQVIA-CVS-000001068 | | | | | | | | | |
| P-15559 | 6/11/2009 | FW: Meeting to be Scheduled - Detailed review of SOM Report | IQVIA-CVS-000001273 | IQVIA-CVS-000001274 | | | | | | | | | |
| P-15560 | 11/24/2009 | RE: PSE and RX SOM Draft SOPs | IQVIA-CVS-000001291 | IQVIA-CVS-000001291 | | | | | | | | | |
| P-15562 | 7/13/2009 | CVS Knoxville Action Items; Report re Cegedim Dendrite Compliance Solutions Visit to CVS Knoxville Distribution Center | IQVIA-CVS-000001399 | IQVIA-CVS-000001433 | | | | | | | | | |
| P-15564 | 8/21/2019 | Email re CVS SOM Services Attachment XIII | IQVIA-CVS-000001564 | IQVIA-CVS-000001567 | | | | | | | | | |
| P-15565 | 8/26/2009 | FW: CVS report | IQVIA-CVS-000001587 | IQVIA-CVS-000001590 | | | | | | | | | |
| P-15566 | 5/12/2009 | SOMs RPT | IQVIA-CVS-000001644 | IQVIA-CVS-000001645 | | | | | | | | | |
| P-15567 | 2/9/2011 | FW: The Retunement document | IQVIA-CVS-000001750 | IQVIA-CVS-000001764 | | | | | | | | | |
| P-15568 | 8/26/2009 | RE: CVS revised coefficients | IQVIA-CVS-000001835 | IQVIA-CVS-000001836 | | | | | | | | | |
| P-15569 | 7/29/2009 | RE: CVS | IQVIA-CVS-000001859 | IQVIA-CVS-000001859 | | | | | | | | | |
| P-15570 | 11/17/2009 | Re: PSE and RX SOM Draft SOPs | IQVIA-CVS-000001907 | IQVIA-CVS-000001907 | | | | | | | | | |
| P-15571 | 1/27/2011 | Re: CVS retunement | IQVIA-CVS-000001921 | IQVIA-CVS-000001937 | | | | | | | | | |
| P-15572 | 8/25/2009 | Re: SOM Report | IQVIA-CVS-000001957 | IQVIA-CVS-000001959 | | | | | | | | | |
| P-15573 | 7/30/2012 | re Ratio Calculation | SA AGI 00013073 | SA AGI 00013076 | | | | | | | | | |
| P-15579 | 9/24/2012 | Email re Call Request | SA AGI 00016026 | SA AGI 00016027 | | | | | | | | | |
| P-15580 | 10/31/2012 | Email re Today's IRR | SA AGI 00018682 | SA AGI 00018683 | | | | | | | | | |
| P-15582 | 1/10/2013 | Update of Store Dispensing Metrics Spreadsheet | SA AGI 00018871 | SA AGI 00018872 | | | | | | | | | |
| P-15583 | 2/22/2013 | Dream List | SA AGI 00018911 | SA AGI 00018912 | | | | | | | | | |
| P-15584 | 4/24/2013 | Order Flagging Reasons | SA AGI 00019042 | SA AGI 00019044 | | | | | | | | | |
| P-15588 | 12/12/2012 | AGI Proposal | SA AGI 00068485 | SA AGI 00068499 | | | | | | | | | |
| P-15589 | 2/5/2014 | Email re 219 and 5195 | CVS-MDLT1-000123374 | CVS-MDLT1-000123376 | | | | | | | | | |
| P-15590 | 2/19/2015 | 6. Cocktail_Revised_2_18_15_final_20150220091928364 | CVS-DR22-000004875 | CVS-DR22-000004876 | | | | | | | | | |
| P-15592 | 12/11/2009 | Data Distribution and Services Agreement | VCOMDL-0000926 | VCOMDL-0000955 | | | | | | | | | |
| P-15593 | 4/1/2011 | Restricted Data Agreement | VCOMDL-0000956 | VCOMDL-0000968 | | | | | | | | | |
| P-15594 | 2/5/2014 | Re: proportions comparison after parameter change; Parameter Change Proportion 04FEB2014 | CVS-NYMDL-000008059 | CVS-NYMDL-000008061 | | | | | | | | | |
| P-15595 | 4/14/2014 | Store #_2060; 2060 RLPM CS Visit 01012014 | CVS-NYMDL-000011833 | CVS-NYMDL-000011834 | | | | | | | | | |
| P-15597 | 3/9/2016 | Store 2060 Pharmacy CII Hard Copy Prescription Overview | CVS-NYMDL-000011849 | CVS-NYMDL-000011849 | | | | | | | | | |
| P-15598 | 5/26/2016 | Re: Store 2060 | CVS-NYMDL-000011852 | CVS-NYMDL-000011855 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15600 | 12/2/2016 | Press Release about Dr Emmanuel Lambrakis, Charged In Manhattan Federal Court For Illegal Distribution Of Millions Of Oxycodone Pills | N/A | N/A | | | | | | | | | |
| P-15601 | 12/21/2004 | ROPP-0001 - Professional Standards, December 21, 2004 | CVS-DR22-000001199 | CVS-DR22-000001207 | | | | | | | | | |
| P-15602 | 11/1/2006 | ROPP-00042/ROPP-045491 - Filling / Dispensing Prescriptions and Patient Counseling | CVS-MDLT1B-000002328 | CVS-MDLT1B-000002365 | | | | | | | | | |
| P-15604 | 2006 | 2006 Pharmacist Incentive Plan | CVS-MDLT1-000060949 | CVS-MDLT1-000060955 | | | | | | | | | |
| P-15607 | 2007 | 2007 Pharmacist Incentive Plan | CVS-MDLT1-000061066 | CVS-MDLT1-000061072 | | | | | | | | | |
| P-15608 | 2007 | Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000060930 | CVS-MDLT1-000060935 | | | | | | | | | |
| P-15610 | 2008 | ROPP-045491 - Filling/Dispensing RXs 9/2008 | CVS-MDLT1-000055551 | CVS-MDLT1-000055552 | | | | | | | | | |
| P-15614 | 2008 | 2008 Pharmacist Incentive Plan | CVS-MDLT1-000060989 | CVS-MDLT1-000060995 | | | | | | | | | |
| P-15615 | 2008 | Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000060936 | CVS-MDLT1-000060941 | | | | | | | | | |
| P-15616 | 2009 | ROPP-00040 - Robbery, Shoplifting and Burglary | CVS-MDLT1B-000002225 | CVS-MDLT1B-000002232 | | | | | | | | | |
| P-15621 | 2009 | Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000060956 | CVS-MDLT1-000060962 | | | | | | | | | |
| P-15623 | 2010 | 2010 Pharmacist Incentive Plan | CVS-MDLT1-000061039 | CVS-MDLT1-000061045 | | | | | | | | | |
| P-15624 | 2010 | Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000061017 | CVS-MDLT1-000061022 | | | | | | | | | |
| P-15625 | 2010 | Supplemental Procedures: Pharmacy Maintenance of Records on Receipt and Dispensing of Controlled Substance Prescriptions | CVS-NYAG-000034713 | CVS-NYAG-000034719 | | | | | | | | | |
| P-15626 | 10/14/2010 | DOJ Press Release: CVS Admits Illegally Selling Pseudoephedrine to Criminals who made Methamphetamine, Agrees to pay \$77.6 Million to Resolve Government Investigation | N/A | N/A | | | | | | | | | |
| P-15630 | 2011 | Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000060942 | CVS-MDLT1-000060948 | | | | | | | | | |
| P-15631 | 2011 | Calculated Bonuses Chart | CVS-FLAG-000045749 | CVS-FLAG-000045749 | | | | | | | | | |
| P-15632 | 3/1/2011 | March 2011 Bi-Annual Compliance Training: Pharmacist and Intern Version Course #800131, Self Paced Training Guide | CVS-NYAG-000030693 | CVS-NYAG-000030752 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15633 | 3/1/2011 | Supplemental DEA Training Course #800650 Self-paced Workbook | CVS-NYAG-000034720 | CVS-NYAG-000034739 | | | | | | | | | |
| P-15634 | 1/4/2012 | ROPP-0061 – Protocol for Dispensing Narcotic Drugs for Pain Treatment | CVS-DR22-000001062 | CVS-DR22-000001064 | | | | | | | | | |
| P-15635 | 2/22/2012 | ROPP-0001, Professional Standards Policy | CVS-MDLT1-000081508 | CVS-MDLT1-000081516 | | | | | | | | | |
| P-15638 | 2012 | Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000061059 | CVS-MDLT1-000061065 | | | | | | | | | |
| P-15639 | 2/1/2013 | 2012 Pharmacist Performance Review Pharmacy Supervisor Guide | CVS-DR22-000004812 | CVS-DR22-000004828 | | | | | | | | | |
| P-15640 | 2012 | DEA & Pharmacy Regulatory Training Course #800670 | CVS-NYAG-000034431 | CVS-NYAG-000034481 | | | | | | | | | |
| P-15641 | 5/1/2012 | Prescription Monitoring Program (PMP): RxConnect. Self-Paced Training Guide | CVS-NYAG-000036526 | CVS-NYAG-000036535 | | | | | | | | | |
| P-15642 | 2012 | Red Flag Analysis and Due Diligence Factors | CVS-MDLT1B-000001813 | CVS-MDLT1B-000001813 | | | | | | | | | |
| P-15643 | 2012 | Q3 2012 Prescribers Support Table | CVS-MDLT1B-000001817 | CVS-MDLT1B-000001817 | | | | | | | | | |
| P-15644 | 2012 | Intermin Prescriber Metrics and Percentiles | CVS-MDLT1B-000001563 | CVS-MDLT1B-000001563 | | | | | | | | | |
| P-15645 | 2012 | High-Risk Drug Overview: Adolph Harper | CVS-MDLT1B-000001561 | CVS-MDLT1B-000001561 | | | | | | | | | |
| P-15646 | 2012 | Trial Doctors All High Risk STACKED Monthly Charts | CVS-MDLT1B-000001562 | CVS-MDLT1B-000001562 | | | | | | | | | |
| P-15647 | 2012 | Distinct Patients with High Risk RXs by Zip Code | CVS-MDLT1B-000001564 | CVS-MDLT1B-000001564 | | | | | | | | | |
| P-15649 | 2013 | District Manager Incentive Plan | CVS-MDLT1B-000001824 | CVS-MDLT1B-000001832 | | | | | | | | | |
| P-15651 | 2013 | 2013 Pharmacist Incentive Plan | CVS-MDLT1-000061084 | CVS-MDLT1-000061094 | | | | | | | | | |
| P-15652 | 2013 | Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000061023 | CVS-MDLT1-000061030 | | | | | | | | | |
| P-15653 | 2/1/2014 | 2013 Pharmacist Performance Review Pharmacy Supervisor Guide | CVS-DR22-000004829 | CVS-DR22-000004845 | | | | | | | | | |
| P-15654 | 2013 | Pharmacy Supervisor Guide to Discussion Points | CVS-NYAG-000036551 | CVS-NYAG-000036551 | | | | | | | | | |
| P-15655 | 2013 | Review of Corresponding Responsibility - 2013 Pharmacist Review | CVS-NYAG-000030633 | CVS-NYAG-000030634 | | | | | | | | | |
| P-15656 | 2013 | Pharmacy Huddle Guide: Awareness of Red Flags Associated with the Non-legitimate use of Controlled Substances | CVS-NYAG-000033717 | CVS-NYAG-000033722 | | | | | | | | | |
| P-15657 | 5/6/2009 | FW: SOM Report | IQVIA-CVS-000001857 | IQVIA-CVS-000001858 | | | | | | | | | |
| P-15658 | 11/5/2013 | Prescribers Suspension List | CVS-NYAG-000039921 | CVS-NYAG-000039922 | | | | | | | | | |
| P-15659 | 2013 | November 2013 Prescriber Status file | CVS-NYAG-000039943 | CVS-NYAG-000039945 | | | | | | | | | |
| P-15660 | 2013 | Q2_2013_Prescriber Outreach Tracking | CVS-MDLT1B-000001585 | CVS-MDLT1B-000001585 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15662 | 7/5/2013 | Outreach letter to set up interview for prescriber identified as a potential problem. | CVS-MDLT1B-000001566 | CVS-MDLT1B-000001566 | | | | | | | | | |
| P-15663 | 2013 | Phone interview conducted by CVS of questionable high volume prescriber. | CVS-MDLT1B-000001576 | CVS-MDLT1B-000001578 | | | | | | | | | |
| P-15664 | 2013 | Bruce Pizel Prescriber Slide | CVS-MDLT1B-000001679 | CVS-MDLT1B-000001680 | | | | | | | | | |
| P-15665 | 2013 | Q3 2013 Tier 1_2 Prescribers | CVS-MDLT1B-000001814 | CVS-MDLT1B-000001814 | | | | | | | | | |
| P-15666 | 5/1/2013 | Email Most concerning Tier 2 doctors; Most Concerning Tier 2 Doctor Profile Drafts | CVS-MDLT1B-000006378 | CVS-MDLT1B-000006396 | | | | | | | | | |
| P-15667 | 11/21/2013 | RE: Call regarding prescriber and hydrocodone analyses; Summary of Q2 Algorithm Tier 2 Prescribers | CVS-MDLT1B-000006575 | CVS-MDLT1B-000006580 | | | | | | | | | |
| P-15668 | 9/16/2013 | RE: Privileged and Confidential; Store review based on an alert system. | CVS-MDLT1B-000006544 | CVS-MDLT1B-000006568 | | | | | | | | | |
| P-15669 | 6/4/2013 | Email Privileged and Confidential: Top 10 OxyPrescribers; Attachments Copy of 2013.5.17_Top ten oxy prescribers with detailed data; top 10 prescriber analysis PPT | CVS-MDLT1B-000006397 | CVS-MDLT1B-000006410 | | | | | | | | | |
| P-15670 | 7/9/2013 | Email with attachments of investigation into Genevieve Tryon | CVS-MDLT1B-000009260 | CVS-MDLT1B-000009266 | | | | | | | | | |
| P-15671 | 8/2/2013 | Email Prescriber Block Tracking Log Master | CVS-NYAG-000042670 | CVS-NYAG-000042671 | | | | | | | | | |
| P-15672 | 11/6/2013 | Email Alternate Prescriber Escalation file; 2013_November_Prescriber_Alternate Identification Log | CVS-NYAG-000042706 | CVS-NYAG-000042707 | | | | | | | | | |
| P-15673 | 8/1/2013 | Email Prescriber Concerns for Algorithm 2 Run; Red Flag Documentation stored in Archer and LP for review internally | CVS-NYAG-000037247 | CVS-NYAG-000037248 | | | | | | | | | |
| P-15674 | 2013 | Algorithm output for specific prescriber | CVS-MDLT1B-000001584 | CVS-MDLT1B-000001584 | | | | | | | | | |
| P-15675 | 7/25/2013 | Interim Prescriber Metrics and Percentiles | CVS-MDLT1B-000006542 | CVS-MDLT1B-000006543 | | | | | | | | | |
| P-15676 | 2013 | Raw data of prescriptions written by a specific provider. | CVS-MDLT1B-000001567 | CVS-MDLT1B-000001567 | | | | | | | | | |
| P-15677 | 2012 | ROPP-00001 Professional Standards | CVS-DR22-000001138 | CVS-DR22-000001149 | | | | | | | | | |
| P-15678 | 10/1/2014 | ROPP-047561 -Federal Guidelines for Controlled Substances | CVS-DR22-000001039 | CVS-DR22-000001052 | | | | | | | | | |
| P-15679 | 10/24/2014 | DOC-047681 - Stolen Prescriptions | CVS-DR22-000001410 | CVS-DR22-000001411 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15682 | 2014 | 2014 Staff Pharmacist Incentive Plan | CVS-MDLT1-000060996 | CVS-MDLT1-000061003 | | | | | | | | | |
| P-15683 | 2014 | Pharmacist in Charge Incentive Plan | CVS-NYAG-000010387 | CVS-NYAG-000010394 | | | | | | | | | |
| P-15684 | 2014 | Pharmacy Manager Incentive Plan | CVS-MDLT1-000061046 | CVS-MDLT1-000061053 | | | | | | | | | |
| P-15685 | 2014 | Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000061031 | CVS-MDLT1-000061038 | | | | | | | | | |
| P-15686 | 2/1/2015 | 2014 Pharmacist Performance Review Pharmacy Manager Guide | CVS-DR22-000004861 | CVS-DR22-000004873 | | | | | | | | | |
| P-15688 | 2014 | January/February 2014 Bi-Annual Training: Pharmacist/Grad Intern Version Course #800142 | CVS-NYAG-000032260 | CVS-NYAG-000032390 | | | | | | | | | |
| P-15689 | 2014 | Review of Corresponding Responsibility | CVS-NYAG-000033655 | CVS-NYAG-000033660 | | | | | | | | | |
| P-15690 | 2014 | Dispensing Controlled Substances and Refusal to Fill | CVS-NYAG-000033652 | CVS-NYAG-000033654 | | | | | | | | | |
| P-15692 | 2/13/2015 | Email Outreach Letter; Copy of Prescriber Outreach_Tracking | CVS-MDLT1B-000007798 | CVS-MDLT1B-000007799 | | | | | | | | | |
| P-15694 | 12/10/2014 | Reinstatement outreach letter | CVS-MDLT1B-000001654 | CVS-MDLT1B-000001654 | | | | | | | | | |
| P-15695 | 12/29/2014 | Reinstatement packet submitted | CVS-MDLT1B-000001658 | CVS-MDLT1B-000001678 | | | | | | | | | |
| P-15697 | 2014 | Summary slide for interview with high volume prescriber | CVS-MDLT1B-000001589 | CVS-MDLT1B-000001589 | | | | | | | | | |
| P-15698 | 11/19/2014 | Email RE: Algorithm Rxer Update; Q4 2014_Tier 1_2 Prescribers | CVS-MDLT1B-000007394 | CVS-MDLT1B-000007395 | | | | | | | | | |
| P-15699 | 1/15/2014 | Email Store Review | CVS-MDLT1B-000006773 | CVS-MDLT1B-000006802 | | | | | | | | | |
| P-15701 | 9/8/2014 | FW: Blocked Prescriber Report; PBM System Block Condensed Log | CVS-NYAG-000042883 | CVS-NYAG-000042884 | | | | | | | | | |
| P-15702 | 6/24/2014 | Email Files for Reference When Building Access Database; Alternate Prescriber Escalations Identification Log; Suspended Prescribers; Alternate Prescriber Research GuidepostV2 | CVS-NYAG-000042858 | CVS-NYAG-000042865 | | | | | | | | | |
| P-15703 | 6/17/2014 | Email and attachment Prescribers of Concern | CVS-NYAG-000036941 | CVS-NYAG-000036942 | | | | | | | | | |
| P-15704 | 2014 | Astramed Prescriber Analysis | CVS-NYAG-000021817 | CVS-NYAG-000021817 | | | | | | | | | |
| P-15705 | 2014 | Demangone Prescriber Dashboard v2 | CVS-MDLT1B-000001597 | CVS-MDLT1B-000001597 | | | | | | | | | |
| P-15706 | 12/22/2011 | RE: Questions on the new IRR/SOM system | IQVIA-CVS-000000757 | IQVIA-CVS-000000760 | | | | | | | | | |
| P-15707 | 1/26/2015 | ROPP-00001, Professional Standards | CVS-DR22-000001130 | CVS-DR22-000001137 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-15708 | 8/12/2015 | DOC-047401 - RxConnect Operational Prescriber Validation Policy and Procedures. Version 2.0 | CVS-FLAG-000020289 | CVS-FLAG-000020299 | | | | | | | | | |
| P-15709 | 2015 | RxConnect Operational Prescriber Validation Policy and Procedures. Version 2.1 | CVS-INDAG-00014236 | CVS-INDAG-00014246 | | | | | | | | | |
| P-15710 | 2015 | DOC-047401 - RxConnect Operational Prescriber Validation Policy and Procedures. Version 2.2 | CVS-NYAG-000026968 | CVS-NYAG-000026978 | | | | | | | | | |
| P-15711 | 2015 | DOC-047401 - RxConnect Operational Prescriber Validation Policy and Procedures. Version 2.3 | CVS-WASHAG-00000911 | CVS-WASHAG-00000921 | | | | | | | | | |
| P-15712 | 2015 | ROPP-049066 - Controlled Substance Prescriber Monitoring and Review Program | CVS-NYAG-000010605 | CVS-NYAG-000010610 | | | | | | | | | |
| P-15713 | 1/23/2015 | ROPP-048255 - Early Fill of Controlled Substance Prescriptions | CVS-DR22-000001371 | CVS-DR22-000001372 | | | | | | | | | |
| P-15714 | 6/15/2015 | ROPP-00059 - 6/15/15 –Suspected Fraudulent or Altered Prescriptions: New requirement: Under Responsibilities of Pharmacists | CVS-NYAG-000011030 | CVS-NYAG-000011036 | | | | | | | | | |
| P-15715 | 6/15/2015 | ROPP-047561 - Federal Guidelines for Controlled Substances | CVS-FLAG-000020764 | CVS-FLAG-000020774 | | | | | | | | | |
| P-15716 | 10/28/2015 | ROPP-047561 - Federal Guidelines for Controlled Substances | CVS-FLAG-000020808 | CVS-FLAG-000020822 | | | | | | | | | |
| P-15720 | 2015 | Pharmacist in Charge Incentive Plan | CVS-NYAG-000010395 | CVS-NYAG-000010402 | | | | | | | | | |
| P-15721 | 2015 | Pharmacy Manager Incentive Plan | CVS-NYAG-000010428 | CVS-NYAG-000010436 | | | | | | | | | |
| P-15722 | 2015 | Pharmacy Supervisor Incentive Plan | CVS-NYAG-000010352 | CVS-NYAG-000010361 | | | | | | | | | |
| P-15723 | 2015 | Store Level "Blanket" Policies Concerning Controlled Substances | CVS-NYAG-000030635 | CVS-NYAG-000030636 | | | | | | | | | |
| P-15724 | 2015 | Understanding the Dangers of Dispensing Combinations of Controlled Substances | CVS-NYAG-000036552 | CVS-NYAG-000036553 | | | | | | | | | |
| P-15725 | 3/1/2015 | Prescription Monitoring Program Registration: RxConnect | CVS-NYAG-000036541 | CVS-NYAG-000036542 | | | | | | | | | |
| P-15726 | 8/1/2015 | Bi-Annual Training: Pharmacist/Grad Intern Version Course #800142 | CVS-NYAG-000032920 | CVS-NYAG-000032999 | | | | | | | | | |
| P-15728 | 3/5/2012 | Email re Investigation Request | CVS-MDLT1-000023754 | CVS-MDLT1-000023757 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15729 | 4/8/2015 | Email Initial Outreach; Prescriber Outreach_Tracking | CVS-MDLT1B-000009359 | CVS-MDLT1B-000009360 | | | | | | | | | |
| P-15730 | 2/23/2015 | Reinstatement Outreach Letter | CVS-MDLT1B-000001656 | CVS-MDLT1B-000001656 | | | | | | | | | |
| P-15731 | 2015 | Prescriber Reinstatement Questionnaire | CVS-MDLT1B-000001682 | CVS-MDLT1B-000001685 | | | | | | | | | |
| P-15732 | 3/10/2015 | letter denying reinstatement | CVS-MDLT1B-000001691 | CVS-MDLT1B-000001691 | | | | | | | | | |
| P-15733 | 2015 | Demangone David Prescriber Notes 4 17 15 | CVS-MDLT1B-000001593 | CVS-MDLT1B-000001594 | | | | | | | | | |
| P-15735 | 3/13/2015 | Email and attachment SOM Weekly Update WE 3_13_2015 | CVS-MDLT1B-000007900 | CVS-MDLT1B-000007901 | | | | | | | | | |
| P-15736 | 5/5/2015 | Email and attachment SOM Weekly Update WE 3_13_2016 | CVS-NYAG-000037050 | CVS-NYAG-000037051 | | | | | | | | | |
| P-15737 | 2015 | Q1 2015 Tier1_2 Prescribers | CVS-MDLT1B-000001797 | CVS-MDLT1B-000001797 | | | | | | | | | |
| P-15738 | 2015 | Q4 2015 Tier 2 Hydro and Oxy Prescribers | CVS-MDLT1B-000001794 | CVS-MDLT1B-000001794 | | | | | | | | | |
| P-15739 | 8/22/2012 | Email re Bulleted SOMs Process | CVS-MDLT1-000023758 | CVS-MDLT1-000023758 | | | | | | | | | |
| P-15740 | 1/2/2015 | Email and attachment Store Review | CVS-MDLT1B-000007542 | CVS-MDLT1B-000007681 | | | | | | | | | |
| P-15742 | 2/2/2015 | Email and attachments for investigation into Bruce Pizsel | CVS-MDLT1B-000009317 | CVS-MDLT1B-000009343 | | | | | | | | | |
| P-15743 | 3/18/2015 | Email and attachment Suspended Prescribers Active List | CVS-NYAG-000041717 | CVS-NYAG-000041718 | | | | | | | | | |
| P-15744 | 7/7/2015 | Email and attachment Prescriber Block Tracking Log Master | CVS-NYAG-000042961 | CVS-NYAG-000042962 | | | | | | | | | |
| P-15745 | 2015 | 40 Script Floor: Prescriber Algorithm 201504 | CVS-NYAG-000022120 | CVS-NYAG-000022120 | | | | | | | | | |
| P-15746 | 2015 | Enhanced CS Prescriber Algorithm, Priority Metric Dashboard | CVS-NYAG-000039379 | CVS-NYAG-000039379 | | | | | | | | | |
| P-15747 | 1/9/2015 | Email and attachment Tracking_Cardinal_Inquiries_7_3 1_13 | CVS-MDLT1B-000007540 | CVS-MDLT1B-000007541 | | | | | | | | | |
| P-15749 | 2015 | Demangone Algorithm Output | CVS-MDLT1B-000001598 | CVS-MDLT1B-000001598 | | | | | | | | | |
| P-15750 | 2015 | David Demangone Tableau Dashboard v3 | CVS-MDLT1B-000001599 | CVS-MDLT1B-000001612 | | | | | | | | | |
| P-15752 | 5/10/2016 | ROPP-0061 - Guidelines for Dispensing Controlled Substances | CVS-FLAG-000020639 | CVS-FLAG-000020641 | | | | | | | | | |
| P-15753 | 9/26/2016 | ROPP-0061 - Guidelines for Dispensing Controlled Substances | CVS-FLAG-000020963 | CVS-FLAG-000020967 | | | | | | | | | |
| P-15754 | 2016 | ROPP-049714 CS Dispensing Program | CVS-NYAG-000038789 | CVS-NYAG-000038791 | | | | | | | | | |
| P-15755 | 2016 | ROPP-048255 - Early Fill of Controlled Substance Prescription | CVS-NYAG-000026856 | CVS-NYAG-000026857 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15756 | 1/12/2016 | ROPP-047561 - Federal Guidelines for Controlled Substances | CVS-FLAG-000020884 | CVS-FLAG-000020889 | | | | | | | | | |
| P-15757 | 8/19/2016 | DOC-047401: RxConnect Operational Prescriber Validation Policy and Procedures, Version 3.0 | CVS-FLAG-000020246 | CVS-FLAG-000020263 | | | | | | | | | |
| P-15758 | 8/19/2016 | RxConnect Operational Prescriber Validation Policy and Procedures, Version 3.1 | CVS-INDAG-00014193 | CVS-INDAG-00014210 | | | | | | | | | |
| P-15759 | 8/19/2016 | DOC-047401: RxConnect Operational Prescriber Validation Policy and Procedures, Version 3.2 | CVS-NYAG-000026934 | CVS-NYAG-000026951 | | | | | | | | | |
| P-15760 | 9/27/2016 | ROPP-047561 - Federal Guidelines for Controlled Substances | CVS-FLAG-000020840 | CVS-FLAG-000020857 | | | | | | | | | |
| P-15761 | 12/28/2016 | ROPP-047561 - Federal Guidelines for Controlled Substances | CVS-FLAG-000020823 | CVS-FLAG-000020839 | | | | | | | | | |
| P-15768 | 1/7/2017 | FW 2016 Performance Review Guide | CVS-MDLT1B-000010184 | CVS-MDLT1B-000010188 | | | | | | | | | |
| P-15769 | 2016 | Pharmacists: On the Front Lines | CVS-NYAG-000036557 | CVS-NYAG-000036558 | | | | | | | | | |
| P-15770 | 8/1/2016 | Pharmacist-on-Duty Drug Loss Reporting Job Aid | CVS-NYAG-000033424 | CVS-NYAG-000033425 | | | | | | | | | |
| P-15771 | 9/6/2016 | Email Opioid Cocktail Awareness | CVS-NYAG-000033232 | CVS-NYAG-000033232 | | | | | | | | | |
| P-15772 | 12/1/2016 | Calculating Morphine Milligram Equivalent Daily Dosing | CVS-NYAG-000035194 | CVS-NYAG-000035196 | | | | | | | | | |
| P-15774 | 3/16/2016 | Email and attachment Outreach; Prescriber Outreach_Tracking1 | CVS-MDLT1B-000009810 | CVS-MDLT1B-000009814 | | | | | | | | | |
| P-15775 | 2016 | Interview Notes | CVS-MDLT1B-000001646 | CVS-MDLT1B-000001648 | | | | | | | | | |
| P-15776 | 3/9/2019 | Email and attachment Weekly SOM MAQ Updates WE 3_4_2016 | CVS-NYAG-000043032 | CVS-NYAG-000043033 | | | | | | | | | |
| P-15777 | 7/8/2016 | Email and attachment 2016.7.8_Fraud | CVS-MDLT1B-000009915 | CVS-MDLT1B-000009916 | | | | | | | | | |
| P-15780 | 1/12/2016 | Email FW: Prescriber Block Report; PBM DEA Prescriber Block Tracking Log Master | CVS-NYAG-000043004 | CVS-NYAG-000043005 | | | | | | | | | |
| P-15781 | 2016 | Algorithm used as part of investigation into a prescriber. | CVS-MDLT1B-000008985 | CVS-MDLT1B-000008985 | | | | | | | | | |
| P-15782 | 9/26/2017 | ROPP-0001, Professional Standards | CVS-FLAG-000020921 | CVS-FLAG-000020930 | | | | | | | | | |
| P-15788 | 2017 | Annual Review Pharmacy Manager Pre-Work | CVS-NYAG-000033426 | CVS-NYAG-000033428 | | | | | | | | | |
| P-15789 | 11/30/2017 | Email Monthly Professional Practice Brief: 4 Key Elements in Keeping our Patients Safe | CVS-NYAG-000033870 | CVS-NYAG-000033870 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15790 | 2017 | Prescriber Outreach_Tracking16 | CVS-MDLT1B-000001619 | CVS-MDLT1B-000001619 | | | | | | | | | |
| P-15793 | 2017 | RE: SOM MAQ Escalation Status; Chart tracking suspicious prescribers | CVS-MDLT1B-000010687 | CVS-MDLT1B-000010689 | | | | | | | | | |
| P-15794 | 11/8/2017 | Email and attachment MAQ/SOM Assessment Questions | CVS-MDLT1B-000010842 | CVS-MDLT1B-000010844 | | | | | | | | | |
| P-15795 | 1/23/2017 | Email and attachment Fraudulent_Script | CVS-MDLT1B-000010189 | CVS-MDLT1B-000010190 | | | | | | | | | |
| P-15796 | 2017 | Spreadsheet CS Analysis | CVS-MDLT1B-000001641 | CVS-MDLT1B-000001641 | | | | | | | | | |
| P-15803 | 4/19/2017 | Email and attachment Pharmacy Supervisor Controlled Substances Deep Dive | CVS-MDLT1B-000010357 | CVS-MDLT1B-000010366 | | | | | | | | | |
| P-15804 | 8/16/2017 | RE: SOM MAQ Escalation Status; Excel spreadsheet reflecting results of weekly SOM MAQ escalation status | CVS-MDLT1B-000010685 | CVS-MDLT1B-000010686 | | | | | | | | | |
| P-15805 | 8/21/2017 | Email and attachment re weekly SOM-MAQ updates citing concerns about specific prescribers after corporate outreach following an audit revealing stores that were exceeding or approaching their SOM/MAQ limit | CVS-MDLT1B-000010718 | CVS-MDLT1B-000010719 | | | | | | | | | |
| P-15806 | 10/1/2017 | Email and attachment Cascade Materials Workbook | CVS-MDLT1B-000010817 | CVS-MDLT1B-000010832 | | | | | | | | | |
| P-15808 | 7/10/2018 | ROPP-00061 V.11 Guidelines for Dispensing Controlled Substances | CVS-FLAG-000013839 | CVS-FLAG-000013843 | | | | | | | | | |
| P-15809 | 2018 | ROPP-059583 - Prescription Forgery Identification Program | CVS-FLAG-000020177 | CVS-FLAG-000020180 | | | | | | | | | |
| P-15810 | 5/2/2018 | ROPP-47561 – Federal Guidelines for Controlled Substances | CVS-FLAG-000020543 | CVS-FLAG-000020563 | | | | | | | | | |
| P-15818 | 2018 | 2018 Project Report Annual Review Rx Manager Guide | CVS-MDLT1B-000005023 | CVS-MDLT1B-000005024 | | | | | | | | | |
| P-15819 | 2018 | A Guide to Safe Use of Pain Medication | CVS-NYAG-000036544 | CVS-NYAG-000036545 | | | | | | | | | |
| P-15820 | 2018 | Using Opioids Appropriately in the Community Pharmacy Setting Volume 2016, Course No. 243, Self-Study Course #160243 | CVS-NYAG-000035143 | CVS-NYAG-000035158 | | | | | | | | | |
| P-15822 | 3/8/2018 | RE: PLA Report: February 2018; Fraud spreadsheet | CVS-MDLT1B-000011593 | CVS-MDLT1B-000011594 | | | | | | | | | |
| P-15823 | 2018 | CS Analysis (Germany) | CVS-MDLT1B-000001634 | CVS-MDLT1B-000001634 | | | | | | | | | |
| P-15824 | 2018 | 12 Prescriber Algorithm Dashboard | CVS-FLAG-000060922 | CVS-FLAG-000060922 | | | | | | | | | |
| P-15825 | 1/16/2018 | Guide to Controlled Substance Store Visit | CVS-MDLT1B-000009148 | CVS-MDLT1B-000009148 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15826 | 4/4/2018 | Email PLA Report: March 2018; Patient Level Alerter Script Report | CVS-MDLT1B-000011595 | CVS-MDLT1B-000011596 | | | | | | | | | |
| P-15827 | 2018 | Flagging Definitions and Summary | CVS-MDLT1B-000001806 | CVS-MDLT1B-000001806 | | | | | | | | | |
| P-15828 | 2/6/2019 | ROPP-47561 – Federal Guidelines for Controlled Substances | CVS-FLAG-000020600 | CVS-FLAG-000020621 | | | | | | | | | |
| P-15831 | 2019 | 2019 Staff Pharmacist Incentive Plan | CVS-MDLT1B-000001899 | CVS-MDLT1B-000001906 | | | | | | | | | |
| P-15835 | 5/1/2019 | Medication for Opioid Use Disorder: How Pharmacists can help | CVS-NYAG-000035124 | CVS-NYAG-000035124 | | | | | | | | | |
| P-15836 | 3/1/2019 | Annual Retail Compliance (ARC) Responsibilities & Expectations Training--Pharmacy Supplement - Pharmacist | CVS-NYAG-000035025 | CVS-NYAG-000035075 | | | | | | | | | |
| P-15837 | 4/16/2019 | CVS settlement agreement with the USAO of the District of Rhode Island for \$535,000.00. | N/A | N/A | | | | | | | | | |
| P-15838 | 2019 | Fraud Tracker | CVS-MDLT1B-000000003 | CVS-MDLT1B-000000003 | | | | | | | | | |
| P-15840 | 2019 | Master Prescriber Flagging Document | CVS-MDLT1B-000001810 | CVS-MDLT1B-000001810 | | | | | | | | | |
| P-15841 | 2019 | Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances | CVS-NYAG-000035125 | CVS-NYAG-000035142 | | | | | | | | | |
| P-15842 | 11/1/2003 | CVS Policy & Procedure, Prescription Refunds/Incidents | CVS-DR22-000001392 | CVS-DR22-000001397 | | | | | | | | | |
| P-15843 | 9/25/2015 | CVS Prescription Drug Monitoring Program, ROPP-0062 | CVS-FLAG-000020952 | CVS-FLAG-000020955 | | | | | | | | | |
| P-15844 | 2/18/2016 | CVS Controlled Substance Dispensing Program; ROPP-049714 | CVS-FLAG-000051203 | CVS-FLAG-000051205 | | | | | | | | | |
| P-15845 | 10/29/2014 | Dispensing by GCN | CVS-FLAG-000066429 | CVS-FLAG-000066430 | | | | | | | | | |
| P-15848 | 9/20/2013 | Email SOM SOP; Attachment CVS/Corporate Logistics, SOM Process - Stop Order / Order Resumption SOP 1/10/2013 | CVS-MDLT1-000000428 | CVS-MDLT1-000000432 | | | | | | | | | |
| P-15850 | 1/6/2014 | Email SOM Materials for Review; Attachments SOM Business Requirements Document; SOM flowcharts with listed chemicals - 25JUL13; SOM Parameters with Valid Ranges; SOM Process Overview 121412; SOM System Flow | CVS-MDLT1-000013446 | CVS-MDLT1-000013510 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-15852 | 10/31/2018 | CVS Caremark Dispensing Guidelines for Pain Management | CVS-MDLT1-000061095 | CVS-MDLT1-000061095 | | | | | | | | | |
| P-15853 | 10/18/2010 | Email IRR info; Attachment DEA Speaking Points IRR PPT | CVS-MDLT1-000075266 | CVS-MDLT1-000075278 | | | | | | | | | |
| P-15854 | 1/1/2006 | CVS Policy & Procedure, Accepting Prescriptions, Policy No. 000-000-000 | CVS-MDLT1-000081402 | CVS-MDLT1-000081428 | | | | | | | | | |
| P-15855 | 11/7/2008 | CVS/Corporate Logistics, ARCOS Reporting DC SOP | CVS-MDLT1-000081429 | CVS-MDLT1-000081435 | | | | | | | | | |
| P-15857 | 10/1/2010 | CVS Distribution Centers, Reporting Thefts and Significant Losses | CVS-MDLT1-000081443 | CVS-MDLT1-000081444 | | | | | | | | | |
| P-15858 | 11/17/2006 | CVS ARCOS Reporting - DC Procedure | CVS-MDLT1-000081445 | CVS-MDLT1-000081450 | | | | | | | | | |
| P-15859 | 2012 | CVS Controlled Substance Prescriptions for Hospice Patients, ROPP-045861 | CVS-MDLT1-000081451 | CVS-MDLT1-000081453 | | | | | | | | | |
| P-15860 | 9/25/2013 | CVS Accepting Prescriptions, ROPP-0010 | CVS-MDLT1-000081454 | CVS-MDLT1-000081459 | | | | | | | | | |
| P-15861 | 2/4/2013 | CVS Professional Standards, ROPP-0001 | CVS-MDLT1-000081460 | CVS-MDLT1-000081470 | | | | | | | | | |
| P-15862 | 3/1/2011 | CVS Policy & Procedure, Pharmacy Warehouse Delivery, ROPP-0057 | CVS-MDLT1-000081471 | CVS-MDLT1-000081476 | | | | | | | | | |
| P-15863 | 5/10/2013 | CVS Prescription Drug Monitoring Program, ROPP-0062 | CVS-MDLT1-000081477 | CVS-MDLT1-000081481 | | | | | | | | | |
| P-15864 | 8/20/2013 | CVS Professional Standards, ROPP-0001 | CVS-MDLT1-000081482 | CVS-MDLT1-000081492 | | | | | | | | | |
| P-15865 | 4/30/2012 | CVS Professional Standards, ROPP-0001 | CVS-MDLT1-000081493 | CVS-MDLT1-000081502 | | | | | | | | | |
| P-15867 | 3/27/2012 | CVS Accepting Prescriptions, ROPP-0010 | CVS-MDLT1-000081517 | CVS-MDLT1-000081522 | | | | | | | | | |
| P-15868 | 1/11/2012 | CVS Professional Standards, ROPP-0001 | CVS-MDLT1-000081523 | CVS-MDLT1-000081531 | | | | | | | | | |
| P-15869 | 1/16/2014 | CVS Accepting Prescriptions, ROPP-0010 | CVS-MDLT1-000081532 | CVS-MDLT1-000081538 | | | | | | | | | |
| P-15870 | 5/31/2012 | CVS Suspected Fraudulent or Altered Prescription, ROPP-0059 | CVS-MDLT1-000081539 | CVS-MDLT1-000081544 | | | | | | | | | |
| P-15871 | 4/24/2012 | CVS Prescription Drug Monitoring Websites, ROPP-0062 | CVS-MDLT1-000081545 | CVS-MDLT1-000081546 | | | | | | | | | |
| P-15872 | 7/17/2014 | CVS Prescription Drug Monitoring Program, ROPP-0062 | CVS-MDLT1-000081547 | CVS-MDLT1-000081551 | | | | | | | | | |
| P-15873 | 12/17/2013 | CVS Suspected Fraudulent or Altered Prescription, ROPP-0059 | CVS-MDLT1-000081552 | CVS-MDLT1-000081558 | | | | | | | | | |
| P-15874 | 1/9/2013 | Email re IRR Statistics | CVS-MDLT1-000103850 | CVS-MDLT1-000103851 | | | | | | | | | |
| P-15875 | 6/30/2011 | CVS Policy & Procedure, Suspected Fraudulent or Altered Prescriptions, Policy No. ROPP-0059 | CVS-MDLT1-000081559 | CVS-MDLT1-000081567 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-15876 | 1/4/2012 | CVS Protocol For Dispensing Narcotic Drugs for Pain Treatment, ROPP-0061 | CVS-MDLT1-000081566 | CVS-MDLT1-000081568 | | | | | | | | | |
| P-15877 | 5/15/2014 | Email; Attachment CVS Suspicious Order Monitoring, May 2014; CVS Suspicious Order Monitoring PPT | CVS-MDLT1-000081679 | CVS-MDLT1-000081684 | | | | | | | | | |
| P-15878 | 7/9/2012 | Re: INSPECT presentation / speaking request; Attachment Identifying Drug Loss In Our Stores PPT | CVS-MDLT1-000086759 | CVS-MDLT1-000086783 | | | | | | | | | |
| P-15879 | 11/3/2003 | CVS Policy & Procedure, Pharmacy Operations Manual, Pharmacy Access and Security, Policy No. 000-000-000 | CVS-MDLT1-000099680 | CVS-MDLT1-000099688 | | | | | | | | | |
| P-15880 | 2/4/2013 | CVS Pharmacy Access and Security, ROPP-0039 | CVS-MDLT1-000099689 | CVS-MDLT1-000099695 | | | | | | | | | |
| P-15881 | 3/4/2013 | CVS Pharmacy Employee Loss Prevention/Drug Diversion Policy | CVS-MDLT1-000099696 | CVS-MDLT1-000099701 | | | | | | | | | |
| P-15882 | 10/18/2010 | RE: IRR info | CVS-MDLT1-000110330 | CVS-MDLT1-000110330 | | | | | | | | | |
| P-15883 | 8/20/2014 | CVS Controlled Substance Monitoring Program | CVS-MDLT1-000114347 | CVS-MDLT1-000114352 | | | | | | | | | |
| P-15884 | 3/27/2012 | Re: Oxy-Hydro Reports by Prescriber | CVS-MDLT1-000117645 | CVS-MDLT1-000117645 | | | | | | | | | |
| P-15885 | 2/1/2012 | FW: Launch of the new Archer Drug Loss Reporting Solution; Attachment Pharmacist on Duty Drug Loss Reporting Job Aid | CVS-MDLT1B-000002436 | CVS-MDLT1B-000002438 | | | | | | | | | |
| P-15886 | 2/1/2015 | CVS Pharmacy Professional Practice Controlled Substance Programs and Corresponding Responsibility | CVS-MDLT1B-000006200 | CVS-MDLT1B-000006226 | | | | | | | | | |
| P-15888 | 1/13/2012 | Email RX Contracts - Daily (4); Attachment RX Contacts - Daily | CVS-MDLT1B-000009183 | CVS-MDLT1B-000009184 | | | | | | | | | |
| P-15889 | 2/8/2016 | Email 2016-2 Emerging Leader; Attachment Emerging Leader PPT | CVS-MDLT1B-000009715 | CVS-MDLT1B-000009740 | | | | | | | | | |
| P-15890 | 6/9/2017 | Email PMP For July Compliance; Attachment 2016 Pharmacy Supervisor Annual RPH Review Guide | CVS-MDLT1B-000010501 | CVS-MDLT1B-000010505 | | | | | | | | | |
| P-15891 | 9/20/2012 | Email CS Monitoring SOP Drafts; Attachments CS Monitoring Prescriber Program Draft 9.18.12; Flow Chart for CS Monitoring (Draft 9 18 12) - Detailed | CVS-MDLT1B-000012599 | CVS-MDLT1B-000012611 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|-------------------------|--|--|--|--|--|--|--|--|--|
| P-15892 | 1/26/2016 | Email Grad training Day_2_Presentation 2015; Attachments Key_Takeaways_Workbook0 grad training 2015; FW: Access to GTM Materials | CVS-MDLT1B-000016512 | CVS-MDLT1B-000016640 | | | | | | | | | |
| P-15894 | 2/19/2016 | Email Q1 CSDP; Attachment 2016_2_19 Emails | CVS-NYMDL-000011841 | CVS-NYMDL-000011843 | | | | | | | | | |
| P-15895 | 2/22/2016 | Email Quarter 1 Stores Entering the CSDP | CVS-NYMDL-000011850 | CVS-NYMDL-000011851 | | | | | | | | | |
| P-15896 | 2/14/2008 | USA Today, Retired pharmacist: There is a correlation between workload and errors | N/A | N/A | | | | | | | | | |
| P-15897 | 12/24/2012 | Email Revised proposal; Attachment CVS SOM proposal edited 23DEC12 | SA AGI 00018818 | SA AGI 00018833 | | | | | | | | | |
| P-15898 | 2/12/2013 | Re: Privileged and Confidential: Order entry data; Attachment Flagged Orders 12_2010-2_2013 | SA AGI 00068524 | SA AGI 00068525 | | | | | | | | | |
| P-15899 | 11/13/2009 | Email re CVS Gap Analysis; Gap Analysis Attachment | IQVIA-CVS-000001506 | IQVIA-CVS-000001510 | | | | | | | | | |
| P-15901 | 3/27/2006 | CVS DEA ARCOS Reporting SOP | CVS-MDLT1-000055514 | CVS-MDLT1-000055519 | | | | | | | | | |
| P-15902 | 11/3/2011 | Email re Questions on the new IRR/SOM System | CVS-NYMDL-000006418 | CVS-NYMDL-000006419 | | | | | | | | | |
| P-15903 | 11/14/2012 | Email re Control IRR Statistics 10/1/12 - 11/11/12 | CVS-NYMDL-000006420 | CVS-NYMDL-000006420 | | | | | | | | | |
| P-15904 | 11/13/2012 | Email re Control IRR Statistics 10/11 | CVS-NYMDL-000006422 | CVS-NYMDL-000006422 | | | | | | | | | |
| P-15907 | 10/5/2012 | Email attaching Pharmacy DC Ordering Process Recap 10 4 11 | CVS-NYMDL-000008043 | CVS-NYMDL-000008044 | | | | | | | | | |
| P-15908 | 6/15/2011 | Email re Friday Meeting to discuss SOM/IRR Revisions and new roles/responsibilities | CVS-NYMDL-000008052 | CVS-NYMDL-000008053 | | | | | | | | | |
| P-15914 | 10/31/2012 | CVS Corporation Item Review Report, Control Drugs | CVS-NYMDL-000005004 | CVS-NYMDL-000005088 | | | | | | | | | |
| P-15915 | 8/6/2013 | FW: Privileged and Confidential - SOM Huddle Materials | CVS-MDLT1-000110158 | CVS-MDLT1-000110164 | | | | | | | | | |
| P-15916 | 8/5/2013 | FW: SOP on SOM | CVS-MDLT1-000103852 | CVS-MDLT1-000103856 | | | | | | | | | |
| P-15917 | 7/31/2012 | IRR sample | CVS-MDLT1-000011511 | CVS-MDLT1-000011756 | | | | | | | | | |
| P-15918 | 8/5/2013 | FW: SOM policies | CVS-MDLT1-000123203 | CVS-MDLT1-000123204.016 | | | | | | | | | |
| P-15920 | 11/29/2012 | Som plan_112912 | CVS-MDLT1-000059996 | CVS-MDLT1-000060231 | | | | | | | | | |
| P-15921 | Sep-12 | Rannazzisi Drug trend presentation "Drug Trends" | N/A | N/A | | | | | | | | | |
| P-15922 | Undated | CVS amended objections and responses to FCR | N/A | N/A | | | | | | | | | |
| P-15923 | Undated | Federal Register - Masters | N/A | NA | | | | | | | | | |
| P-15924 | 11/30/2018 | 2018-11-30 CVS Rx Services, Inc.'s and CVS Indiana, L.L.C.'s Objections ... | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-15925 | 1/24/2013 | 20130124-DSaRM-T1-Transcript | N/A | N/A | | | | | | | | | |
| P-15926 | 9/14/2018 | CVS Custodian List - Moffat | N/A | N/A | | | | | | | | | |
| P-15927 | 11/15/2018 | 20181115 CVS's Written Responses to Topics 8, 9, 12, 13, and 14 of Plaintiff's' Amended Second Rule 30(b)(6) Notice | N/A | N/A | | | | | | | | | |
| P-15929 | 11/16/2018 | CVS Health at a Glance | N/A | N/A | | | | | | | | | |
| P-15930 | Undated | CVS Health Trade Association and Coalition Participation | N/A | N/A | | | | | | | | | |
| P-15931 | Undated | Impact of the tobacco sales removal on smoking cessation | N/A | N/A | | | | | | | | | |
| P-15932 | 1/24/2013 | January 24, 2013 DEA Presentation | N/A | N/A | | | | | | | | | |
| P-15933 | Undated | Joint_Pharmacy_Stakeholders_HCP_Rescheduling_Comments_to_DEA_pdf | N/A | N/A | | | | | | | | | |
| P-15934 | Undated | The top 15 us pharmacies of 2017 market | N/A | N/A | | | | | | | | | |
| P-15935 | Undated | IMS v CVS - 20110427 Verified Complaint - Redacted | N/A | N/A | | | | | | | | | |
| P-15937 | Undated | NACDS Leadership | N/A | N/A | | | | | | | | | |
| P-15938 | Undated | Amicus Briefs | N/A | N/A | | | | | | | | | |
| P-15939 | Undated | 19-10 Rannazzisi declaration attachment 4 | N/A | N/A | | | | | | | | | |
| P-15940 | Undated | CVS USA map | N/A | N/A | | | | | | | | | |
| P-15941 | 2/22/2012 | Government's prehearing statement in the matter of Cardinal Health | N/A | N/A | | | | | | | | | |
| P-15942 | Undated | 2019-01-14 CVS Written Responses to Topics 2, 4, 10, 16, and 17 | N/A | N/A | | | | | | | | | |
| P-15944 | Undated | Baker LinkedIn | N/A | N/A | | | | | | | | | |
| P-15950 | 6/14/2018 | Distribution Center ID XREF | N/A | N/A | | | | | | | | | |
| P-15951 | 7/19/2011 | CVS internal email with attached Logistics BSR Tasks chart | CVS-MDLT1-000108935 | CVS-MDLT1-000108936 | | | | | | | | | |
| P-15954 | 2012 | 2012 Ohio Drug Overdose Deaths: https://recoveryohio.gov/wps/wcm/connect/gov/8b8cd4c9-129b-4924-8d65-c88288437525/2012_OhioDrugOverdoseReport.pdf?MOD=AJPERES&CONVERT_TO=url&CACHEID=ROOTWORKSPACE.Z18_M1HGGIK0N0JO00QO9DDDM3000-8b8cd4c9-129b-4924-8d65-c88288437525-nmuJlS | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-15955 | 2/7/2015 | DEA Controlled Substance and Legend Drug Diversion; A Law Enforcement and Regulatory Perspective. South Point Casino and Resort, Las Vegas, NV, February 7/8, 2015 | N/A | N/A | | | | | | | | | |
| P-15956 | 12/31/2018 | PeopleSoft Fulfillment Check Register | N/A | N/A | | | | | | | | | |
| P-15957 | 10/25/2011 | October 2011 Control IRR Recap | CVS-NYAG-000027625 | CVS-NYAG-000027626 | | | | | | | | | |
| P-15962 | Undated | DEA Controlled Substance and Legend Drug Diversion; A Law Enforcement and Regulatory Perspective. Sheraton Hotel, Norfolk, VA, May 30/31, 2015 | N/A | N/A | | | | | | | | | |
| P-15964 | 6/15/2018 | Amended first notice of deposition pursuant to rule 30b6 | N/A | N/A | | | | | | | | | |
| P-15965 | 6/15/2018 | Amended second notice of deposition pursuant to rule 30b6 | N/A | N/A | | | | | | | | | |
| P-15966 | 9/21/2018 | Letter re 30b6 topics | N/A | N/A | | | | | | | | | |
| P-15967 | 10/22/2018 | Letter re 30b6 topics changes | N/A | N/A | | | | | | | | | |
| P-15968 | 3/5/2015 | CVS Year-End Review - 2012 (Finalized) Review of Henry Mortelliti Iii, Reviewing Manager: Judith Hughes | N/A | N/A | | | | | | | | | |
| P-15970 | 5/8/2012 | Email re Work Instruction: IRR & Attached Policy for Review | CVS-MDLT1-000083972 | CVS-MDLT1-000083979 | | | | | | | | | |
| P-15977 | 11/23/2012 | IRR Order Logistics Communication | CVS-NYMDL-000008588 | CVS-NYMDL-000008602 | | | | | | | | | |
| P-15980 | 2/12/2013 | RE: Privileged and Confidential: Order entry data; Attachment Flagged Orders 12_2010-2_2013 | CVS-MDLT1-000128031 | CVS-MDLT1-000128032 | | | | | | | | | |
| P-15981 | 10/6/2014 | Suspicious Order Monitoring DC Update | CVS-MDLT1-000113485 | CVS-MDLT1-000113487 | | | | | | | | | |
| P-15982 | 1/5/2019 | Mid-Year Review - Mortelliti 2010 | CVS-MDLT1-000121550 | CVS-MDLT1-000121553 | | | | | | | | | |
| P-15983 | 1/5/2019 | Mortelliti 2010a | CVS-MDLT1-000121554 | CVS-MDLT1-000121558 | | | | | | | | | |
| P-16073 | 5/20/2016 | Suspicious Order Report | WMT_MDL_000415981 | WMT_MDL_000415982 | | | | | | | | | |
| P-16096 | 11/3/2017 | CVS Health Approach to Opioids; SMartin AAFP Letter 110317 | AAFP0003032 | AAFP0003035 | | | | | | | | | |
| P-16097 | 4/14/2015 | Meeting presentations | WMT_MDL_000455894 | WMT_MDL_000455904 | | | | | | | | | |
| P-16098 | 8/28/2013 | Output QC highlights - Practice Compliance Reports | WMT_MDL_000495113 | WMT_MDL_000495116 | | | | | | | | | |
| P-16114 | 41907 | Fw: Suspicious MD under investigation | WMT_MDL_000621245 | WMT_MDL_000621247 | | | | | | | | | |
| P-16115 | 42732 | FW: Filling C2--dr under investigation | WMT_MDL_000677382 | WMT_MDL_000677384 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-16117 | 43236 | RE: Vincent Stenger [DEA AS8122614] | WMT_MDL_000689442 | WMT_MDL_000689443 | | | | | | | | | |
| P-16119 | 42042 | RE: Filling C2--dr under investigation | WMT_MDL_000699040 | WMT_MDL_000699043 | | | | | | | | | |
| P-16132 | 42042 | FW: Filling C2 electronic prescriptions and refusal to fill web forms | WMT_MDL_000699044 | WMT_MDL_000699046 | | | | | | | | | |
| P-16142 | 2/7/2015 | Filling C2 electronic prescriptions and refusal to fill web forms | WMT_MDL_000699047 | WMT_MDL_000699049 | | | | | | | | | |
| P-16150 | 6/19/2014 | FW: The Master Spreadsheet RTF 2013 ytd | WMT_MDL_000699391 | WMT_MDL_000699392 | | | | | | | | | |
| P-16152 | 11/26/2014 | Office today | WMT_MDL_000699454 | WMT_MDL_000699456 | | | | | | | | | |
| P-16153 | 11/26/2014 | Fwd: Controls from a local DR | WMT_MDL_000699457 | WMT_MDL_000699458 | | | | | | | | | |
| P-16156 | 2/7/2015 | RE: Filling C2--dr under investigation | WMT_MDL_000716756 | WMT_MDL_000716758 | | | | | | | | | |
| P-16157 | 2/7/2015 | FW: Filling C2--dr under investigation | WMT_MDL_000734116 | WMT_MDL_000734118 | | | | | | | | | |
| P-16168 | 6/20/2014 | FW: The Master Spreadsheet RTF 2013 ytd | WMT_MDL_000739207 | WMT_MDL_000739208 | | | | | | | | | |
| P-16214 | 9/1/2016 | Press Release: CVS Pharmacy to Strengthen Policies Around Dispensing Opioids and Require Use of Prescription Monitoring Program in Groundbreaking Settlement | N/A | N/A | | | | | | | | | |
| P-16215 | 6/30/2016 | Press Release: CVS to Pay \$3.5 Million to Resolve Allegations that Pharmacists Filled Fake Prescriptions | N/A | N/A | | | | | | | | | |
| P-16216 | 8/10/2015 | Press Release: Drug Diversion Claims Against CVS Health Corp. Resolved With \$450,000 Civil Settlement | N/A | N/A | | | | | | | | | |
| P-16217 | 9/5/2014 | Press Release: CVS and H-E-B Pay Civil Penalties for Alleged Violations of the Controlled Substances Act | N/A | N/A | | | | | | | | | |
| P-16218 | 9/5/2014 | Press Release: Houston Chronicle, HEB, CVS pay more than \$2 million in drug penalties | N/A | N/A | | | | | | | | | |
| P-16219 | 4/3/2013 | Press Release: CVS To Pay \$11 Million To Settle Civil Penalty Claims Involving Violations Of Controlled Substances Act | N/A | N/A | | | | | | | | | |
| P-16220 | 4/8/2019 | Settlement Agreement between DEA and CVS | N/A | N/A | | | | | | | | | |
| P-16227 | 1/17/2020 | The Opioid Files, Drilling into the DEA's pain pill database - The Washington Post | N/A | N/A | | | | | | | | | |
| P-16233 | 3/29/2015 | DEA Presentation Pharmaceutical Use & Abuse | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------------------|--------------------------------|--|--|--|--|--|--|--|--|--|
| P-16323 | 3/11/2011 | Administrative Memorandum of Agreement between, U.S. DOJ, DEA and Walmart | WMT_MDL_000043490 | WMT_MDL_000043496 | | | | | | | | | |
| P-16371 | 8/22/2006 | NACDS - Pharmacy & Technology Mtg - August 2006 | ENDO-OPIOID_MDL-04920264 | ENDO-OPIOID_MDL-04920270 | | | | | | | | | |
| P-16445 | 5/16/2013 | Email re DEA Drugs of Concern; Drug Fact Sheet | CVS-MDLT1-000055595 | CVS-MDLT1-000055646 | | | | | | | | | |
| P-16446 | 6/29/2018 | Data Drives Success at CVS Health | N/A | N/A | | | | | | | | | |
| P-16593 | 4/24/1971 | 21 C.F.R. § 1301.76(c) | N/A | N/A | | | | | | | | | |
| P-16701 | 12/12/2017 | Statement of Demetra Ashley before the Judiciary Committee for a Hearing | N/A | N/A | | | | | | | | | |
| P-16702 | 1/30/2018 | Letter from D. Ashley to Hon. D. Polster re ARCOS data | N/A | N/A | | | | | | | | | |
| P-16750 | 7/12/1996 | Phase IV Oxycontin Tablets Team Meeting Minutes | PDD1505010159 | PDD1505010162 | | | | | | | | | |
| P-16770 | 10/29/2014 | Summary on NC Mutual, Walmart, and Navarro | PPLP004472218 | PPLP004472223 | | | | | | | | | |
| P-16774 | 6/6/2012 | Fwd: Opportunity for Walmart to partner with manufacturer to reduce Oxycontin abuse - no cost to Walmart | PPLPC017000387452 | PPLPC017000387457 | | | | | | | | | |
| P-16780 | 1/17/2000 | Walgreens request for money | E15_00007557 | E15_00007557 | | | | | | | | | |
| P-16781 | 10/28/2001 | Walgreens Programs National Accounts | E15_00012925 | E15_00012925 | | | | | | | | | |
| P-16782 | 4/17/2001 | Re: lipman CE for Walgreens | E15_00034535 | E15_00034535 | | | | | | | | | |
| P-16783 | 3/26/1999 | Purdue's Letter to Mary Whitley RPh, Walgreens. | PDD1701269026 | PDD1701269026 | | | | | | | | | |
| P-16784 | 7/31/2000 | RE: Walgreen's Program | PDD1800007497 | PDD1800007498 | | | | | | | | | |
| P-16790 | 4/19/2001 | Walgreens District Mgrs. meeting 04/17/2001 | PDD8801126584 | PDD8801126585 | | | | | | | | | |
| P-16792 | 11/11/2001 | Walgreens Pharmacy Meeting | PDD8806098809 | PDD8806098811 | | | | | | | | | |
| P-16793 | 6/1/2001 | Letter to Walgreens re drug diversion | PKY180136027 | PKY180136027 | | | | | | | | | |
| P-16802 | N/A | Walgreens Timeline | PPLP004384930 PPLP004384979 | PPLP004384980 PPLP004385066 | | | | | | | | | |
| P-16813 | 10/24/2001 | Walgreens Continuing Education Seminar; Pain Management for Pharmacists | PPLPC008000021199 | PPLPC008000021204 | | | | | | | | | |
| P-16815 | 6/26/2002 | Walgreen notes from 6/25/02 meeting; Walgreens meeting notes 6-25-02 | PPLPC008000025396 | PPLPC008000025401 | | | | | | | | | |
| P-16816 | 3/31/2003 | FW: CE programs and grants at Walgreens | PPLPC008000029920 | PPLPC008000029921 | | | | | | | | | |
| P-16817 | 3/7/2001 | RE: Walgreens District Meetings | PPLPC012000027280 | PPLPC012000027282 | | | | | | | | | |
| P-16823 | 7/27/2000 | RE: Walgreen's Program | PPLPC021000004460 | PPLPC021000004461 | | | | | | | | | |
| P-16827 | 11/8/2017 | RE: Walgreens meeting | PPLPC023000963186 | PPLPC023000963186 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-16829 | 9/8/1999 | Two Walgreens Programs Back To Back; 01051005-October 25,1999-Walgreens; 01051005-October 26,1999-Walgreens | PPLPC024000006603 | PPLPC024000006610 | | | | | | | | | |
| P-16830 | 2/16/2000 | 01051005 - March 14, 2000 - Walgreens (Strickland) & 01051005 -March 15, 2000 (Strickland) | PPLPC024000012000 | PPLPC024000012006 | | | | | | | | | |
| P-16833 | 12/18/2014 | Email walgreen summary Attachment Walgreens_follow_up_notes | PPLPC025000186037 | PPLPC025000186041 | | | | | | | | | |
| P-16834 | 12/18/2014 | Email walgreen Attachment Customer Meeting Template walgreens 1217 | PPLPC025000186075 | PPLPC025000186076 | | | | | | | | | |
| P-16848 | 1/27/2016 | Strategic Account Plan Walgreens 2016 January 27 PPT | PPLPC034001133571 | PPLPC034001133571 | | | | | | | | | |
| P-16865 | 7/1/2014 | Post Access Call Sheet | PPLP004384859 | PPLP004384861 | | | | | | | | | |
| P-16870 | 1/13/2015 | RE: Purdue - CVS call this coming Thursday | PPLP004384901 | PPLP004384903 | | | | | | | | | |
| P-16875 | 7/12/2001 | FW: Request for CE Support | PPLPC008000018452 | PPLPC008000018455 | | | | | | | | | |
| P-16878 | 6/26/2014 | RE: CVS Draft Presentation; Overview of OMS and ADD Programs CVS Meeting July 1 2014 | PPLPC012000485444 | PPLPC012000485446 | | | | | | | | | |
| P-16881 | 7/23/2012 | RE: CVS access to pmps | PPLPC018000701343 | PPLPC018000701346 | | | | | | | | | |
| P-16882 | 4/17/2001 | RE: CVS Issues | PPLPC019000016321 | PPLPC019000016323 | | | | | | | | | |
| P-16890 | 4/18/2014 | CVS Common Interest Agreement | PPLPC065000000818 | PPLPC065000000825 | | | | | | | | | |
| P-17039 | 9/16/2012 | Re: CCI | WAGFLAG00093216 | WAGFLAG00093218 | | | | | | | | | |
| P-17158 | 5/3/2013 | 43-5933267; U.S. Department of Justice DEA Report of Investigation | DEA-T3CC-00014159 | DEA-T3CC-00014159 | | | | | | | | | |
| P-17159 | 10/12/2012 | Conference Call re Opposing the Rescheduling of Hydrocodone Products | PPLP004308925 | PPLP004308926 | | | | | | | | | |
| P-17160 | 9/18/2015 | Suspicious Order Report | SORS-000234 | SORS-000234 | | | | | | | | | |
| P-17161 | 12/2/2019 | Rx Fulfillment Research Report Presentation research report v6 presentation | TCS00000396 | TCS00000452 | | | | | | | | | |
| P-17162 | 4/16/2018 | FW: incident at store 783 | WAGCASF00046090 | WAGCASF00046096 | | | | | | | | | |
| P-17163 | 1/6/2013 | December 2012 Controlled Substances Sample Report | WAGFLAG000000003 | WAGFLAG000000016 | | | | | | | | | |
| P-17164 | 1/9/2013 | Pharmacist Index 01-09-13.xlsx | WAGFLAG00012325 | WAGFLAG00012325 | | | | | | | | | |
| P-17165 | 12/26/2012 | Re: 'Pill Mill' Crackdown Sets Off Rush - The Wall Street Journal. | WAGFLAG00016495 | WAGFLAG00016497 | | | | | | | | | |
| P-17166 | 8/8/2013 | Melbourne - Rx Snapshot | WAGFLAG00027531 | WAGFLAG00027532 | | | | | | | | | |
| P-17167 | 9/18/2012 | RE: IMS Controlled Substance Reporting; IMS CS Ratings Offering Pilot Slides | WAGMDBL00004777 | WAGMDBL00004781 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-17168 | 6/14/2017 | RE: Questions from pharmacist on GFD opportunity report | WAGMDL00000912 | WAGMDL00000915 | | | | | | | | | |
| P-17169 | 11/1/2013 | FW: Rx Integrity - Southern Division Conference Call/Webinar; Pharmacist GFD Coaching Opportunities | WAGMDL00021304 | WAGMDL00021328 | | | | | | | | | |
| P-17170 | 9/11/2015 | Rx Integrity Process Summaries | WAGMDL00037093 | WAGMDL00037094 | | | | | | | | | |
| P-17171 | 9/2/2014 | HC Rescheduling | WAGMDL00053719 | WAGMDL00053723 | | | | | | | | | |
| P-17172 | 2/16/2013 | Re: DEA Vegas Pilot; Las Vegas Market Comments on Target Drug Good Faith Dispensing; TD GFD V2 checklist_FINAL; Target Drug Good Faith Dispensing Policy V2[1] | WAGMDL00066740 | WAGMDL00066747 | | | | | | | | | |
| P-17173 | 10/26/2016 | FW: GFD policy clarification | WAGMDL00093658 | WAGMDL00093659 | | | | | | | | | |
| P-17174 | 9/11/2013 | FW: DEA Working Group Conference Call - August 28 at 4:00 p.m. NACDS Corresponding Responsibility (DRAFT).docx | WAGMDL00237364 | WAGMDL00237373 | | | | | | | | | |
| P-17175 | 1/11/2017 | RE: RHD Deck FINAL TribuneRHD PresentationFINAL | WAGMDL00250893 | WAGMDL00250900 | | | | | | | | | |
| P-17176 | 5/8/2017 | Naloxone and GFD/TD GFD for HCS Toolkit; TD GFD October 2017; GFD May 2017 version; national_tdgfd_policy_10.2; naloxone_dispensing_policy; naloxone patient handout 07122016; naloxone_order_procedures_update_v3; naloxone_faqs_update | WAGMDL00258020 | WAGMDL00258045 | | | | | | | | | |
| P-17177 | 4/9/2013 | National TD GFD Compass Communication | WAGMDL00316360 | WAGMDL00316361 | | | | | | | | | |
| P-17178 | 5/24/2012 | RE: Controlled Substance Order Override Form | WAGMDL00325262 | WAGMDL00325262 | | | | | | | | | |
| P-17179 | 9/8/2010 | Resp't Ex. 297 - Email Re. Mt. Vernon DEA Audit | WAGMDL00387641 | WAGMDL00387641 | | | | | | | | | |
| P-17180 | 5/22/2015 | Pharmaceutical Integrity June BCI questions v2.docx | WAGMDL00487576 | WAGMDL00487576 | | | | | | | | | |
| P-17181 | 8/31/2015 | "Compliance with Compassion" | WAGMDL00492867 | WAGMDL00492887 | | | | | | | | | |
| P-17182 | 12/13/2011 | Ohio Automated Rx Reporting System | WAGMDL00580502 | WAGMDL00580504 | | | | | | | | | |
| P-17183 | 9/1/2013 | FW: Fiscal 2013 - Store Audit Results - Report Issued February 28, 2014; FY13 Store Audit Report_2_28_14_FINAL | WAGMDL00580669 | WAGMDL00580691 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-17184 | 4/1/2014 | FW: Follow-up on DEA takeback day | WAGMDL00590913 | WAGMDL00590956 | | | | | | | | | |
| P-17185 | 1/17/2013 | DEA update Jan2013 | WAGMDL00707642 | WAGMDL00707653 | | | | | | | | | |
| P-17186 | 9/30/2013 | Good Faith Dispensing Conf Call 9/30-13 | WAGMDL00708555 | WAGMDL00708556 | | | | | | | | | |
| P-17187 | 9/13/2012 | ORDER TO SHOW CAUSE AND IMMEDIATE SUSPENSION OF REGISTRATION | WAGMDL00709398 | WAGMDL00709411 | | | | | | | | | |
| P-17188 | 4/16/2013 | Walgreens National TD-GFD Policy (Updated FAQs); NATIONAL TARGET DRUG (TD) GOOD FAITH DISPENSING (GFD) FAQs | WAGMDL00744586 | WAGMDL00744591 | | | | | | | | | |
| P-17189 | 12/7/2012 | Gov't Ex. 031 - 2012 Oxy 30mg Purchases Exceeding 2012 Trigger | WAGMDL00760271 | WAGMDL00760293 | | | | | | | | | |
| P-17190 | 3/15/2011 | Gov't Ex. 046 - Oviedo Police Letters | WAGMDL00760560 | WAGMDL00760575 | | | | | | | | | |
| P-17191 | 10/26/2011 | Gov't Ex. 047 - Oviedo Walgreens Arrests Presented to Walgreens. | WAGMDL00760576 | WAGMDL00760576 | | | | | | | | | |
| P-17192 | 12/3/2012 | Gov't Ex. 048 - Oviedo Surveillance Stats Presented to Walgreens | WAGMDL00760577 | WAGMDL00760578 | | | | | | | | | |
| P-17193 | 11/27/2012 | Resp't Ex. 239-A - RxSchool.com - The Pharmacist's Role | WAGMDL00766952 | WAGMDL00766954 | | | | | | | | | |
| P-17194 | 1/28/2013 | Updated Top 500 Store Potential Risk Index; Oxycodone Fill Denied Complaints By Operation | WAGMDL00774516 | WAGMDL00774517 | | | | | | | | | |
| P-17195 | 6/26/2013 | DEA Timeline | WAGMDL00778492 | WAGMDL00778493 | | | | | | | | | |
| P-17196 | 1/26/2013 | FW: Updated GFD Filing Procedures | WAGMDL00781245 | WAGMDL00781248 | | | | | | | | | |
| P-17197 | 11/11/2015 | Pharmacy Standard Operating Procedures (SOPs) – Drug Utilization Review (DUR); Performing a Drug Utilization Review (DUR) | WAGMDL00792693 | WAGMDL00792703 | | | | | | | | | |
| P-17198 | 8/18/2020 | Suspicious Order Report | WAGMDL00852039 | WAGMDL00852039 | | | | | | | | | |
| P-17199 | 11/27/2012 | Re: Payroll Concerns | WAGMDL00862246 | WAGMDL00862250 | | | | | | | | | |
| P-17200 | 2/19/2020 | Compliance Budget Summary | WAGMDL00864374 | WAGMDL00864392 | | | | | | | | | |
| P-17201 | 12/19/2012 | GFD - Store Walk and Key Initiative for Jan | WAGMDL00871295 | WAGMDL00871295 | | | | | | | | | |
| P-17202 | 4/27/2011 | Fw: Pharmacy Renewal updated deck; Pharmacy Renewal V14.2 04272011 DRAFT | WAGMDL00883946 | WAGMDL00883995 | | | | | | | | | |
| P-17203 | 5/11/2019 | INFO: FW: Additional DF for 070119 RLT Call; This Policy Sets Forth Walgreens' Requirements Related to Prescription Product Dispensing Activities | WAGMDL00895339 | WAGMDL00895370 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-17204 | 5/11/2012 | Final copies (and store checklist) from contingency planning (evening 5/10/12); Process Talking Points; DEA Contingency Plan; Final copies (and store checklist) from contingency planning (evening 5/10/12) | WAGMDL00897156 | WAGMDL00897169 | | | | | | | | | |
| P-17205 | 2/11/2013 | RE: Training deployed dates | WAGMDL00912297 | WAGMDL00912298 | | | | | | | | | |
| P-17206 | 4/8/2013 | Walgreens Policies and Procedures | WAGMDL00922999 | WAGMDL00923132 | | | | | | | | | |
| P-17207 | 8/8/2018 | PDMP Integration Business Case_krw comments; Prescription Drug Monitoring Program Integration | WAGMDL00939067 | WAGMDL00939074 | | | | | | | | | |
| P-17208 | 3/19/2013 | Top 500 Potential Risk Stores - Oxycodone - 3 months ending February 2013 Ohio Market | WAGMDL01068350 | WAGMDL01068351 | | | | | | | | | |
| P-17209 | 10/15/2013 | RxIntegrity Videoconference - Update Pharmacist GFD Coaching Opportunities | WAGMDL01107122 | WAGMDL01107145 | | | | | | | | | |
| P-17210 | 6/18/2013 | FW: GFD Site Announcement | WAGMDL01109033 | WAGMDL01109034 | | | | | | | | | |
| P-17211 | 12/29/2012 | Fwd: SIMS Enhancement For Controlled Substance Orders | WAGMDL01109065 | WAGMDL01109069 | | | | | | | | | |
| P-17212 | 1/26/2020 | RE: Discussion on Updated Personas and Research Findings | WAGMDL01109276 | WAGMDL01109282 | | | | | | | | | |
| P-17213 | 4/17/2013 | Compass 4/17/13 | WAGMDL01132111 | WAGMDL01132118 | | | | | | | | | |
| P-17214 | 1/28/2013 | Good Faith Dispensing Policy - Drug Diversion Self-Education Module DLPM Role - GFD 1-2013.docx Director Kerlikowske Presentation | WAGMDL01132293 | WAGMDL01132324 | | | | | | | | | |
| P-17215 | 10/15/2012 | Pharmacy Fill Denied Complaint trend report | WAGMDL01132853 | WAGMDL01132855 | | | | | | | | | |
| P-17216 | 1/5/2013 | Re: GFD customer concerns | WAGMDL01166670 | WAGMDL01166670 | | | | | | | | | |
| P-17217 | 5/24/2013 | FW: RXS Feedback Call Notes_5/24/13 - Please respond by June 27,2013; RXS Feedback Call Notes | WAGMDL01166881 | WAGMDL01166884 | | | | | | | | | |
| P-17218 | 5/12/2013 | FW: OpsAdmin Weekly dashboard 5/8 Field Feedback - Pharmacy Managers n Current Challenges and Pain Points | WAGMDL01166990 | WAGMDL01166995 | | | | | | | | | |
| P-17219 | 12/13/2012 | Executive Report: Nov 2012 Top 500 Potential Risk Stores - Oxycodone; Oxycodone Store Potential Risk Overview | WAGMDL01176292 | WAGMDL01176293 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-17220 | 1/14/2013 | Heat Map Slides end of December 2012 | WAGMDL01176413 | WAGMDL01176425 | | | | | | | | | |
| P-17221 | 12/13/2012 | Top 500 Potential Store Index for Field Distribution: 3 mo end Nov 2012 | WAGMDL01176484 | WAGMDL01176485 | | | | | | | | | |
| P-17222 | 11/27/2012 | For Your Review: October Store Index Report; Top 500 Store Index | WAGMDL01176488 | WAGMDL01176490 | | | | | | | | | |
| P-17223 | 9/19/2012 | Updated Reports for Aug 2012: Exec Summary Top 100 Potential Risk Stores; Store Potential Risk Index - end Aug 2012 - Exec Top 100 | WAGMDL01176500 | WAGMDL01176500 | | | | | | | | | |
| P-17224 | 7/2/2012 | Fw: Controlled Substance Program Exec Sum 7 2 12 Final; Controlled Substance Program Exec Sum 7 2 12 Final | WAGMDL01189805 | WAGMDL01189807 | | | | | | | | | |
| P-17225 | 6/17/2012 | FW: Status Report -- Controlled Substances Program; Controlled Substance Program Exec Sum 6 18 12 | WAGMDL01189978 | WAGMDL01189980 | | | | | | | | | |
| P-17226 | 11/21/2008 | DEA Exhibit Review Perrysburg DC | WAGMDLPER00000313 | WAGMDLPER00000313 | | | | | | | | | |
| P-17227 | 12/15/2016 | Hotel Notice - NACDS Policy Council; Are More Mistakes Happening at Pharmacies?; Pharmacies Miss Half of Dangerous Drug Combinations; Risks Inherent in Pharmacists' Workloads Earn Attention of Legislators; Reducing Regulatory Burdens Imposed by the Patent Protection and Affordable Care Act & Improving Healthcare Choices to Empower Patients; State Medicaid Activity and Status Chart; June Policy Council Meeting Agenda | WAGNMAG00009844 | WAGNMAG00009910 | | | | | | | | | |
| P-17228 | 2/27/2015 | Good Faith Dispensing: Training Overdue | WAGNYNS00033695 | WAGNYNS00033696 | | | | | | | | | |
| P-17229 | 12/12/2012 | Guidelines for Prescriber Comments | WAGNYNS00033698 | WAGNYNS00033698 | | | | | | | | | |

| | | | | | | | | | | | | |
|---------|-----|---------------------------------------|--|-----------|--|--|--|--|--|--|--|--|
| P-17230 | N/A | Walgreens Refusal to Fill Compilation | WAGMDL00940734 - WAGMDL00940780; WAGMDL00947263 - WAGMDL00947339; WAGMDL00951290 - WAGMDL00951309; WAGMDL00958654 - WAGMDL00958842; WAGMDL00999815 - WAGMDL00999828; WAGMDL01073768 - WAGMDL01073984; WAGMDL01090486 - WAGMDL01090573; WAGMDL01094410 - WAGMDL01094510; WAGMDL01101126 - WAGMDL01101138; WAGMDL01138731 - WAGMDL01139295; WAGMDL01152843 - WAGMDL01152848; WAGMDL01158568 - WAGMDL01158899; | composite | | | | | | | | |
| P-17231 | N/A | Walgreens TD GFD Compilation | WAGMDL00940781 - WAGMDL00947262; WAGMDL00947340 - WAGMDL00951289; WAGMDL00951310 - WAGMDL00958653; WAGMDL00958843 - WAGMDL00966133; WAGMDL00999829 - WAGMDL01013447; WAGMDL01073985 - WAGMDL01084325; WAGMDL01090574 - WAGMDL01094409; WAGMDL01094511 - WAGMDL01096022; WAGMDL01101139 - WAGMDL01107112; WAGMDL01139296 - WAGMDL01152842; WAGMDL01152849 - WAGMDL01158567; WAGMDL01158900 - WAGMDL01166300; | composite | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---|-------------------|--|--|--|--|--|--|--|--|--|
| P-17232 | 2000-2020 | WAG Annual Report Composite Exhibit | WAGFLAG00082714 - WAGFLAG00082809; WAGMDL_T1_TX00000328 - WAGMDL_T1_TX00000344; WAGMDL_T1_TX00000392 - WAGMDL_T1_TX00000405; WAGMDL_T1_TX00002774 - WAGMDL_T1_TX00002806; WAGMDL_T1_TX00003549 - WAGMDL_T1_TX00003586; WAGMDL_T1_TX00010347 - WAGMDL_T1_TX00010497; WAGMDL_T1_TX00011607 - WAGMDL_T1_TX00011754; N/A | composite | | | | | | | | | |
| P-17233 | 4/13/2017 | FW: 1487 IN - DEA visit | WMT_MDL_000949501 | WMT_MDL_000949524 | | | | | | | | | |
| P-17234 | N/A | WAG CT3 Stores - Suspicious Drug Control Order Report Composite | WAGMDL00852082; WAGMDL00852084; WAGMDL00852102; WAGMDL00852105; WAGMDL00852107; WAGMDL00852109- WAGMDL00852112; WAGMDL00852114- WAGMDL00852115; WAGMDL00852117; WAGMDL00852119; WAGMDL00852121- WAGMDL00852122; WAGMDL00852124- WAGMDL00852125; WAGMDL00852127; WAGMDL00852129; WAGMDL00852131; WAGMDL00852133; WAGMDL00852135; WAGMDL00852137; WAGMDL00852139; WAGMDL00852141; WAGMDL00852143; WAGMDL00852145- WAGMDL00852146; WAGMDL00852148- | composite | | | | | | | | | |
| P-17235 | 5/2/2011 | Walgreens CT3 Suspicious Drug Control Order Report | WAGMDL00852184 | WAGMDL00852184 | | | | | | | | | |
| P-17236 | 5/5/2015 | pharmacy_metadata (8) | WAGNMAG00053391 | WAGNMAG00053392 | | | | | | | | | |
| P-17237 | 3/8/2018 | EDW Pharmacy Metadata 20171020 | WAGMDL00790910 | WAGMDL00790910 | | | | | | | | | |
| P-17238 | 10/26/2012 | FY2013 Goals are loaded in TMP | WAGFLAG00090568 | WAGFLAG00090572 | | | | | | | | | |
| P-17239 | 4/3/2015 | RE: RTF | WMT_MDL_000956399 | WMT_MDL_000956400 | | | | | | | | | |
| P-17241 | 3/28/2015 | RE: RTF | WMT_MDL_000958795 | WMT_MDL_000958796 | | | | | | | | | |
| P-17242 | 12/10/2012 | LP Market Tour/Roadshow | WAGMDL01132507 | WAGMDL01132568 | | | | | | | | | |
| P-17243 | 7/1/2021 | Copy of ITProvided_ZipCodes | WAGMDL01191401 | WAGMDL01191401 | | | | | | | | | |
| P-17244 | 1/7/2021 | GFD2.0 | WAGMDL01191402 | WAGMDL01191457 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------------|----------------------------|--|--|--|--|--|--|--|--|--|
| P-17245 | 7/9/2021 | DUR Policies and Procedures | WAGMDL01191458 | WAGMDL01191458 | | | | | | | | | |
| P-17246 | 7/1/2020 | Medispan Email | WAGMDL01191463 | WAGMDL01191465 | | | | | | | | | |
| P-17247 | 2/6/2017 | WAG DUR Overview | WAGMDL01191469 | WAGMDL01191489 | | | | | | | | | |
| P-17322 | 6/20/2001 | Letter from R. Reder to CVS Pharmacists re: "How to Stop Drug Diversion & Protect Your Pharmacy." | PPLPC008000017909 | PPLPC008000017909 | | | | | | | | | |
| P-17323 | 7/31/2001 | Email from S. Seid to P. Kasprzycki re: FW: CVS Pharmacists Program | PPLPC008000018884 | PPLPC008000018884 | | | | | | | | | |
| P-17387 | 6/3/2013 | Russ - Walgreens 053013 | PPLP004471589 | PPLP004471590 | | | | | | | | | |
| P-17405 | 8/20/2001 | CVS Grant Request | 7003208125 | 7003208125 | | | | | | | | | |
| P-17406 | 2/7/2001 | Purdue Letter to Sharon Galzarano, RPh | 7003208134 | 7003208135 | | | | | | | | | |
| P-17407 | 1/31/2001 | CVS Call - Sharon Galzarano, RPh | 7003208136 | 7003208136 | | | | | | | | | |
| P-17408 | 4/17/2001 | FW: Lipman CE for Walgreens | 8841944138 | 8841944138 | | | | | | | | | |
| P-17409 | 1997 | AAPM and APS - The Use of Opioids for the Treatment of Chronic Pain | PDD1501721211 | PDD1501721214 | | | | | | | | | |
| P-17410 | 5/11/2001 | Anti-Diversion Brochures | PDD8801132198 | PDD8801132199 | | | | | | | | | |
| P-17411 | 12/31/2002 | Maribeth B. Kowalski, PharmD, Territory # 5031500 | PKY181435446 | PKY181435486 | | | | | | | | | |
| P-17412 | 6/1/2001 | CVS CE 5 ACPE Approved Hours of Live Continuing Education Credit Available, "Addressing Controlled Substance Issues in Retail Pharmacy" | PKY182071023 | PKY182071024 | | | | | | | | | |
| P-17413 | 4/23/2001 | FW: CVS CE programs | PPLPC008000016083 | PPLPC008000016084 | | | | | | | | | |
| P-17414 | 5/8/2001 | Email BCR | PPLPC008000016651 | PPLPC008000016651 | | | | | | | | | |
| P-17415 | 7/29/2014 | Email CVS Patient Access Meeting Summary | PPLPC034000955231 | PPLPC034000955231 | | | | | | | | | |
| P-17416 | 10/24/2016 | Email Quarterly Follow up Call: Purdue Abuse Deterrent Formulations Slide Presentation and Discussion | PPLPC034001149574 | PPLPC034001149574 | | | | | | | | | |
| P-17417 | 8/25/2016 | FW: The Surgeon General is calling on us to lead | OhioMedBoard_RossCo_390157 | OhioMedBoard_RossCo_390159 | | | | | | | | | |
| P-17418 | 2/24/2016 | FW: Obama Rejects Governors Pain Killer Proposal | OhioMedBoard_RossCo_392864 | OhioMedBoard_RossCo_392866 | | | | | | | | | |
| P-17420 | 5/14/2013 | Presentation materials for Kim Anderson's segment of 5-17 meeting | OhioMedBoard_RossCo_312224 | OhioMedBoard_RossCo_312232 | | | | | | | | | |
| P-17421 | 9/22/2016 | Compliance with Mandatory OARRS Checks | OhioMedBoard_RossCo_336324 | OhioMedBoard_RossCo_336837 | | | | | | | | | |
| P-17422 | 4/19/2018 | FW: Doug Oplinger Commentary in Dispatch: Medical community avoided discussions about opioid crisis | OhioMedBoard_RossCo_319836 | OhioMedBoard_RossCo_319847 | | | | | | | | | |
| P-17423 | 5/8/2018 | Fwd: Draft Report from the OIG for the Opioid Evaluation OEI-05-18-00010 | OhioMedBoard_RossCo_387034 | OhioMedBoard_RossCo_387076 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------------|----------------------------|--|--|--|--|--|--|--|--|--|
| P-17424 | 1/15/2015 | Red Flags | OhioMedBoard_RossCo_379927 | OhioMedBoard_RossCo_379943 | | | | | | | | | |
| P-17450 | 5/1/2017 | Notice of Central Prescriber Block | WMT_MDL_001004177 | WMT_MDL_001004178 | | | | | | | | | |
| P-17454 | 9/27/2013 | RE: Friendly Reminder | WMT_MDL_001015997 | WMT_MDL_001015997 | | | | | | | | | |
| P-17455 | 7/12/2017 | RE: Prescriber Contacts Report | WMT_MDL_001017236 | WMT_MDL_001017238 | | | | | | | | | |
| P-17458 | 1/23/2018 | Notice of Central Prescriber Block for DR. Wade (Walmart/ Sam's Club) | WMT_MDL_001029530 | WMT_MDL_001029531 | | | | | | | | | |
| P-17461 | 1/23/2018 | Notice of Central Prescriber Block for DR. Wade (Walmart/ Sam's Club) | WMT_MDL_001073396 | WMT_MDL_001073397 | | | | | | | | | |
| P-17462 | 6/5/2014 | FW: 042814 Stores #2555, New Castle, DE and #5436, Wilmington, DE-Over 20 Drug Orders | WMT_MDL_001074526 | WMT_MDL_001074531 | | | | | | | | | |
| P-17468 | 6/5/2014 | RE: 042814 Stores #2555, New Castle, DE and #5436, Wilmington, DE-Over 20 Drug Orders | WMT_MDL_001075514 | WMT_MDL_001075519 | | | | | | | | | |
| P-17469 | 2/11/2014 | RE: KROGER & WALGREENS | WMT_MDL_001075832 | WMT_MDL_001075832 | | | | | | | | | |
| P-17471 | 2/17/2017 | RE: Blanket Refusal at 4278-US | WMT_MDL_001077177 | WMT_MDL_001077178 | | | | | | | | | |
| P-17472 | 10/5/2016 | FW: Controlled substance problems in 2481 - Dr Raymond Kraynak | WMT_MDL_001078368 | WMT_MDL_001078371 | | | | | | | | | |
| P-17477 | 4/15/2015 | RTF from 4-14-15 James Pro | WMT_MDL_001091252 | WMT_MDL_001091253 | | | | | | | | | |
| P-17479 | 10/14/2014 | RE: Dr. Lazzerini | WMT_MDL_001131831 | WMT_MDL_001131832 | | | | | | | | | |
| P-17483 | 5/2/2013 | FW: RTF Data sheets | WMT_MDL_001147703 | WMT_MDL_001147708 | | | | | | | | | |
| P-17484 | 2/28/2013 | RE: GoodStart for Butrans - Follow Up - 2 - 2:30 for Analytics/ 2:30 - 3 for Proposal | PPLPC004000348762 | PPLPC004000348765 | | | | | | | | | |
| P-17485 | 4/19/2018 | FW: Operations communication proposal draft | WMT_MDL_001150343 | WMT_MDL_001150347 | | | | | | | | | |
| P-17486 | 4/19/2013 | Oxycontin Sale and Inventory Analysis Findings | PPLPC004000354499 | PPLPC004000354500 | | | | | | | | | |
| P-17519 | 2/8/2019 | James Prommersberger Indictment - Mahoning County, Ohio | N/A | N/A | | | | | | | | | |
| P-17520 | 6/29/2015 | RE: WMT-15-06-4417 - Ethics Concern | WMT_MDL_001182599 | WMT_MDL_001182603 | | | | | | | | | |
| P-17521 | 10/10/2014 | DR Frank Lazzerini - RTF store 1911 | WMT_MDL_001183077 | WMT_MDL_001183082 | | | | | | | | | |
| P-17523 | 3/13/2014 | FW: DEA AND DR COCKTAILS | WMT_MDL_001203327 | WMT_MDL_001203328 | | | | | | | | | |
| P-17524 | 11/12/2015 | FW: Deep Concerns by MHWD at store 4142 | WMT_MDL_001203948 | WMT_MDL_001203952 | | | | | | | | | |
| P-17525 | 11/12/2015 | RE: Deep Concerns by MHWD at store 4425 | WMT_MDL_001203953 | WMT_MDL_001203956 | | | | | | | | | |
| P-17526 | 10/5/2016 | RE: Controlled substance problems in 2481 - Dr Raymond Kraynak | WMT_MDL_001204210 | WMT_MDL_001204212 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|------------------------|------------------------|--|--|--|--|--|--|--|--|--|
| P-17527 | 9/11/2011 | FW: Emailing: AP Diversion Software Justification (Revision 2) | WMT_MDL_001219254 | WMT_MDL_001219256 | | | | | | | | | |
| P-17528 | 4/13/2018 | RE: OTM Opioid Stewardship Dashboard Link | WMT_MDL_001233224 | WMT_MDL_001233229 | | | | | | | | | |
| P-17529 | 10/7/2015 | Archer Spreadsheet 9.28 to 10.2 | WMT_MDL_001256474 | WMT_MDL_001256475 | | | | | | | | | |
| P-17539 | 10/6/2015 | RE: Order Needing Review - 914 | WMT_MDL_000994030 | WMT_MDL_000994031 | | | | | | | | | |
| P-17540 | 1/1/2016 | Track 3 Know Your Customer Data | WMT_MDL_000286238 | WMT_MDL_000286238 | | | | | | | | | |
| P-17541 | 10/7/2014 | SOM documents email attaching Walmart Pharmacy Manual 21-402, HDMA guidelines and SOM flowchart | WMT_MDL_000067582 | WMT_MDL_000067608 | | | | | | | | | |
| P-17542 | 3/17/2015 | RTF notification spreadsheet | WMT_MDL_000286394 | WMT_MDL_000286396 | | | | | | | | | |
| P-17543 | 1/30/2014 | Email enclosing RTF notification spreadsheet and letter re: new format of RTF notifications to DEA | WMT_MDL_000785314 | WMT_MDL_000785317 | | | | | | | | | |
| P-17544 | 6/13/2011 | 1927 Refusal to fill RX Notification 6-3.pdf | WMT_MDL_000286532 | WMT_MDL_000286533 | | | | | | | | | |
| P-17545 | 12/31/2018 | Corporately Blocked Prescribers as of 12/31/18 | WMT_MDL_001209988 | WMT_MDL_001209997 | | | | | | | | | |
| P-17546 | 12/30/2020 | Jones Day letter including list of corporate blocked prescribers as of 7/31/19 | WMT_MDL_SD_0002424 | WMT_MDL_SD_0002424 | | | | | | | | | |
| P-17547 | 2/28/2014 | Refusal to Fill Notification Report | WMT_MDL_000270904 | WMT_MDL_000270905 | | | | | | | | | |
| P-17548 | 3/3/2015 | Feb 15 RTF | WMT_MDL_000955914 | WMT_MDL_000955915 | | | | | | | | | |
| P-17549 | 8/3/2015 | JULY 15 RTF | WMT_MDL_000956413 | WMT_MDL_000956414 | | | | | | | | | |
| P-17550 | 6/3/2014 | MAY RTF 2014 | WMT_MDL_000960466 | WMT_MDL_000960467 | | | | | | | | | |
| P-17551 | N/A | Store order data set | WMT_MDL_000024968_0001 | WMT_MDL_000024968_0001 | | | | | | | | | |
| P-17552 | N/A | Store order data set | WMT_MDL_000024968_0002 | WMT_MDL_000024968_0002 | | | | | | | | | |
| P-17553 | N/A | Store order data set | WMT_MDL_000024968_0003 | WMT_MDL_000024968_0003 | | | | | | | | | |
| P-17554 | N/A | Store order data set | WMT_MDL_000024968_0004 | WMT_MDL_000024968_0004 | | | | | | | | | |
| P-17555 | N/A | Store order data set | WMT_MDL_000012776_001 | WMT_MDL_000012776_001 | | | | | | | | | |
| P-17556 | N/A | Store order data set | WMT_MDL_000012776_002 | WMT_MDL_000012776_002 | | | | | | | | | |
| P-17557 | N/A | Store order data set | WMT_MDL_000012776_003 | WMT_MDL_000012776_003 | | | | | | | | | |
| P-17558 | N/A | Store order data set | WMT_MDL_000012776_004 | WMT_MDL_000012776_004 | | | | | | | | | |
| P-17559 | N/A | Store order data set | WMT_MDL_000012776_005 | WMT_MDL_000012776_005 | | | | | | | | | |
| P-17560 | N/A | Store order data set | WMT_MDL_000012776_006 | WMT_MDL_000012776_006 | | | | | | | | | |
| P-17561 | 2/14/2015 | Master Spreadsheet 2015 | WMT_MDL_000969107 | WMT_MDL_000969108 | | | | | | | | | |
| P-17562 | 8/10/2016 | RTF date corrections; RTF | WMT_MDL_001185868 | WMT_MDL_001185869 | | | | | | | | | |
| P-17563 | 2/3/2014 | Master Spreadsheet 2014 | WMT_MDL_000961309 | WMT_MDL_000961310 | | | | | | | | | |
| P-17564 | N/A | Susanne Hiland Earnings Spreadsheet | WMT_MDL_000058759 | WMT_MDL_000058768 | | | | | | | | | |
| P-17565 | 3/26/2018 | Susanne Hiland Performance Evaluation | WMT_MDL_000058769 | WMT_MDL_000058815 | | | | | | | | | |
| P-17566 | 6/6/2012 | Connexus Pharmacy Ssystem Drug Summary Report | WMT_MDL_001214102 | WMT_MDL_001214105 | | | | | | | | | |
| P-17567 | 10/22/2013 | CCTV & Controlled Substance Risk Assessment Update Presentation | WMT_MDL_001451764 | WMT_MDL_001451793 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------------|-------------------------|--|--|--|--|--|--|--|--|--|
| P-17568 | 11/13/2013 | 5410 Forged or Fraudulent Rx 11-12 | WMT_MDL_000826937 | WMT_MDL_000826938 | | | | | | | | | |
| P-17569 | 8/4/2015 | RTF Raw Data Spreadsheet for 2015 | WMT_MDL_001233455 | WMT_MDL_001233455 | | | | | | | | | |
| P-17570 | 1/1/2014 | List of Kentucky Refusal to Fill | WMT_KY_AG_000000310 | WMT_KY_AG_000000310 | | | | | | | | | |
| P-17571 | 6/22/2016 | Copy of RTF_Analysis_2.29.16 ref | WMT_MDL_001240851 | WMT_MDL_001240851 | | | | | | | | | |
| P-17572 | N/A | National BRTF list | WMT_MA_000008510 | WMT_MA_000008510 | | | | | | | | | |
| P-17573 | 1/31/2006 | Walmart SEC Form 10-K 2006 | N/A | N/A | | | | | | | | | |
| P-17574 | 1/31/2007 | Walmart SEC Form 10-K 2007 | WMT_MDL_TRIAL_000004229 | WMT_MDL_TRIAL_000004229 | | | | | | | | | |
| P-17575 | 1/31/2008 | Walmart SEC Form 10-K 2008 | WMT_MDL_TRIAL_000004258 | WMT_MDL_TRIAL_000004258 | | | | | | | | | |
| P-17576 | 1/31/2009 | Walmart SEC Form 10-K 2009 | WMT_MDL_TRIAL_000004288 | WMT_MDL_TRIAL_000004288 | | | | | | | | | |
| P-17577 | 1/31/2010 | Walmart SEC Form 10-K 2010 | WMT_MDL_TRIAL_000004326 | WMT_MDL_TRIAL_000004326 | | | | | | | | | |
| P-17578 | 1/31/2011 | Walmart SEC Form 10-K 2011 | WMT_MDL_TRIAL_000004355 | WMT_MDL_TRIAL_000004355 | | | | | | | | | |
| P-17579 | 1/31/2012 | Walmart SEC Form 10-K 2012 | WMT_MDL_TRIAL_000004386 | WMT_MDL_TRIAL_000004386 | | | | | | | | | |
| P-17580 | 1/31/2013 | Walmart SEC Form 10-K 2013 | WMT_MDL_TRIAL_000004419 | WMT_MDL_TRIAL_000004419 | | | | | | | | | |
| P-17581 | 1/31/2014 | Walmart SEC Form 10-K 2014 | WMT_MDL_TRIAL_000004460 | WMT_MDL_TRIAL_000004460 | | | | | | | | | |
| P-17582 | 1/31/2015 | Walmart SEC Form 10-K 2015 | N/A | N/A | | | | | | | | | |
| P-17583 | 1/31/2016 | Walmart SEC Form 10-K 2016 | WMT_MDL_TRIAL_000004546 | WMT_MDL_TRIAL_000004546 | | | | | | | | | |
| P-17584 | 1/31/2017 | Walmart SEC Form 10-K 2017 | N/A | N/A | | | | | | | | | |
| P-17585 | 1/31/2018 | Walmart SEC Form 10-K 2018 | WMT_MDL_TRIAL_000004639 | WMT_MDL_TRIAL_000004639 | | | | | | | | | |
| P-17586 | 1/31/2019 | Walmart SEC Form 10-K 2019 | N/A | N/A | | | | | | | | | |
| P-17587 | 1/31/2020 | Walmart SEC Form 10-K 2020 | N/A | N/A | | | | | | | | | |
| P-17588 | 2/2/2012 | FY13 February Audit Committee Meeting Materials - Health and Wellness Compliance | WMT_BR_OPC_00011035 | WMT_BR_OPC_00011049 | | | | | | | | | |
| P-17589 | 10/1/2012 | 1863 Refusal to fill Notification 9-28-12 | WMT_MDL_000082327 | WMT_MDL_000082328 | | | | | | | | | |
| P-17590 | 9/29/2012 | 1863 Forged or Fraudulent Rx 9-28 | WMT_MDL_000083604 | WMT_MDL_000083605 | | | | | | | | | |
| P-17591 | 7/17/2018 | Chronic Pain Management Slideshow.pdf | WMT_MDL_000950711 | WMT_MDL_000950733 | | | | | | | | | |
| P-17592 | 6/20/2014 | The Master Spreadsheet | WMT_MDL_000960403 | WMT_MDL_000960404 | | | | | | | | | |
| P-17593 | 8/26/2013 | 2845 Forged or Fraudulent Rx 8-25 | WMT_MDL_000966138 | WMT_MDL_000966139 | | | | | | | | | |
| P-17594 | 3/17/2015 | 03172015 RTF spreadsheet | WMT_MDL_001233458 | WMT_MDL_001233458 | | | | | | | | | |
| P-17595 | 3/30/2018 | WMT Pain Program V2033018 | WMT_MDL_001309207 | WMT_MDL_001309216 | | | | | | | | | |
| P-17596 | 1/3/2018 | RE: DisposeRx Flyer for Document Ship - WWD | WMT_MDL_001364650 | WMT_MDL_001364653 | | | | | | | | | |
| P-17597 | 7/2/2018 | NarxCare FLAG ON TONIGHT (live date June 3rd) | WMT_MDL_001370171 | WMT_MDL_001370176 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-17598 | 12/19/2018 | EXT: Health & Wellness Ticket #24255 for TX Has Been Assigned to You | WMT_MDL_001370389 | WMT_MDL_001370390 | | | | | | | | | |
| P-17599 | 5/19/2016 | RE: PILL MILL IN RENO, NV | WMT_NV_0000002621 | WMT_NV_0000002625 | | | | | | | | | |
| P-17600 | 10/3/2013 | FW: Corrections for RTF from Sept | WMT_NV_0000004627 | WMT_NV_0000004628 | | | | | | | | | |
| P-17601 | 2/27/2019 | JD DOJ Presentation. | WMT_MA_000001485 | WMT_MA_000001545 | | | | | | | | | |
| P-17602 | 2/1/2019 | ASHPMidyearCESummary | WMT_MDL_001371478 | WMT_MDL_001371560 | | | | | | | | | |
| P-17603 | 2/24/2020 | WM_Home_Eval022120 | WMT_MDL_001371595 | WMT_MDL_001371807 | | | | | | | | | |
| P-17604 | 7/5/2017 | FW: Info regarding refusal to refill | WMT_MDL_001373163 | WMT_MDL_001373170 | | | | | | | | | |
| P-17605 | 7/17/2014 | RE: H&W Diversion Analytic Tool Update - 7/16/14 | WMT_MDL_001373190 | WMT_MDL_001373190 | | | | | | | | | |
| P-17606 | 4/12/2012 | SuggestionsMarch2012 | WMT_MDL_001373524 | WMT_MDL_001373525 | | | | | | | | | |
| P-17607 | 12/23/2014 | RE: Letter to the medical board | WMT_MDL_001375975 | WMT_MDL_001375977 | | | | | | | | | |
| P-17608 | 5/7/2015 | Re: Refusal to fill question | WMT_MDL_001376547 | WMT_MDL_001376548 | | | | | | | | | |
| P-17609 | 10/10/2017 | Regulatory Contact | WMT_MDL_001384882 | WMT_MDL_001384882 | | | | | | | | | |
| P-17610 | 7/17/2013 | Week 25 Pain Opiod Counseling | WMT_MDL_001384952 | WMT_MDL_001384952 | | | | | | | | | |
| P-17611 | 9/24/2007 | Dr ellington | WMT_MDL_001387777 | WMT_MDL_001387777 | | | | | | | | | |
| P-17612 | 2/14/2006 | FW: 1685 SD Inspection Controlled Substances Inspection Report State of South Dakota - Board of Pharmacy | WMT_MDL_001387810 | WMT_MDL_001387818 | | | | | | | | | |
| P-17613 | 6/12/2013 | 853 Forged or Fraudulent Rx 06-11-13 | WMT_MDL_001430212 | WMT_MDL_001430213 | | | | | | | | | |
| P-17614 | 6/4/2013 | 866 Forged or Fraudulent Rx 05-29-13 | WMT_MDL_001430534 | WMT_MDL_001430535 | | | | | | | | | |
| P-17615 | 2/25/2016 | RE: Patient Controlled Substance Usage Notification | WMT_MDL_001440801 | WMT_MDL_001440802 | | | | | | | | | |
| P-17616 | 2/24/2016 | Walmart Taylor Steven 1 19 16 | WMT_MDL_001440824 | WMT_MDL_001440829 | | | | | | | | | |
| P-17617 | 8/23/2011 | Utah | WMT_NM_AG_000020861 | WMT_NM_AG_000020862 | | | | | | | | | |
| P-17618 | 9/30/2011 | DEA 106 Final Report | WMT_NM_AG_000020882 | WMT_NM_AG_000020895 | | | | | | | | | |
| P-17619 | 7/8/2014 | RE: SOM ISD issue | WMT_NM_AG_000022714 | WMT_NM_AG_000022714 | | | | | | | | | |
| P-17620 | 12/29/2015 | Strategy Template -- H&W Compliance_December Offsite | WMT_NM_AG_000023399 | WMT_NM_AG_000023400 | | | | | | | | | |
| P-17621 | 11/9/2017 | CII Slide Deck | WMT_NM_AG_000023455 | WMT_NM_AG_000023458 | | | | | | | | | |
| P-17622 | 12/3/2018 | Re: quick question for capital committee | WMT_NM_AG_000030399 | WMT_NM_AG_000030400 | | | | | | | | | |
| P-17624 | 5/30/2018 | FW: Pharmacy CII safes capital ask | WMT_NM_AG_000030411 | WMT_NM_AG_000030413 | | | | | | | | | |
| P-17625 | 5/30/2018 | RE: Pharmacy CII safes capital ask | WMT_NM_AG_000030416 | WMT_NM_AG_000030418 | | | | | | | | | |
| P-17626 | 6/6/2007 | FW: On hands changes and manual orders lock downs | WMT_NM_AG_000030424 | WMT_NM_AG_000030427 | | | | | | | | | |
| P-17627 | 7/12/2011 | HW Compliance Risk Assessment Status Report Template (2) | WMT_NM_AG_000031291 | WMT_NM_AG_000031292 | | | | | | | | | |
| P-17629 | 1/31/2021 | Walmart SEC Form 10-K 2021 | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-17633 | 6/13/2011 | Archer P & O.pdf, Combined PROJECT GALAHAD (OPERATIONAL & COMPLIANCE REVIEW) | WMT_NM_AG_000031340 | WMT_NM_AG_000031806 | | | | | | | | | |
| P-17634 | 12/6/2012 | SysRepublic | WMT_NM_AG_000031875 | WMT_NM_AG_000031876 | | | | | | | | | |
| P-17635 | 11/14/2012 | Compliance Monitoring draft | WMT_NM_AG_000032154 | WMT_NM_AG_000032155 | | | | | | | | | |
| P-17636 | 9/12/2014 | RE: CII Invoice | WMT_NM_AG_000032391 | WMT_NM_AG_000032394 | | | | | | | | | |
| P-17646 | 2/23/2012 | RE: RX Presentation-McKinsey 03302009.ppt | WMT_MDL_000033397 | WMT_MDL_000033412 | | | | | | | | | |
| P-17647 | 9/30/2014 | 2008 Ops Compliance Update2014-09-30-101533.pdf | WMT_MDL_000423485 | WMT_MDL_000423586 | | | | | | | | | |
| P-17648 | 6/8/2010 | RE: Oracle BI | WMT_MDL_000454464 | WMT_MDL_000454497 | | | | | | | | | |
| P-17649 | 7/21/2011 | FW: POM 814 - Log Sheet Attached | WMT_MDL_000480757 | WMT_MDL_000480759 | | | | | | | | | |
| P-17650 | 10/22/2013 | RE: Suboxone/Subutex | WMT_MDL_001014911 | WMT_MDL_001014917 | | | | | | | | | |
| P-17651 | 10/19/2013 | FW: Suboxone/Subutex | WMT_MDL_001019338 | WMT_MDL_001019342 | | | | | | | | | |
| P-17652 | 10/22/2013 | FW: Suboxone/Subutex | WMT_MDL_001019442 | WMT_MDL_001019448 | | | | | | | | | |
| P-17653 | 5/27/2010 | RE: PA Pharmacy Oppty -- Urgent | WMT_MDL_001306456 | WMT_MDL_001306458 | | | | | | | | | |
| P-17654 | 7/1/2013 | RE: FL-Drug Orders | WMT_MDL_001458995 | WMT_MDL_001458996 | | | | | | | | | |
| P-17655 | 6/27/2013 | RE: FL-Drug Orders | WMT_MDL_001506036 | WMT_MDL_001506037 | | | | | | | | | |
| P-17817 | 9/1/2004 | DEA/OD 11th Pharmaceutical Industry Conference, Risk Management of Pharmaceutical Controlled Substances, Tuesday, September 16, New Orleans, Louisiana | PPLPC030000179742 | PPLPC030000179742 | | | | | | | | | |
| P-17873 | 2/28/2013 | RE: Situational Analysis w/Blue Fin | PPLPC035000183903 | PPLPC035000183905 | | | | | | | | | |
| P-17944 | 12/13/2007 | email with Above Average Order Monitoring Procedures attached | Rite_Aid_OMDL_0016297 | Rite_Aid_OMDL_0016330 | | | | | | | | | |
| P-18047 | 1/12/2009 | DOJ Press Release, Rite Aid Corporation and Subsidiaries Agree to Pay \$5 Million in Civil Penalties to Resolve Violations | N/A | N/A | | | | | | | | | |
| P-18048 | 3/9/2017 | DOJ Press Release, Rite Aid Corporation Pays \$834,200 to Settle Allegations of Violating the CSA | N/A | N/A | | | | | | | | | |
| P-18049 | 4/23/2019 | For First Time, Pharmaceutical Distributor Faces Federal Criminal Charges Over Opioid Crisis -NYT | N/A | N/A | | | | | | | | | |
| P-18193 | 9/16/2013 | Prescription Drug Abuse & Alliance to Prevent the Abuse of Medicines | TEVA_MDL_A_00694962 | TEVA_MDL_A_00694963 | | | | | | | | | |
| P-19397 | 9/12/2012 | Memorandum Distributor Briefing with Actavis Elizabeth, LLC (RK016806), on September 12, 2012 | US-DEA-00000001 | US-DEA-00000141 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|--------------------|--------------------|--|--|--|--|--|--|--|--|--|
| P-19410 | 9/27/2006 | Suspicious order letters | US-DEA-00001767 | US-DEA-00001772 | | | | | | | | | |
| P-19419 | 9/19/2005 | DEA Audit Report 2005 | US-DEA-00026903 | US-DEA-00026924 | | | | | | | | | |
| P-19422 | 1/19/2010 | DEA Audit Report 2010 | US-DEA-00026925 | US-DEA-00026937 | | | | | | | | | |
| P-19423 | 7/6/2012 | DEA ARCOS request | US-DEA-00026938 | US-DEA-00026939 | | | | | | | | | |
| P-19426 | 7/30/2012 | DEA Audit Report | US-DEA-00027006 | US-DEA-00027029 | | | | | | | | | |
| P-19427 | 3/1/2014 | DEA audit license records | US-DEA-00027030 | US-DEA-00027058 | | | | | | | | | |
| P-19428 | 12/2/2014 | DEA Audit Report | US-DEA-00027059 | US-DEA-00027060 | | | | | | | | | |
| P-19430 | 1/5/2015 | DEA Audit Report | US-DEA-00027061 | US-DEA-00027084 | | | | | | | | | |
| P-19444 | 5/29/2008 | ODL-08-057 / DEA Response to NCPA | US-DEA-00005911 | US-DEA-00005917 | | | | | | | | | |
| P-19453 | 6/22/2016 | FW: Follow-up from HDA Board Meeting; Final Final Questions for DEA 06-01-11; Final HDMA Questions for DEA Discussion on 07-31-13 | US-DEA-00008563 | US-DEA-00008583 | | | | | | | | | |
| P-19478 | 7/7/2012 | FINAL RannazzisitestSenatedrugcaucus written stmt July 6 | US-DEA-00016467 | US-DEA-00016479 | | | | | | | | | |
| P-19483 | 12/27/2007 | December 2007 Rannazzisi Letter | US-DEA-00017912 | US-DEA-00017913 | | | | | | | | | |
| P-19485 | 9/22/2016 | DEA Statement - TREATING THE OPIOID EPIDEMIC - Milione for HJC | US-DEA-00018501 | US-DEA-00018512 | | | | | | | | | |
| P-19513 | 11/19/1997 | Notice of Establishment of Task Force on Suspicious Orders | US-DEA-00025302 | US-DEA-00025302 | | | | | | | | | |
| P-19518 | 7/23/1988 | Chris Zimmerman Ltr 07-23-1998 (2)_Redacted | US-DEA-00025671 | US-DEA-00025671 | | | | | | | | | |
| P-19524 | 6/21/1993 | NWDA Suspicious Order Monitoring System | US-DEA-00026139 | US-DEA-00026150 | | | | | | | | | |
| P-19525 | 12/8/1993 | Excessive Purchase Reports (FFS: 630-04 D1) | US-DEA-00026154 | US-DEA-00026155 | | | | | | | | | |
| P-19529 | 1/1/2012 | Staff Pharmacist Bonus Program | WAGFLDEA00000007 | WAGFLDEA00000009 | | | | | | | | | |
| P-19530 | 9/30/2011 | Accepting and Filling New Prescriptions Policy | WAGFLDEA000000045 | WAGFLDEA000000046 | | | | | | | | | |
| P-19531 | 11/28/2012 | 05. 70020 Perrysburg DC DEA Review 1st Quarter Fiscal 2013 Index 1 of 2 | WAGMDLPER000000028 | WAGMDLPER000000312 | | | | | | | | | |
| P-19533 | 7/6/2010 | Re: Question about Fla board holding rph's liable for excessive c2 rx's | WAGFLDEA000000356 | WAGFLDEA000000356 | | | | | | | | | |
| P-19534 | 8/6/2010 | Email Fw: RXM Meeting- Oxycodone; Pharmacist Manager Meeting - role in main management video class | WAGFLDEA000000363 | WAGFLDEA000000364 | | | | | | | | | |
| P-19535 | 9/7/2011 | WALGREENS OXYCODONE Controlled Substance Best Practices Update Email | WAGFLDEA000000396 | WAGFLDEA000000397 | | | | | | | | | |
| P-19536 | 7/5/2011 | Florida prescription drug monitoring program protocol | WAGFLDEA000000383 | WAGFLDEA000000383 | | | | | | | | | |
| P-19537 | 10/25/2011 | DEA RED FLAGS | WAGFLDEA000000467 | WAGFLDEA000000468 | | | | | | | | | |
| P-19538 | 7/8/2010 | re: oxycodone 30 mgEl | WAGFLDEA000000459 | WAGFLDEA000000460 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|------------------|------------------|--|--|--|--|--|--|--|--|--|
| P-19540 | 7/27/2010 | Email Re: Handling Pain Management RXs; Pain Management problem in Florida | WAGFLDEA00000659 | WAGFLDEA00000660 | | | | | | | | | |
| P-19542 | 4/16/2012 | WALGREENS Store 06997 Standards of Practice for the Dispensing of Controlled Substances for Treatment of Pain | WAGFLDEA00000766 | WAGFLDEA00000772 | | | | | | | | | |
| P-19543 | 8/2/2010 | Email Oxycodone Sales; WAG concerned Florida pharmacists are turning away good scripts | WAGFLDEA00000812 | WAGFLDEA00000823 | | | | | | | | | |
| P-19544 | 3/25/2011 | Best Practices conf call | WAGFLDEA00000988 | WAGFLDEA00000988 | | | | | | | | | |
| P-19545 | 3/25/2011 | FL best practices conf call continued | WAGFLDEA00000989 | WAGFLDEA00000990 | | | | | | | | | |
| P-19546 | 3/28/2011 | FW: STORE 3099 increase in oxy scripts | WAGFLDEA00001011 | WAGFLDEA00001012 | | | | | | | | | |
| P-19547 | 11/26/2011 | Fw: U.S. Department of Justice | WAGFLDEA00001248 | WAGFLDEA00001249 | | | | | | | | | |
| P-19548 | 2/22/2012 | EJS Reply: Florida Controlled Substances (Merten) | WAGFLDEA00001478 | WAGFLDEA00001487 | | | | | | | | | |
| P-19549 | 3/25/2011 | Re: Pharmacist Best Practices | WAGFLDEA00001013 | WAGFLDEA00001016 | | | | | | | | | |
| P-19550 | 3/28/2011 | STORE 3099-RxS Due Diligence | WAGFLDEA00001017 | WAGFLDEA00001019 | | | | | | | | | |
| P-19551 | 5/21/2011 | change in sales drug counts | WAGFLDEA00001710 | WAGFLDEA00001710 | | | | | | | | | |
| P-19552 | 3/30/2011 | Pharmacist Best Practices (Svihra) | WAGFLDEA00001022 | WAGFLDEA00001031 | | | | | | | | | |
| P-19553 | 5/18/2011 | Fw: Florida Physicians | WAGFLDEA00001080 | WAGFLDEA00001080 | | | | | | | | | |
| P-19554 | 7/20/2011 | Oxycodone dispensing- IMPORTANT | WAGFLDEA00001154 | WAGFLDEA00001155 | | | | | | | | | |
| P-19555 | 8/23/2011 | District #227 Oxycodone Action Plan | WAGFLDEA00001174 | WAGFLDEA00001175 | | | | | | | | | |
| P-19556 | 10/19/2011 | Fw: Controlled Substance Update: Florida Prescription Drug Monitoring Program | WAGFLDEA00001213 | WAGFLDEA00001216 | | | | | | | | | |
| P-19557 | 5/17/2011 | Florida Focus on Profit (Svihra) | WAGFLDEA00001890 | WAGFLDEA00001896 | | | | | | | | | |
| P-19558 | 3/17/2012 | Re: DEA Compliance Suggestions Ed Lanzetti | WAGFLDEA00001569 | WAGFLDEA00001570 | | | | | | | | | |
| P-19559 | 5/1/2016 | WAG / ABDC - Fifth Amendment to the Pharmaceutical Purchase and Distribution Agreement | WAGMDL00000369 | WAGMDL00000373 | | | | | | | | | |
| P-19560 | 5/31/2017 | Sixth Amendment to the Pharmaceutical Purchase And Distribution Agreement | WAGMDL00000374 | WAGMDL00000380 | | | | | | | | | |
| P-19561 | 6/1/2017 | WAG/ABDC - Joinder Agreement & Seventh Amendment to the Pharmaceutical Purchase And Distribution Agreement | WAGMDL00000381 | WAGMDL00000384 | | | | | | | | | |
| P-19562 | 3/18/2013 | WAG/ABDC - Pharmaceutical Purchase and Distribution Agreement | WAGMDL00000417 | WAGMDL00000492 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------------|---------------------------|--|--|--|--|--|--|--|--|--|
| P-19563 | 4/2/2012 | DEA meeting aks about pharmacists using PDMP data | WAGFLDEA00001626 | WAGFLDEA00001626 | | | | | | | | | |
| P-19566 | 6/28/2010 | DEA issue at store 6094 (Cheryl Creek & Tasha Polster) guidelines for dispensing | WAGFLDEA00001861 | WAGFLDEA00001868 | | | | | | | | | |
| P-19568 | 6/28/2010 | DEA issue at store 6094 (Cheryl Creek & Tasha Polster) | WAGFLDEA00001869 | WAGFLDEA00001876 | | | | | | | | | |
| P-19569 | 2/10/2012 | State of Florida Individual District Plans Oxycodone related | WAGFLDEA0001297_unitized | WAGFLDEA00001309_unitized | | | | | | | | | |
| P-19572 | 12/9/2014 | Rx Integrity Tools & Reports | WAGMDL00015162 | WAGMDL00015165 | | | | | | | | | |
| P-19573 | 2/26/2015 | CPO Server RxIntegrity and Third Party | WAGMDL00015204 | WAGMDL00015229 | | | | | | | | | |
| P-19574 | 7/19/2012 | FW: Targeted drugs for GFD; DEA Financial Impact Project Control3 | WAGMDL00015230 | WAGMDL00015236 | | | | | | | | | |
| P-19575 | 9/9/2010 | Regulatory Investigation | US-DEA-00030873 | US-DEA-00030897 | | | | | | | | | |
| P-19576 | 8/30/2012 | Regulatory Investigation | US-DEA-00030898 | US-DEA-00030920 | | | | | | | | | |
| P-19577 | 8/14/2013 | Draft RXS communication | WAGMDL00021189 | WAGMDL00021190 | | | | | | | | | |
| P-19578 | 9/10/2015 | RE: Important Good Faith Dispensing Webcast - You Are Invited | WAGMDL00037567 | WAGMDL00037569 | | | | | | | | | |
| P-19584 | 7/7/2015 | BCI Breakdown | WAGMDL00039478 | WAGMDL00039479 | | | | | | | | | |
| P-19587 | 7/7/2015 | RE: Asset Protection Solutions BCI Update | WAGMDL00045776 | WAGMDL00045778 | | | | | | | | | |
| P-19588 | 7/6/2015 | BCI 2015-06 Pharmaceutical Integrity | WAGMDL00045782 | WAGMDL00045784 | | | | | | | | | |
| P-19589 | 6/6/2013 | FW: CII ordering | WAGMDL00060486 | WAGMDL00060488 | | | | | | | | | |
| P-19590 | 5/11/2015 | FW: EOC meeting Friday; GFD Training Overview | WAGMDL00045935 | WAGMDL00045936 | | | | | | | | | |
| P-19591 | 9/17/2013 | RE: Good Faith Dispensing | WAGMDL00049236 | WAGMDL00049237 | | | | | | | | | |
| P-19592 | 11/16/2012 | Executive Summary for the American Academy of Pain Medicine on Walgreen's Opioid Dispensing Policy AAPM executive summary_V4 | WAGMDL00049722 | WAGMDL00049738 | | | | | | | | | |
| P-19593 | 11/30/2012 | Target Drug (TD) Good Faith Dispensing (GFD) Parameters Pilot | WAGMDL00049864 | WAGMDL00049887 | | | | | | | | | |
| P-19594 | 3/24/2014 | RE: Issue with a prescriber | WAGMDL00053882 | WAGMDL00053883 | | | | | | | | | |
| P-19595 | 4/1/2013 | Pharmacist GFD Review - Pharmaceutical Integrity Team Pharmacist Coaching Opportunities | WAGMDL00054501 | WAGMDL00054523 | | | | | | | | | |
| P-19598 | 2/4/2014 | Completed Market 12 Presentation; Market 12 Rx Integrity Presentation | WAGMDL00095316 | WAGMDL00095336 | | | | | | | | | |
| P-19600 | 3/5/2013 | RE: Lortab out of stock 6033 | WAGMDL00060597 | WAGMDL00060599 | | | | | | | | | |
| P-19602 | 2/19/2013 | Re: Interstore from 11171 of gen. 10/650 | WAGMDL00101723 | WAGMDL00101732 | | | | | | | | | |
| P-19604 | 8/15/2014 | Rx Integrity tools & reports | WAGMDL00094965 | WAGMDL00094967 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-19605 | 2/7/2014 | Non-Dispensing Controlled Substance Pharmacist Report | WAGMDL00095304 | WAGMDL00095307 | | | | | | | | | |
| P-19606 | 8/7/2013 | Board Briefing Jan2013 | WAGMDL00095577 | WAGMDL00095579 | | | | | | | | | |
| P-19607 | 1/24/2014 | RE: RPh Non-dispensing report; Pharmacist Controlled Substance Dispensing Opportunities V3 (4) | WAGMDL00099513 | WAGMDL00099515 | | | | | | | | | |
| P-19608 | 7/25/2013 | Re: DEA | WAGMDL00099852 | WAGMDL00099854 | | | | | | | | | |
| P-19609 | 1/25/2013 | Order Inquiry | WAGMDL00107084 | WAGMDL00107084 | | | | | | | | | |
| P-19610 | 11/4/2016 | Aug-Oct '16 COVP Slides; Monthly Store Manager Compliance Walk Through PPT (Tasha Polster) | WAGMDL00112831 | WAGMDL00112850 | | | | | | | | | |
| P-19611 | 11/12/2012 | System Job Title: Manager Pharmaceutical Integrity | WAGMDL00112893 | WAGMDL00112899 | | | | | | | | | |
| P-19612 | 8/15/2013 | Good Faith Dispensing Opportunities Report Now Available! | WAGMDL00113763 | WAGMDL00113763 | | | | | | | | | |
| P-19613 | 6/26/2006 | Good Faith Practices/Fraudulent Prescriptions; TDGFD June 2016 Version; GFD Video | WAGMDL00254688 | WAGMDL00254838 | | | | | | | | | |
| P-19616 | 7/15/2017 | RE: National TD GFD policy Powerpoint; Pharmacist Coaching Opportunities V2; Day 1 Policies, Prescription Processing | WAGMDL00256671 | WAGMDL00256729 | | | | | | | | | |
| P-19617 | 11/5/2012 | FW: GFD Audit for store 2865 in Modesto, CA | WAGMDL00113808 | WAGMDL00113810 | | | | | | | | | |
| P-19619 | 9/27/2012 | Changes in Schedule II Controlled Substances PDQ Ordering Process | WAGMDL00113824 | WAGMDL00113824 | | | | | | | | | |
| P-19620 | 12/7/2012 | Pharmacy Purchasing & Supply Chain Quarterly Meeting; Pharmacy Purchasing & Supply Chain PP & SC Qtrly Meeting 013113 Final | WAGMDL00114602 | WAGMDL00114625 | | | | | | | | | |
| P-19622 | 4/27/2012 | DEA Suspicious Store Ordering; DEA Suspicious Store Ordering Application Proposed Enhancement | WAGMDL00119539 | WAGMDL00119541 | | | | | | | | | |
| P-19624 | 10/25/2013 | 3 District Analysis | WAGMDL00286665 | WAGMDL00286684 | | | | | | | | | |
| P-19625 | 4/16/2012 | RE: C2 orders for #13056 | WAGMDL00119552 | WAGMDL00119555 | | | | | | | | | |
| P-19626 | 8/26/2013 | Status 2013-08-26 - RX integrity Status (Polster and Bratton) | WAGMDL00286693 | WAGMDL00286694 | | | | | | | | | |
| P-19627 | 2/22/2013 | GFD Pilot – Drug Sales Trends | WAGMDL00289179 | WAGMDL00289185 | | | | | | | | | |
| P-19628 | 3/1/2018 | RE: UPDATED: REQUEST: Opioid Questions for Scripts Over 90MMEQs | WAGMDL00295193 | WAGMDL00295199 | | | | | | | | | |
| P-19629 | 4/17/2014 | WAG pharmacist not following GFD | WAGMDL00300924 | WAGMDL00300925 | | | | | | | | | |
| P-19630 | 2/14/2013 | FW: TD GFD Info | WAGMDL00303246 | WAGMDL00303247 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-19631 | 10/2/2012 | Business Requirements DEA Suspicious Ordering - Phase 5 Project Number INVSO-54 | WAGMDL00133996 | WAGMDL00134003 | | | | | | | | | |
| P-19632 | 11/12/2012 | Investigation of Stores | WAGMDL00311368 | WAGMDL00311369 | | | | | | | | | |
| P-19633 | 10/31/2013 | ABC visit | WAGMDL00237263 | WAGMDL00237265 | | | | | | | | | |
| P-19634 | 3/26/2013 | FW: National Target Drug Good Faith Dispensing (TD GFD) Documents | WAGMDL00312837 | WAGMDL00312884 | | | | | | | | | |
| P-19635 | 4/30/2014 | Tasha Polster Audit Goals | WAGMDL00316927 | WAGMDL00316961 | | | | | | | | | |
| P-19637 | 10/16/2012 | RE: Walgreens # 2865 DEA: BW4243426 | WAGMDL00242055 | WAGMDL00242057 | | | | | | | | | |
| P-19638 | 5/1/2014 | Rx Integrity Audit Questions 2 & 3 | WAGMDL00316962 | WAGMDL00316991 | | | | | | | | | |
| P-19639 | 12/7/2012 | RE: Saturdays' holiday meeting challenges - Action Required! | WAGMDL00317073 | WAGMDL00317074 | | | | | | | | | |
| P-19640 | 4/10/2018 | Lean Six Sigma Center of Excellence Update | WAGMDL00320805 | WAGMDL00320835 | | | | | | | | | |
| P-19641 | 10/9/2012 | FW: ORDER OF INTEREST - WALGREENS 5088 (DEA # BB6213487) | WAGMDL00246284 | WAGMDL00246285 | | | | | | | | | |
| P-19642 | 1/9/2018 | Re: UPDATED: REQUEST: Opioid Questions for Scripts Over 90MMEQs | WAGMDL00400710 | WAGMDL00400714 | | | | | | | | | |
| P-19643 | 1/8/2018 | RE: UPDATED: REQUEST: Opioid Questions for Scripts Over 90MMEQs | WAGMDL00400743 | WAGMDL00400746 | | | | | | | | | |
| P-19644 | 11/5/2013 | RE: NE Pharmacies | WAGMDL00407147 | WAGMDL00407149 | | | | | | | | | |
| P-19645 | 3/7/2012 | The VIGIL System for Community Pharmacy Practice | WAGMDL00424919 | WAGMDL00424936 | | | | | | | | | |
| P-19646 | 10/16/2013 | Rx Integrity Stored Procedures | WAGMDL00487296 | WAGMDL00487297 | | | | | | | | | |
| P-19647 | 8/6/2013 | Status 2013-08-06 - Bratton; WAG RX integrity status (Polster and Bratton) | WAGMDL00491116 | WAGMDL00491116 | | | | | | | | | |
| P-19648 | 7/20/2017 | RE: CSOS Multi Wholesaler flex estimate | WAGMDL00499380 | WAGMDL00499383 | | | | | | | | | |
| P-19649 | 12/12/2012 | TD GFD market feedback | WAGMDL00502517 | WAGMDL00502520 | | | | | | | | | |
| P-19650 | 4/13/2013 | DEA strategy meeting 4 12 13 | WAGMDL00574828 | WAGMDL00574831 | | | | | | | | | |
| P-19651 | 4/7/2011 | San Diego MOA | WAGMDL00578349 | WAGMDL00578356 | | | | | | | | | |
| P-19652 | 6/13/2012 | Mindmap of Controlled Substances Program | WAGMDL00578421 | WAGMDL00578437 | | | | | | | | | |
| P-19653 | 9/13/2018 | nacds pay history | WAGMDL00286426 | WAGMDL00286428 | | | | | | | | | |
| P-19655 | 3/3/2015 | GFD Training Outline_notes | WAGMDL00656248 | WAGMDL00656249 | | | | | | | | | |
| P-19656 | 12/21/2012 | Rannazzisi Presentation - Drug Trends Indianapolis - December 2012 | WAGMDL00289068 | WAGMDL00289178 | | | | | | | | | |
| P-19657 | 5/5/2015 | GFD Training Overview | WAGMDL00656379 | WAGMDL00656380 | | | | | | | | | |
| P-19662 | 3/6/2013 | FW: Cardinal Meeting Today | WAGMDL00302958 | WAGMDL00302960 | | | | | | | | | |
| P-19664 | 5/16/2017 | FW: Rx integrity presentation; Market 26 6-11-14 | WAGMDL00674920 | WAGMDL00674946 | | | | | | | | | |
| P-19665 | 9/9/2013 | AMA GFD document 9 9 13 v2 | WAGMDL00675213 | WAGMDL00675214 | | | | | | | | | |
| P-19666 | 10/22/2015 | rxintegritywebcast_101915 | WAGMDL00692057 | WAGMDL00692126 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|------------------|------------------|--|--|--|--|--|--|--|--|--|
| P-19667 | 6/11/2011 | Customer Satisfaction Action Plan -editing; WAGMDL00698804 | WAGMDL00698803 | WAGMDL00698833 | | | | | | | | | |
| P-19668 | 7/19/2013 | Market Leader Meeting DEA Settlement Overview | WAGMDL00700079 | WAGMDL00700138 | | | | | | | | | |
| P-19669 | 9/14/2013 | FY14 Performance and Bonus Metrics_v0 | WAGMDL00706260 | WAGMDL00706301 | | | | | | | | | |
| P-19670 | 1/24/2014 | FY14 RXM Tier 1 Bonus Plan | WAGMDL00706302 | WAGMDL00706309 | | | | | | | | | |
| P-19671 | 8/26/2018 | FY19 Business Planning, Pharmacy & Retail Operations | WAGMDL00706531 | WAGMDL00706589 | | | | | | | | | |
| P-19672 | 8/26/2018 | Talking Points for District and Area Leaders - IMPROVE Changes for FY19 | WAGMDL00706590 | WAGMDL00706592 | | | | | | | | | |
| P-19673 | 7/26/2013 | Controlled Substance Legend Drug Diversion Law Enforcement and Regulatory Perspective | WAGMDL00707693 | WAGMDL00707780 | | | | | | | | | |
| P-19674 | 10/1/2012 | DEA Rx Mail Communications from June 2012; Email Controlled Substance Action Plan: Exception Store Visits and Survey | WAGMDL00316373 | WAGMDL00316393 | | | | | | | | | |
| P-19675 | 8/17/2012 | Good Faith Dispensing Policy Actions Timeline | WAGMDL00709439 | WAGMDL00709447 | | | | | | | | | |
| P-19676 | 5/3/2012 | Walgreens CII Drugs Procedure to Create President's Plaza Order Schedule II Three Distribution Places. New or Relocating Stores must set up schedule in SIMS. AS/400 Steps | WAGFLDEA00000117 | WAGFLDEA00000117 | | | | | | | | | |
| P-19677 | 12/7/2015 | RE: triple cocktail Attachment CVS Decision | WAGMDL00037521 | WAGMDL00037554 | | | | | | | | | |
| P-19678 | 10/1/2018 | Ohio Flagged Orders | WAGMDL00400360 | WAGMDL00400360 | | | | | | | | | |
| P-19679 | 1/9/2013 | RE: CII Orders | WAGMDL00415348 | WAGMDL00415350 | | | | | | | | | |
| P-19680 | 10/1/2012 | Exception Store Audit Process | WAGMDL00317131 | WAGMDL00317133 | | | | | | | | | |
| P-19681 | 1/24/2019 | Tab 10 - DEA Communication | WAGMDL00757759 | WAGMDL00757761 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-----------------|-----------------|--|--|--|--|--|--|--|--|--|
| P-19682 | 10/12/2012 | BuzzoPDMA SOM Seminar - Electronic Presentations; SOM Seminar - Regulatory Issues and Handling Increased Enforcement; The Basics: SOM Regulatory and Police Requirements; Through the Looking Glass: Legal Considerations for Your SOM Program; System Considerations- Computer Models, Algorithms, Statistics and More; Building an Effective Investigation Program; 2012 Powerpoint: Case Study- Real World SOM Challenges | WAGMDL00319129 | WAGMDL00319239 | | | | | | | | | |
| P-19683 | 1/8/2014 | Re: Targeted drugs for GFD; Project Control3 | WAGMDL00745706 | WAGMDL00745711 | | | | | | | | | |
| P-19684 | 6/11/2012 | Controlled Substance Program Exec Sum 6 11 12 | WAGMDL00745752 | WAGMDL00745754 | | | | | | | | | |
| P-19686 | 9/1/2009 | Walgreen Co. Management Incentive Plan | WAGMDL00747972 | WAGMDL00747975 | | | | | | | | | |
| P-19687 | 2/9/2015 | FW: Controlled Substance Order Monitoring Process Review - Attachment A Draft; GFD Review Attach A Closing Meeting 2_05_15 | WAGMDL00750223 | WAGMDL00750242 | | | | | | | | | |
| P-19688 | 2/5/2013 | Operation Oxymoron | WAGMDL00762092 | WAGMDL00762093 | | | | | | | | | |
| P-19689 | 5/24/2012 | Re: Walgreens Florida | WAGMDL00766469 | WAGMDL00766475 | | | | | | | | | |
| P-19690 | 11/27/2012 | Navigating the Management of Chronic Pain | WAGMDL00766955 | WAGMDL00766971 | | | | | | | | | |
| P-19691 | 8/12/2015 | Fiscal 2016 Pay Ranges for Front End Team Members and Fiscal 2016 Pay Ranges for Pharmacy Technicians and Pharmacy Interns | WAGMDL00773916 | WAGMDL00773917 | | | | | | | | | |
| P-19692 | 8/13/2012 | Fw: MetroHealth 340B; Stores- Volume 073012 | WAGMDL00797482 | WAGMDL00797486 | | | | | | | | | |
| P-19693 | 12/11/2017 | Opioid Crisis Webinar 12-11-2017Final | WAGMDL00334471 | WAGMDL00334495 | | | | | | | | | |
| P-19694 | 9/26/2012 | FW: Check out this page on Nj.com | WAGNYAG00000018 | WAGNYAG00000020 | | | | | | | | | |
| P-19696 | 12/17/2019 | Suffolk County Stores | WAGNYNS00000793 | WAGNYNS00000793 | | | | | | | | | |
| P-19697 | 4/2/2017 | Re: Rx Compliance Issue | WAGNYNS00005866 | WAGNYNS00005873 | | | | | | | | | |
| P-19699 | 7/21/2016 | Stakeholders Challenges and Warning Signs Executive Summary and Consensus | WAGNYNS00017965 | WAGNYNS00017982 | | | | | | | | | |
| P-19700 | 8/27/2018 | Improve Scorecard Talking Points (District and Area Leaders) 08272018 vF | WAGNYNS00020927 | WAGNYNS00020989 | | | | | | | | | |
| P-19701 | 12/7/2012 | Prescriber Index - Potential Risk Prescriber Indexing | WAGNYNS00032014 | WAGNYNS00032014 | | | | | | | | | |
| P-19702 | 1/20/2020 | Nassau pharmacists | WAGNYNS00032149 | WAGNYNS00032149 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-19704 | 2/5/2014 | Manhattan Bronx clinic illegal distribution | WAGNYNS00032742 | WAGNYNS00032746 | | | | | | | | | |
| P-19705 | 11/16/2012 | crazy idea; WALGREENS Pharmacy Baseline Information Request | WAGNYNS00033235 | WAGNYNS00033241 | | | | | | | | | |
| P-19706 | 1/30/2013 | NY Hydrocodone | WAGNYNS00033288 | WAGNYNS00033289 | | | | | | | | | |
| P-19707 | 5/25/2012 | Follow-up to Conference Call: Call Center Outreach; Store FAQ for Closing Prescriptions_vF_5-25-201 | WAGNYNS00033723 | WAGNYNS00033725 | | | | | | | | | |
| P-19708 | 9/23/2011 | Oxy ER IOH vs Sales 09222011 | WAGNYNS00033904 | WAGNYNS00033905 | | | | | | | | | |
| P-19709 | 10/28/2011 | Suspicious Orders 7-1-11 to 7-15-11 | WAGNYNS00033983 | WAGNYNS00033984 | | | | | | | | | |
| P-19710 | 6/5/2012 | Corporate Org Chart | WAGMDL00387629 | WAGMDL00387629 | | | | | | | | | |
| P-19711 | 1/1/2012 | Pharmacy Services Org Chart | WAGMDL00387631 | WAGMDL00387631 | | | | | | | | | |
| P-19712 | N/A | Pharmacy Purchasing & Supply Chain Org Chart | WAGMDL00387632 | WAGMDL00387632 | | | | | | | | | |
| P-19713 | 7/21/2011 | Suspicious Order 7/01/11 to 7/15/11 | WAGNYNS00033985 | WAGNYNS00033986 | | | | | | | | | |
| P-19714 | 6/23/2011 | Suspicious Order 06/01/2011 to 06/15/2011 | WAGNYNS00033987 | WAGNYNS00033988 | | | | | | | | | |
| P-19715 | 7/6/2011 | Suspicious Order June 15-30 | WAGNYNS00033989 | WAGNYNS00033990 | | | | | | | | | |
| P-19716 | 6/11/2013 | Appendix | WAGMDL00387708 | WAGMDL00387974 | | | | | | | | | |
| P-19717 | 9/28/2016 | Annual_Performance_Review__FY16__-_Support_Office__Non-Retail-STEVEN_MILLS | WAGMDL00389389 | WAGMDL00389397 | | | | | | | | | |
| P-19718 | 8/31/2016 | Annual_Performance_Review__FY16__-_Support_Office__Non-Retail-STEVEN_MILLS (1) | WAGMDL00389398 | WAGMDL00389408 | | | | | | | | | |
| P-19719 | 6/8/2011 | Suspicious Order; 05-17-11 to 05-31-11 | WAGNYNS00033991 | WAGNYNS00033992 | | | | | | | | | |
| P-19720 | 1/3/2012 | Suspicious Control Drug Orders for Month of 12/2011 | WAGMDL00394499 | WAGMDL00394500 | | | | | | | | | |
| P-19721 | 6/3/2014 | more info from Naddi listserv | WAGNYNS00036489 | WAGNYNS00036491 | | | | | | | | | |
| P-19722 | 3/13/2013 | RE: Walgreens Not Approved Orders; Control Data for Anda Stores | WAGNYNS00042555 | WAGNYNS00042563 | | | | | | | | | |
| P-19723 | 6/1/2012 | NY Hydrocodone Report May 2012 | WAGNYNS00043501 | WAGNYNS00043501 | | | | | | | | | |
| P-19724 | 4/20/2007 | Suspicious Control Drug Orders for Month of 12/2006 | WAGMDL00396133 | WAGMDL00396134 | | | | | | | | | |
| P-19727 | 9/26/2018 | ohio_cso_override_history_updated_drug_list | WAGMDL00400358 | WAGMDL00400358 | | | | | | | | | |
| P-19730 | 6/25/2012 | Pharmaceutical Distribution and Dispensing Integrity | WAGMDL00589682 | WAGMDL00589690 | | | | | | | | | |
| P-19732 | N/A | Store Manager Pharmacist Bonus Program | WAGFLDEA00000010 | WAGFLDEA00000013 | | | | | | | | | |
| P-19733 | 7/13/2010 | Standards of Practice for the Dispensing of Controlled Substances for Treatment of Pain | WAGFLDEA000000463 | WAGFLDEA000000464 | | | | | | | | | |
| P-19734 | 11/4/2011 | Control Substances and Good Faith Dispensing Outline | WAGFLDEA000000471 | WAGFLDEA000000475 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|------------------|------------------|--|--|--|--|--|--|--|--|--|
| P-19735 | 12/7/2011 | Oxy percent data | WAGFLDEA00001288 | WAGFLDEA00001327 | | | | | | | | | |
| P-19736 | N/A | NY Transactional Data | WAGNYNS00032151 | WAGNYNS00032151 | | | | | | | | | |
| P-19738 | 9/5/2012 | Bill Winsley's presentation; Pain Clinics or Pill Mills - William T Winsley Presentation | WAGMDL00441397 | WAGMDL00441431 | | | | | | | | | |
| P-19741 | 5/6/2011 | Walgreens Pharmacy and Health Care Code of Conduct and General Training | WAGFLDEA00000127 | WAGFLDEA00000130 | | | | | | | | | |
| P-19743 | 3/12/2013 | National Target Drug Good Faith Dispensing Policy Final | WAGMDL00049775 | WAGMDL00049780 | | | | | | | | | |
| P-19744 | 12/17/2017 | Good Faith Dispensing Checklist | WAGMDL00064897 | WAGMDL00064898 | | | | | | | | | |
| P-19745 | 8/1/1998 | Good Faith Practices | WAGMDL00093366 | WAGMDL00093368 | | | | | | | | | |
| P-19746 | 3/12/2013 | Store Potential Risk Index 03-07-13 through February | WAGMDL00489274 | WAGMDL00489274 | | | | | | | | | |
| P-19747 | 4/3/2013 | Store Potential Risk Index 04-03-13 through March | WAGMDL00489276 | WAGMDL00489276 | | | | | | | | | |
| P-19748 | 8/7/2015 | SOP Blocked Prescriber Process | WAGMDL00094681 | WAGMDL00094683 | | | | | | | | | |
| P-19749 | 4/1/2013 | National Target Drug Good Faith Dispensing Policy | WAGMDL00289026 | WAGMDL00289030 | | | | | | | | | |
| P-19750 | 3/27/2013 | National Target Drug Good Faith Dispensing Policy | WAGMDL00289054 | WAGMDL00289057 | | | | | | | | | |
| P-19756 | 4/4/2003 | Good Faith Practices | WAGMDL00670938 | WAGMDL00670939 | | | | | | | | | |
| P-19757 | 8/1/1998 | Good Faith Practices | WAGMDL00670940 | WAGMDL00670941 | | | | | | | | | |
| P-19758 | 1/20/2010 | Project 09002 – Intercept Suspicious Orders Micro-ORPB305 | WAGMDL00492076 | WAGMDL00492081 | | | | | | | | | |
| P-19759 | 2/9/2005 | Good Faith Practices | WAGMDL00670942 | WAGMDL00670943 | | | | | | | | | |
| P-19760 | 2/24/2009 | Q'sCommentNotess Suspicious Orders | WAGMDL00492160 | WAGMDL00492163 | | | | | | | | | |
| P-19761 | 10/11/2018 | Managing Controlled Substance Theft or Loss | WAGMDL00674143 | WAGMDL00674143 | | | | | | | | | |
| P-19762 | 11/23/2012 | Target Drug (TD) Good Faith Dispensing (GFD) | WAGMDL00675592 | WAGMDL00675618 | | | | | | | | | |
| P-19767 | 6/20/2011 | Controlled Substance Prescriptions & Good Faith Dispensing Policy | WAGMDL00767020 | WAGMDL00767021 | | | | | | | | | |
| P-19768 | 2/5/2013 | 20130205 DEA Subpoena No 17-13-341894 | WAGMDL00493701 | WAGMDL00493703 | | | | | | | | | |
| P-19769 | 2/5/2013 | 20130205 DEA Subpoena No 17-13-341994 | WAGMDL00493704 | WAGMDL00493706 | | | | | | | | | |
| P-19770 | 2/5/2013 | 20130205 DEA Subpoena No 17-13-342226 | WAGMDL00493707 | WAGMDL00493709 | | | | | | | | | |
| P-19771 | 2/5/2013 | 20130205 DEA Subpoena No 17-13-342388 | WAGMDL00493710 | WAGMDL00493712 | | | | | | | | | |
| P-19772 | 2/5/2013 | 20130205 DEA Subpoena No 17-13-342624 | WAGMDL00493713 | WAGMDL00493715 | | | | | | | | | |
| P-19773 | 2/5/2013 | 20130205 DEA Subpoena No 17-13-343964 | WAGMDL00493716 | WAGMDL00493718 | | | | | | | | | |
| P-19776 | 1/1/2013 | Good Faith Dispensing PPT | WAGMDL00779090 | WAGMDL00779114 | | | | | | | | | |
| P-19777 | 3/22/2013 | Good Faith Dispensing (GFD), Pharmaceutical Integrity | WAGMDL00779115 | WAGMDL00779139 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|------------------|------------------|--|--|--|--|--|--|--|--|--|
| P-19781 | 9/16/2012 | RE: Update on Suspicious Ordering Monitoring | WAGMDL00528179 | WAGMDL00528180 | | | | | | | | | |
| P-19782 | 9/30/2011 | Accepting and Filling New Prescriptions Policy | WAGMDL00801185 | WAGMDL00801186 | | | | | | | | | |
| P-19785 | 11/20/2012 | Rex Status 12.12 | WAGMDL00574824 | WAGMDL00574825 | | | | | | | | | |
| P-19788 | 5/3/2012 | Dispensing Prescription Drugs Policy | WAGMDL00801301 | WAGMDL00801301 | | | | | | | | | |
| P-19792 | 4/30/2012 | Good Faith Dispensing, Preventing the Inappropriate Use of Controlled Substances, Your Responsibilities | WAGMDL00801324 | WAGMDL00801345 | | | | | | | | | |
| P-19793 | 6/27/2007 | Theft or Diversion of Prescription Drugs by Walgreens Family of Companies Employees | WAGMDL00801468 | WAGMDL00801468 | | | | | | | | | |
| P-19796 | 11/17/1999 | Filling the Prescription | WAGMDL00801539 | WAGMDL00801540 | | | | | | | | | |
| P-19799 | 12/8/2015 | PSO Committee Meeting; PSO presentation_Feb | WAGMDL00608995 | WAGMDL00609009 | | | | | | | | | |
| P-19802 | 10/12/2017 | Pharmacy Inventory Audit: prior audit documentation; Walgreen - AmerisourceBergen First Amendment to the Pharmaceutical Purchase and Distribution Agreement; Walgreen - AmerisourceBergen Second Amendment to the Pharmaceutical Purchase and Distribution Agreement; Walgreen - AmerisourceBergen Third Amendment to the Pharmaceutical Purchase and Distribution Agreement; Walgreen - AmerisourceBergen Settlement Agreement & Fourth Amendment to the Pharmaceutical Purchase and Distribution Agreement | WAGMDL00609699 | WAGMDL00609859 | | | | | | | | | |
| P-19810 | 11/29/2016 | NACDS PAC & WalgreenCoPAC | WAGMDL00612639 | WAGMDL00612654 | | | | | | | | | |
| P-19814 | 6/23/2008 | The DEA Measurement | WAGMDL00624527 | WAGMDL00624532 | | | | | | | | | |
| P-19817 | 6/4/2012 | CSR Talking Points 06-04-12 | WAGMDL00625218 | WAGMDL00625265 | | | | | | | | | |
| P-19821 | 12/1/2010 | Pharmacy Manager Bonus Program | WAGFLDEA00000001 | WAGFLDEA00000005 | | | | | | | | | |
| P-19823 | 8/28/2009 | Suspicious Ordering Pilot | WAGMDL00658227 | WAGMDL00658227 | | | | | | | | | |
| P-19826 | 10/28/2014 | FY14 Staff Pharmacist Bonus Calculations- District 3 | WAGMDL00706318 | WAGMDL00706319 | | | | | | | | | |
| P-19827 | 11/9/2012 | November 8th DEA meeting at NABP | WAGMDL00658246 | WAGMDL00658248 | | | | | | | | | |
| P-19830 | 6/17/2013 | Jupiter C2 update | WAGMDL00660146 | WAGMDL00660146 | | | | | | | | | |
| P-19831 | 11/8/2011 | DEA Statistics Aug. 2011 | WAGMDL00660329 | WAGMDL00660330 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|------------------|------------------|--|--|--|--|--|--|--|--|--|
| P-19832 | N/A | FY17 Business Planning, Scorecards/Target Setting/Performance/Bonus, Pharmacy & Retail Operations | WAGMDL00706414 | WAGMDL00706459 | | | | | | | | | |
| P-19833 | 6/24/2010 | Re: Fw: DEA Pilot Updates | WAGMDL00660344 | WAGMDL00660353 | | | | | | | | | |
| P-19835 | 7/1/2016 | Walgreens Boots Alliance, Inc. Management Incentive Plan | WAGMDL00707619 | WAGMDL00707623 | | | | | | | | | |
| P-19840 | 10/16/2012 | Divisional MIP Clarification | WAGMDL00757461 | WAGMDL00757461 | | | | | | | | | |
| P-19842 | 1/1/2013 | FY2013 Management Incentive Plan- Pharmacy Purchasing, Eligibility, Measures, Funding and Computation | WAGMDL00757486 | WAGMDL00757488 | | | | | | | | | |
| P-19856 | 1/1/2013 | Fiscal Year 2013 Management Incentive Plan - Community Operations, Eligibility, Measures, Funding and Compensation | WAGMDL00774326 | WAGMDL00774328 | | | | | | | | | |
| P-19857 | 5/1/2009 | Senior Certified Technician Bonus Plan Details | WAGFLDEA00000006 | WAGFLDEA00000006 | | | | | | | | | |
| P-19861 | 8/27/2014 | FY15 Business Planning & Performance Management | WAGMDL00706320 | WAGMDL00706332 | | | | | | | | | |
| P-19863 | 2/15/2017 | FY16 Business Planning, Scorecards/Target Setting/Performance & Bonus, Pharmacy & Retail Operations | WAGMDL00706364 | WAGMDL00706403 | | | | | | | | | |
| P-19871 | 10/11/2012 | Duane Reade | WAGMDL00757462 | WAGMDL00757463 | | | | | | | | | |
| P-19873 | 1/1/2013 | Fiscal Year 2013 Management Incentive Plan - Pharmacy, Health and Wellness, Eligibility, Measures, Funding and Compensation | WAGMDL00757489 | WAGMDL00757491 | | | | | | | | | |
| P-19880 | 2/22/2013 | Re: Cardinal and DEA/Kaufman Call to Kermit | WAGMDL00705303 | WAGMDL00705304 | | | | | | | | | |
| P-19881 | 10/1/2012 | Re: OXYCODONE no longer being ordered via PDQ | WAGMDL00705321 | WAGMDL00705322 | | | | | | | | | |
| P-19883 | 5/30/2013 | New Rx Integrity Update May 2013 | WAGMDL00707955 | WAGMDL00707973 | | | | | | | | | |
| P-19888 | 1/7/2013 | Fiscal Year 2013 Management Incentive Plan - Specialty Solutions Group, Eligibility, Measures, Funding and Compensation | WAGMDL00774329 | WAGMDL00774331 | | | | | | | | | |
| P-19891 | 4/3/2012 | DEA Compliance Task Force Meeting | WAGMDL00709482 | WAGMDL00709484 | | | | | | | | | |
| P-19892 | 1/24/2014 | Walgreen Co. - Incentive Compensation Plan for Store Manager Tier 1 | WAGMDL00706310 | WAGMDL00706317 | | | | | | | | | |
| P-19894 | 9/20/2017 | Additional Business Planning FAQs | WAGMDL00706469 | WAGMDL00706472 | | | | | | | | | |
| P-19896 | 9/1/2003 | Walgreen Management Incentive Plan | WAGMDL00747976 | WAGMDL00747982 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-19898 | 1/21/2016 | Purdue_ProductUpdate_MSA_FE | WAGMDL00749580 | WAGMDL00749588 | | | | | | | | | |
| P-19902 | 10/19/2012 | Walgreens Management Incentive Plan (MIP) - Divisional Bonus Design and Calculations | WAGMDL00757464 | WAGMDL00757471 | | | | | | | | | |
| P-19903 | 1/1/2013 | Fiscal Year 2013 Management Incentive Plan, Eligibility, Measures and Computation | WAGMDL00757482 | WAGMDL00757483 | | | | | | | | | |
| P-19904 | 12/22/2008 | Exit Meeting Outline - DEA Review - Perrysburg DC - Date of Review: 11/17/2008 - 11/21/2008 | WAGMDLPER00000020 | WAGMDLPER00000027 | | | | | | | | | |
| P-19905 | 1/1/2013 | Fiscal Year 2013 Management Incentive Plan - Retail Pharmacy, Eligibility, Measures, Funding and Computation | WAGMDL00757492 | WAGMDL00757494 | | | | | | | | | |
| P-19908 | 9/20/2017 | Pharmacists Merit Plan & 2017 Merit Conversation | WAGMDL00757627 | WAGMDL00757627 | | | | | | | | | |
| P-19910 | 10/8/2012 | Focus on Profit Program | WAGMDL00767009 | WAGMDL00767009 | | | | | | | | | |
| P-19911 | N/A | Sample Suspicious Orders | WAGMDL00767044 | WAGMDL00767067 | | | | | | | | | |
| P-19912 | 8/22/2011 | Walgreen's Management Meeting in Weston | WAGMDL00768931 | WAGMDL00768934 | | | | | | | | | |
| P-19913 | N/A | Distribution of Suspicious Order Reports | WAGMDL00768935 | WAGMDL00768936 | | | | | | | | | |
| P-19914 | 12/18/2012 | DBPR v. WAG Final Order | WAGMDL00768937 | WAGMDL00768942 | | | | | | | | | |
| P-19915 | 2/22/2012 | Notes from call with Susan Langston acting Division Program Manager | WAGMDL00770956 | WAGMDL00770957 | | | | | | | | | |
| P-19916 | 12/12/2018 | Bamberg Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771049 | WAGMDL00771140 | | | | | | | | | |
| P-19917 | 1/6/2019 | Bancroft Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771141 | WAGMDL00771206 | | | | | | | | | |
| P-19918 | 1/29/2019 | Bish Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771207 | WAGMDL00771272 | | | | | | | | | |
| P-19919 | 12/13/2018 | Bratton Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771273 | WAGMDL00771356 | | | | | | | | | |
| P-19920 | 1/21/2019 | Diebert Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771357 | WAGMDL00771401 | | | | | | | | | |
| P-19921 | 1/21/2019 | Dymon Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771402 | WAGMDL00771468 | | | | | | | | | |
| P-19922 | 1/9/2019 | Lanzetti Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771469 | WAGMDL00771530 | | | | | | | | | |
| P-19923 | 12/13/2018 | Martin Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771531 | WAGMDL00771584 | | | | | | | | | |
| P-19924 | 1/11/2019 | Merritello Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771585 | WAGMDL00771606 | | | | | | | | | |
| P-19925 | 9/20/2013 | Annual Performance Review (FY11) - Core (Senior Management) | WAGMDL00771607 | WAGMDL00771643 | | | | | | | | | |
| P-19926 | 12/17/2018 | Peterson Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771644 | WAGMDL00771646 | | | | | | | | | |
| P-19927 | 1/18/2019 | Polster Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771647 | WAGMDL00771753 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-19928 | 1/11/2019 | Zaccaro Personnel File - HIGHLY CONFIDENTIAL | WAGMDL00771754 | WAGMDL00771790 | | | | | | | | | |
| P-19930 | 1/6/2013 | December Controls Data | WAGMDL00774295 | WAGMDL00774295 | | | | | | | | | |
| P-19933 | 6/13/2012 | Control Substance Suspicious Ordering Team | WAGMDL00774723 | WAGMDL00774724 | | | | | | | | | |
| P-19935 | 1/2/2013 | FW: Top 500 | WAGMDL00774760 | WAGMDL00774760 | | | | | | | | | |
| P-19940 | 12/14/2012 | Change Request Form-DEA 5a- Zero out order qty | WAGMDL00774793 | WAGMDL00774795 | | | | | | | | | |
| P-19941 | 12/14/2012 | Change Request Form-DEA 5a- Limit Vendor Order at time of Generation | WAGMDL00774796 | WAGMDL00774798 | | | | | | | | | |
| P-19943 | 4/10/2012 | Controlled Substance Order Monitoring and Prevention System | WAGMDL00777098 | WAGMDL00777157 | | | | | | | | | |
| P-19944 | 4/3/2012 | Warrant for Inspection - Jupiter Distribution Center | WAGMDL00777158 | WAGMDL00777160 | | | | | | | | | |
| P-19951 | 9/13/2016 | Walgreen Co. - Incentive Compensation Plan for Field Leaders, Pharmacy & Retail Operations Division - Fiscal Year 2016 | WAGMDL00706355 | WAGMDL00706362 | | | | | | | | | |
| P-19952 | 3/18/2018 | FY17 Business Planning, Scorecards/Target Setting/Performance/Bonus, Pharmacy & Retail Operations | WAGMDL00706404 | WAGMDL00706413 | | | | | | | | | |
| P-19953 | 7/14/2017 | FY18 Business Planning, Scorecards/Target Setting/Performance/Bonus, Pharmacy & Retail Operations | WAGMDL00706473 | WAGMDL00706520 | | | | | | | | | |
| P-19961 | 10/23/2012 | FY2012 Corporate Management Incentive Plan Divisional MIPs, FAQ | WAGMDL00757472 | WAGMDL00757477 | | | | | | | | | |
| P-19963 | 1/7/2013 | Fiscal Year 2013 Management Incentive Plan, Eligibility, Measures and Computation | WAGMDL00757484 | WAGMDL00757485 | | | | | | | | | |
| P-19964 | 10/11/2012 | Retail Pharmacy Communication | WAGMDL00757495 | WAGMDL00757496 | | | | | | | | | |
| P-19972 | 3/9/2017 | Fiscal 2017 Pay Ranges by Area, Store Management | WAGMDL00773914 | WAGMDL00773914 | | | | | | | | | |
| P-19974 | 3/9/2017 | FY17 CSP Structure w Geo Diff | WAGMDL00773923 | WAGMDL00773923 | | | | | | | | | |
| P-19977 | 5/10/2017 | Quintiles IMS and WAG Contract | WAGMDL00710215 | WAGMDL00710215 | | | | | | | | | |
| P-19978 | 7/25/2017 | Notice Regarding Transaction with Walgreens Boots Alliance and Walgreen Co. involving 2,186 Rite Aid Stores, 3 Distribution Centers and Related Assets | WAGMDL00710216 | WAGMDL00710218 | | | | | | | | | |
| P-19979 | 12/13/2018 | Data acquisition agreement for Chain Retail Pharmacy Data and Sales Data pt 2 | WAGMDL00710230 | WAGMDL00710240 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-19980 | 12/28/2010 | Data acquisition agreement for Chain Retail Pharmacy Data and Sales Data | WAGMDL00710241 | WAGMDL00710249 | | | | | | | | | |
| P-19981 | 12/29/2010 | DATA ACQUISITION AGREEMENT FOR CHAIN RETAIL PHARMACY DATA AND SALES DATA between IMS Health Incorporated and Walgreens | WAGMDL00710250 | WAGMDL00710269 | | | | | | | | | |
| P-19982 | 10/1/2013 | First Amendment | WAGMDL00710219 | WAGMDL00710229 | | | | | | | | | |
| P-19997 | 10/22/2013 | DEA Diversion Investigator's Manual | CAH_MDL2804_02145395 | CAH_MDL2804_02145781 | | | | | | | | | |
| P-20002 | 11/9/2018 | Rite Aid's Written Responses to Second 30(b)(6) (Topics 1 and 2) | N/A | N/A | | | | | | | | | |
| P-20003 | 9/21/2018 | Rite Aid's Amended Responses to Plaintiff's' Interrogatories, Set One | N/A | N/A | | | | | | | | | |
| P-20004 | 3/4/2019 | Rite Aid's Third Supplemental Responses to Interrogatories, Set One | N/A | N/A | | | | | | | | | |
| P-20005 | 1/7/2019 | Rite Aid's Written Responses to 30(b)(6) Topics | N/A | N/A | | | | | | | | | |
| P-20006 | 7/5/2018 | Rite Aid's Responses to Plaintiff's' RFPs, Set One | N/A | N/A | | | | | | | | | |
| P-20007 | 8/14/2018 | Rite Aid's Objections to 30(b)(6) Notices | N/A | N/A | | | | | | | | | |
| P-20008 | 9/25/2018 | Rite Aid's Supplemental Responses to Plaintiff's' RFPs, Set One | N/A | N/A | | | | | | | | | |
| P-20009 | 1/25/2019 | Rite Aid's Second Supplemental Responses to Interrogatories, Set One | N/A | N/A | | | | | | | | | |
| P-20010 | 7/5/2018 | Rite Aid's Responses to Plaintiff's' Interrogatories, Set One | N/A | N/A | | | | | | | | | |
| P-20011 | 11/30/2018 | Rite Aid's Responses to Combined Discovery Requests, Set One | N/A | N/A | | | | | | | | | |
| P-20012 | 6/1/2015 | GAO-15-471 - Report RE "Prescription Drugs More DEA Information about Registrants' Controlled Substances Role Could Improve Their Understanding and Help Ensure Access | N/A | N/A | | | | | | | | | |
| P-20013 | 6/20/2019 | DOJ letter to Special Master Cohen RE "Response to Motion to Compel Filed by Rite Aid of Maryland, d/b/a Mid-Atlantic Customer Support Center" | N/A | N/A | | | | | | | | | |
| P-20025 | 10/12/2016 | Controlled substances SOM | WMT_MDL_000004237 | WMT_MDL_000004239 | | | | | | | | | |
| P-20026 | 4/20/2017 | Controlled substances SOM | WMT_MDL_000004781 | WMT_MDL_000004783 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-20027 | 3/11/2010 | Updated: Walmart Dendrite Conf. Call -Mon. March 15 @ 11:00 Eastern / 10:00 Central | WMT_MDL_000011558 | WMT_MDL_000011575 | | | | | | | | | |
| P-20046 | 2/3/2011 | Scan - Pharmacy Replenishment System Store Order History | Rite_Aid_OMDL_0015301 | Rite_Aid_OMDL_0015307 | | | | | | | | | |
| P-20113 | 1/12/2009 | DOJ Release: Rite Aid Corporation and Subsidiaries Agree to Pay \$5 Million in Civil Penalties | N/A | N/A | | | | | | | | | |
| P-20116 | 10/20/2014 | DOJ Release: Akron Doctor Pleads Guilty to Illegally Prescribing Painkillers | N/A | N/A | | | | | | | | | |
| P-20118 | 1/14/2009 | Article re: Rite Aid Pharmacy Deemed Central to Multi-State Drug Probe | N/A | N/A | | | | | | | | | |
| P-20120 | 1/31/2019 | Binder Index (Materials Brought to Deposition) | N/A | N/A | | | | | | | | | |
| P-20123 | 11/2/2010 | Order of the State Board of Pharmacy, Docket Number D-100621-134 | N/A | N/A | | | | | | | | | |
| P-20128 | 3/25/2014 | Northern District of Ohio Indictment re Adolph Harper, Jr., Adria Harper, Patricia Laughman, and Tequilla Berry | N/A | N/A | | | | | | | | | |
| P-20129 | 2019 | Andy Palmer LinkedIn Page | N/A | N/A | | | | | | | | | |
| P-20132 | 6/3/2009 | Emailed entitled "RE: Perryman visit week of 6/8" | Rite_Aid_OMDL_0012958 | Rite_Aid_OMDL_0013030 | | | | | | | | | |
| P-20142 | 10/10/2007 | Document entitled "Controlled Drug Above Average Order Monitoring Program" | Rite_Aid_OMDL_0016520 | Rite_Aid_OMDL_0016524 | | | | | | | | | |
| P-20209 | 7/10/2012 | 2012 DEA audit case file; Notice of Inspection of Controlled Premises | US-DEA-00026940 | US-DEA-00027005 | | | | | | | | | |
| P-20210 | 7/10/2012 | Handwritten notes related to DEA audit | US-DEA-00027085 | US-DEA-00027101 | | | | | | | | | |
| P-20213 | 3/5/2019 | E. Bratton Errata | N/A | N/A | | | | | | | | | |
| P-20512 | 7/30/2018 | Re: Suspicious Prescribing Habits | WAGMDAA00032126 | WAGMDAA00032128 | | | | | | | | | |
| P-20523 | 11/11/2009 | DEA Memorandum Oxycontin and Hydrocodone Abuse | Rite_Aid_OMDL_0046560 | Rite_Aid_OMDL_0046561 | | | | | | | | | |
| P-20530 | 3/11/2010 | 03-Monday Pm_Field Ops Meeting-March 2010 PPT | Rite_Aid_OMDL_0132321 | Rite_Aid_OMDL_0132711 | | | | | | | | | |
| P-20536 | 6/16/2010 | RE: CII | Rite_Aid_OMDL_0143733 | Rite_Aid_OMDL_0143733 | | | | | | | | | |
| P-20538 | 10/13/2007 | Email CII Prescription Dispensings Attachment Company Compare of Filled RXs to C2s | Rite_Aid_OMDL_0111511 | Rite_Aid_OMDL_0111512 | | | | | | | | | |
| P-20539 | 4/30/2008 | Email Rite Aid | CHI_001584425 | CHI_001584425 | | | | | | | | | |
| P-20602 | 3/11/2016 | WALGREENS_STORE_5821_02864 | WAGMDL01002678 | WAGMDL01002685 | | | | | | | | | |
| P-20603 | 4/18/2019 | Review GFD build for IT; GFD 2.0 Clinical GFD DUR | WAGMDL00911307 | WAGMDL00911321 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-20605 | N/A | PHARMACY- LEADERSHIP_MESSAGE_1 - Video | WMT_MDL_000385191 | WMT_MDL_000385191 | | | | | | | | | |
| P-20606 | 2/13/2013 | Re: NACDS CS Work Group Meeting Recap | WMT_MDL_000233234 | WMT_MDL_000233235 | | | | | | | | | |
| P-20607 | 2018 | FY18 Annual Officer Performance Evaluation for Paul E Beahm Jr | WMT_MDL_001213995 | WMT_MDL_001214003 | | | | | | | | | |
| P-20608 | 2018 | FY18 Annual Officer Self Evaluation for Paul E Beahm Jr | WMT_MDL_001214004 | WMT_MDL_001214012 | | | | | | | | | |
| P-20609 | 2012 | FY12 Annual Performance Evaluation (50/40/10) for Paul E Beahm Jr | WMT_MDL_001213931 | WMT_MDL_001213937 | | | | | | | | | |
| P-20610 | 2014 | FY14 Annual Officer Self Evaluation for Paul E Beahm Jr | WMT_MDL_001213955 | WMT_MDL_001213966 | | | | | | | | | |
| P-20611 | 1/14/2013 | Fulfillment Work Stream Deck for 1.17.13; Compliance Focus Areas_Fulfillment Work Stream 1.17.13 | WMT_MDL_000475017 | WMT_MDL_000475018 | | | | | | | | | |
| P-20612 | 1/18/2016 | RE: Refusal to Fill Dashboard | WMT_MDL_000483492 | WMT_MDL_000483493 | | | | | | | | | |
| P-20613 | 1/23/2017 | HW Strategy Cascade meeting 1- 25-17 | WMT_MDL_000979699 | WMT_MDL_000979700 | | | | | | | | | |
| P-20614 | 3/13/2014 | Re: DISCOUNT CARDS | WMT_MDL_001107901 | WMT_MDL_001107905 | | | | | | | | | |
| P-20616 | 4/6/2015 | RE: Your Oregon Prescription Drug Monitoring Program Reporting Waiver is Due for Renewal; OR, 10-10-2008, Oregon Patient Safety Reporting Program response letter | WMT_MDL_001085366 | WMT_MDL_001085376 | | | | | | | | | |
| P-20617 | 8/28/2008 | FW: pill chart | WMT_MDL_000143760 | WMT_MDL_000143761 | | | | | | | | | |
| P-20618 | 11/30/2009 | RE: Inventory control | WMT_MDL_000201806 | WMT_MDL_000201807 | | | | | | | | | |
| P-20619 | 11/28/2011 | Emailing: Pharmacy Robbery Analysis | WMT_MDL_000239885 | WMT_MDL_000239886 | | | | | | | | | |
| P-20620 | 5/10/2012 | RE: cvs cardinal dea | WMT_MDL_000261623 | WMT_MDL_000261624 | | | | | | | | | |
| P-20621 | 10/25/2013 | Advisory Panel Meeting 20131023 | WMT_MDL_001209673 | WMT_MDL_001209674 | | | | | | | | | |
| P-20622 | N/A | dec of William Boyd in support of non party cvs pharmacy | N/A | N/A | | | | | | | | | |
| P-20623 | N/A | 4729-5-22 Patient counseling | N/A | N/A | | | | | | | | | |
| P-20625 | 11/20/2019 | RE: R2F Guide; KL Refusal to Fill Guide draft V5 | CVS-MDLT3-000003695 | CVS-MDLT3-000003697 | | | | | | | | | |
| P-20626 | 8/13/2020 | Store Statistics for SOM Order Review; Store #4606 | CVS-MDLT3-000000369 | CVS-MDLT3-000000370 | | | | | | | | | |
| P-20627 | 9/25/2018 | PM CSDP Store Guide_9_24_18 | CVS-MDLT3-000088851 | CVS-MDLT3-000088865 | | | | | | | | | |
| P-20631 | N/A | 4729-5-20 Prospective drug utilization review | N/A | N/A | | | | | | | | | |
| P-20632 | 8/21/2018 | Email Blitz 1-3-1 and Files Attachments | CVS-MDLT3-000006214 | CVS-MDLT3-000006236 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-20633 | 9/5/2021 | Email Pharmacist POWER Schedules Attachments RPhTrainingSchedule_v12_09052012; RPhTrainingSchedule_POWER_v2_090512 | WAGMDL00912291 | WAGMDL00912293 | | | | | | | | | |
| P-20634 | 9/7/2012 | RE: Controlled substance language | WAGMDL00873548 | WAGMDL00873549 | | | | | | | | | |
| P-20635 | 11/15/2012 | Respondent's Prehearing Statement | WAGMDL_T1_TX00002807 | WAGMDL_T1_TX00002856 | | | | | | | | | |
| P-20636 | 12/15/2012 | FW: Streamlined Steps to GFD - Revised | WAGMDL00874808 | WAGMDL00874810 | | | | | | | | | |
| P-20637 | 12/31/2012 | FW: Market 7 GFD Operational Plan - Action Required Attachments Good Faith Dispensing Market 7 Operational Plan; Key Points to Remember; Good Faith Dispensing Refusal Verbiage; GFD binder cover page | WAGMDL00905531 | WAGMDL00905539 | | | | | | | | | |
| P-20638 | 1/6/2013 | FW: PRIORITY LIST: January 6th - January 12th | WAGMDL00871296 | WAGMDL00871299 | | | | | | | | | |
| P-20639 | 1/1/2012 | DEA market leadership Jan 2013 PowerPoint | WAGMDL01013472 | WAGMDL01013497 | | | | | | | | | |
| P-20640 | 3/15/2013 | FW: National TD GFD Attachments National Target Drug - Good Faith Dispensing; National Target Drug Good Faith Dispensing Checklist; National Target Drug Good Faith Dispensing Policy; Prescriber Good Faith Dispensing Letter; Patient Internal Talking Points | WAGMDL00981059 | WAGMDL00981098 | | | | | | | | | |
| P-20641 | 4/8/2013 | RE: Positions Currently Enrolled in Good Faith Dispensing of Controlled Substances - Policy Acknowledgment | WAGMDL00858191 | WAGMDL00858193 | | | | | | | | | |
| P-20642 | 9/30/2009 | DEA Walgreens Order to Show Cause | WAGMDL00768976 | WAGMDL00768979 | | | | | | | | | |
| P-20644 | 8/22/2014 | Retail Compliance August 2014 - Draft 5 (4) | CVS-MDLT1-000030116 | CVS-MDLT1-000030130 | | | | | | | | | |
| P-20645 | 2019 | WeCARE_Metrics_Toolkit | CVS-MDLT3-000006734 | CVS-MDLT3-000006755 | | | | | | | | | |
| P-20646 | 5/7/2013 | Corresponding Responsibility Huddle v4 | CVS-MDLT3-000102855 | CVS-MDLT3-000102862 | | | | | | | | | |
| P-20647 | N/A | Patient_Specific_Red_Flags | CVS-MDLT1B-000005667 | CVS-MDLT1B-000005667 | | | | | | | | | |
| P-20648 | N/A | pharmacists_brochure-a_20161024132031288 | CVS-INDAG-00016651 | CVS-INDAG-00016652 | | | | | | | | | |
| P-20649 | N/A | Prescriber_Specific_Red_Flags | CVS-MDLT1B-000005673 | CVS-MDLT1B-000005673 | | | | | | | | | |
| P-20650 | 2003 | CVS Corporation 2003 Annual Report | N/A | N/A | | | | | | | | | |
| P-20651 | 2013 | CVS 2013 Annual Report | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------|--------------------|--|--|--|--|--|--|--|--|--|
| P-20652 | 5/14/2020 | CVS Annual Meeting of Stockholders and Proxy Statement | N/A | N/A | | | | | | | | | |
| P-20653 | 2009 | CVSMDDEA.008.0000619; Triple S, What it Means, How it Works | CVS-DR22-000031602 | CVS-DR22-000031627 | | | | | | | | | |
| P-20654 | N/A | Part 1301 - Registration of Manufacturers, Distributors, and Dispensers of Controlled Substances, Section 1301.74 Other Security controls for non-practitioners: narcotic treatment programs and compounders for narcotic treatment programs | P-GEN-0010 | P-GEN-0010 | | | | | | | | | |
| P-20656 | 2/22/2008 | DEA Compliance Review - Woodland Distribution Center | WAGMDLPER00000350 | WAGMDLPER00000352 | | | | | | | | | |
| P-20657 | 2/22/2008 | Woodland DC DEAR Review | WAGMDLPER00000338 | WAGMDLPER00000349 | | | | | | | | | |
| P-20658 | 7/28/2008 | Mt. Vernon DC DEA Review | WAGMDLPER00000353 | WAGMDLPER00000364 | | | | | | | | | |
| P-20659 | 3/9/2006 | Add to the DEA Manual | WAGMDL01166369 | WAGMDL01166380 | | | | | | | | | |
| P-20661 | 11/19/2010 | Jupiter DC DEA Review Third Quarter Fiscal 2010 Index | WAGMDLPER00000379 | WAGMDLPER00000643 | | | | | | | | | |
| P-20662 | 12/15/2010 | Controlled Substance / Pseudoephedrine | WAGMDL00851422 | WAGMDL00851422 | | | | | | | | | |
| P-20663 | 2/26/2012 | Fw: C2 | WAGFLDEA00001518 | WAGFLDEA00001523 | | | | | | | | | |
| P-20664 | 3/1/2012 | Florida Trip - Best Practices and Comments | WAGFLDEA00001538 | WAGFLDEA00001541 | | | | | | | | | |
| P-20665 | 4/12/2012 | Rescheduled: Policy Committee Meeting (Apr 13 10:00 CDT in 200 Wilmot/1A5) | WAGMDL00607195 | WAGMDL00607203 | | | | | | | | | |
| P-20666 | N/A | National Hydrocodone Distributor Market Share to Retail and Chain Pharmacies in Dosage Unit 2004-2014 | N/A | N/A | | | | | | | | | |
| P-20667 | N/A | Candidate handbook, Certified in Healthcare Compliance (CHC) | N/A | N/A | | | | | | | | | |
| P-20668 | N/A | National Oxycodone Distributor Market Share to Retail and Chain Pharmacies in Dosage Unit 2004-2014 | N/A | N/A | | | | | | | | | |
| P-20669 | N/A | Walgreens National Distribution of Oxycodone & Hydrocodone 2006-2012 | N/A | N/A | | | | | | | | | |
| P-20670 | 1/16/2013 | DLPM Store Walk Review; Compass DLPM Store Walk Inputs | WAGMDL01167480 | WAGMDL01167482 | | | | | | | | | |
| P-20671 | 1/16/2013 | Quarter 3 Compliance Day Checklist; Quarter 3 Compliance Day Checklist; Help Document - Q3 Compliance Day Checklist | WAGNYAG00006667 | WAGNYAG00006690 | | | | | | | | | |
| P-20672 | 10/2/2014 | Draft Message for Greg Wasson | WAGMDL01174482 | WAGMDL01174548 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-20673 | 2/24/2019 | RE: Monitoring Protocol Policy Mapping; Response to EY questions on Monitoring Assessment_2 23 19 | WAGMDL01137448 | WAGMDL01137496 | | | | | | | | | |
| P-20674 | 4/20/2015 | More EOC work; Compliance and Privacy Division Legal Division Town Hall Overview of Compliance and Privacy | WAGMDL01175945 | WAGMDL01175945 | | | | | | | | | |
| P-20675 | 7/28/2008 | Mt-Vernon- Internal Audit Report | WAGMDL00757569 | WAGMDL00757570 | | | | | | | | | |
| P-20677 | 4/2/2012 | Completed Workbook v2; Embedded BIN | HBC_MDL00190685 | HBC_MDL00190876 | | | | | | | | | |
| P-20678 | 2/10/2014 | Narcotic Audit Procedures; Completing a Narcotic Audit; Controlled Substance Dispensing Guideline; Narcotic Audit Best Practices; Logging onto the Narcotic Audit Program; Discrepancy Resolution: Trouble Shooting the Narcotic Audit | GE_TL00001798 | GE_TL00001816 | | | | | | | | | |
| P-20680 | 2006 | 2006 YE Tankut | CVS-MDLT3-000130998 | CVS-MDLT3-000131001 | | | | | | | | | |
| P-20681 | 1/27/2013 | RE: Controlled Substances Prescribing Paper; TB Controlled Substances Paper Draft (5) | CVS-MDLT1-000129603 | CVS-MDLT1-000129612 | | | | | | | | | |
| P-20682 | 1/15/2013 | Prescriber Initiative_Briefing Document_011512 | CVS-MDLT3-000126997 | CVS-MDLT3-000127005 | | | | | | | | | |
| P-20683 | 1/31/2013 | RE: Controlled Substances Prescribing Paper | CVS-MDLT1-000129623 | CVS-MDLT1-000129635 | | | | | | | | | |
| P-20684 | 3/13/2013 | RE: Follow-up on voicemail; Controlled Substances Paper Draft fin; RE: paper; Controlled Substances Paper Draft fin | CVS-MDLT3-000026330 | CVS-MDLT3-000026352 | | | | | | | | | |
| P-20685 | 10/11/2012 | RE: Privileged and Confidential - Data Request; Drug share by chain_v2 for TB | CVS-MDLT3-000113018 | CVS-MDLT3-000113020 | | | | | | | | | |
| P-20686 | 1/31/2012 | Cleveland doctor on a CVS "don't fill" list? | CVS-MDLT3-000112997 | CVS-MDLT3-000112997 | | | | | | | | | |
| P-20687 | 5/10/2012 | Prescriber review 050912 final | CVS-MDLT3-000126881 | CVS-MDLT3-000126916 | | | | | | | | | |
| P-20688 | 12/12/2012 | Prescriber Algorithm Evolution and Update | CVS-MDLT3-000033969 | CVS-MDLT3-000034380 | | | | | | | | | |
| P-20689 | 2007 | 2007 YE Tankut | CVS-MDLT3-000131040 | CVS-MDLT3-000131045 | | | | | | | | | |
| P-20690 | 6/4/2015 | ROPP 0061-05-31-13 (pp) | CVS-DR22-000001056 | CVS-DR22-000001058 | | | | | | | | | |
| P-20691 | 9/29/2015 | RE: Talking points around the prescriber program; 29010a New England Journal of Medicine FAQ Final | CVS-NYAG-000042087 | CVS-NYAG-000042095 | | | | | | | | | |
| P-20692 | 4/17/2012 | DEA Follow-up Tracking - 17 Apr 2012 | CVS-MDLT3-000082439 | CVS-MDLT3-000082440 | | | | | | | | | |
| P-20693 | 2/8/2013 | Privileged and Confidential: FW: Archer snapshot; Archer summary 02.07.13 for AGI | SA AGI 00068510 | SA AGI 00068511 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|--------------------------|--------------------------|--|--|--|--|--|--|--|--|--|
| P-20694 | 3/7/2012 | 1627915--Store report_ 4351 -- 56341; High-Risk Drug Overview: Store # 4351 | CVS-MDLT3-000030198 | CVS-MDLT3-000030198 | | | | | | | | | |
| P-20695 | N/A | WeCARE_Metric_Toolkit_2013 | CVS-MDLT3-000006649 | CVS-MDLT3-000006673 | | | | | | | | | |
| P-20696 | 2/14/2008 | Five year old took wrong medication for two months | N/A | N/A | | | | | | | | | |
| P-20697 | 12/21/2004 | Professional Practices | CVS-MDLT1-000055540 | CVS-MDLT1-000055547 | | | | | | | | | |
| P-20698 | 2/24/2012 | Rannazzisi declaration; Holiday CVS LLC v Holder | N/A | N/A | | | | | | | | | |
| P-20699 | 12/10/2010 | Pain Management Dispensing Guidelines | CVS-MDLT1B-000017587 | CVS-MDLT1B-000017588 | | | | | | | | | |
| P-20700 | 5/5/2012 | RE: PROTOCOL FOR DISPENSING NARCOTIC DRUGS-2nd request | CVS-MDLT1B-000017678 | CVS-MDLT1B-000017679 | | | | | | | | | |
| P-20701 | undated | Red Flag Spreadsheet | WMT_MDL_000438445 | WMT_MDL_000438445 | | | | | | | | | |
| P-20702 | undated | Red Flag Spreadsheet | WMT_MDL_000438446 | WMT_MDL_000438446 | | | | | | | | | |
| P-20703 | undated | Red Flag Spreadsheet | WMT_MDL_000287292 | WMT_MDL_000287292 | | | | | | | | | |
| P-20704 | 4/30/2018 | PRC-Admin 4.12.18_final_draft | WMT_MDL_000497446 | WMT_MDL_000497456 | | | | | | | | | |
| P-20705 | 6/5/2020 | Jones day letter to P Weinberger | N/A | N/A | | | | | | | | | |
| P-20706 | 1/17/2017 | Email; ATT44862 | WMT_MDL_000265033 | WMT_MDL_000265034 | | | | | | | | | |
| P-20707 | 2/15/2013 | 1857 Forged or Fraudulent Rx 2- 14 | WMT_MDL_000287228 | WMT_MDL_000287229 | | | | | | | | | |
| P-20708 | 2/26/2018 | RE: Refusal to Fill - POM 1311 question; Refusal_to_Fill_Training | WMT_MDL_000440452 | WMT_MDL_000440460 | | | | | | | | | |
| P-20709 | undated | Red Flag Spreadsheet | WMT_MDL_000287293 | WMT_MDL_000287293 | | | | | | | | | |
| P-20710 | 3/27/2009 | Root Causes | WMT_MDL_001217101 | WMT_MDL_001217117 | | | | | | | | | |
| P-20718 | 2019 | Physicians' Powerful Ally in Patient Care 2019 Annual Report | N/A | N/A | | | | | | | | | |
| P-20719 | 6/19/2019 | MedPage Today, Don't Believe AMA's Hype, Membership Still Declining | N/A | N/A | | | | | | | | | |
| P-20720 | 2019 | Legislature of the State of Idaho House Bill No. 182 | N/A | N/A | | | | | | | | | |
| P-20721 | 11/19/2019 | Inside Purdue Pharma's Media Playbook: How it Planted the Opioid - ProPublica | N/A | N/A | | | | | | | | | |
| P-20722 | 11/19/2019 | KHN Morning Briefing: November 19, 2019 | AMA_T3_PharmSub000226350 | AMA_T3_PharmSub000226371 | | | | | | | | | |
| P-20723 | 2/19/2015 | AMA Foundation Corporate Roundtable Reminder and Information | AMA_T3_PharmSub000197599 | AMA_T3_PharmSub000197601 | | | | | | | | | |
| P-20725 | 2/14/2017 | Opioid-related morbidity and mortality: What every physician should know | N/A | N/A | | | | | | | | | |
| P-20727 | 11/16/2000 | High-Tech Stealth Being Used to Sway Doctor Prescriptions - NYT | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | | |
|---------|------------|--|---------------------|--------------------------|--|--|--|--|--|--|--|--|--|--|
| P-20728 | 8/13/2018 | The Augusta Chronicle - Dr. Patrice Harris Talks about Opioids | N/A | N/A | | | | | | | | | | |
| P-20729 | 2/16/2021 | Letter RE: AMA's Opposition to Dose & Duration Guidance for Opioid Prescribing | N/A | N/A | | | | | | | | | | |
| P-20730 | N/A | Compilation of Personnel Files for Grimes | CVS-MDLT3-000131394 | CVS-MDLT3-000131713 | | | | | | | | | | |
| P-20731 | 3/14/2014 | Prescriber Questionnaire/Evaluation aids; Prescriber_Questionnaire November 2013; Prescriber Decision Checklist 1_29_14; Alternate Prescriber Research Guidepost | CVS-MDLT3-000011119 | CVS-MDLT3-000011126 | | | | | | | | | | |
| P-20734 | 11/28/2012 | Heroin's popularity goes up in Monroeville | N/A | N/A | | | | | | | | | | |
| P-20735 | 5/16/2017 | FW: Wrong DEA Number Attachments GE Rx Dist Ctr DEA_2017; Pharmacy_Store_List_W7 | HBC_MDL00131247 | HBC_MDL00131249 | | | | | | | | | | |
| P-20736 | 1/15/2015 | Giant Eagle Loss Prevention Department PPT by Richard Shaheen, Pharmacy Investigator | GE_TL00014176 | GE_TL00014176 | | | | | | | | | | |
| P-20737 | 10/2/2014 | RE: Narcs found in tote | HBC_MDL00137072 | HBC_MDL00137073 | | | | | | | | | | |
| P-20738 | 7/28/2015 | FW: Oxy limit | HBC_MDL00133762 | HBC_MDL00133764 | | | | | | | | | | |
| P-20739 | 8/11/2015 | RE: Procedural Inconsistency | HBC_MDL00064010 | HBC_MDL00064011 | | | | | | | | | | |
| P-20740 | 8/17/2015 | Email Pharmacy Team Leader Calls Attachment Agenda | HBC_MDL00092047 | HBC_MDL00092049 | | | | | | | | | | |
| P-20741 | 10/20/2014 | Giant Eagle Suspected Controlled Substance Loss DEA Notification | GE_TL00008360 | GE_TL00008360 | | | | | | | | | | |
| P-20742 | 11/10/2014 | Email 1405 audit question | GE_TL00008359 | GE_TL00008359 | | | | | | | | | | |
| P-20743 | 9/3/2016 | Prescription Pickup Signature Liberty Township Police Department | GE_TL00008392 | GE_TL00008394 | | | | | | | | | | |
| P-20744 | 11/30/2015 | FW: Fraudulent Prescriptions received | GE_TL00008105 | GE_TL00008105 | | | | | | | | | | |
| P-20745 | 6/13/2017 | Email Loss Attachment Giant Eagle Suspected Controlled Substance Loss DEA Notification | GE_TL00004425 | GE_TL00004426 | | | | | | | | | | |
| P-20746 | 12/7/2017 | Email 4056 Jamestown Youngstown | GE_TL00008397 | GE_TL00008397 | | | | | | | | | | |
| P-20747 | 12/8/2017 | Email Brenton Cornwell statement | GE_TL00008426 | GE_TL00008433 | | | | | | | | | | |
| P-20748 | 6/6/2018 | FW: LP Pharmacy Wins FY18 | GE_TL00006072 | GE_TL00006073 | | | | | | | | | | |
| P-20749 | 3/13/2018 | Email BOLO... Attachment Oxycodone Prescription | GE_TL00001307 | GE_TL00001308 | | | | | | | | | | |
| P-20750 | 8/13/2018 | Pharmacy Hot Sheet | GE_TL00008389 | GE_TL00008390 | | | | | | | | | | |
| P-20751 | 11/2/2009 | Ohio Board of Pharmacy Meeting Minutes November 2009 | OBPM_MDL_000000031 | OBPM_MDL_000000031-.0036 | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|--------------------|--------------------------|--|--|--|--|--|--|--|--|--|
| P-20752 | 12/5/2011 | Ohio Board of Pharmacy Meeting Minutes December 2011 | OBPM_MDL_000000063 | OBPM_MDL_000000063-.0040 | | | | | | | | | |
| P-20753 | 9/11/2017 | Ohio Board of Pharmacy Meeting Minutes September 2017 | OBPM_MDL_000000184 | OBPM_MDL_000000184-.0031 | | | | | | | | | |
| P-20754 | 7/3/2019 | Email 2019 Accomplishments | GE_TL00006070 | GE_TL00006070 | | | | | | | | | |
| P-20755 | 6/6/2019 | Re: Response Requested: Quarterly Team Leader Call Topics | GE_TL00001987 | GE_TL00001988 | | | | | | | | | |
| P-20756 | 4/10/2016 | Presentation Materials; Resume_1; Presentation Dialogue; Compliance_A Changing Landscape | HBC_MDL00030274 | HBC_MDL00030279 | | | | | | | | | |
| P-20757 | 6/4/2013 | 2013 Graduate Intern Presentation | HBC_MDL00190998 | HBC_MDL00190998 | | | | | | | | | |
| P-20758 | N/A | Compilation of Performance Reviews for Chunderlik | GE_TL00014983 | GE_TL00015131 | | | | | | | | | |
| P-20759 | 7/22/2013 | Controlled Substance Dispensing Guideline | HBC_MDL00191292 | HBC_MDL00191295 | | | | | | | | | |
| P-20760 | 2/23/2016 | Fwd: Dr Letizio | HBC_MDL00056686 | HBC_MDL00056687 | | | | | | | | | |
| P-20761 | 9/6/2016 | RE: Lighthouse Medical | HBC_MDL00061011 | HBC_MDL00061011 | | | | | | | | | |
| P-20762 | 10/14/2011 | Action Required - Pharmacy - 10/15/11: OARRS communication; Case for OARRS; Ohio Automated Rx Reporting System requirements for all OH licensed pharmacists; OH BOP OARRS Rule FINAL | HBC_MDL00078158 | HBC_MDL00078164 | | | | | | | | | |
| P-20763 | 11/21/2013 | DUR Policy | HBC_MDL00191824 | HBC_MDL00191824 | | | | | | | | | |
| P-20764 | 5/17/2018 | DUR Notes; 10-031 Drug Utilization Review (DUR) Policy | GE_TL00004829 | GE_TL00004831 | | | | | | | | | |
| P-20765 | 6/3/2016 | Agenda and PowerPoint for TL calls | HBC_MDL00158840 | HBC_MDL00158848 | | | | | | | | | |
| P-20766 | 12/4/2016 | Weekly Notes; GESG_12_1_16; POA_Revised_Doerr_Signed_11. 2016; Controlled Drug Box Memo - 2017 Box; Temperature Monitoring Standard; Weekly Notes December 4; Period 5 Performance; Period 5 Trend; VOC Report we 12_3; we 12_4 Sales | HBC_MDL00059191 | HBC_MDL00059269 | | | | | | | | | |
| P-20767 | 6/6/2016 | RE: Q4 Team Leader Calls; Quarterly Team Leader Call; Quarterly Team Leader Meeting | GE_TL00001225 | GE_TL00001306 | | | | | | | | | |
| P-20768 | 6/3/2013 | Giant Eagle Pharmacy Controlled Substances Manual | HBC_MDL00032653 | HBC_MDL00032699 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------|--------------------|--|--|--|--|--|--|--|--|--|
| P-20769 | 2/24/2014 | RANNAZZISI MEMO ON SCHEDULED INVESTIGATION 10-27-09 | US-DEA-00056902 | US-DEA-00056915 | | | | | | | | | |
| P-20770 | 10/26/2009 | DEA Report of Investigation for Giant Eagle in Washington, PA | DEA-T1BCC-00001833 | DEA-T1BCC-00001845 | | | | | | | | | |
| P-20771 | 9/25/2020 | List of CFR code sections relating to Controlled Substance regulation and list of Pittsburgh District Office investigators and staff | DEA-T1BCC-00001825 | DEA-T1BCC-00001825 | | | | | | | | | |
| P-20772 | 10/12/2012 | DEA-NABP 2012*Invite Letters | US-DEA-00026067 | US-DEA-00026098 | | | | | | | | | |
| P-20773 | 8/13/2013 | DEA6 Case Closing and Cyclic Investigation of HBC Service Company 2013 | US-DEA-00030485 | US-DEA-00030501 | | | | | | | | | |
| P-20774 | 12/3/2014 | DEA 6 | US-DEA-00030618 | US-DEA-00030633 | | | | | | | | | |
| P-20775 | 1/11/2016 | DEA Report of Investigation for Giant Eagle Distribution Center in Freedom PA | DEA-T1BCC-00001846 | DEA-T1BCC-00001859 | | | | | | | | | |
| P-20776 | 12/17/2015 | RE: Daily HBC Suspicious Purchasing Report - 12/16/15 | HBC_MDL00080562 | HBC_MDL00080562 | | | | | | | | | |
| P-20777 | 1/15/2016 | FW: Daily HBC Suspicious Purchasing Report - 01/14/16 | HBC_MDL00057875 | HBC_MDL00057877 | | | | | | | | | |
| P-20778 | N/A | Video - What every prescriber should know about opioid morbidity and mortality | N/A | N/A | | | | | | | | | |
| P-20779 | 11/30/2018 | HBC Service Company's Responses to Plaintiffs' (First) Set of Combined Discovery Requests | N/A | N/A | | | | | | | | | |
| P-20780 | 1/10/2019 | George Chunderlik LinkedIn page | N/A | N/A | | | | | | | | | |
| P-20785 | 5/18/2009 | Report Re: In-depth regulatory investigation of WALGREEN CO., 28727 Oregon Rd., Perrysburg, OH 43551, DEA #RW0294493 | US-DEA-00033081 | US-DEA-00033107 | | | | | | | | | |
| P-20786 | 6/9/2015 | Report Re: Case Closing and Regulatory Investigation of WALGREENS CORPORATION - DEA# RW0294493 | US-DEA-00033064 | US-DEA-00033077 | | | | | | | | | |
| P-20787 | 5/25/2012 | INFO: Suspicious Drug process | WAGMDL01172574 | WAGMDL01172576 | | | | | | | | | |
| P-20788 | N/A | Steven Kneller CV and Performance Reviews | N/A | N/A | | | | | | | | | |
| P-20789 | 2/23/2013 | Email National Target Drug Good Faith Dispensing (TD GFD) Documents Attachments | WAGNYAG00006361 | WAGNYAG00006417 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-20790 | 3/10/2015 | Email Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances & Press Release Attachments | WAGMDL00502238 | WAGMDL00502260 | | | | | | | | | |
| P-20791 | 7/2/2015 | Email Re: Phone call Attachments Therapeutic Top 20 - Dr. 1 from Advanced Pain Center; Therapeutic Top 20 - Dr. 2 from Advanced Pain Center | WAGMDL00095721 | WAGMDL00095724 | | | | | | | | | |
| P-20792 | 8/17/2011 | Pharmacy Jurisprudence For Pharmacists in States with a Pharmacy Law Continuing Education (CE) requirement | WAGMDL00766972 | WAGMDL00766988 | | | | | | | | | |
| P-20793 | 12/1/2019 | Rx Fulfillment, Research Report | TCS00000196 | TCS00000281 | | | | | | | | | |
| P-20794 | 11/20/2019 | Email Inform: Walgreens Electronic Good Faith Dispensing (GFD) Pilot- Pharmacy Attachments Electronic Good Faith Dispensing Pilot Store List; Electronic Good Faith Dispensing (GFD) FAQs; Electronic Good Faith Dispensing Review Worksheet Job Aid | WAGMDL01037325 | WAGMDL01037340 | | | | | | | | | |
| P-20795 | 11/21/2019 | Re: Inform: Walgreens Electronic Good Faith Dispensing (GFD) Pilot- Pharmacy | WAGMDL01037322 | WAGMDL01037324 | | | | | | | | | |
| P-20796 | 11/9/2011 | Fw: Ohio Board of Pharmacy | WAGMDL00923236 | WAGMDL00923237 | | | | | | | | | |
| P-20797 | 10/1/2019 | Email REVIEW: Sept. Portfolio Slides for Team Tasha Attachment Sept 2019 Portfolio Review | WAGMDL01071830 | WAGMDL01071844 | | | | | | | | | |
| P-20798 | 2012 | Annual Performance Review (FY12) for Senior Managers, Review Period 9/1/2001 - 8/31/2012 | N/A | N/A | | | | | | | | | |
| P-20799 | 10/11/2012 | Fwd: Good Faith Dispensing - High Risk Products Discussion | WAGMDL01109078 | WAGMDL01109081 | | | | | | | | | |
| P-20800 | 3/17/2013 | Email March legal issues | WAGMDL00797345 | WAGMDL00797346 | | | | | | | | | |
| P-20801 | 4/8/2013 | FW: Target Drug Good Faith Dispensing Questions | WAGMDL00100054 | WAGMDL00100056 | | | | | | | | | |
| P-20803 | 6/30/2015 | RE: T-GFD Sheets | WAGMDL00045962 | WAGMDL00045963 | | | | | | | | | |
| P-20804 | 7/13/2015 | Controlled Substance Order Monitoring System Attachments | WAGMDL00750667 | WAGMDL00750696 | | | | | | | | | |
| P-20805 | 11/28/2017 | WALGREENS_STORE_13058_053 42 | WAGMDL00963995 | WAGMDL00963998 | | | | | | | | | |
| P-20806 | N/A | Julie DeMay CV | N/A | N/A | | | | | | | | | |
| P-20807 | N/A | Brian M. Joyce, RPh résumé | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-20808 | 4/1/2013 | RE: Drug Abuse Powerpoint | WAGMDL01113458 | WAGMDL01113482 | | | | | | | | | |
| P-20809 | 1/15/2016 | FW: The rest of your presentation stuff | BOP_MDL026939 | BOP_MDL027055 | | | | | | | | | |
| P-20810 | N/A | 4729-5-20 Prospective drug utilization review drafts | N/A | N/A | | | | | | | | | |
| P-20811 | 8/11/2011 | Ohio Board New/Concerns | WAGMDL00923252 | WAGMDL00923253 | | | | | | | | | |
| P-20812 | 9/7/2011 | Fw: OH Conference Call - Thursday 9/8 at 2pm EST - call in # 1-1719-457-6443 pc 148371-OARRS update/prep for 9/12 public hearing | WMT_MDL_000187706 | WMT_MDL_000187739 | | | | | | | | | |
| P-20814 | 1/16/2013 | FW: Action Requested: NACDS DEA WG -- Code of Conduct Survey; Working Group Survey_Proposed Concepts WG Co-Chairs 1-16-13 | WAGMDL00496402 | WAGMDL00496418 | | | | | | | | | |
| P-20815 | 11/7/2013 | OARRS legislation introduced; HB 341 (Smith) 130th | WAGMDL00626214 | WAGMDL00626283 | | | | | | | | | |
| P-20816 | 9/24/2014 | RE: Pharmacy Operations and Care Committee Conference Call; A Pharmacy Pilot or Demonstration Research Project for a New Practice Model for Community Pharmacy; Pharmacist Educational Program: Satisfying DEA Standards When Dispensing Controlled Substances By Larry Cote, Quarles & Brady And The National Association of Chain Drug Stores; Pharmacy Technician Educational Program: Satisfying DEA Standards For Controlled Substances; Store Manager Educational Program: DEA Compliance Overview; Re: Follow-Up Pharmacy Operations & Care Committee Call | WAGMDL01041660 | WAGMDL01041713 | | | | | | | | | |
| P-20817 | 2/18/2021 | Shelley Tustison Employment History | WMT_MDL_001216863 | WMT_MDL_001216876 | | | | | | | | | |
| P-20818 | 3/4/2015 | RE: LA Board Hearing, 10-1109 RAYVILLE, LA | WMT_MDL_000532251 | WMT_MDL_00053254 | | | | | | | | | |
| P-20819 | 7/23/2015 | FW: Consumer Complaint | WMT_MDL_001081218 | WMT_MDL_001081220 | | | | | | | | | |
| P-20820 | N/A | Excel Spreadsheet Personnel File Document | WMT_MDL_001216880 | WMT_MDL_001216880 | | | | | | | | | |
| P-20821 | 2012 | FY12 Annual Performance Evaluation | WMT_MDL_001216834 | WMT_MDL_001216835 | | | | | | | | | |
| P-20822 | 2013 | FY13 Annual Performance Evaluation | WMT_MDL_001216836 | WMT_MDL_001216837 | | | | | | | | | |
| P-20823 | 2/7/2014 | Offsite RFT Meeting Notes | WMT_MDL_000376833 | WMT_MDL_000376836 | | | | | | | | | |

| | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|
| P-20824 | 3/26/2013 | Professional judgment | WMT_MDL_000451381 | WMT_MDL_000451381 | | | | | | | | |
| P-20825 | 6/3/2016 | FW: Store #1951 Suspicious Order Remediation | WMT_MDL_001140980 | WMT_MDL_001140982 | | | | | | | | |
| P-20826 | 11/26/2014 | RE: Controls from a local DR | WMT_MDL_000734379 | WMT_MDL_000734381 | | | | | | | | |
| P-20827 | 2/6/2015 | FW: Dr. Diamond (Pain Management Clinic) | WMT_MDL_001085004 | WMT_MDL_001085005 | | | | | | | | |
| P-20828 | 8/10/2018 | Dr. Diamond Investigation Document | N/A | N/A | | | | | | | | |
| P-20829 | 8/7/2013 | FW: CO. Board heads up; Board Policy 40-11 (Proposed) | WMT_MDL_000649191 | WMT_MDL_000649195 | | | | | | | | |
| P-20830 | 9/8/2017 | GI Concern | WMT_MDL_000290046 | WMT_MDL_000290046 | | | | | | | | |
| P-20831 | 11/23/2017 | FW: SBOP Presentation of Opioid Crisis; CS Red Flags Handout from SBOP | WMT_MDL_000649670 | WMT_MDL_000649675 | | | | | | | | |
| P-20832 | 2011 | FY11 Director Performance Eval | WMT_MDL_001215431 | WMT_MDL_001215433 | | | | | | | | |
| P-20833 | 2014 | FY14 Director Performance Eval | WMT_MDL_001215439 | WMT_MDL_001215441 | | | | | | | | |
| P-20834 | 3/25/2013 | OH Recaps; OH Recap Diversion Training Trip; OH HW Diversion Training Feedback Form; OH AP Recap Diversion Training Feedback Form | WMT_MDL_000300645 | WMT_MDL_000300651 | | | | | | | | |
| P-20835 | 3/8/2013 | Emailing: _2013_Investigations One Team RPH; _2013_Investigations One Team RPH | WMT_MDL_000458944 | WMT_MDL_000458967 | | | | | | | | |
| P-20836 | 11/11/2010 | Incident Closure, Store 3860, Youngstown, OH; 3860 | WMT_MDL_000480896 | WMT_MDL_000480897 | | | | | | | | |
| P-20837 | 3/26/2014 | 1510 Florence, KY , Lorazepam audit results; 1510 | WMT_MDL_000899282 | WMT_MDL_000899285 | | | | | | | | |
| P-20838 | 9/15/2012 | Oxy Report; CII Emergency Process; Oxy News Article Walgreens | WMT_MDL_000530312 | WMT_MDL_000530316 | | | | | | | | |
| P-20839 | 3/27/2013 | FW: Oxycodone and PMP Information; Oxycodone 30 mg Posting; Mandatory Oxycodone Immediate Release 30 mg PMP Check FAQs Final; MHWD CS Order Review Process; MHWD CS Order Review Process; Emergency CII Change Posting; c2_whse_orderform | WMT_MA_000001162 | WMT_MA_000001177 | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-20840 | 7/25/2012 | FW: CS Documents; CS Order Exception Response; MHWD CS Order Review Process; MHWD Emergency CII Order Review Process; POM 1316 PMPs 030211 (branded) update 7-23-12; Mandatory Oxycodone Immediate Release 30 mg PMP Check FAQs v.1; CII Prescription Tool Kit v.1; pmpstatusmap2012; Mandatory Oxycodone Immediate Release 30 mg PMP Check FAQs | WMT_MDL_000026674 | WMT_MDL_000026691 | | | | | | | | | |
| P-20841 | 9/24/2012 | RE: Over 20 Report 9.20.12 | WMT_MDL_000458924 | WMT_MDL_000458926 | | | | | | | | | |
| P-20842 | 9/24/2012 | FW: Over 20 Report 9.20.12 | WMT_MDL_000459539 | WMT_MDL_000459541 | | | | | | | | | |
| P-20843 | 9/24/2012 | RE: CII Utilization Review | WMT_MDL_001214168 | WMT_MDL_001214169 | | | | | | | | | |
| P-20844 | 10/11/2012 | FW: CII Reporting / Utilization Review; Oxy Tracking Report of Stores Sent 10-9-12 | WMT_MDL_000480060 | WMT_MDL_000480063 | | | | | | | | | |
| P-20845 | 12/17/2012 | Over 20 Report | WMT_MDL_000457887 | WMT_MDL_000457888 | | | | | | | | | |
| P-20846 | 2/22/2014 | RE: Store #1255, Laurinburg, NC- Over 20 Drug Orders | WMT_MDL_000916399 | WMT_MDL_000916401 | | | | | | | | | |
| P-20847 | 10/31/2012 | Yellow: Refuse to Fill-Oct 2012; RTF-Oct 2012 | WMT_MDL_000458935 | WMT_MDL_000458936 | | | | | | | | | |
| P-20848 | 7/29/2013 | RE: Refusal to Fill follow up | WMT_MDL_000459510 | WMT_MDL_000459512 | | | | | | | | | |
| P-20849 | 3/7/2016 | RE: RE: Refusal to fill reporting | WMT_MDL_000484702 | WMT_MDL_000484704 | | | | | | | | | |
| P-20850 | 2/9/2015 | Re: Filling C2 electronic prescriptions and refusal to fill web forms | WMT_MDL_000699036 | WMT_MDL_000699039 | | | | | | | | | |
| P-20851 | 1/12/2011 | FW: Activity Log Insights | WMT_MDL_000194228 | WMT_MDL_000194229 | | | | | | | | | |
| P-20852 | 2/13/2015 | RE: RTF Jan 2015 sorted by State and Market | WMT_MDL_000232072 | WMT_MDL_000232072 | | | | | | | | | |
| P-20853 | N/A | Caroline Riogi employment history | WMT_MDL_001217165 | WMT_MDL_001217165 | | | | | | | | | |
| P-20854 | 3/2/2015 | RE: Merchandise Hotline Incident #: MHINCD011560780 | WMT_MDL_000617117 | WMT_MDL_000617119 | | | | | | | | | |
| P-20855 | 12/12/2013 | FW: c2_red_flags | WMT_MDL_000096555 | WMT_MDL_000096561 | | | | | | | | | |
| P-20856 | 5/20/2016 | Store #3802 Suspicious Order Remediation | WMT_MDL_001203792 | WMT_MDL_001203794 | | | | | | | | | |
| P-20857 | 10/20/2017 | RE: poke holes | WMT_MDL_001012433 | WMT_MDL_001012434 | | | | | | | | | |
| P-20859 | 10/18/2010 | Email AP Presentation and Notes Attachments MHWD Orientation PP-Terry 10-01-10 PPT; H&W Asset Protection – Terry Crabb | WMT_MDL_000476412 | WMT_MDL_000476415 | | | | | | | | | |
| P-20863 | 11/24/2014 | FW: GI Update for Bob Attachment GI Update for Bob PPT | WMT_MDL_000266968 | WMT_MDL_000266969 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-20864 | 2013 | FY13 Annual Performance Evaluation (60/40) for John Oldfather | WMT_MDL_001212986 | WMT_MDL_001212996 | | | | | | | | | |
| P-20865 | 4/7/2010 | RE: Data Elements Attachment Data Elements | WMT_MDL_000468180 | WMT_MDL_000468181 | | | | | | | | | |
| P-20866 | 9/2/2011 | RE: Raw Data | WMT_MDL_000187320 | WMT_MDL_000187320 | | | | | | | | | |
| P-20867 | 11/3/2010 | Email Control Drug Exception Report 103110 Attachment Control Drug Exception Report 103110 | WMT_MDL_000043233 | WMT_MDL_000043234 | | | | | | | | | |
| P-20868 | 2/10/2012 | Email Club #4820 Attachment Oxy Fills from 01-01-12 through 02-10-12 | WMT_MDL_001188818 | WMT_MDL_001188820 | | | | | | | | | |
| P-20869 | 2/25/2012 | RE: Thinking of you!! | WMT_MDL_000281388 | WMT_MDL_000281391 | | | | | | | | | |
| P-20870 | N/A | rev_FDA Production_July 2020 | FDACDER2020_000001 | FDACDER2020_000654 | | | | | | | | | |
| P-20871 | N/A | rev_FDA Production_2019_08_07 | FDACDER2020_000655 | FDACDER2020_001160 | | | | | | | | | |
| P-20872 | N/A | rev_FDA Production_2019_08_31 | FDACDER2020_001161 | FDACDER2020_001581 | | | | | | | | | |
| P-20873 | N/A | rev_FDA Production_2020_09_30 | FDACDER2020_001582 | FDACDER2020_002029 | | | | | | | | | |
| P-20874 | N/A | rev_FDA Production_2020_10_21 | FDACDER2020_002030 | FDACDER2020_002630 | | | | | | | | | |
| P-20876 | 11/27/2020 | McKinsey Proposed Paying Pharmacy Companies Rebates for OxyContin Overdoses - NYT | N/A | N/A | | | | | | | | | |
| P-20877 | 11/18/2020 | US Bankruptcy Court Southern District of New York In re: Purdue Pharma, L.P., et al. | N/A | N/A | | | | | | | | | |
| P-20878 | 11/18/2020 | US Bankruptcy Court Southern District of New York In re: Purdue Pharma, L.P., et al. - Exhibits A thru J | N/A | N/A | | | | | | | | | |
| P-20879 | 11/18/2020 | US Bankruptcy Court Southern District of New York In re: Purdue Pharma, L.P., et al. - Exhibits K thru Q | N/A | N/A | | | | | | | | | |
| P-20880 | 11/18/2020 | US Bankruptcy Court Southern District of New York In re: Purdue Pharma, L.P., et al. - Exhibits R thru T | N/A | N/A | | | | | | | | | |
| P-20881 | 10/21/2020 | Purdue 2020 Plea Agreement - Exhibit B | N/A | N/A | | | | | | | | | |
| P-20882 | 10/21/2020 | Purdue 2020 Proposed Order in Bankruptcy Case | N/A | N/A | | | | | | | | | |
| P-20883 | 5/10/2007 | Purdue Medical Officer, Goldenheim Guilty Plea | N/A | N/A | | | | | | | | | |
| P-20884 | 5/10/2007 | Purdue President, Friedman Guilty Plea | N/A | N/A | | | | | | | | | |
| P-20885 | 5/31/2013 | Walgreens Fioricet Costs; MPU FAQ (2) | ALLERGAN_MDL_00993982 | ALLERGAN_MDL_00993986 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-20886 | 4/5/2012 | Email HW email search; Attachments Email DEA Activities, RE: Oxy Dr Research-- July | WMT_MDL_000239859 | WMT_MDL_000239864 | | | | | | | | | |
| P-20887 | 5/2/2012 | RE: Information We Discussed | WMT_MDL_000316539 | WMT_MDL_000316540 | | | | | | | | | |
| P-20888 | 7/3/2013 | FW: Oxycodone and Walgreens Article | WMT_MDL_000253457 | WMT_MDL_000253457 | | | | | | | | | |
| P-20889 | 9/20/2012 | Email Over 20 Report 9.20.12 | WMT_MDL_000415952 | WMT_MDL_000415952 | | | | | | | | | |
| P-20890 | 10/16/2013 | FW: Over 20 Report 10.16.13 Attachment Over 20 Report 10.16.13 | WMT_NV_000001588 | WMT_NV_000001590 | | | | | | | | | |
| P-20891 | 12/9/2013 | RE: Store #627, Dillon, SC-Over 20 Drug Orders | WMT_MDL_001148784 | WMT_MDL_001148786 | | | | | | | | | |
| P-20892 | 12/20/2013 | Email Conference call discussion for today at 4pm Attachment Fw: Store #627, Dillon, SC-Over 20 Drug Orders | WMT_MDL_001110389 | WMT_MDL_001110392 | | | | | | | | | |
| P-20893 | 12/25/2013 | Email FW: Over 20 Report 12 21 13 Attachment FW: Over 20 Report 12 21 13.xls | WMT_NV_000001539 | WMT_NV_000001540 | | | | | | | | | |
| P-20894 | 5/22/2015 | Re: 052215 RE: CR-Incident #: 000000042752071 | WMT_MDL_001074200 | WMT_MDL_001074205 | | | | | | | | | |
| P-20896 | 4/11/2012 | Re: Investigative Guidelines | WMT_MDL_000417849 | WMT_MDL_000417849 | | | | | | | | | |
| P-20900 | 3/12/2015 | 21-0402 Controlled Substance Monitoring (2015-03-12 to 2015-12-16) | WMT_MDL_000000963 | WMT_MDL_000000965 | | | | | | | | | |
| P-20901 | 12/16/2015 | 21-0402 Controlled Substance Monitoring (2015-12-16 to 2017-06-23) | WMT_MDL_000000966 | WMT_MDL_000000968 | | | | | | | | | |
| P-20902 | 6/23/2017 | 21-0402 Controlled Substance Monitoring (2017-06-23 to current) | WMT_MDL_000000969 | WMT_MDL_000000971 | | | | | | | | | |
| P-20903 | 2/10/2017 | H&W Weekly Update Week 2 | WMT_MDL_000001004 | WMT_MDL_000001005 | | | | | | | | | |
| P-20904 | 10/24/2017 | Press Release from McKesson | WMT_MDL_000002203 | WMT_MDL_000002205 | | | | | | | | | |
| P-20906 | 8/9/2017 | Buzzeo | WMT_MDL_000002717 | WMT_MDL_000002717 | | | | | | | | | |
| P-20907 | 1/18/2017 | FW: MCKESSON AGREES TO PAY RECORD \$150 MILLION SETTLEMENT FOR FAILURE TO REPORT SUSPICIOUS ORDERS OF PHARMACEUTICAL DRUGS | WMT_MDL_000002729 | WMT_MDL_000002731 | | | | | | | | | |
| P-20908 | 12/19/2017 | RE: Follow-up Materials - Controlled Substance Discussion | WMT_MDL_000003598 | WMT_MDL_000003599 | | | | | | | | | |
| P-20909 | 1/25/2016 | Reddwerks | WMT_MDL_000003683 | WMT_MDL_000003683 | | | | | | | | | |
| P-20910 | 1/11/2016 | RE: SOMP | WMT_MDL_000003862 | WMT_MDL_000003862 | | | | | | | | | |
| P-20911 | 2/19/2016 | Corp Rep -- FW: Areas of Focus - 2/16 - 2/19 | WMT_MDL_000003906 | WMT_MDL_000003907 | | | | | | | | | |
| P-20912 | 12/10/2015 | Controlled Substance Webinar Training | WMT_MDL_000003937 | WMT_MDL_000003938 | | | | | | | | | |
| P-20913 | 5/26/2016 | RE: SOM Cloud Data Document - Current Version ver. 1.3 | WMT_MDL_000004624 | WMT_MDL_000004626 | | | | | | | | | |

| | | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|--|
| P-20915 | 10/5/2017 | Buzzco SOM Algorithm | WMT_MDL_000005896 | WMT_MDL_000005896 | | | | | | | | | | |
| P-20916 | 6/30/2017 | RE: Thursday, July 6 | WMT_MDL_000006197 | WMT_MDL_000006197 | | | | | | | | | | |
| P-20920 | 8/9/2017 | 10RE: SOM Alerts | WMT_MDL_000007345 | WMT_MDL_000007345 | | | | | | | | | | |
| P-20921 | 1/5/2018 | RE: SOM Talking Points & FAQs Updated Jan. 5 | WMT_MDL_000007350 | WMT_MDL_000007354 | | | | | | | | | | |
| P-20923 | 1/26/2017 | Oxy List Update | WMT_MDL_000008070 | WMT_MDL_000008070 | | | | | | | | | | |
| P-20924 | 9/27/2012 | RE: CII utilization review | WMT_MDL_000008089 | WMT_MDL_000008090 | | | | | | | | | | |
| P-20925 | 1/16/2015 | RE: SOM Pilot at DC 6045 | WMT_MDL_000008147 | WMT_MDL_000008148 | | | | | | | | | | |
| P-20929 | 7/25/2014 | Practice Compliance Process | WMT_MDL_000008377 | WMT_MDL_000008382 | | | | | | | | | | |
| P-20930 | 6/10/2014 | RE: Cut Report from D.C. | WMT_MDL_000008419 | WMT_MDL_000008419 | | | | | | | | | | |
| P-20931 | 8/28/2015 | RE: Email Notification of SOM Eval | WMT_MDL_000008688 | WMT_MDL_000008689 | | | | | | | | | | |
| P-20933 | 5/23/2016 | [Updated] "SOM Eval - Add CS schedule for Top 3 Docs" | WMT_MDL_000009030 | WMT_MDL_000009030 | | | | | | | | | | |
| P-20935 | 12/29/2014 | Fwd: Control Drug Monitoring | WMT_MDL_000009075 | WMT_MDL_000009075 | | | | | | | | | | |
| P-20936 | 11/23/2014 | SOM overview; Overview of SOM Progress | WMT_MDL_000009158 | WMT_MDL_000009160 | | | | | | | | | | |
| P-20937 | 3/2/2016 | Emailing: 6045 OH Records 2015 May - Present | WMT_MDL_000009161 | WMT_MDL_000009161 | | | | | | | | | | |
| P-20938 | 8/1/2011 | FW: Emailing: Suspicious Order Monitoring | WMT_MDL_000009183 | WMT_MDL_000009183 | | | | | | | | | | |
| P-20939 | 9/30/2013 | Re: Reddwerks Inquiries | WMT_MDL_000009224 | WMT_MDL_000009225 | | | | | | | | | | |
| P-20940 | 3/16/2015 | RE: Suspicious Order Monitoring - Future | WMT_MDL_000009267 | WMT_MDL_000009267 | | | | | | | | | | |
| P-20941 | 1/14/2015 | FW: Quantity cuts | WMT_MDL_000009277 | WMT_MDL_000009277 | | | | | | | | | | |
| P-20942 | 7/23/2012 | FW: CII Limits | WMT_MDL_000009319 | WMT_MDL_000009320 | | | | | | | | | | |
| P-20943 | 7/23/2012 | FW: CII Ordering 07/23/12 | WMT_MDL_000009321 | WMT_MDL_000009323 | | | | | | | | | | |
| P-20944 | 10/28/2014 | SOM Strategy Deck - Updated; SOM Strategy | WMT_MDL_000009385 | WMT_MDL_000009386 | | | | | | | | | | |
| P-20945 | 8/14/2014 | Over 20 Report 8.14.14 | WMT_MDL_000009393 | WMT_MDL_000009393 | | | | | | | | | | |
| P-20946 | 4/3/2014 | Over 20 Report 4.3.14 | WMT_MDL_000009397 | WMT_MDL_000009397 | | | | | | | | | | |
| P-20947 | 2/12/2013 | Over 20 Report 2.12.13 | WMT_MDL_000009423 | WMT_MDL_000009423 | | | | | | | | | | |
| P-20948 | 7/25/2012 | CS POA | WMT_MDL_000009427 | WMT_MDL_000009427 | | | | | | | | | | |
| P-20949 | 6/5/2013 | FW: May 405-1 | WMT_MDL_000009437 | WMT_MDL_000009437 | | | | | | | | | | |
| P-20954 | 1/30/2014 | Methodology for flagging of store orders_30JAN; Walmart - Methodology for flagging of store orders - Jan 30 2014 | WMT_MDL_000009629 | WMT_MDL_000009630 | | | | | | | | | | |
| P-20955 | 1/24/2014 | RE: The raw data along with questions | WMT_MDL_000009635 | WMT_MDL_000009638 | | | | | | | | | | |
| P-20956 | 10/16/2014 | Over 20/50 Report; Over 20 Report 10.16.14 | WMT_MDL_000009807 | WMT_MDL_000009807 | | | | | | | | | | |
| P-20957 | 10/28/2014 | SOM Threshold & Order files | WMT_MDL_000009819 | WMT_MDL_000009819 | | | | | | | | | | |
| P-20958 | 9/4/2013 | Investigation Info | WMT_MDL_000009834 | WMT_MDL_000009834 | | | | | | | | | | |
| P-20959 | 10/15/2013 | Agenda | WMT_MDL_000009838 | WMT_MDL_000009838 | | | | | | | | | | |
| P-20960 | 10/14/2013 | RE: Meeting Notes - Please Review | WMT_MDL_000009872 | WMT_MDL_000009874 | | | | | | | | | | |
| P-20961 | 7/3/2013 | Over 20 Report 7.3.13 | WMT_MDL_000009987 | WMT_MDL_000009988 | | | | | | | | | | |
| P-20962 | 7/30/2012 | Health and Wellness Week 26 Recap | WMT_MDL_000010215 | WMT_MDL_000010215 | | | | | | | | | | |
| P-20963 | 11/8/2013 | Reporting Flow Chart.vsd | WMT_MDL_000010287 | WMT_MDL_000010287 | | | | | | | | | | |
| P-20965 | 11/30/2010 | 21-0402 Controlled Substance Monitoring (2010-12-01 to 2014- 10-08) | WMT_MDL_000011106 | WMT_MDL_000011106 | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-20966 | 10/8/2014 | 21-0402 Controlled Substance Monitoring (2014-10-08 to 2015-03-12) | WMT_MDL_000011107 | WMT_MDL_000011109 | | | | | | | | | |
| P-20969 | 10/3/2014 | FW: Logistics SOM webform; Webform elements July 2014 | WMT_MDL_000011178 | WMT_MDL_000011182 | | | | | | | | | |
| P-20971 | 3/30/2017 | RE: WV call follow up | WMT_MDL_000011626 | WMT_MDL_000011627 | | | | | | | | | |
| P-20972 | 10/24/2014 | SOM Interim Process - Launch Oct 27 | WMT_MDL_000011656 | WMT_MDL_000011656 | | | | | | | | | |
| P-20975 | 9/27/2012 | CII utilization review | WMT_MDL_000012194 | WMT_MDL_000012194 | | | | | | | | | |
| P-20976 | 11/8/2013 | Reporting Flow Chart | WMT_MDL_000012678 | WMT_MDL_000012678 | | | | | | | | | |
| P-20977 | 4/5/2011 | Walmart Health & Wellness Distribution Chart | WMT_MDL_000012737 | WMT_MDL_000012737 | | | | | | | | | |
| P-20978 | 5/1/2007 | 07-6045 Walmart Pharmacy Logistics Organizational Chart | WMT_MDL_000012771 | WMT_MDL_000012771 | | | | | | | | | |
| P-20979 | 8/19/2014 | Interim SOM Processes | WMT_MDL_000016070 | WMT_MDL_000016070 | | | | | | | | | |
| P-20981 | 2/18/2015 | RE: Sr. Controlled Substances Analyst - For Review | WMT_MDL_000016104 | WMT_MDL_000016105 | | | | | | | | | |
| P-20982 | 3/10/2010 | Re: NABP VAWD Mtg. | WMT_MDL_000016173 | WMT_MDL_000016174 | | | | | | | | | |
| P-20983 | 4/14/2015 | RE: Archer | WMT_MDL_000016206 | WMT_MDL_000016207 | | | | | | | | | |
| P-20984 | 9/3/2014 | Meeting notes 20140902 | WMT_MDL_000016232 | WMT_MDL_000016232 | | | | | | | | | |
| P-20985 | 9/4/2014 | RE: Walmart Stores East, LP, Bentonville, AR - 1st Corporate P&P Review Report | WMT_MDL_000016251 | WMT_MDL_000016254 | | | | | | | | | |
| P-20986 | 11/21/2014 | RE: Logistics SOM webform | WMT_MDL_000016261 | WMT_MDL_000016263 | | | | | | | | | |
| P-20987 | 11/5/2014 | SOM web forms | WMT_MDL_000016313 | WMT_MDL_000016313 | | | | | | | | | |
| P-20989 | 8/22/2015 | Pharmacy Projects Update wk 29 | WMT_MDL_000016554 | WMT_MDL_000016554 | | | | | | | | | |
| P-20990 | 10/17/2014 | Pharmacy Update | WMT_MDL_000016631 | WMT_MDL_000016634 | | | | | | | | | |
| P-20991 | 9/19/2014 | RE: Som position | WMT_MDL_000016686 | WMT_MDL_000016687 | | | | | | | | | |
| P-20992 | 9/3/2014 | RE: Walmart Stores East, LP, Bentonville, AR - 1st Corporate P&P Review Report | WMT_MDL_000016690 | WMT_MDL_000016693 | | | | | | | | | |
| P-20993 | 9/21/2015 | RE: SOM Evaluation Notifications | WMT_MDL_000016816 | WMT_MDL_000016816 | | | | | | | | | |
| P-20995 | 8/30/2016 | RE: Reddwerks list | WMT_MDL_000017434 | WMT_MDL_000017435 | | | | | | | | | |
| P-20996 | 7/26/2016 | RE: RE: updates | WMT_MDL_000017458 | WMT_MDL_000017459 | | | | | | | | | |
| P-20997 | 7/1/2013 | FW: Oxy from 6045 | WMT_MDL_000017502 | WMT_MDL_000017502 | | | | | | | | | |
| P-20998 | 7/14/2014 | Policy to be Covered in Today's Call | WMT_MDL_000017510 | WMT_MDL_000017510 | | | | | | | | | |
| P-20999 | 3/13/2014 | RE: Reddwerks Order Alerts | WMT_MDL_000017565 | WMT_MDL_000017567 | | | | | | | | | |
| P-21000 | 1/14/2013 | DVP Template EBU Strategy Meeting FY13 | WMT_MDL_000017581 | WMT_MDL_000017582 | | | | | | | | | |
| P-21001 | 10/16/2014 | Over 20/50 Report | WMT_MDL_000018858 | WMT_MDL_000018858 | | | | | | | | | |
| P-21002 | 10/16/2014 | RE: Over 20/50 Report | WMT_MDL_000018862 | WMT_MDL_000018863 | | | | | | | | | |
| P-21004 | 7/10/2013 | Look what I found | WMT_MDL_000019125 | WMT_MDL_000019125 | | | | | | | | | |
| P-21005 | 1/3/2014 | Order of Interest Investigation Form Jan 3 | WMT_MDL_000019182 | WMT_MDL_000019184 | | | | | | | | | |
| P-21006 | 5/14/2015 | FW: Updated SOM Overview May 2015.1 | WMT_MDL_000019339 | WMT_MDL_000019339 | | | | | | | | | |
| P-21007 | 8/25/2014 | SOM meeting with Jim | WMT_MDL_000019443 | WMT_MDL_000019443 | | | | | | | | | |
| P-21008 | 9/11/2014 | Re: Per your call | WMT_MDL_000019447 | WMT_MDL_000019448 | | | | | | | | | |
| P-21010 | 5/8/2015 | Email from Chad Ducote to Michael Stephenson | WMT_MDL_000020060 | WMT_MDL_000020061 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-21011 | 8/10/2015 | RE: Project ID 28098 - Walmart - 62128 - Drug Tracking | WMT_MDL_000020368 | WMT_MDL_000020368 | | | | | | | | | |
| P-21012 | 7/6/2015 | Email between Roxy Reed and Miranda Johnson re Drug Tracking | WMT_MDL_000020529 | WMT_MDL_000020531 | | | | | | | | | |
| P-21013 | 10/14/2015 | RE: Store 3140 | WMT_MDL_000020718 | WMT_MDL_000020718 | | | | | | | | | |
| P-21015 | 12/6/2012 | QI Update Divisional Meeting 12 4 12 vfinal | WMT_MDL_000021092 | WMT_MDL_000021099 | | | | | | | | | |
| P-21016 | 1/31/2018 | RE: Suspicious Order Monitoring | WMT_MDL_000021115 | WMT_MDL_000021117 | | | | | | | | | |
| P-21017 | 1/16/2017 | FW: Oxy/APAP OS Strategy | WMT_MDL_000021571 | WMT_MDL_000021571 | | | | | | | | | |
| P-21018 | 10/23/2015 | FW: oxy 10 and 20 | WMT_MDL_000021669 | WMT_MDL_000021670 | | | | | | | | | |
| P-21020 | 10/5/2010 | Letter to Patsy Little Re: Side Letter for change to Walmart Vendor Agreement dated December 14, 1999 | WMT_MDL_000021801 | WMT_MDL_000021802 | | | | | | | | | |
| P-21021 | 11/4/2015 | FW: oxy 10 and 20 | WMT_MDL_000021921 | WMT_MDL_000021922 | | | | | | | | | |
| P-21024 | 2/24/2016 | FW: State of Ohio Board of Pharmacy | WMT_MDL_000022799 | WMT_MDL_000022802 | | | | | | | | | |
| P-21025 | 8/19/2014 | REVIEW - Interim SOM Processes | WMT_MDL_000022832 | WMT_MDL_000022833 | | | | | | | | | |
| P-21026 | 11/16/2009 | Stand Alone Offer between Actavis and Walmart re Oxycodone Hydrochloride Controlled-Release Tablets | WMT_MDL_000025225 | WMT_MDL_000025226 | | | | | | | | | |
| P-21028 | 8/8/2018 | Proposal by Apotex Advanced Generics to Walmart for Oxycodone Tablets | WMT_MDL_000025550 | WMT_MDL_000025550 | | | | | | | | | |
| P-21029 | 8/23/2012 | Letter to Patsy Little from Ginger Collier regarding a price adjustment for Methadone Hydrochloride and Oxycodone HCl tablets | WMT_MDL_000025900 | WMT_MDL_000025900 | | | | | | | | | |
| P-21030 | 12/20/2005 | Letter to David Badeen from Vincent Kaiman regarding price decrease | WMT_MDL_000025989 | WMT_MDL_000025990 | | | | | | | | | |
| P-21033 | 11/7/2014 | September_Summary_Final_Draft - October updates mkj | WMT_MDL_000026982 | WMT_MDL_000026988 | | | | | | | | | |
| P-21035 | 4/27/2015 | Areas of Focus - Week 13 | WMT_MDL_000027961 | WMT_MDL_000027962 | | | | | | | | | |
| P-21037 | 12/23/2014 | November_HW_Compliance_Scorecard | WMT_MDL_000027994 | WMT_MDL_000027999 | | | | | | | | | |
| P-21038 | 3/1/2016 | 6045 OH Records 2011 | WMT_MDL_000028014 | WMT_MDL_000028014 | | | | | | | | | |
| P-21041 | 8/27/2014 | Corp RepRE: SOM Reqs | WMT_MDL_000028599 | WMT_MDL_000028599 | | | | | | | | | |
| P-21044 | 10/22/2015 | RE: Stores Needing Threshold Evaluation | WMT_MDL_000028865 | WMT_MDL_000028866 | | | | | | | | | |
| P-21045 | 12/4/2014 | Step_2_Threshold_Calc | WMT_MDL_000029318 | WMT_MDL_000029318 | | | | | | | | | |
| P-21051 | 1/4/2018 | RE: Meeting with Special Assignment Pharmacist | WMT_MDL_000029545 | WMT_MDL_000029547 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-21053 | 9/28/2017 | Emailing: Prescriber Review pp template_update, Prescriber Review Process_Analyst, SOM Incident Process, Archer Reports Process, Controlled Substances Team Process Documentation Prescriber Review Checklist | WMT_MDL_000030095 | WMT_MDL_000030095 | | | | | | | | | |
| P-21054 | 1/28/2015 | RE: Over 20 Report | WMT_MDL_000030175 | WMT_MDL_000030177 | | | | | | | | | |
| P-21055 | 1/27/2015 | FW: Over 20 Report | WMT_MDL_000030184 | WMT_MDL_000030185 | | | | | | | | | |
| P-21057 | 12/19/2017 | RE: Industry Letter | WMT_MDL_000032595 | WMT_MDL_000032595 | | | | | | | | | |
| P-21059 | 8/1/2012 | Re: Excess CS Orders | WMT_MDL_000033418 | WMT_MDL_000033424 | | | | | | | | | |
| P-21060 | 11/16/2016 | POM Alerts | WMT_MDL_000034339 | WMT_MDL_000034340 | | | | | | | | | |
| P-21061 | 3/30/2016 | Control Flow | WMT_MDL_000034546 | WMT_MDL_000034546 | | | | | | | | | |
| P-21062 | 7/25/2012 | FW: CS Discussion | WMT_MDL_000037807 | WMT_MDL_000037808 | | | | | | | | | |
| P-21066 | 5/3/2017 | RE: Logistics Order Routing Project | WMT_MDL_000041598 | WMT_MDL_000041599 | | | | | | | | | |
| P-21067 | 5/30/2017 | POM 1311 March 292017 | WMT_MDL_000041628 | WMT_MDL_000041636 | | | | | | | | | |
| P-21069 | 10/24/2014 | Email 405 report DC 6045- Sept. | WMT_MDL_000042782 | WMT_MDL_000042782 | | | | | | | | | |
| P-21070 | 7/8/2013 | June 405-1 Report - email between Donna Auldridge, Greg Beam, Terry Crabb, George Chapman & Kristy Sprull re Store 4264 (Oro Valley) significant increase in Oxy 15 | WMT_MDL_000042794 | WMT_MDL_000042794 | | | | | | | | | |
| P-21071 | 8/23/2015 | Corp Rep | WMT_MDL_000042877 | WMT_MDL_000042877 | | | | | | | | | |
| P-21090 | 7/20/2015 | POM 1703 | WMT_MDL_000043026 | WMT_MDL_000043034 | | | | | | | | | |
| P-21092 | 4/12/2017 | POM 1703 | WMT_MDL_000043044 | WMT_MDL_000043052 | | | | | | | | | |
| P-21113 | 2/15/2007 | Settlement Agreement | WMT_MDL_000043479 | WMT_MDL_000043483 | | | | | | | | | |
| P-21114 | 1/6/2009 | Settlement Agreement | WMT_MDL_000043484 | WMT_MDL_000043489 | | | | | | | | | |
| P-21116 | 5/15/2015 | Settlement Agreement | WMT_MDL_000043497 | WMT_MDL_000043506 | | | | | | | | | |
| P-21117 | 9/8/2015 | Settlement Agreement | WMT_MDL_000043507 | WMT_MDL_000043516 | | | | | | | | | |
| P-21119 | 12/27/2007 | DEA Letter from Joseph Rannazzisi to Walmart re duty to report suspicious orders | WMT_MDL_000043648 | WMT_MDL_000043649 | | | | | | | | | |
| P-21120 | 9/14/2007 | Fax from Walmart to DEA re Drug Diversion Review | WMT_MDL_000044441 | WMT_MDL_000044499 | | | | | | | | | |
| P-21121 | 7/23/2010 | Fax from Walmart to DEA re Drug Diversion Review | WMT_MDL_000045963 | WMT_MDL_000046007 | | | | | | | | | |
| P-21122 | 8/4/2010 | Fax from Walmart to DEA re Drug Diversion Review | WMT_MDL_000046008 | WMT_MDL_000046051 | | | | | | | | | |
| P-21123 | 11/4/2015 | USEC FY16 Q3 Nominations | WMT_MDL_000046434 | WMT_MDL_000046441 | | | | | | | | | |
| P-21124 | 12/13/2016 | H&W Compliance Oversight Meeting Materials - December 14, 2016 2:00-4:00pm, Soderquist Hall Conference Room | WMT_MDL_000046442 | WMT_MDL_000046442 | | | | | | | | | |
| P-21125 | 9/25/2012 | RE: Significant Compliance Issues | WMT_MDL_000047185 | WMT_MDL_000047187 | | | | | | | | | |
| P-21128 | 8/25/2014 | FW: Hydrocodone to CII meeting 8.25.14 | WMT_MDL_000047417 | WMT_MDL_000047417 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-21131 | 6/4/2015 | FW: 6.4.15 HW Compliance Focus Areas Deck | WMT_MDL_000047753 | WMT_MDL_000047754 | | | | | | | | | |
| P-21132 | 6/18/2014 | FW: SOM ask for FYE16 | WMT_MDL_000047826 | WMT_MDL_000047829 | | | | | | | | | |
| P-21133 | 7/24/2014 | SOM - DC processes | WMT_MDL_000047871 | WMT_MDL_000047871 | | | | | | | | | |
| P-21134 | 7/22/2014 | FW: SOM ISD Request Form | WMT_MDL_000048096 | WMT_MDL_000048107 | | | | | | | | | |
| P-21136 | 9/28/2015 | Areas of Focus - Week 35 | WMT_MDL_000048214 | WMT_MDL_000048215 | | | | | | | | | |
| P-21139 | 11/3/2014 | November_Oversight - Adobe Acrobat Professional | WMT_MDL_000048562 | WMT_MDL_000048598 | | | | | | | | | |
| P-21140 | 5/20/2015 | "4th Thursday" H&W Compliance Focus Areas deck | WMT_MDL_000049545 | WMT_MDL_000049545 | | | | | | | | | |
| P-21141 | 8/17/2012 | Prescription Drug Abuse and Diversion - Senator Harkin | WMT_MDL_000049685 | WMT_MDL_000049685 | | | | | | | | | |
| P-21143 | 7/26/2012 | RE: CS Discussion | WMT_MDL_000049760 | WMT_MDL_000049761 | | | | | | | | | |
| P-21145 | 11/1/2013 | CS Risk Assessment | WMT_MDL_000052996 | WMT_MDL_000052997 | | | | | | | | | |
| P-21146 | 11/8/2013 | Practice Compliance update - 11-12-2013 Phyllis Deep dive | WMT_MDL_000053017 | WMT_MDL_000053017 | | | | | | | | | |
| P-21147 | 8/18/2015 | 6045 Threshold File | WMT_MDL_000053351 | WMT_MDL_000053352 | | | | | | | | | |
| P-21148 | 3/6/2018 | 6045 DEA SOM reports | WMT_MDL_000053813 | WMT_MDL_000053815 | | | | | | | | | |
| P-21149 | 12/4/2007 | Email between Jimmie Sherl, Mike Mullin, Monty Mason & Susanne Hiland re DEA scheduled visit of DC 6045 on 12/5/2007 | WMT_MDL_000054021 | WMT_MDL_000054022 | | | | | | | | | |
| P-21150 | 9/17/2014 | FW: DEA at DC 6028 | WMT_MDL_000054651 | WMT_MDL_000054653 | | | | | | | | | |
| P-21152 | 3/1/2012 | FW: | WMT_MDL_000054729 | WMT_MDL_000054731 | | | | | | | | | |
| P-21153 | 11/30/2017 | Corp RepDEA SOM reports | WMT_MDL_000055271 | WMT_MDL_000055271 | | | | | | | | | |
| P-21154 | 12/7/2018 | FY15 Annual Performance Evaluation for Miranda Johnson | WMT_MDL_000055406 | WMT_MDL_000055432 | | | | | | | | | |
| P-21155 | 12/11/2018 | Roxanne Reed Performance Evaluations | WMT_MDL_000056046 | WMT_MDL_000056076 | | | | | | | | | |
| P-21194 | 9/27/2010 | RE: DEA Audit at DC 6013 | WMT_MDL_000057259 | WMT_MDL_000057260 | | | | | | | | | |
| P-21195 | 1/2/2019 | FY12 Annual Performance Evaluation (50/40/10) for Gregory Beam | WMT_MDL_000057274 | WMT_MDL_000057362 | | | | | | | | | |
| P-21196 | 4/23/2013 | Thanks for stopping by | WMT_MDL_000058522 | WMT_MDL_000058522 | | | | | | | | | |
| P-21204 | 8/29/2013 | Sept 3 V2 | WMT_MDL_000062667 | WMT_MDL_000062674 | | | | | | | | | |
| P-21207 | 1/26/2016 | Cover Note Objective_18 | WMT_MDL_000067537 | WMT_MDL_000067541 | | | | | | | | | |
| P-21208 | 12/21/2015 | FW: please take a look | WMT_MDL_000067542 | WMT_MDL_000067543 | | | | | | | | | |
| P-21226 | 7/30/2012 | POM 1002 - Rx Flow v5.1 eff 7-30-2012 to 1-23-2014 | WMT_MDL_000068598 | WMT_MDL_000068599 | | | | | | | | | |
| P-21228 | 3/31/2009 | POM 1311 - Proper Prescriber Patient Relationship v1.1 eff 3-31-2009 to 1-26-2010 | WMT_MDL_000069077 | WMT_MDL_000069079 | | | | | | | | | |
| P-21236 | 3/28/2011 | POM 1311 - Proper Prescriber Patient Relationship v3.1 eff 3-28-2011 to 3-29-2011 | WMT_MDL_000069117 | WMT_MDL_000069120 | | | | | | | | | |
| P-21237 | 3/29/2011 | POM 1311 - Proper Prescriber Patient Relationship v4.1 eff 3-29-2011 to 4-7-2011 | WMT_MDL_000069121 | WMT_MDL_000069124 | | | | | | | | | |
| P-21470 | 8/4/2017 | PI 14 - Retail Services Program Summary WK27 | WMT_MDL_000001101 | WMT_MDL_000001103 | | | | | | | | | |
| P-21471 | 1/28/2016 | Email re SOM Review and Kickoff Meeting | WMT_MDL_000002544 | WMT_MDL_000002546 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-21473 | 9/27/2019 | Letter from K Hewitt to G Eyler | N/A | N/A | | | | | | | | | |
| P-21474 | 8/10/2018 | Letter from K Hewitt to B Benczkowski | N/A | N/A | | | | | | | | | |
| P-21477 | 1/3/2017 | Controlled Substance Dispensing Tool Kit | WMT_MDL_000001792 | WMT_MDL_000001814 | | | | | | | | | |
| P-21479 | 6/14/2017 | Re: GGPMD Meeting | WMT_MDL_000003908 | WMT_MDL_000003911 | | | | | | | | | |
| P-21480 | 11/29/2017 | SOM Ops Comm_mkjedits_11.10.17 | WMT_MDL_000004269 | WMT_MDL_000004269 | | | | | | | | | |
| P-21481 | 12/1/2017 | Suspicious Order Monitoring Talking Points & Frequently Asked Questions | WMT_MDL_000004272 | WMT_MDL_000004274 | | | | | | | | | |
| P-21483 | 12/15/2015 | Email Controlled Substances Webinar Training; Attachment Controlled Substance Webinar Training PPT | WMT_MDL_000004295 | WMT_MDL_000004296 | | | | | | | | | |
| P-21484 | 11/23/2015 | FW: Week 42: Conference Call Agenda Attachment Suspicious Order Monitoring and Controlled Substances Div B Meeting (FINAL) | WMT_MDL_000004528 | WMT_MDL_000004536 | | | | | | | | | |
| P-21486 | 12/1/2017 | RE: SOM Talking Points & FAQs Attachment Suspicious Order Monitoring Talking Points & Frequently Asked Questions (updated draft) | WMT_MDL_000004709 | WMT_MDL_000004712 | | | | | | | | | |
| P-21492 | 1/5/2018 | Email Update to SOM Talking Points & FAQs Attachment Suspicious Order Monitoring Talking Points & Frequently Asked Questions (updated draft) | WMT_MDL_000005329 | WMT_MDL_000005332 | | | | | | | | | |
| P-21493 | 12/14/2017 | RE: **Assistance Requested** D-38 Controlled Substance Order Investigation Attachment Suspicious Order Monitoring Talking Points & Frequently Asked Questions | WMT_MDL_000006356 | WMT_MDL_000006364 | | | | | | | | | |
| P-21497 | 1/15/2018 | RE: 3214-US Order Pending for Review | WMT_MDL_000007489 | WMT_MDL_000007493 | | | | | | | | | |
| P-21498 | N/A | Managed Schedule Report Distributions: DEA_SOM_Reports_IN | WMT_MDL_000009042 | WMT_MDL_000009042 | | | | | | | | | |
| P-21502 | 11/10/2017 | FW: Proposed Communication to the MHWDS on SOM Changes Which will Accompany the Link to the Recorded Training | WMT_MDL_000017012 | WMT_MDL_000017013 | | | | | | | | | |
| P-21503 | 11/9/2017 | Email Proposed Communication to the MHWDS on SOM Changes Which will Accompany the Link to the Recorded Training | WMT_MDL_000017037 | WMT_MDL_000017037 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-21505 | 11/15/2017 | RE: Webinar Attachment Ops_Training_SOM_Final PPT | WMT_MDL_000017427 | WMT_MDL_000017430 | | | | | | | | | |
| P-21507 | 6/20/2017 | RE: FY18/19/20 Future IT Needs | WMT_MDL_000018899 | WMT_MDL_000018900 | | | | | | | | | |
| P-21510 | 5/31/2007 | Controlled Substances: Corresponding Responsibility & Suspicious Order Monitoring PPT | WMT_MDL_000020256 | WMT_MDL_000020256 | | | | | | | | | |
| P-21511 | 12/15/2015 | Controlled Substances: Corresponding Responsibility & Suspicious Order Monitoring PPT | WMT_MDL_000020264 | WMT_MDL_000020264 | | | | | | | | | |
| P-21512 | 1/13/2016 | Controlled Substance Webinar Training PPT | WMT_MDL_000020266 | WMT_MDL_000020266 | | | | | | | | | |
| P-21513 | 4/8/2016 | Logistics GM Meeting Presentation PPT | WMT_MDL_000020270 | WMT_MDL_000020270 | | | | | | | | | |
| P-21517 | 6/23/2015 | RE: Review Oversight Committee Deck Attachment July 2015 Oversight Meeting PPT | WMT_MDL_000020330 | WMT_MDL_000020332 | | | | | | | | | |
| P-21518 | 11/10/2017 | RE: Webinar Attachment Ops_Training_SOM_Final PPT | WMT_MDL_000020614 | WMT_MDL_000020616 | | | | | | | | | |
| P-21523 | N/A | Technology proposal | WMT_MDL_000030527 | WMT_MDL_000030527 | | | | | | | | | |
| P-21525 | 8/31/2015 | FW: DEA Meeting Recap | WMT_MDL_000037817 | WMT_MDL_000037818 | | | | | | | | | |
| P-21533 | 8/4/2006 | Walmart Pharmacy DC 6045; To DEA Agent Carolyn Adams From Jimmie D. Sherl Operations Manager; Subject Drug Diversion Review | WMT_MDL_000046368 | WMT_MDL_000046420 | | | | | | | | | |
| P-21545 | 9/17/2014 | RE: ABC Questionnaire Reponses | WMT_MDL_000063712 | WMT_MDL_000063713 | | | | | | | | | |
| P-21550 | 11/14/2013 | Email SOMP - Logistics Leadership Update Attachment Controlled Substance Risk Assessment | WMT_MDL_000064365 | WMT_MDL_000064366 | | | | | | | | | |
| P-21557 | 6/30/2018 | POM 1322 Dispensing Limits for the Initial Fill for an Acute Condition | WMT_MDL_000069842 | WMT_MDL_000069844 | | | | | | | | | |
| P-21571 | 3/6/2020 | POM 1322 - Dispensing Limits FAQs | WMT_MDL_000071294 | WMT_MDL_000071298 | | | | | | | | | |
| P-21572 | 2012 | Pharmacy Facility Management Incentive Plan | WMT_MDL_000043526 | WMT_MDL_000043546 | | | | | | | | | |
| P-21574 | 2014 | Pharmacy Facility Management Incentive Plan | WMT_MDL_000043566 | WMT_MDL_000043584 | | | | | | | | | |
| P-21575 | 2015 | Pharmacy Facility Management Incentive Plan | WMT_MDL_000043585 | WMT_MDL_000043597 | | | | | | | | | |
| P-21576 | 2016 | Pharmacy Facility Management Incentive Plan | WMT_MDL_000043598 | WMT_MDL_000043612 | | | | | | | | | |
| P-21577 | 4/26/2016 | Pharmacy Facility Management Incentive Plan | WMT_MDL_000043613 | WMT_MDL_000043629 | | | | | | | | | |
| P-21578 | 8/1/2017 | Pharmacy Facility Management Incentive Plan | WMT_MDL_000043630 | WMT_MDL_000043646 | | | | | | | | | |
| P-21580 | 3/5/2005 | Pharmacy Management Pay Guidelines | WMT_MDL_000056348 | WMT_MDL_000056358 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------|--------------------|--|--|--|--|--|--|--|--|--|
| P-21587 | 2006 | Pharmacy Field Management (Salaried Exempt) Incentive Plan (excluding California) | WMT_MDL_000056423 | WMT_MDL_000056428 | | | | | | | | | |
| P-21627 | 10/31/2017 | RE: 2 Questions | WMT_MDL_000018943 | WMT_MDL_000018944 | | | | | | | | | |
| P-21628 | 4/15/2014 | RE: February Oversight Meeting Follow-up | WMT_MDL_000018993 | WMT_MDL_000018994 | | | | | | | | | |
| P-21632 | 11/8/2017 | Temp Responsibilities | WMT_MDL_000026428 | WMT_MDL_000026432 | | | | | | | | | |
| P-21633 | 11/6/2012 | Over 20 Report | WMT_MDL_000032882 | WMT_MDL_000032882 | | | | | | | | | |
| P-21635 | 7/17/2014 | Re: Job Valuation Questions | WMT_MDL_000038269 | WMT_MDL_000038270 | | | | | | | | | |
| P-21636 | 6/5/2014 | Suspicious Orders | WMT_MDL_000046588 | WMT_MDL_000046596 | | | | | | | | | |
| P-21640 | 10/14/2010 | RE: DEA Suspicious Order Reports | WMT_MDL_000055281 | WMT_MDL_000055282 | | | | | | | | | |
| P-21648 | 12/1/2016 | POM 1311 (2016-12-14 to 2017-01-06) | WMT_IN_AG_00000084 | WMT_IN_AG_00000089 | | | | | | | | | |
| P-21651 | 1/10/2018 | Opioid Stewardship Script (2018-01-10 to 2018-01-12) | WMT_IN_AG_00000653 | WMT_IN_AG_00000658 | | | | | | | | | |
| P-21659 | 3/6/2020 | POM 1323 - POM 1311 FAQs Corresponding Responsibility and Refusal to Fill as of 2020-3-6 | WMT_MDL_000071299 | WMT_MDL_000071302 | | | | | | | | | |
| P-21660 | 1/9/2017 | POM 1311 - FAQs v1 2017-1-6 to 2017-1-9 | WMT_MDL_000071306 | WMT_MDL_000071310 | | | | | | | | | |
| P-21664 | 12/3/2014 | SOM - Archer | WMT_MDL_000009489 | WMT_MDL_000009491 | | | | | | | | | |
| P-21665 | 1/21/2010 | Walmart Produced Document | WMT_MDL_000012752 | WMT_MDL_000012752 | | | | | | | | | |
| P-21666 | 8/19/2015 | 2015 Distributor Briefing | WMT_MDL_000043650 | WMT_MDL_000043788 | | | | | | | | | |
| P-21670 | 1/22/2019 | 30(b)(6) Binder | N/A | N/A | | | | | | | | | |
| P-21671 | 42969 | XMPP, 2 Users, 50 Messages, 191 Minutes | WMT_MDL_000002209 | WMT_MDL_000002211 | | | | | | | | | |
| P-21672 | 1/18/2017 | FW: MCKESSON AGREES TO PAY RECORD \$150 MILLION SETTLEMENT FOR FAILURE TO REPORT SUSPICIOUS ORDERS OF PHARMACEUTICAL DRUGS | WMT_MDL_000002702 | WMT_MDL_000002704 | | | | | | | | | |
| P-21674 | 7/25/2012 | Controlled Substance Order Exception Response | WMT_MDL_000009478 | WMT_MDL_000009479 | | | | | | | | | |
| P-21675 | 10/21/2014 | SOM Strategy PPT | WMT_MDL_000011128 | WMT_MDL_000011129 | | | | | | | | | |
| P-21676 | 3/30/2017 | RE: WV call follow up | WMT_MDL_000011645 | WMT_MDL_000011645 | | | | | | | | | |
| P-21678 | 4/5/2017 | RE: Procedures | WMT_MDL_000016188 | WMT_MDL_000016188 | | | | | | | | | |
| P-21679 | 6/19/2014 | DC Flow | WMT_MDL_000016191 | WMT_MDL_000016192 | | | | | | | | | |
| P-21680 | 9/4/2014 | FW: Walmart Stores East, LP, Bentonville, AR - 1st Corporate P&P Review Report | WMT_MDL_000016362 | WMT_MDL_000016366 | | | | | | | | | |
| P-21681 | 11/4/2014 | RE: order monitoring | WMT_MDL_000016772 | WMT_MDL_000016773 | | | | | | | | | |
| P-21682 | 3/11/2015 | Letter to DEA | WMT_MDL_000016909 | WMT_MDL_000016911 | | | | | | | | | |
| P-21683 | 9/8/2016 | RE: CII Follow-Up | WMT_MDL_000020123 | WMT_MDL_000020124 | | | | | | | | | |
| P-21687 | 7/1/2013 | FW: Oxy from 6045 | WMT_MDL_000028836 | WMT_MDL_000028837 | | | | | | | | | |
| P-21691 | 7/17/2014 | Re: Job Valuation Questions | WMT_MDL_000032603 | WMT_MDL_000032605 | | | | | | | | | |
| P-21693 | 6/18/2014 | FYE 16 SOM - Prioritization_scoring_model v3 Finalized | WMT_MDL_000046622 | WMT_MDL_000046627 | | | | | | | | | |
| P-21695 | 5/20/2014 | Suspicious Orders | WMT_MDL_000047865 | WMT_MDL_000047870 | | | | | | | | | |
| P-21698 | 8/25/2014 | SOM meeting with Jim | WMT_MDL_000050893 | WMT_MDL_000050895 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------------|-------------------------|--|--|--|--|--|--|--|--|--|
| P-21701 | 2/22/2017 | BUZZEOPDMA SUSPICIOUS ORDER MONITORING (SOM) MODEL Regulatory and Statistical Foundation Document | WMT_IQVIA_MDL_000032444 | WMT_IQVIA_MDL_000032458 | | | | | | | | | |
| P-21708 | 1/30/2015 | FYE 2016 H&W Project Summary DEC 2014 PPT | WMT_MDL_000072403 | WMT_MDL_000072404 | | | | | | | | | |
| P-21716 | 1/28/2014 | Program Enhancement Outline - Aug 23 | WMT_MDL_000028424 | WMT_MDL_000028427 | | | | | | | | | |
| P-21717 | 7/17/2015 | RE Immediate review please | WMT_MDL_000047188 | WMT_MDL_000047197 | | | | | | | | | |
| P-21718 | 1/13/2014 | AP Meeting - Data Strategy - Jan 9 | WMT_MDL_000137442 | WMT_MDL_000137443 | | | | | | | | | |
| P-21719 | 11/19/2014 | FW SOM Presentation | WMT_MDL_000139201 | WMT_MDL_000139206 | | | | | | | | | |
| P-21720 | 8/29/2015 | Roxy_Reed2015-08-29_09-35-23 | WMT_MDL_000139380 | WMT_MDL_000139380 | | | | | | | | | |
| P-21721 | 9/26/2013 | Pharmacy Risk Assessment | WMT_MDL_000197652 | WMT_MDL_000197653 | | | | | | | | | |
| P-21722 | 11/10/2014 | RE Our 1:00 call | WMT_MDL_000308350 | WMT_MDL_000308351 | | | | | | | | | |
| P-21723 | 9/2/2011 | Revised Justification | WMT_MDL_000317743 | WMT_MDL_000317744 | | | | | | | | | |
| P-21724 | 3/12/2013 | FW Please take a look are revise | WMT_MDL_000374668 | WMT_MDL_000374669 | | | | | | | | | |
| P-21725 | 2/5/2015 | RE CII - CSOS Limitations | WMT_MDL_000521215 | WMT_MDL_000521216 | | | | | | | | | |
| P-21726 | 11/7/2014 | Suspicious Order Report | WMT_MDL_000931975 | WMT_MDL_000931976 | | | | | | | | | |
| P-21727 | 1/30/2015 | SOM Regulatory Reporting Form-DEA | WMT_MDL_001256141 | WMT_MDL_001256142 | | | | | | | | | |
| P-21728 | 11/24/2014 | RE SOM role- Chad Ducote | WMT_MDL_000008226 | WMT_MDL_000008229 | | | | | | | | | |
| P-21729 | 6/12/2013 | FW: Over 20 Report 6.12.13 | WMT_NV_000000658 | WMT_NV_000000659 | | | | | | | | | |
| P-21730 | 2/7/2019 | Emailing: 01-10-19 Master Training PP | WMT_MDL_000430578 | WMT_MDL_000430579 | | | | | | | | | |
| P-21731 | 2/10/2015 | Diversion Training 08-26-14 | WMT_MDL_000667369 | WMT_MDL_000667370_0067 | | | | | | | | | |
| P-21732 | 2/7/2015 | RE: Filling C2--dr under investigation | WMT_MDL_000736131 | WMT_MDL_000736133 | | | | | | | | | |
| P-21733 | 3/4/2014 | RE: DEA AND DR COCKTAILS | WMT_MDL_001182882 | WMT_MDL_001182883 | | | | | | | | | |
| P-21734 | 7/27/2012 | FW: OXY script review | WMT_MDL_001247404 | WMT_MDL_001247407 | | | | | | | | | |
| P-21736 | 5/13/2002 | Richard Dana - Florida Sun Sentinel Multiple Patients died overdose | N/A | N/A | | | | | | | | | |
| P-21737 | 7/29/2014 | Lorenzo Lalli - Cleveland.com Bay - Village doctor sentenced a year running pill mill | N/A | N/A | | | | | | | | | |
| P-21738 | 11/11/2016 | Randall Wade - McKinney doctor connected to two more deaths; 8 total WFAA.com | N/A | N/A | | | | | | | | | |
| P-21739 | 7/10/2017 | James Prommersberger - WV Board of Medicine Consent Order | N/A | N/A | | | | | | | | | |
| P-21740 | 7/17/2017 | Frank Bynes - Savannah physician sentenced to 20 years in prison for 'substantially contributing to opioid crisis' | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|--|
| P-21741 | 7/17/2017 | Raymond Kraynak - DOJ Kraynak Indicted | N/A | N/A | | | | | | | | | | |
| P-21742 | 2/2/2018 | Randall Wade - McKinney doctor who gave Rx heroin | N/A | N/A | | | | | | | | | | |
| P-21743 | 2/18/2019 | James Prommersberger - Boardman podiatrist indicted in opioid prescription case -WFMJ | N/A | N/A | | | | | | | | | | |
| P-21744 | 5/9/2019 | Howard Diamond - DOJ Press Release: 2 North Texas Doctors, One Nurse Go to Prison | N/A | N/A | | | | | | | | | | |
| P-21745 | 3/5/2020 | Martin Escobar - APNews -Ohio doctor accused by feds of operating a pill mill | N/A | N/A | | | | | | | | | | |
| P-21746 | 3/5/2020 | Martin Escobar - DOJ OH Youngstown physician indicted pill mill 2 deaths | N/A | N/A | | | | | | | | | | |
| P-21747 | 1/21/2020 | DOJ Press Release Pill Mill Doctor Egisto Salerno Pleads Guilty | N/A | N/A | | | | | | | | | | |
| P-21748 | 7/14/2019 | CantonRep: Former Stark County doctor Frank Lazzerini 113 years | N/A | N/A | | | | | | | | | | |
| P-21749 | 12/17/2014 | Email re conference call re Metrics | WMT_MDL_001178256 | WMT_MDL_001178264 | | | | | | | | | | |
| P-21771 | 3/14/2018 | CS Slides for Rachel | WMT_MDL_000034313 | WMT_MDL_000034316 | | | | | | | | | | |
| P-21772 | 7/17/2015 | POM 1311 Practice Compliance Proper Prescriber - Patient Relationship/Corresponding Responsibility | WMT_MDL_000042957 | WMT_MDL_000042961 | | | | | | | | | | |
| P-21784 | 9/30/2019 | POM 1311 - Corresponding Responsibility and Dispensing Practices | WMT_MDL_000067636 | WMT_MDL_000067639 | | | | | | | | | | |
| P-21788 | 7/25/2012 | Mandatory Oxycodone Check (2012-07-25 to 2015-12-31) | WMT_MDL_000069746 | WMT_MDL_000069746 | | | | | | | | | | |
| P-21792 | 6/25/2013 | FW: Outdated H & W modules | WMT_MDL_000101210 | WMT_MDL_000101686 | | | | | | | | | | |
| P-21794 | 9/27/2008 | FW: CE Webinar Presentation; Walmart controlled substance FINAL1; Diversion Talking point; Unnamed presentation; Diversion Talking point | WMT_MDL_000224291 | WMT_MDL_000224299 | | | | | | | | | | |
| P-21796 | 9/2/2011 | Raw Data | WMT_MDL_000260779 | WMT_MDL_000260779 | | | | | | | | | | |
| P-21801 | 8/26/2014 | Fwd: Hydrocodone Schedule Change/Yesterday's Call | WMT_MDL_000297954 | WMT_MDL_000297956 | | | | | | | | | | |
| P-21803 | 3/2/2008 | Org Chart Narratives; Org Chart Memo [3-2-08] | WMT_MDL_000325299 | WMT_MDL_000325303 | | | | | | | | | | |
| P-21805 | 2/22/2013 | FW: DEA WG Follow-Up - Potential Areas of Consensus; 2.12.13 - Areas of Consensus; Working Group Summary 2.12.13 | WMT_MDL_000357867 | WMT_MDL_000357876 | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-21806 | 10/14/2016 | Please Review: Communication/Guidance on Blocked Prescribers; Communication to Leadership; Sample Email to pharmacist; POM 1311 September 2016; POM 1311 FAQs; POM 1311 Patient Communication_Oct 2016(1) | WMT_MDL_000366465 | WMT_MDL_000366477 | | | | | | | | | |
| P-21808 | 5/8/2012 | FW: Counseling flow charts; Health and Wellness Key Decision Document TQ Decision Document Counseling for Success (8-12-2010) | WMT_MDL_000388886 | WMT_MDL_000388911 | | | | | | | | | |
| P-21811 | 4/12/2018 | POM 1311; POM 1311_Final Draft 4.10.18_mkjedits | WMT_MDL_000404148 | WMT_MDL_000404158 | | | | | | | | | |
| P-21813 | 4/9/2012 | On Boarding decks; 2 hour CARE SOP ONBOARDING final (2) (3); 2 hour technician deck draft; 4 hour CARE web-based draft | WMT_MDL_000423926 | WMT_MDL_000423928 | | | | | | | | | |
| P-21814 | 11/18/2009 | FW: PMP documents; PMPWirePosting; PMPTalkingPoints; PMPFAQ's; RE: PMP documents | WMT_MDL_000424881 | WMT_MDL_000424890 | | | | | | | | | |
| P-21815 | 1/7/2020 | Controlled Substance Tour Guide Update; FW: RxM Tour - Draft V6 12-24-19; Pharmacy Manager Controlled Substances Tour Assessment RxM Tour - Draft V6 12-24-19; FW: MHWD CS Tour one page - FINAL DRAFT; MHWD CS Tour one page - FINAL DRAFT | WMT_MDL_000429606 | WMT_MDL_000429616 | | | | | | | | | |
| P-21816 | 10/21/2014 | International CS presentation 10- 21-14 | WMT_MDL_000448134 | WMT_MDL_000448135 | | | | | | | | | |
| P-21817 | 9/14/2018 | Associate Listening Session Update; Problem Statements for Product Teams | WMT_MDL_000450156 | WMT_MDL_000450161 | | | | | | | | | |
| P-21818 | 10/13/2017 | FW: CS Analyst Training; Controlled Substance Compliance CS_Compliance_final_draft | WMT_MDL_000450343 | WMT_MDL_000450345 | | | | | | | | | |
| P-21820 | 9/3/2013 | Galahad Root Cause Analysis; Galahad National Findings | WMT_MDL_000451010 | WMT_MDL_000451019 | | | | | | | | | |
| P-21822 | 9/15/2010 | Controlled_Substance_Project_Plan (draft_8_5_10)[1] | WMT_MDL_000452476 | WMT_MDL_000452735 | | | | | | | | | |
| P-21823 | 7/1/2013 | RE: Tomorrow's Video Shoot; 28013233_2 DOCX.clean_wAssignment | WMT_MDL_000466694 | WMT_MDL_000466705 | | | | | | | | | |
| P-21824 | 10/21/2014 | Updated SOM Strategy Deck; SOM Strategy | WMT_MDL_000008075 | WMT_MDL_000008076 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-21825 | 2/17/2014 | Updated roadmap for logistics compliance; Logistics Compliance Roadmap_17Feb | WMT_MDL_00009852 | WMT_MDL_00009853 | | | | | | | | | |
| P-21826 | 8/21/2012 | FW: Oxy 30mg | WMT_MDL_000011949 | WMT_MDL_000011949 | | | | | | | | | |
| P-21827 | 8/27/2014 | RE: SOM Reqs | WMT_MDL_000016257 | WMT_MDL_000016258 | | | | | | | | | |
| P-21828 | 3/1/2015 | DEA close out DC6028 | WMT_MDL_000038273 | WMT_MDL_000038273 | | | | | | | | | |
| P-21829 | 10/13/2017 | Oversight Committee_10.17.17 | WMT_MDL_000048115 | WMT_MDL_000048115 | | | | | | | | | |
| P-21830 | 11/13/2013 | CS Risk Assessment Executive Summary; Controlled Substance Risk Assessment: Executive Summary | WMT_MDL_000053023 | WMT_MDL_000053024 | | | | | | | | | |
| P-21831 | 1/11/2016 | Oversight Committee Deck; January 2016 Oversight Meeting | WMT_MDL_000138509 | WMT_MDL_000138510 | | | | | | | | | |
| P-21832 | 9/25/2014 | Re: VAWD Submission | WMT_MDL_000139199 | WMT_MDL_000139200 | | | | | | | | | |
| P-21833 | 6/15/2017 | RE: Buzzzo | WMT_MDL_000141298 | WMT_MDL_000141300 | | | | | | | | | |
| P-21834 | 4/19/2017 | 4.20.17 HW Compliance Focus Areas Deck; Compliance Focus Areas_042017 | WMT_MDL_000143355 | WMT_MDL_000143375 | | | | | | | | | |
| P-21835 | 10/11/2013 | FW: Meeting Notes - Please Review; Processes used at DC6046 for Controls and non controlled drugs; Error; 201310100848 | WMT_MDL_000195033 | WMT_MDL_000195041 | | | | | | | | | |
| P-21836 | 4/11/2016 | RE: IMPORTANT: CSOS Alerts | WMT_MDL_000215753 | WMT_MDL_000215753 | | | | | | | | | |
| P-21837 | 10/16/2014 | FW: Walmart Stores East, LP, Bentonville, AR - 1st Corporate P&P Review Report; 06-0602 | WMT_MDL_000222305 | WMT_MDL_000222420 | | | | | | | | | |
| P-21838 | N/A | WMT_MDL_000254857 HIGHLY CONFIDENTIAL SQLA Export for Ohio (less Tracks 1 & 3)_20200721A | WMT_MDL_000254857 | WMT_MDL_000254857 | | | | | | | | | |
| P-21839 | N/A | WMT_MDL_000254870 HIGHLY CONFIDENTIAL VSAM Export for Ohio CT3 Stores Year2012 | WMT_MDL_000254870 | WMT_MDL_000254870 | | | | | | | | | |
| P-21840 | 11/23/2015 | FW: Cindy Strategy Template -- Practice Compliance | WMT_MDL_000365539 | WMT_MDL_000365540 | | | | | | | | | |
| P-21841 | 9/16/2014 | RE: SOM; DC Policy 21-402 Controlled Substance Monitoring; DC Policy 21-403 Prescription Drug Monitoring; SOM policy - DRAFT - August 2014 | WMT_MA_000001622 | WMT_MA_000001628 | | | | | | | | | |
| P-22618 | 5/10/2013 | CSMP Questionnaire | MCKMDL00514052 | MCKMDL00514057 | | | | | | | | | |
| P-22619 | 7/13/2017 | FW: Relay Health/Walmart Top to Top | MCKMDL00650092 | MCKMDL00650104 | | | | | | | | | |
| P-23011 | 8/12/2021 | Robert Hill Track 3 Expert Report Response | N/A | N/A | | | | | | | | | |
| P-23012 | 8/12/2021 | Nancy Coffey Track 3 Expert Report Response | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-23058 | 4/6/2018 | EXT: Walmart Stores East, LP dba Walmart Pharmacy Warehouse #45, Rogers, AR - VAWD Three-Year Reaccreditation Compliance Review | WMT_MDL_000007305 | WMT_MDL_000007339 | | | | | | | | | |
| P-23059 | N/A | Daily_HBC_Controls_W7 | HBC_MDL00002242 | HBC_MDL00002242 | | | | | | | | | |
| P-23060 | 2/11/2017 | 20170211_Daily_HBC_Controls_W7 | HBC_MDL00003463 | HBC_MDL00003463 | | | | | | | | | |
| P-23061 | 10/1/2013 | October_2013_PSE_IRR_Recap | CVS-FLAG-000021160 | CVS-FLAG-000021160 | | | | | | | | | |
| P-23062 | 2008 | Your Druggist Pharmacy, 73 Fed. Reg. 75,774, 75,775 n.1 (DEA Dec. 2008) - | N/A | N/A | | | | | | | | | |
| P-23063 | 2018 | Actions of the 2018 American Pharmacists Association House of Delegates (March 2018), | N/A | N/A | | | | | | | | | |
| P-23064 | 2012 | 2012 Pharmacy Supervisor Incentive Plan | CVS-MDLT1-000060922 | CVS-MDLT1-000060929 | | | | | | | | | |
| P-23065 | 09/00/2012 | Institute for Safe Medication Practices, Prescription Drug Time Guarantees and Their Impact on Patient Safety in Community Pharmacies. ISMP Medication Safety Alert! | N/A | N/A | | | | | | | | | |
| P-23066 | 10/00/2008 | Institute for Safe Medication Practices, Speed trap. ISMP Medication Safety Alert! Community/Ambulatory Care Edition | N/A | N/A | | | | | | | | | |
| P-23067 | 03/00/2011 | Institute for Safe Medication Practices, Return of the speed trap. ISMP Medication Safety Alert! Community/Ambulatory Care Edition | N/A | N/A | | | | | | | | | |
| P-23068 | N/A | Stakeholders' Challenges and Red Flag Warning Signs Related to Prescribing and Dispensing Controlled Substances | NABP_00022121 | NABP_00022137 | | | | | | | | | |
| P-23069 | 2021 | National Coordinating Council for Medication Error Reporting and Prevention. Statement Advocating for the Elimination of Prescription Time Guarantees in Community Pharmacy | N/A | N/A | | | | | | | | | |
| P-23070 | 2017 | Pharmacists Provide Care, Fighting to let pharmacists keep patients safe, APhA | N/A | N/A | | | | | | | | | |
| P-23071 | 2019 | Rite Aid Board Report on Opioid Oversight, at 6 | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-23072 | 1/1/2016 | ACE Property and Casualty Insurance Company - Dec Sheet & Forms - Umbrella Excess - 2016 - \$25,000,000 General Aggregate | Rite_Aid_OMDL_0000218 | Rite_Aid_OMDL_0000306 | | | | | | | | | |
| P-23073 | | In the Matter of the Complaint Against: CVS Pharmacy No. 1049, State Board of Pharmacy, State of Oklahoma, Case No. 1593. | N/A | N/A | | | | | | | | | |
| P-23074 | 8/25/2015 | State of Ohio Board of Pharmacy, How to Read an OARRS Report, YouTube (Aug. 25, 2015) | N/A | N/A | | | | | | | | | |
| P-23075 | 8/25/2015 | State of Ohio Board of Pharmacy, How to Run an OARRS Report, YouTube (Aug. 25, 2015) | N/A | N/A | | | | | | | | | |
| P-23076 | 3/23/2016 | FW: 5349 | WAGCASF00113475 | WAGCASF00113478 | | | | | | | | | |
| P-23077 | 7/12/2016 | 2 of 2 Ohio Store Leadership Launch Event 2-day v2 | WAGFLAG00080494 | WAGFLAG00080626 | | | | | | | | | |
| P-23078 | 8/1/2008 | Workflow | WAGMDL00779646 | WAGMDL00779658 | | | | | | | | | |
| P-23079 | 2/12/2013 | NACDS DEA Compliance Working Group Meeting Summary | WMT_MDL_000233226 | WMT_MDL_000233233 | | | | | | | | | |
| P-23080 | 2/1/2013 | CS Work group responses | WMT_MDL_000361054 | WMT_MDL_000361069 | | | | | | | | | |
| P-23081 | 11/1/2017 | Pharmacy Conference Call Notes 11/1/17 | WMT_MDL_001177305 | WMT_MDL_001177312 | | | | | | | | | |
| P-23082 | N/A | 1006 Exhibit; Catizone Composite | N/A | N/A | | | | | | | | | |
| P-23100 | 4/16/2021 | Expert Report of G. Caleb Alexander, MD, MS | N/A | N/A | | | | | | | | | |
| P-23101 | 4/16/2021 | Appendix A to Alexander's CT3 report | N/A | N/A | | | | | | | | | |
| P-23102 | 4/16/2021 | Appendix B to Alexander's CT3 report | N/A | N/A | | | | | | | | | |
| P-23103 | 4/16/2021 | Appendix C to Alexander's CT3 report | N/A | N/A | | | | | | | | | |
| P-23104 | 4/16/2021 | Appendix D to Alexander's CT3 report | N/A | N/A | | | | | | | | | |
| P-23105 | 4/16/2021 | Appendix E to Alexander's CT3 report | N/A | N/A | | | | | | | | | |
| P-23106 | 4/16/2021 | Appendix F to Alexander's CT3 report | N/A | N/A | | | | | | | | | |
| P-23107 | 4/16/2021 | Expert Report of Carmen Catizone | N/A | N/A | | | | | | | | | |
| P-23108 | 4/16/2021 | Appendix A to Catizone's CT3 report | N/A | N/A | | | | | | | | | |
| P-23109 | 4/16/2021 | Appendix B to Catizone's CT3 report | N/A | N/A | | | | | | | | | |
| P-23110 | 5/19/2021 | Supplemental Expert Report of Carmen Catizone 05/19/2021 | N/A | N/A | | | | | | | | | |
| P-23111 | 2020 | Carmen Catizone CV September 2020 | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|-----|-----|--|--|--|--|--|--|--|--|--|
| P-23112 | 4/16/2021 | Expert Report of David M. Cutler | N/A | N/A | | | | | | | | | |
| P-23113 | 4/21/2021 | Supplement to David M. Cutler Expert Report 04/21/2021 | N/A | N/A | | | | | | | | | |
| P-23114 | 5/19/2021 | Supplement to David M. Cutler Expert Report 05/19/2021 | N/A | N/A | | | | | | | | | |
| P-23115 | 5/29/2021 | David M. Cutler production | N/A | N/A | | | | | | | | | |
| P-23116 | 4/16/2021 | Expert Report of Katherine Keyes, PHD | N/A | N/A | | | | | | | | | |
| P-23117 | 4/16/2021 | Katherine Keyes, PHD Expert Report Exhibits A-D | N/A | N/A | | | | | | | | | |
| P-23118 | 5/25/2021 | Katherine Keyes, PHD production | N/A | N/A | | | | | | | | | |
| P-23119 | 6/2/2021 | Supplemental Material Considered List for Katherine Keyes, PHD | N/A | N/A | | | | | | | | | |
| P-23120 | 4/16/2021 | Expert Report of Anna Lembke, M.D. | N/A | N/A | | | | | | | | | |
| P-23121 | 5/27/2021 | Supplemental Materials Considered List for Anna Lembke, M.D. | N/A | N/A | | | | | | | | | |
| P-23122 | 4/15/2021 | Expert Report of Daniel C. Malone, BS Pharmacy, MS, PhD, FACMP | N/A | N/A | | | | | | | | | |
| P-23123 | 2021 | Daniel Malone CV | N/A | N/A | | | | | | | | | |
| P-23124 | 5/27/2021 | Daniel C. Malone, BS Pharmacy, MS, PhD, FACMP production | N/A | N/A | | | | | | | | | |
| P-23125 | 4/16/2021 | Expert Report of James Rafalski | N/A | N/A | | | | | | | | | |
| P-23126 | 4/16/2021 | James Rafalski Schedule I | N/A | N/A | | | | | | | | | |
| P-23127 | 4/16/2021 | Expert Report of Harvey S. Rosen, Ph.D. | N/A | N/A | | | | | | | | | |
| P-23128 | 4/16/2021 | Expert Report of Nancy K. Young, Ph.D., M.S.W. | N/A | N/A | | | | | | | | | |
| P-23129 | 4/16/2021 | Appendices I - III and Materials Considered for Nancy K. Young, Ph.D., M.S.W. | N/A | N/A | | | | | | | | | |
| P-23130 | 4/16/2021 | McCann Expert Report - CT3 04.16.2021 | N/A | N/A | | | | | | | | | |
| P-23131 | 5/4/2021 | McCann Expert Report - CT3 Supplemental 05.04.2021 | N/A | N/A | | | | | | | | | |
| P-23132 | 5/19/2021 | McCann Expert Report - CT3 Second Supplemental 05.19.2021 | N/A | N/A | | | | | | | | | |
| P-23133 | 4/16/2021 | McCann CT3 Report Appendix 2. Corrections to ARCOS Data | N/A | N/A | | | | | | | | | |
| P-23134 | 4/16/2021 | McCann CT3 Report Appendix 3. Frequency and definition of transaction codes | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|-----|-----|--|--|--|--|--|--|--|--|--|
| P-23135 | 4/16/2021 | McCann CT3 Report Appendix 4: Corrections to DEA's NDC Dictionary | N/A | N/A | | | | | | | | | |
| P-23136 | 4/16/2021 | McCann CT3 Report Appendix 5: MME Conversion Factors (from CDC) | N/A | N/A | | | | | | | | | |
| P-23137 | 4/16/2021 | McCann CT3 Report Appendix 6: MME on Base Weight and on Label | N/A | N/A | | | | | | | | | |
| P-23138 | 4/16/2021 | McCann CT3 Report Appendix 7: ARCOS Summary | N/A | N/A | | | | | | | | | |
| P-23139 | 5/4/2021 | McCann CT3 Report Appendix 8A Supplemented: Flagged Distributor Defendant Transaction Reports | N/A | N/A | | | | | | | | | |
| P-23140 | 4/16/2021 | McCann CT3 Report Appendix 8B: Flagged Chain Pharmacy Defendant Transaction Reports | N/A | N/A | | | | | | | | | |
| P-23141 | 4/16/2021 | McCann CT3 Report Appendix 8C: SOMs on Walmart Defendant Data | N/A | N/A | | | | | | | | | |
| P-23142 | 4/16/2021 | McCann CT3 Report Appendix 9: Processing the Dispensing Data | N/A | N/A | | | | | | | | | |
| P-23143 | 4/16/2021 | McCann CT3 Report Appendix 10A: State Oxycodone and Hydrocodone MME Per Capita, 1997-2019 | N/A | N/A | | | | | | | | | |
| P-23144 | 4/16/2021 | McCann CT3 Report Appendix 10B: All Defendants, Combined and Individually, 12 Opioid Drug Distribution by Distributor Defendant | N/A | N/A | | | | | | | | | |
| P-23145 | 4/16/2021 | McCann CT3 Report Appendix 10C: All Distributor Defendants, Combined and Individually, 12 Opioid Drug Distribution by Drug Code | N/A | N/A | | | | | | | | | |
| P-23146 | 4/16/2021 | McCann CT3 Report Appendix 10D: All Seller 12 Opioid Drug Distribution, by Zip Code and by Drug | N/A | N/A | | | | | | | | | |
| P-23147 | 4/16/2021 | McCann CT3 Report Appendix 10E: Individual Defendant Oxycodone Distribution in Lake County and Trumbull County, OH, by Total Dosage, Total MME, Total Drug Base Weight | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|-----|-----|--|--|--|--|--|--|--|--|--|
| P-23148 | 4/16/2021 | McCann CT3 Report Appendix 10F: Individual Defendant Hydrocodone Distribution in Lake County and Trumbull County, OH, by Total Dosage, Total MME, Total Drug Base | N/A | N/A | | | | | | | | | |
| P-23149 | 4/16/2021 | McCann CT3 Report Appendix 10G: Oxycodone and Hydrocodone Distribution to Individual Pharmacies by All Distributors | N/A | N/A | | | | | | | | | |
| P-23150 | 4/16/2021 | McCann CT3 Report Appendix 10H: Pharmacy Reports | N/A | N/A | | | | | | | | | |
| P-23151 | 4/16/2021 | McCann CT3 Report Appendix 10I: Distributor Reports | N/A | N/A | | | | | | | | | |
| P-23152 | 4/16/2021 | McCann CT3 Report Appendix 10J: Oxycodone and Hydrocodone Distribution to Individual Pharmacies by Defendant | N/A | N/A | | | | | | | | | |
| P-23153 | 4/16/2021 | McCann CT3 Report Appendix 11: Opioid Top Down Reports | N/A | N/A | | | | | | | | | |
| P-23154 | 4/16/2021 | McCann CT3 Report Appendix 12A: Highlighted Flag Total Summary And Bar Chart | N/A | N/A | | | | | | | | | |
| P-23155 | 4/16/2021 | McCann CT3 Report Appendix 12B: Highlighted Flag Summary by Year | N/A | N/A | | | | | | | | | |
| P-23156 | 4/16/2021 | McCann CT3 Report Appendix 12C: Highlighted Flag Summary – Number of Flags Triggered | N/A | N/A | | | | | | | | | |
| P-23157 | 4/16/2021 | McCann CT3 Report Appendix 12D: 43 Flag Total Summary and Bar Chart | N/A | N/A | | | | | | | | | |
| P-23158 | 4/16/2021 | McCann CT3 Report Appendix 12E: 43 Flag Summary by Year | N/A | N/A | | | | | | | | | |
| P-23159 | 4/16/2021 | McCann CT3 Report Appendix 12F: 43 Flag Summary – Number of Flags Triggered | N/A | N/A | | | | | | | | | |
| P-23160 | 4/16/2021 | McCann CT3 Report Appendix 12G: Red Flag Calculations for Impact Analysis | N/A | N/A | | | | | | | | | |
| P-23161 | 4/16/2021 | McCann CT3 Report Appendix 12H: High Dosage Patient Summary | N/A | N/A | | | | | | | | | |
| P-23162 | 4/16/2021 | McCann CT3 Report Appendix 12I: Specific Prescriber Summary Report | N/A | N/A | | | | | | | | | |
| P-23163 | 4/16/2021 | McCann CT3 Report Appendix 12J: Data Quality Summary | N/A | N/A | | | | | | | | | |
| P-23164 | 4/16/2021 | McCann CT3 Report Appendix 12K: Single Ingredient Drug Summary | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-23165 | 4/16/2021 | McCann CT3 Report Appendix 12L: Average and Total Shipment from Selected Distributors to Retail and Chain Pharmacies | N/A | N/A | | | | | | | | | |
| P-23166 | 4/16/2021 | McCann CT3 Report Appendix 12M: Average and Total Shipment from All Distributors to Selected Chain Pharmacies | N/A | N/A | | | | | | | | | |
| P-23167 | 4/16/2021 | McCann CT3 Report Appendix 13 | N/A | N/A | | | | | | | | | |
| P-23168 | 5/19/2021 | McCann CT3 Report Appendix 14A. Combination Red Flagged Prescriptions - Red Flag Computation 1-16 Summary and Chart | N/A | N/A | | | | | | | | | |
| P-23169 | 5/19/2021 | McCann CT3 Report Appendix 14B. Combination Red Flagged Prescriptions - Red Flag Computation 1-16 Summary by Year | N/A | N/A | | | | | | | | | |
| P-23170 | 5/19/2021 | McCann CT3 Report Appendix 14C. Combination Red Flagged Prescriptions - Red Flag Computation 1-16 No of Flags Triggered | N/A | N/A | | | | | | | | | |
| P-23171 | 5/19/2021 | McCann CT3 Report Appendix 14D. Combination Red Flagged Prescriptions - Red Flag Computation 1-43 Summary and Chart | N/A | N/A | | | | | | | | | |
| P-23172 | 5/19/2021 | McCann CT3 Report Appendix 14E. Combination Red Flagged Prescriptions - Red Flag Computation 1-43 Summary by Year | N/A | N/A | | | | | | | | | |
| P-23173 | 5/19/2021 | McCann CT3 Report Appendix 14F. Combination Red Flagged Prescriptions - Red Flag Computation 1-43 No of Flags Triggered | N/A | N/A | | | | | | | | | |
| P-23174 | 5/19/2021 | McCann CT3 Report Appendix 14G. Calculations for Impact Analysis | N/A | N/A | | | | | | | | | |
| P-23175 | 4/6/2020 | ARCOS Retail Drug Summary Reports, Drug Enforcement Administration, 2019 | N/A | N/A | | | | | | | | | |
| P-23176 | 8/1/2009 | Masters SOMS Algorithm. | CAH_MDL2804_01423521 | CAH_MDL2804_01423598 | | | | | | | | | |
| P-23177 | 12/11/2017 | Lake County Original Complaint | N/A | N/A | | | | | | | | | |
| P-23178 | 12/18/2017 | Trumbull County Original Complaint | N/A | N/A | | | | | | | | | |
| P-23179 | 3/18/2019 | Lake County Short Form Amended Complaint | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-23180 | 3/18/2019 | Trumbull County Short Form Amended Complaint | N/A | N/A | | | | | | | | | |
| P-23181 | 6/5/2020 | Lake County Supplemental and Amended Complaint | N/A | N/A | | | | | | | | | |
| P-23182 | 6/5/2020 | Trumbull County Supplemental and Amended Complaint | N/A | N/A | | | | | | | | | |
| P-23183 | 4/17/2019 | Prevoznik, Thomas Depo Transcript 4.17.2019 | N/A | N/A | | | | | | | | | |
| P-23184 | 4/18/2019 | Prevoznik, Thomas Depo Transcript 4.18.2019 | N/A | N/A | | | | | | | | | |
| P-23185 | 5/17/2019 | Prevoznik, Thomas Depo Transcript 5.17.2019 | N/A | N/A | | | | | | | | | |
| P-23186 | 7/21/2020 | HIGHLY CONFIDENTIAL SCLA Export for Ohio (less Tracks 1 & 3) 20200721B | WMT_MDL_000254858 | WMT_MDL_000254858 | | | | | | | | | |
| P-23187 | 7/21/2020 | HIGHLY CONFIDENTIAL SCLA Export for Ohio (less Tracks 1 & 3) 20200721C | WMT_MDL_000254859 | WMT_MDL_000254859 | | | | | | | | | |
| P-23188 | 2009 | HIGHLY CONFIDENTIAL VSAM Export for Ohio (less Tracks 1 & 3) Year 2009 | WMT_MDL_000254860 | WMT_MDL_000254860 | | | | | | | | | |
| P-23189 | 2010 | HIGHLY CONFIDENTIAL VSAM Export for Ohio (less Tracks 1 & 3) Year 2010 | WMT_MDL_000254861 | WMT_MDL_000254861 | | | | | | | | | |
| P-23190 | 2011 | HIGHLY CONFIDENTIAL VSAM Export for Ohio (less Tracks 1 & 3) Year 2011 | WMT_MDL_000254862 | WMT_MDL_000254862 | | | | | | | | | |
| P-23191 | 2012 | HIGHLY CONFIDENTIAL VSAM Export for Ohio (less Tracks 1 & 3) Year 2012 | WMT_MDL_000254863 | WMT_MDL_000254863 | | | | | | | | | |
| P-23192 | N/A | HIGHLY CONFIDENTIAL VSAM EXPORT FOR Supplemental Ohio data | WMT_MDL_000254864 | WMT_MDL_000254864 | | | | | | | | | |
| P-23193 | 7/21/2020 | HIGHLY CONFIDENTIAL SCLA Export for Ohio CT3 Stores 20200721A | WMT_MDL_000254865 | WMT_MDL_000254865 | | | | | | | | | |
| P-23194 | 7/21/2020 | HIGHLY CONFIDENTIAL SCLA Export for Ohio CT3 Stores 20200721B | WMT_MDL_000254866 | WMT_MDL_000254866 | | | | | | | | | |
| P-23195 | 2009 | HIGHLY CONFIDENTIAL VSAM Export for Ohio CT3 Stores Year 2009 | WMT_MDL_000254867 | WMT_MDL_000254867 | | | | | | | | | |
| P-23196 | 2010 | HIGHLY CONFIDENTIAL VSAM Export for Ohio CT3 Stores Year 2010 | WMT_MDL_000254868 | WMT_MDL_000254868 | | | | | | | | | |
| P-23197 | 2011 | HIGHLY CONFIDENTIAL VSAM Export for Ohio CT3 Stores Year 2011 | WMT_MDL_000254869 | WMT_MDL_000254869 | | | | | | | | | |
| P-23198 | N/A | Defendant Transactional Data. | GE_TL00014980 | GE_TL00014980 | | | | | | | | | |
| P-23199 | 9/28/2020 | PRODUCTION_CVS_Shipment_Data_All_OH_09282020 | CVS-MDLT3-000009932 | CVS-MDLT3-000009932 | | | | | | | | | |
| P-23200 | N/A | Chain Pharmacy Defendants' Dispensing Data | CVS-MDLT1B-000012531 | CVS-MDLT1B-000012531 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-23201 | N/A | Chain Pharmacy Defendants' Dispensing Data | CVS-MDLT1B-000012532 | CVS-MDLT1B-000012532 | | | | | | | | | |
| P-23202 | N/A | Chain Pharmacy Defendants' Dispensing Data | CVS-MDLT1B-000012533 | CVS-MDLT1B-000012533 | | | | | | | | | |
| P-23203 | N/A | Chain Pharmacy Defendants' Dispensing Data | CVS-MDLT1B-000012534 | CVS-MDLT1B-000012534 | | | | | | | | | |
| P-23204 | N/A | Chain Pharmacy Defendants' Dispensing Data | CVS-MDLT1B-000012535 | CVS-MDLT1B-000012535 | | | | | | | | | |
| P-23205 | N/A | Chain Pharmacy Defendants' Dispensing Data | CVS-MDLT1B-000012536 | CVS-MDLT1B-000012536 | | | | | | | | | |
| P-23206 | N/A | Chain Pharmacy Defendants' Dispensing Data | HBC_MDL00192642 | HBC_MDL00192642 | | | | | | | | | |
| P-23208 | N/A | Chain Pharmacy Defendants' Dispensing Data | WAGMDLDATA00002 | WAGMDLDATA00002 | | | | | | | | | |
| P-23209 | N/A | Chain Pharmacy Defendants' Dispensing Data | WMT_MDL_000071426 | WMT_MDL_000071426 | | | | | | | | | |
| P-23211 | 1/6/2020 | "National Drug Code Dictionary," Drug Enforcement Administration, January 2020 | N/A | N/A | | | | | | | | | |
| P-23212 | N/A | US Processed ARCOS | N/A | N/A | | | | | | | | | |
| P-23213 | N/A | OH Processed ARCOS | N/A | N/A | | | | | | | | | |
| P-23322 | 12/20/2005 | IQVIA Second Amendment Agreement with IMS Health | CVS-MDLT1-000119294 | CVS-MDLT1-000119317 | | | | | | | | | |
| P-23323 | 1/29/2001 | IMS Health and CVS Pharmacy Inc Agreement; Amendment | CVS-MDLT1-000119318 | CVS-MDLT1-000119327 | | | | | | | | | |
| P-23324 | 1/1/2001 | IMS Health Information Services Agreement with CVS; CVS-01 | CVS-MDLT1-000119328 | CVS-MDLT1-000119339 | | | | | | | | | |
| P-23325 | 1/1/2007 | IMS Health and CVS Pharmacy Inc Agreement; Third Amendment | CVS-MDLT1-000119340 | CVS-MDLT1-000119340 | | | | | | | | | |
| P-23326 | 2/2/1998 | Master Data Agreement between CVS Pharmacy Inc. and IMS America Ltd. | CVS-MDLT1-000119346 | CVS-MDLT1-000119362 | | | | | | | | | |
| P-23327 | 1/1/2014 | IMS Health and CVS Pharmacy Inc Agreement; Sixth Amendment | CVS-MDLT1-000119363 | CVS-MDLT1-000119380 | | | | | | | | | |
| P-23328 | 6/24/2011 | IMS Health and CVS Pharmacy Inc Agreement; Fifth Amendment | CVS-MDLT1-000119381 | CVS-MDLT1-000119398 | | | | | | | | | |
| P-23329 | 1/1/2014 | IMS Health and CVS Pharmacy Inc Agreement; Seventh Amendment | CVS-MDLT1-000119399 | CVS-MDLT1-000119400 | | | | | | | | | |
| P-23330 | 3/29/2018 | Frank Veres, Prescriber Interview Notes | CVS-MDLT3-000100233 | CVS-MDLT3-000100235 | | | | | | | | | |
| P-23331 | 6/24/2020 | June 24, 2020 Letter to Dr. Veres | CVS-MDLT3-000132096 | CVS-MDLT3-000132096 | | | | | | | | | |
| P-23332 | 7/1/2020 | July 1, 2020 Letter to Dr. Veres - Second Notice | CVS-MDLT3-000132097 | CVS-MDLT3-000132097 | | | | | | | | | |
| P-23333 | 2/5/2014 | FORM 8-K; CVS Caremark Corporation | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------------|--------------------------|--|--|--|--|--|--|--|--|--|
| P-23334 | 4/3/2018 | FW: ACTION NEEDED: Please Respond by 4/10 - Kick-Off for ROPP- 047561 | CVS-MDLT3-000164969.0001 | CVS-MDLT3-000164969.0068 | | | | | | | | | |
| P-23335 | 4/25/2012 | In the Matter of: Holiday CVS, L.L.C., d/b/a CVS/Pharmacy #00219 Transcript; April 25, 2012 | CVS-FLAG-000045982 | CVS-FLAG-000046081 | | | | | | | | | |
| P-23336 | NA | CVS Annual Reports 1997-2020 | N/A | N/A | | | | | | | | | |
| P-23337 | 6/11/2021 | Corrected Dispensing Data from CVS; corrects the fill date-time field in CVS's dispensing data | CVS-MDLT3-000165523 | CVS-MDLT3-000165525 | | | | | | | | | |
| P-23338 | 12/27/2011 | IRR HYDROCOD 5/500 Store 3305 | CVS-NYAG-000025495 | CVS-NYAG-000026460 | | | | | | | | | |
| P-23339 | 2/15/2011 | IRR HYDROCOD 7.5/325 Store 4327 | CVS-MDLT3-000009729 | CVS-MDLT3-000009734 | | | | | | | | | |
| P-23340 | 2/22/2011 | IRR HYDROCOD 7.5/325 Store 4327 | CVS-MDLT3-000009735 | CVS-MDLT3-000009748 | | | | | | | | | |
| P-23341 | 8/30/2011 | IRR HYDROCOD 5/500 Store 4327 | CVS-MDLT3-000009749 | CVS-MDLT3-000009808 | | | | | | | | | |
| P-23342 | 8/23/2011 | IRR HYDROCOD 5/500 Store 4327 | CVS-MDLT3-000009809 | CVS-MDLT3-000009831 | | | | | | | | | |
| P-23343 | 6/14/2011 | IRR HYDROCOD 7.5/325 Store 3304 | CVS-MDLT3-000009832 | CVS-MDLT3-000009840 | | | | | | | | | |
| P-23344 | 6/1/2011 | IRR HYDROCOD 5/500 Store 3305 IRR HYDROCOD 5/500 Store 3356 IRR HYDROCOD APAP10/325 Store 4351 | CVS-MDLT3-000009841 | CVS-MDLT3-000009896 | | | | | | | | | |
| P-23345 | 11/1/2013 | FW: Hydrocodone, attaching High Does APAP_Communications_FINAL | CVS-MDLT1-00128660 | CVS-MDLT1-000128673 | | | | | | | | | |
| P-23346 | 12/12/2012 | Email RE: Rachel, Shauna, Nicole | CVS-MDLT1-000009808 | CVS-MDLT1-000009809 | | | | | | | | | |
| P-23347 | 7/24/2012 | Som Report | CVS-MDLT1-000031864 | CVS-MDLT1-000031865 | | | | | | | | | |
| P-23348 | 11/26/2013 | SOM status update for Tuesday, 11/26 | CVS-MDLT1-000037789 | CVS-MDLT1-000037790 | | | | | | | | | |
| P-23349 | 11/21/2013 | SOM status update for Thursday, November 21 | CVS-MDLT1-000037915 | CVS-MDLT1-000037917 | | | | | | | | | |
| P-23350 | 11/20/2013 | SOM status update for Wednesday, November 20 | CVS-MDLT1-000038024 | CVS-MDLT1-000038026 | | | | | | | | | |
| P-23351 | 9/29/2014 | RE: SOM Jobs - No listed Chemicals - cocktail | CVS-MDLT1-000044592 | CVS-MDLT1-000045588 | | | | | | | | | |
| P-23352 | 1/10/2014 | FW: Cycle 1 | CVS-MDLT1-000046784 | CVS-MDLT1-000048754 | | | | | | | | | |
| P-23353 | 1/24/2014 | RE: 1/23/14 Run Status | CVS-MDLT1-000051900 | CVS-MDLT1-000054737 | | | | | | | | | |
| P-23354 | 3/25/2014 | SOM Output Sample Files | CVS-MDLT1-000058374 | CVS-MDLT1-000058826 | | | | | | | | | |
| P-23355 | 2/5/2014 | End to End Test Cases | CVS-MDLT1-000058875 | CVS-MDLT1-000058876 | | | | | | | | | |
| P-23356 | 2/7/2014 | RE: Step 2 Output | CVS-MDLT1-000058896 | CVS-MDLT1-000059068 | | | | | | | | | |
| P-23357 | 2/3/2014 | RE: Step 2 Output | CVS-MDLT1-000059071 | CVS-MDLT1-000059231 | | | | | | | | | |
| P-23358 | 8/14/2014 | SOM update | CVS-MDLT1-000059438 | CVS-MDLT1-000059447 | | | | | | | | | |
| P-23359 | 11/29/2012 | RE: SOM Flow Chart Process.vsd | CVS-MDLT1-000059760 | CVS-MDLT1-000059995 | | | | | | | | | |
| P-23360 | 5/19/2009 | RX DEA SOP 5-18-09.doc | CVS-MDLT1-000066776 | CVS-MDLT1-000066841 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-23361 | 10/26/2018 | BIS046A_CTL-DRUGS-SUSPICIOUS ORDERS_123112.TXT | CVS-MDLT1-000086021 | CVS-MDLT1-000086097 | | | | | | | | | |
| P-23363 | 2/1/2011 | CVS Item Review Report - Control Drugs | CVS-MDLT1-000100871 | CVS-MDLT1-000100924 | | | | | | | | | |
| P-23364 | 10/28/2013 | Email re NACDS policy council call - good work on Marino Bill | CVS-MDLT1-000079154 | CVS-MDLT1-000079155 | | | | | | | | | |
| P-23365 | 7/8/2020 | CVS suspension letter to Frank Veres | CVS-MDLT3-000132098 | CVS-MDLT3-000132098 | | | | | | | | | |
| P-23368 | 11/3/2006 | Walmart add OxyPromethOxyApap 103106 | MNK-T1_0000367627 | MNK-T1_0000367629 | | | | | | | | | |
| P-23369 | 12/5/2007 | Add various products & VIP 12-03-07 | MNK-T1_0000367648 | MNK-T1_0000367651 | | | | | | | | | |
| P-23370 | 9/17/2007 | Codeine primary & VIP Methylphenidate 9-17-07 | MNK-T1_0000367655 | MNK-T1_0000367657 | | | | | | | | | |
| P-23371 | 11/14/2007 | Decrease HB-APAP 11.13.07 | MNK-T1_0000367665 | MNK-T1_0000367666 | | | | | | | | | |
| P-23372 | 5/2/2007 | Contract Revised Add Morphine Oral 5.2.07 | MNK-T1_0000367674 | MNK-T1_0000367675 | | | | | | | | | |
| P-23373 | 12/14/2007 | VIP established 12-11-07 | MNK-T1_0000367691 | MNK-T1_0000367692 | | | | | | | | | |
| P-23376 | 4/9/2010 | Email between Ginger Collier, Dave Irwin & Kate Mehlenkamp re assessing pain management category; Covidien Market Overview; Covidien: Positive Results for Life | MNK-T1_0001961218 | MNK-T1_0001961220 | | | | | | | | | |
| P-23378 | 8/31/2007 | Letter from Mallinckrodt to Walmart | MNK-T1_0004758253 | MNK-T1_0004758260 | | | | | | | | | |
| P-23379 | 6/21/2016 | Oxycodone marketing plan | MNK-T1_0004830712 | MNK-T1_0004830712 | | | | | | | | | |
| P-23381 | 3/17/2010 | Fentanyl new item information | MNK-T1_0006323328 | MNK-T1_0006323345 | | | | | | | | | |
| P-23400 | 8/22/2013 | Email FW: PIC / OC / Updates (RxRC) attaching RxRCDeficiencyReport_OCDeficientPercent_082113.xlsx | CVS-MDLT3-000141113 | CVS-MDLT3-000141121 | | | | | | | | | |
| P-23401 | 4/27/2018 | Email FW: Program Overview for Call Center | CVS-MDLT3-000004156 | CVS-MDLT3-000004161 | | | | | | | | | |
| P-23402 | 2/15/2015 | R2F Implementation Plan Attached and R2F Project Plan 2015.pdf | CVS-MDLT3-000002764 | CVS-MDLT3-000002781 | | | | | | | | | |
| P-23403 | 4/12/2019 | Refusal to Fill Training | CVS-MDLT3-000007689 | CVS-MDLT3-000007836 | | | | | | | | | |
| P-23404 | 3/26/2014 | PMP Web Access Job Aid attaching PMP Web Access Job Aid v5.docx | CVS-MDLT3-000027006 | CVS-MDLT3-000027010 | | | | | | | | | |
| P-23405 | 11/26/2013 | Email RE: 2014 RX investigative protocol.pptx attaching 2014 Rx Investigative Protocol.pptx | CVS-MDLT1-000129873 | CVS-MDLT1-000129908 | | | | | | | | | |
| P-23406 | 2/7/2012 | Controlled Substance Training for Pharmacists and Pharmacy Interns; Course # 290900; Self-paced Workbook | CVS-NYAG-000031007 | CVS-NYAG-000031031 | | | | | | | | | |
| P-23407 | 9/7/2016 | Email RE: PRF4704-Patient Level Forgery Alert | CVS-MDLT3-000003089 | CVS-MDLT3-000003121 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-23409 | 3/11/2016 | Email attaching: 2016 RPPC Professional Services .pptx | CVS-MDLT3-000069386 | CVS-MDLT3-000069393 | | | | | | | | | |
| P-23410 | 8/5/2011 | RxConnect; Controlled Substance Prescription Request Doc | CVS-FLAG-000085635 | CVS-FLAG-000085635 | | | | | | | | | |
| P-23411 | 8/22/2019 | Email RE: Script For Forgery Video attaching RAC Slide for Video | CVS-MDLT3-000004773 | CVS-MDLT3-000004783 | | | | | | | | | |
| P-23412 | 2/28/2011 | RxConnect; DEA Enhancement_Phase_2_02 242011.pdf | CVS-MDLT3-000006453 | CVS-MDLT3-000006455 | | | | | | | | | |
| P-23413 | 1/31/2013 | February/March 2013 Bi-Annual Training: Pharmacist/Grad Intern Version Course # 800142 | CVS-FLAG-000053099 | CVS-FLAG-000053305 | | | | | | | | | |
| P-23414 | 01/00/2015 | WeCARE_Metric_Toolkit_2015_2 016.pdf | CVS-MDLT3-000006674 | CVS-MDLT3-000006692 | | | | | | | | | |
| P-23415 | 6/1/2014 | 2486_2014_1stHalf_WeCARESc record | CVS-MDLT3-000010970 | CVS-MDLT3-000010970 | | | | | | | | | |
| P-23416 | 6/1/2020 | 3044_2020_1stHalf_WeCARESc record | CVS-MDLT3-000010969 | CVS-MDLT3-000010969 | | | | | | | | | |
| P-23417 | 5/10/2016 | F Veres 12ScriptAlg | CVS-MDLT3-000000114 | CVS-MDLT3-000000114 | | | | | | | | | |
| P-23418 | 5/10/2016 | F Veres 40ScriptAlg | CVS-MDLT3-000000115 | CVS-MDLT3-000000115 | | | | | | | | | |
| P-23419 | 8/30/2019 | Action Required - Prescription Forgery Follow Up | CVS-MDLT3-000100979 | CVS-MDLT3-000100980 | | | | | | | | | |
| P-23420 | 1/28/2019 | Foundations of Drop-off; Learn RX | CVS-MDLT3-000074727 | CVS-MDLT3-000074764 | | | | | | | | | |
| P-23421 | 7/17/2010 | Pharmacy Operations Manual - policy and procedures pharmacy physical inventory | CVS-DR22-000007592 | CVS-DR22-000007751 | | | | | | | | | |
| P-23422 | 1/6/2012 | FW: Protocol For Dispensing Narcotic Drugs For Pain Treatment | CVS-MDLT1B-000012540 | CVS-MDLT1B-000012541 | | | | | | | | | |
| P-23423 | 12/13/2012 | FW: RxConnect Prescriber Hard Stop Messaging | CVS-NYAG-000059609 | CVS-NYAG-000059611 | | | | | | | | | |
| P-23424 | 9/27/2016 | RE: Overview of Prescriber Monitoring and Review Program-- Questions | CVS-NYAG-000043855 | CVS-NYAG-000043866 | | | | | | | | | |
| P-23425 | 4/8/2019 | Rhode Island - 2019 Settlement Agreement | CVS-MDLT1B-000018729 | CVS-MDLT1b-000018735 | | | | | | | | | |
| P-23426 | 1/24/2017 | The Pharmacists Tool Chest for Safely Dispensing Opioid Medication.docx | CVS-MDLT3-000003781 | CVS-MDLT3-000003783 | | | | | | | | | |
| P-23427 | 4/22/2011 | Email re Policy Council attaching Rx Epidemic Response | CVS-MDLT3-000036169 | CVS-MDLT3-000036186 | | | | | | | | | |
| P-23428 | 5/21/2015 | Email Attaching Controlled Substance Mgt - Project Charter_5_21_clean_15.docx & RPPC 3 Year Roadmap_PreSizing_Template final_4_17.pptx | CVS-MDLT3-000124427 | CVS-MDLT3-000124483 | | | | | | | | | |
| P-23429 | 7/3/2013 | Onboarding Compliance | CVS-DR22-000031306 | CVS-DR22-000031353 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------------|--------------------------|--|--|--|--|--|--|--|--|--|
| P-23430 | 4/30/2012 | CVS Holiday Testimony; Redacted April 30, 2012 Holiday Testimony | CVS-FLAG-000046234 | CVS-FLAG-000046323 | | | | | | | | | |
| P-23431 | 9/27/2017 | Prescription Forgery Protocol; Pharmacist on Duty Role/Responsibility | CVS-INDAG-00017069 | CVS-INDAG-00017070 | | | | | | | | | |
| P-23432 | 6/00/2019 | PMP Gateway Integration; | CVS-INDAG-00017374 | CVS-INDAG-00017375 | | | | | | | | | |
| P-23433 | 7/8/2013 | Email re PIC Huddle Guide; attaching PIC Huddle Guide.docx;maq deck.pptx | CVS-MDLT1-000129801 | CVS-MDLT1-000129819 | | | | | | | | | |
| P-23434 | 4/23/2018 | Documentation of Controlled Substance Review; Rx Professional Practice | CVS-MDLT1B-000004949 | CVS-MDLT1B-000004950 | | | | | | | | | |
| P-23435 | 6/18/2013 | FW: som/maq training material; Attaching SOM info_5_24_13.docx | CVS-MDLT1B-000006511 | CVS-MDLT1B-000006526 | | | | | | | | | |
| P-23436 | 11/18/2016 | Email re CR Webinar; 2016 RxSup Corresponding Responsibility Webinar.pptx | CVS-MDLT1B-000010134 | CVS-MDLT1B-000010160 | | | | | | | | | |
| P-23437 | 3/18/2013 | Email re: FW: Team Meeting Monday; attaching RPPC Thought questions.docx;MAQ_SOM_proc ess_improvementdocx.docx | CVS-MDLT1B-000012626 | CVS-MDLT1B-000012632 | | | | | | | | | |
| P-23438 | 1/1/2015 | Prescriber algorithm 40 script floor report - Frank Veres | CVS-MDLT3-000000238 | CVS-MDLT3-000000238 | | | | | | | | | |
| P-23439 | 1/1/2015 | Prescriber report on Frank Veres | CVS-MDLT3-000000239 | CVS-MDLT3-000000239 | | | | | | | | | |
| P-23440 | 2/10/2016 | Champion Family Doctors Testify in Suicide Case - Veres | CVS-MDLT3-000000243 | CVS-MDLT3-000000246 | | | | | | | | | |
| P-23441 | 1/28/2015 | Email re Retail IT Oversight Deck and Listing attaching Retail Compliance Initiatives Oversight Committee PPTs | CVS-MDLT3-000000667 | CVS-MDLT3-000000670 | | | | | | | | | |
| P-23442 | 3/3/2018 | FW: RxNet Corresponding Responsibility Resources | CVS-MDLT3-000002430 | CVS-MDLT3-000002453 | | | | | | | | | |
| P-23443 | | Advisor CS Store Programs PPT | CVS-MDLT3-000002706 | CVS-MDLT3-000002707.0002 | | | | | | | | | |
| P-23444 | 11/4/2019 | Drug Loss and Other Controlled Substance Program Planned Migration to ThinkLP | CVS-MDLT3-000003567 | CVS-MDLT3-000003567 | | | | | | | | | |
| P-23445 | 3/27/2019 | Email re Rules for Red Flags.xlsx | CVS-MDLT3-000006243 | CVS-MDLT3-000006244 | | | | | | | | | |
| P-23446 | 5/22/2014 | MAQ Training Deck; | CVS-MDLT3-000015879 | CVS-MDLT3-000015891.0001 | | | | | | | | | |
| P-23447 | 2/25/2014 | Sup call notes and recap Attaching March 3_2014_ Rx Supervisor Notes.docx; SupCall REcap_MAQ_3_3_14.pptx | CVS-MDLT3-000026988 | CVS-MDLT3-000026995 | | | | | | | | | |
| P-23448 | 3/23/2016 | Target Deck_3_24_16.pptx | <u>CVS-MDLT3-000027642</u> | CVS-MDLT3-000027663 | | | | | | | | | |
| P-23449 | 3/25/2016 | MAQ Review | <u>CVS-MDLT3-000027708</u> | CVS-MDLT3-000027711 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|--------------------------|--|--|--|--|--|--|--|--|--|
| P-23450 | 1/16/2013 | Working Group Summary 1.10.13doc.doc;Working Group Survey_Proposed Concepts WG Co-Chairs 1-16-13.docx | CVS-MDLT3-000030617 | CVS-MDLT3-000030632 | | | | | | | | | |
| P-23451 | 6/30/2014 | Store Program Review | CVS-MDLT3-000033454 | CVS-MDLT3-000033455.0003 | | | | | | | | | |
| P-23452 | 1/9/2014 | Professional Practices Group 2014 Team Strategy | CVS-MDLT3-000033491 | CVS-MDLT3-000033492.0032 | | | | | | | | | |
| P-23453 | 10/16/2018 | Pharmacy Professional Services Resource Planning | CVS-MDLT3-000144580 | CVS-MDLT3-000144621 | | | | | | | | | |
| P-23454 | 10/31/2017 | CSDP Q3 2017 Review.xlsx | CVS-MDLT3-000140039 | CVS-MDLT3-000140039 | | | | | | | | | |
| P-23455 | 3/16/2018 | High MED Patients Review February 2018.xlsx | CVS-MDLT3-000140040 | CVS-MDLT3-000140040 | | | | | | | | | |
| P-23456 | 7/16/2019 | High MME Patients Review June 2019.xlsx | CVS-MDLT3-000140041 | CVS-MDLT3-000140041 | | | | | | | | | |
| P-23457 | 12/6/2012 | Maximum Allowable Quantity (MAQ) Overview | CVS-MDLT3-000140033 | CVS-MDLT3-000140038 | | | | | | | | | |
| P-23458 | 1/23/2015 | The perfect storm opioid risks and holy trinity | CVS-DR22-000004877 | CVS-DR22-000004878 | | | | | | | | | |
| P-23459 | 2/12/2002 | Testimony Submitted on behalf of CVS Pharmacy to US Senate | NA | NA | | | | | | | | | |
| P-23460 | 10/12/2010 | Email re IRRS and Viper Analyst's questions about IRRs | CVS-NYAG-000012120 | CVS-NYAG-000012120 | | | | | | | | | |
| P-23461 | 11/5/2012 | RxConnect Prescriber Hard Stop Messaging | CVS-NYAG-000059779 | CVS-NYAG-000059780 | | | | | | | | | |
| P-23462 | 1/18/2013 | FW: URGENT: CVS All Status | SA AGI 00069086 | SA AGI 00069087 | | | | | | | | | |
| P-23463 | 1/25/2013 | AGI slides for JAMA article.pptx | SA AGI 00069097 | SA AGI 00069099 | | | | | | | | | |
| P-23464 | 1/14/2013 | RE: Internal Algorithm Prescriber Metric and Percentile Reports | SA AGI 00073111 | SA AGI 00073112 | | | | | | | | | |
| P-23465 | 2/16/2012 | A couple of things | SA AGI 00075489 | SA AGI 00075500 | | | | | | | | | |
| P-23466 | 6/11/2012 | RE: Materials | SA AGI 00075670 | SA AGI 00075769 | | | | | | | | | |
| P-23467 | 1/24/2015 | re Oxycodone Policy | CVS-MDLT3-000089901 | CVS-MDLT3-000089903 | | | | | | | | | |
| P-23468 | 2013 | CVS Caremark 2013 Annual Report; Redefining What's Possible | N/A | N/A | | | | | | | | | |
| P-23469 | NA | Aivazis combined personnel file | CVS-MDLT3-000154655 | CVS-MDLT3-000155118 | | | | | | | | | |
| P-23470 | NA | Davis combined personnel file | CVS-MDLT3-000130421 | CVS-MDLT3-000130746 | | | | | | | | | |
| P-23471 | NA | Grimes combined personnel file | CVS-MDLT3-000131394 | CVS-MDLT3-000132144 | | | | | | | | | |
| P-23472 | NA | Harrington combined personnel file | CVS-MDLT3-000140044 | CVS-MDLT3-000145226 | | | | | | | | | |
| P-23473 | NA | Hartman combined personnel file | CVS-MDLT3-000139723 | CVS-MDLT3-000140043 | | | | | | | | | |
| P-23474 | NA | Tankut combined personnel file | CVS-MDLT3-000130747 | CVS-MDLT3-000131092 | | | | | | | | | |
| P-23475 | NA | Travassos combined personnel file | CVS-MDLT3-000139474 | CVS-MDLT3-000139722 | | | | | | | | | |
| P-23476 | 3/17/2021 | Declaration of Christopher Ivanoski | NA | NA | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-23477 | 9/14/2015 | 2015 Prescriber reinstatement cases | CVS-MDLT3-000075772 | CVS-MDLT3-000075781 | | | | | | | | | |
| P-23478 | 1/6/2012 | Protocol for Dispensing Narcotic Drugs for Pain Treatment | CVS-MDLT1B-0000012540 | CVS-MDLT1B-0000012541 | | | | | | | | | |
| P-23479 | 9/28/2017 | Controlled substance forms to sign re store 3304 action plan and CR sign off | CVS-MDLT3-000100735 | CVS-MDLT3-000100737 | | | | | | | | | |
| P-23560 | 12/31/2000 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2000 | PLTF_2804_000117735 | PLTF_2804_000118147 | | | | | | | | | |
| P-23561 | 12/31/2001 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2001 | PLTF_2804_000118148 | PLTF_2804_000119235 | | | | | | | | | |
| P-23563 | 12/31/2002 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2002 | PLTF_2804_000119236 | PLTF_2804_000119958 | | | | | | | | | |
| P-23564 | 12/31/2003 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2003 | PLTF_2804_000119959 | PLTF_2804_000120657 | | | | | | | | | |
| P-23565 | 12/31/2004 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2004 | PLTF_2804_000120658 | PLTF_2804_000121625 | | | | | | | | | |
| P-23566 | 12/31/2005 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2005 | PLTF_2804_000121626 | PLTF_2804_000122352 | | | | | | | | | |
| P-23567 | 12/31/2006 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006 | PLTF_2804_000122353 | PLTF_2804_000122958 | | | | | | | | | |
| P-23568 | 12/31/2006 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006 | PLTF_2804_000122959 | PLTF_2804_000122999 | | | | | | | | | |
| P-23569 | 12/31/2006 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006 | PLTF_2804_000123000 | PLTF_2804_000123043 | | | | | | | | | |
| P-23570 | 12/31/2006 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006 | PLTF_2804_000123044 | PLTF_2804_000123080 | | | | | | | | | |
| P-23571 | 12/31/2006 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006 | PLTF_2804_000123081 | PLTF_2804_000123210 | | | | | | | | | |
| P-23572 | 12/31/2006 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2006 | PLTF_2804_000123211 | PLTF_2804_000123215 | | | | | | | | | |
| P-23573 | 12/31/2007 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007 | PLTF_2804_000123216 | PLTF_2804_000123818 | | | | | | | | | |
| P-23574 | 12/31/2007 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007 | PLTF_2804_000123819 | PLTF_2804_000123861 | | | | | | | | | |
| P-23575 | 12/31/2007 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007 | PLTF_2804_000123862 | PLTF_2804_000123908 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-23576 | 12/31/2007 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007 | PLTF_2804_000123909 | PLTF_2804_000123940 | | | | | | | | | |
| P-23577 | 12/31/2007 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007 | PLTF_2804_000123941 | PLTF_2804_000124071 | | | | | | | | | |
| P-23578 | 12/31/2007 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2007 | PLTF_2804_000124072 | PLTF_2804_000124077 | | | | | | | | | |
| P-23579 | 12/31/2008 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008 | PLTF_2804_000124078 | PLTF_2804_000124705 | | | | | | | | | |
| P-23580 | 12/31/2008 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008 | PLTF_2804_000124706 | PLTF_2804_000124747 | | | | | | | | | |
| P-23581 | 12/31/2008 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008 | PLTF_2804_000124748 | PLTF_2804_000124791 | | | | | | | | | |
| P-23582 | 12/31/2008 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008 | PLTF_2804_000124792 | PLTF_2804_000124836 | | | | | | | | | |
| P-23583 | 12/31/2008 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008 | PLTF_2804_000124837 | PLTF_2804_000124969 | | | | | | | | | |
| P-23584 | 12/31/2008 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2008 | PLTF_2804_000124970 | PLTF_2804_000124975 | | | | | | | | | |
| P-23585 | 12/31/2009 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009 | PLTF_2804_000124976 | PLTF_2804_000125616 | | | | | | | | | |
| P-23586 | 12/31/2009 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009 | PLTF_2804_000125617 | PLTF_2804_000125660 | | | | | | | | | |
| P-23587 | 12/31/2009 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009 | PLTF_2804_000125661 | PLTF_2804_000125706 | | | | | | | | | |
| P-23588 | 12/31/2009 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009 | PLTF_2804_000125707 | PLTF_2804_000125759 | | | | | | | | | |
| P-23589 | 12/31/2009 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009 | PLTF_2804_000125760 | PLTF_2804_000125919 | | | | | | | | | |
| P-23590 | 12/31/2009 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2009 | PLTF_2804_000125920 | PLTF_2804_000125924 | | | | | | | | | |
| P-23591 | 12/31/2010 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010 | PLTF_2804_000125925 | PLTF_2804_000126613 | | | | | | | | | |
| P-23592 | 12/31/2010 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010 | PLTF_2804_000126614 | PLTF_2804_000126668 | | | | | | | | | |
| P-23593 | 12/31/2010 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010 | PLTF_2804_000126669 | PLTF_2804_000126705 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-23594 | 12/31/2010 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010 | PLTF_2804_000126706 | PLTF_2804_000126739 | | | | | | | | | |
| P-23595 | 12/31/2010 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010 | PLTF_2804_000126740 | PLTF_2804_000126874 | | | | | | | | | |
| P-23596 | 12/31/2010 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2010 | PLTF_2804_000126875 | PLTF_2804_000126880 | | | | | | | | | |
| P-23597 | 12/31/2011 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011 | PLTF_2804_000126881 | PLTF_2804_000127358 | | | | | | | | | |
| P-23598 | 12/31/2011 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011 | PLTF_2804_000127359 | PLTF_2804_000127393 | | | | | | | | | |
| P-23599 | 12/31/2011 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011 | PLTF_2804_000127394 | PLTF_2804_000127429 | | | | | | | | | |
| P-23600 | 12/31/2011 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011 | PLTF_2804_000127430 | PLTF_2804_000127464 | | | | | | | | | |
| P-23601 | 12/31/2011 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011 | PLTF_2804_000127465 | PLTF_2804_000127585 | | | | | | | | | |
| P-23602 | 12/31/2011 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2011 | PLTF_2804_000127586 | PLTF_2804_000127591 | | | | | | | | | |
| P-23603 | 12/31/2012 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012 | PLTF_2804_000127592 | PLTF_2804_000128135 | | | | | | | | | |
| P-23604 | 12/31/2012 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012 | PLTF_2804_000128136 | PLTF_2804_000128174 | | | | | | | | | |
| P-23605 | 12/31/2012 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012 | PLTF_2804_000128175 | PLTF_2804_000128209 | | | | | | | | | |
| P-23606 | 12/31/2012 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012 | PLTF_2804_000128210 | PLTF_2804_000128242 | | | | | | | | | |
| P-23607 | 12/31/2012 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012 | PLTF_2804_000128243 | PLTF_2804_000128345 | | | | | | | | | |
| P-23608 | 12/31/2012 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2012 | PLTF_2804_000128346 | PLTF_2804_000128349 | | | | | | | | | |
| P-23609 | 12/31/2013 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013 | PLTF_2804_000128350 | PLTF_2804_000128980 | | | | | | | | | |
| P-23610 | 12/31/2013 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013 | PLTF_2804_000128981 | PLTF_2804_000129022 | | | | | | | | | |
| P-23611 | 12/31/2013 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013 | PLTF_2804_000129023 | PLTF_2804_000129060 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-23612 | 12/31/2013 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013 | PLTF_2804_000129061 | PLTF_2804_000129102 | | | | | | | | | |
| P-23613 | 12/31/2013 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013 | PLTF_2804_000129103 | PLTF_2804_000129261 | | | | | | | | | |
| P-23614 | 12/31/2013 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2013 | PLTF_2804_000129262 | PLTF_2804_000129266 | | | | | | | | | |
| P-23615 | 12/31/2014 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014 | PLTF_2804_000129267 | PLTF_2804_000129745 | | | | | | | | | |
| P-23616 | 12/31/2014 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014 | PLTF_2804_000129746 | PLTF_2804_000129795 | | | | | | | | | |
| P-23617 | 12/31/2014 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014 | PLTF_2804_000129796 | PLTF_2804_000129835 | | | | | | | | | |
| P-23618 | 12/31/2014 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014 | PLTF_2804_000129836 | PLTF_2804_000129873 | | | | | | | | | |
| P-23619 | 12/31/2014 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014 | PLTF_2804_000129874 | PLTF_2804_000130022 | | | | | | | | | |
| P-23620 | 12/31/2014 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2014 | PLTF_2804_000130023 | PLTF_2804_000130028 | | | | | | | | | |
| P-23621 | 12/31/2015 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015 | PLTF_2804_000130029 | PLTF_2804_000130669 | | | | | | | | | |
| P-23622 | 12/31/2015 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015 | PLTF_2804_000130670 | PLTF_2804_000130703 | | | | | | | | | |
| P-23623 | 12/31/2015 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015 | PLTF_2804_000130704 | PLTF_2804_000130758 | | | | | | | | | |
| P-23624 | 12/31/2015 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015 | PLTF_2804_000130759 | PLTF_2804_000130811 | | | | | | | | | |
| P-23625 | 12/31/2015 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015 | PLTF_2804_000130812 | PLTF_2804_000130938 | | | | | | | | | |
| P-23626 | 12/31/2015 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2015 | PLTF_2804_000130939 | PLTF_2804_000130944 | | | | | | | | | |
| P-23627 | 12/31/2016 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2016 | PLTF_2804_000130945 | PLTF_2804_000131667 | | | | | | | | | |
| P-23628 | 12/31/2017 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2017 | PLTF_2804_000131668 | PLTF_2804_000132720 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-23640 | N/A | Automation of Reports and Consolidated Orders System ("ARCOS") electronic data, received from the Drug Enforcement Administration | N/A | N/A | | | | | | | | | |
| P-23645 | N/A | NDC Dictionary Instructions Drug Enforcement Administration, October 2010. | PLTF_2804_000117715 | PLTF_2804_000117720 | | | | | | | | | |
| P-23648 | 5/16/2007 | McKesson Operations Manual Lifestyle Drug Monitoring Program | MCKMDL00355251 | MCKMDL00355256 | | | | | | | | | |
| P-23649 | 12/31/1997 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 1997 | N/A | N/A | | | | | | | | | |
| P-23650 | 12/31/1998 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 1998 | N/A | N/A | | | | | | | | | |
| P-23651 | 12/31/1999 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 1999 | N/A | N/A | | | | | | | | | |
| P-23652 | 12/31/2018 | "ARCOS Retail Drug Summary Reports," Drug Enforcement Administration, 2018 | N/A | N/A | | | | | | | | | |
| P-23654 | 1997 | ARCOS Registrant Handbook 1997 Version | PLTF_2804_000116946 | PLTF_2804_000117136 | | | | | | | | | |
| P-23699 | 2013 | Joseph Rannazzisi Drug Trends, Albuquerque, New Mexico, March 2013 | N/A | N/A | | | | | | | | | |
| P-23720 | 11/4/2011 | CDC, Morbidity and Mortality Weekly Report | N/A | N/A | | | | | | | | | |
| P-23733 | 5/2/2008 | Settlement and Release Agreement and Administrative Memorandum of Agreement | MCKMDL00337001 | MCKMDL00337024 | | | | | | | | | |
| P-23738 | 5/17/2006 | Letter from DEA to Mr. Todd Polarolo regarding regulatory investigation | WAGMDL00753476 | WAGMDL00753641 | | | | | | | | | |
| P-23764 | 7/11/2017 | Mallinckrodt Agrees to pay record \$35 million settlement for failure to report suspicious orders of pharmaceutical drugs and for record keeping violations | N/A | N/A | | | | | | | | | |
| P-23765 | 10/2/2013 | DEA Diversion Investigators Manual with 2013 DEA cover letter | CAH_MDL2804_01563592 | CAH_MDL2804_01563980 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-23766 | 6/22/2007 | AmerisourceBergen Corporation, AmerisourceBergen Signs Agreement with DEA Leading to Reinstatement of its Orlando Distribution Center Suspended License to Distribute Controlled Substances | N/A | N/A | | | | | | | | | |
| P-23787 | 11/29/2007 | Cardinal Health, Press Release, Cardinal Health Receives DEA Order to Temporarily Cease Distribution of Controlled Substances from Auburn Wash. Facility | N/A | N/A | | | | | | | | | |
| P-23795 | 6/1/2007 | Opioid Analgesics for Pain Management: Critical Thinking to Balance Benefits & Risk | CHI_001222272 | CHI_001222287 | | | | | | | | | |
| P-23804 | 6/30/2017 | Masters Pharmaceutical Inc v Drug Enforcement Administration | N/A | N/A | | | | | | | | | |
| P-23842 | 12/7/2007 | Cardinal Health, Press Release, Cardinal Health to Cease Distribution of Controlled Substances from Florida Facility | N/A | N/A | | | | | | | | | |
| P-23843 | 7/10/2017 | Administrative Memorandum of Agreement between DEA and Mallinckrodt | N/A | N/A | | | | | | | | | |
| P-23845 | 4/25/2007 | Letter to DEA from Counsel to McKesson | MCKMDL00330924 | MCKMDL00330930 | | | | | | | | | |
| P-23854 | 11/9/2012 | Email and attachments, RE: Today's IRR | CVS-MDLT1-000055836 | CVS-MDLT1-000055966 | | | | | | | | | |
| P-23855 | 6/10/2013 | Email, RE: Walgreens 12679 | WAGMDL00032660 | WAGMDL00032662 | | | | | | | | | |
| P-23856 | 4/4/2012 | Processing Suspicious Orders and Loss of Controlled Drugs | WAGFLDEA000000028 | WAGFLDEA000000028 | | | | | | | | | |
| P-23857 | 10/27/2011 | Email, DEA Business Reason | WAGMDL00119542 | WAGMDL00119548 | | | | | | | | | |
| P-23858 | 3/11/2013 | Email, Oxy timeline | WAGMDL00246016 | WAGMDL00246016 | | | | | | | | | |
| P-23859 | 1/31/2004 | Chemical Handler's Manual: A Guide to Chemical Control Regulations | WAGMDL00395965 | WAGMDL00396033 | | | | | | | | | |
| P-23860 | 5/9/2012 | Email, FW: Drug Quantities | WAGMDL00751871 | WAGMDL00751872 | | | | | | | | | |
| P-23861 | 8/9/2017 | Email with attachment, RE: RAD/ABC meeting next week to review Action Item tracker | WAGMDL00370894 | WAGMDL00371010 | | | | | | | | | |
| P-23862 | 9/14/2015 | Email, RE: Rx Integrity Process Summaries | WAGMDL00037073 | WAGMDL00037075 | | | | | | | | | |
| P-23863 | 12/31/2012 | Email, SIMS Enhancement for Controlled Substance Orders | WAGMDL00700240 | WAGMDL00700241 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|---------------------------|---------------------------|--|--|--|--|--|--|--|--|--|
| P-24013 | N/A | Oxycodone and Hydrocodone Shipments to Retail and Chain Pharmacies, by County, 2006-2014 | N/A | N/A | | | | | | | | | |
| P-24761 | 10/21/2008 | When Good Medicine Becomes Bad Webcast Transcript | N/A | N/A | | | | | | | | | |
| P-24762 | 2010 | ESP Article - the First Pain Advocacy Step is to Take One, P. Arnstein | N/A | N/A | | | | | | | | | |
| P-24768 | 2005 | ESP.com - Glossary of Terms | N/A | N/A | | | | | | | | | |
| P-25047 | 7/3/2007 | Southwood Drug Enforcement Agency Decision at 72 FR 36487 | N/A | N/A | | | | | | | | | |
| P-25191 | 11/4/2009 | RE: Oxy 30 and 15 Mg CII Issue | Acquired_Actavis_00224011 | Acquired_Actavis_00224012 | | | | | | | | | |
| P-25193 | 6/21/2012 | RE: Walmart Oxy 30mg | Acquired_Actavis_00382802 | Acquired_Actavis_00382808 | | | | | | | | | |
| P-25194 | 9/14/2009 | RE: Walmart - Revised Offer | Acquired_Actavis_00391960 | Acquired_Actavis_00391964 | | | | | | | | | |
| P-25195 | 11/9/2011 | Re: Walmart Oxycodone | ACTAVIS0338574 | ACTAVIS0338579 | | | | | | | | | |
| P-25196 | 11/8/2011 | RE: oxycontin | ACTAVIS0338793 | ACTAVIS0338796 | | | | | | | | | |
| P-25197 | 6/29/2011 | FW: Opana ER 7.5mg & 15mg | ACTAVIS0361535 | ACTAVIS0361538 | | | | | | | | | |
| P-25198 | 9/3/2009 | FW: Walmart Offer | ACTAVIS0639662 | ACTAVIS0639663 | | | | | | | | | |
| P-25199 | 2/25/2010 | Stand-Alone Agreement between Walmart and Actavis | ACTAVIS1144540 | ACTAVIS1144543 | | | | | | | | | |
| P-25200 | 6/22/2012 | Email on Walmart Oxy shipments | ALLERGAN_MDL_00144683 | ALLERGAN_MDL_00144685 | | | | | | | | | |
| P-25201 | 6/26/2012 | FW: Oxycodone 15mg and 30mg | ALLERGAN_MDL_00231481 | ALLERGAN_MDL_00231487 | | | | | | | | | |
| P-25393 | 3/24/2011 | Market 3 Meeting / Market 28 Pharmacy Meeting / Sarasota Walgreen's Diversion Presentation | WAGFLDEA00000925 | WAGFLDEA00000987 | | | | | | | | | |
| P-25397 | 3/1/2012 | DEA Compliance Committee Formation (Invitation) | WAGFLDEA00001536 | WAGFLDEA00001536 | | | | | | | | | |
| P-25398 | 5/31/2011 | Florida June Focus on Compliance- Filling Pain Management Prescriptions (FLORIDA MARKETS ONLY) | WAGFLDEA00001704 | WAGFLDEA00001709 | | | | | | | | | |
| P-25413 | 10/3/2013 | Rx Integrity Update Market Leadership Meeting | WAGMDL00018597 | WAGMDL00018610 | | | | | | | | | |
| P-25476 | 4/26/2012 | Anti-Diversion Walgreens 2012 PPT | WAGFLAG00063627 | WAGFLAG00063645 | | | | | | | | | |
| P-25479 | 6/13/2013 | FW: Site-visit locations | WAGMDL00021431 | WAGMDL00021433 | | | | | | | | | |
| P-25481 | 6/5/2015 | RE: IA - Audit response for B | WAGMDL00062359 | WAGMDL00062361 | | | | | | | | | |
| P-25482 | 12/20/2012 | Target Drug Good Faith Dispensing Policy V2 | WAGMDL00066585 | WAGMDL00066591 | | | | | | | | | |
| P-25489 | 9/28/2016 | RE: SOM documents | WAGMDL00403753 | WAGMDL00403756 | | | | | | | | | |
| P-25490 | 9/22/2016 | RE: number of SOM blocks for the year | WAGMDL00423925 | WAGMDL00423928 | | | | | | | | | |
| P-25492 | 3/22/2015 | Controlled Substance Order Monitoring Process Review_Report_Final031815 | WAGMDL00674320 | WAGMDL00674348 | | | | | | | | | |
| P-25493 | 2/5/2013 | Patty Suspicious Order_pd | WAGMDL00675580 | WAGMDL00675580 | | | | | | | | | |
| P-25494 | 10/18/1999 | Suspicious Controlled Drug report | WAGMDL00751562 | WAGMDL00751563 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|------------------|------------------|--|--|--|--|--|--|--|--|--|
| P-25496 | 4/6/2015 | RE: Dr. Whitecloud | WAGMDL00774369 | WAGMDL00774371 | | | | | | | | | |
| P-25497 | 2/23/2018 | RE: Question | WAGMDL00774438 | WAGMDL00774439 | | | | | | | | | |
| P-25498 | 10/31/2013 | RE: WAG #6574 - GFD concern | WAGMDL00774502 | WAGMDL00774509 | | | | | | | | | |
| P-25500 | 11/27/2017 | RE: Inquiry to Block 2 Physicians | WAGMDL00774755 | WAGMDL00774756 | | | | | | | | | |
| P-25501 | 5/14/2009 | TOP100_By_Rxs_04.2009 | WAGMDL00774761 | WAGMDL00774768 | | | | | | | | | |
| P-25502 | 11/26/2012 | Executive Summary - DEA Action Plan | WAGMDL00774769 | WAGMDL00774772 | | | | | | | | | |
| P-25503 | 12/21/2012 | FW: top pbr report | WAGMDL00781632 | WAGMDL00781633 | | | | | | | | | |
| P-25504 | 4/23/2012 | Invitation (delegated): Jupiter Business Continuity Plan: Cardinal Meeting (Apr 26 12:30 PM CDT in Store OPs 1- 200 Building) | WAGMDL00844988 | WAGMDL00844998 | | | | | | | | | |
| P-25505 | 2/22/2013 | RE: Cardinal and DEA/Kaufman Call to Kermit | WAGMDL00851368 | WAGMDL00851372 | | | | | | | | | |
| P-25506 | 1/28/2013 | Good Faith Dispensing Policy - Drug Diversion Self-Education Module | WAGMDL00851511 | WAGMDL00851542 | | | | | | | | | |
| P-25507 | 3/14/2017 | Re: PDQ orders data for C2's | WAGNYNS00009557 | WAGNYNS00009561 | | | | | | | | | |
| P-25509 | 1/29/2013 | DEA Weekly Report | WAGNYNS00032974 | WAGNYNS00032975 | | | | | | | | | |
| P-25510 | 11/20/2013 | RE: Limit Analysis for 427079 | WAGNYNS00033400 | WAGNYNS00033403 | | | | | | | | | |
| P-25511 | 10/8/2013 | Data | WAGNYNS00037337 | WAGNYNS00037338 | | | | | | | | | |
| P-25512 | 2/28/2013 | RE: CII Processing Update | WAGNYNS00042370 | WAGNYNS00042372 | | | | | | | | | |
| P-25513 | 3/2/2020 | records request suffolk nassau | WAGNYNS00049768 | WAGNYNS00049768 | | | | | | | | | |
| P-25514 | 3/13/2020 | NY-flagged-orders | WAGNYNS00052075 | WAGNYNS00052075 | | | | | | | | | |
| P-25515 | 3/10/2020 | Research Report V6 Presentation | WAGNYNS00055995 | WAGNYNS00056051 | | | | | | | | | |
| P-25516 | 6/11/2020 | SORs (Nassau and Suffolk) | WAGNYNS00056073 | WAGNYNS00056073 | | | | | | | | | |
| P-25517 | 5/3/2012 | WALGREENS Rx Quick Order Add Items by Item Description AS/400 Steps | WAGFLDEA00000293 | WAGFLDEA00000293 | | | | | | | | | |
| P-25518 | 10/22/2011 | CS Update - FI Prescription Drug Monitoring Program E-FORCSE | WAGFLDEA00000403 | WAGFLDEA00000405 | | | | | | | | | |
| P-25519 | 2/17/2012 | DEA conference | WAGFLDEA00000520 | WAGFLDEA00000521 | | | | | | | | | |
| P-25520 | 1/14/2011 | Ft Pierce | WAGFLDEA00000867 | WAGFLDEA00000871 | | | | | | | | | |
| P-25521 | 1/28/2011 | Rx Numbers - Oviedo FL (Svihra) | WAGFLDEA00000885 | WAGFLDEA00000886 | | | | | | | | | |
| P-25522 | 2/9/2011 | Oviedo FL (Stahmann) | WAGFLDEA00000887 | WAGFLDEA00000889 | | | | | | | | | |
| P-25523 | 2/11/2011 | Oviedo, FL | WAGFLDEA00000890 | WAGFLDEA00000890 | | | | | | | | | |
| P-25524 | 2/11/2011 | Re: Fw: 682971 - OXYCODONE HCL 30MG TAB | WAGFLDEA00000891 | WAGFLDEA00000901 | | | | | | | | | |
| P-25526 | 4/14/2011 | Re: Store #06997 | WAGFLDEA00001032 | WAGFLDEA00001033 | | | | | | | | | |
| P-25527 | 8/20/2011 | FL FOC - Recap of Meeting with DEA (Forbes) | WAGFLDEA00001162 | WAGFLDEA00001167 | | | | | | | | | |
| P-25528 | 1/12/2012 | Re: Fw: Oxycodone fills | WAGFLDEA00001728 | WAGFLDEA00001729 | | | | | | | | | |
| P-25529 | 9/21/2010 | CII-CV Controlled Substances Mini Audit for Jupiter June 10-Aug 10 | WAGFLDEA00001747 | WAGFLDEA00001766 | | | | | | | | | |
| P-25530 | 11/19/2010 | Internal Audit Report - DEA Compliance — Jupiter Distribution Center | WAGFLDEA00001767 | WAGFLDEA00001775 | | | | | | | | | |

| | | | | | | | | | | | | | | |
|---------|------------|--|---------------------------|---------------------------|--|--|--|--|--|--|--|--|--|--|
| P-25531 | 1/1/2012 | Handling Suspicious Orders and Loss of Controlled Drugs | WAGFLDEA00001856 | WAGFLDEA00001857 | | | | | | | | | | |
| P-25532 | 1/22/2011 | WAGFLDEA00001314_unitized | WAGFLDEA00001314_unitized | WAGFLDEA00001315_unitized | | | | | | | | | | |
| P-25533 | 9/2/2013 | WAG/ABDC - First Amendment to the Pharmaceutical Purchase And Distribution Agreement | WAGMDL00000390 | WAGMDL00000393 | | | | | | | | | | |
| P-25534 | 9/1/2013 | WAG / ABDC - Second Amendment to the Pharmaceutical Purchase And Distribution Agreement | WAGMDL00000394 | WAGMDL00000397 | | | | | | | | | | |
| P-25535 | 10/1/2014 | Settlement Agreement & Fourth Amendment to the Pharmaceutical Purchase And Distribution Agreement | WAGMDL00000402 | WAGMDL00000416 | | | | | | | | | | |
| P-25536 | 8/9/2017 | RE: SOM | WAGMDL00006645 | WAGMDL00006669 | | | | | | | | | | |
| P-25538 | 11/13/2014 | RE: Rex Deck - almost complete | WAGMDL00015270 | WAGMDL00015286 | | | | | | | | | | |
| P-25540 | 7/3/2013 | Powerpoint for this morning's meeting | WAGMDL00021351 | WAGMDL00021361 | | | | | | | | | | |
| P-25542 | 4/4/2013 | Re: Thought from the Project forest meetings | WAGMDL00021479 | WAGMDL00021479 | | | | | | | | | | |
| P-25543 | 4/17/2013 | RE: ABC Threshold Analysis | WAGMDL00021613 | WAGMDL00021616 | | | | | | | | | | |
| P-25545 | 5/2/2013 | CDC Data Project | WAGMDL00030705 | WAGMDL00030705 | | | | | | | | | | |
| P-25546 | 4/23/2018 | Silence the Stigma: Opioid Use Disorder and Addressing Stigma Walgreen Co./Purdue University College of Pharmacy | WAGMDL00035669 | WAGMDL00035683 | | | | | | | | | | |
| P-25547 | 6/7/2017 | RE: Drug Takeback Program | WAGMDL00038786 | WAGMDL00038791 | | | | | | | | | | |
| P-25548 | 12/15/2015 | FW: RxIC Approvals Requested | WAGMDL00042452 | WAGMDL00042464 | | | | | | | | | | |
| P-25551 | 8/12/2016 | RE: Media Inquiry, Bakersfield Californian by Noon PT tomorrow | WAGMDL00044770 | WAGMDL00044773 | | | | | | | | | | |
| P-25552 | 2/22/2013 | RE: Cardinal Health/Walgreens QRA Discussion | WAGMDL00049750 | WAGMDL00049751 | | | | | | | | | | |
| P-25553 | 2/10/2017 | RE: Approved Controlled Substance Order for store 16559 | WAGMDL00056871 | WAGMDL00056877 | | | | | | | | | | |
| P-25554 | 7/2/2015 | RE: C-2 order | WAGMDL00059074 | WAGMDL00059081 | | | | | | | | | | |
| P-25555 | 3/1/2013 | FW: Market leadership presentation | WAGMDL00060739 | WAGMDL00060767 | | | | | | | | | | |
| P-25556 | 3/9/2018 | FW: EDI OMIT Codes | WAGMDL00060931 | WAGMDL00060933 | | | | | | | | | | |
| P-25557 | 1/30/2016 | Re: Policy Question | WAGMDL00062061 | WAGMDL00062061 | | | | | | | | | | |
| P-25558 | 11/13/2017 | RE: Requesting your support for AMCP Day of Education - CE documentation | WAGMDL00064176 | WAGMDL00064186 | | | | | | | | | | |
| P-25559 | 6/30/2017 | Multi Wholesaler Options | WAGMDL00076693 | WAGMDL00076695 | | | | | | | | | | |
| P-25560 | 11/25/2015 | FW: CSOS Received Quantity Touch Base | WAGMDL00079943 | WAGMDL00079946 | | | | | | | | | | |
| P-25561 | 2/27/2014 | RE: DEA Publishes Proposal to Reschedule Hydrocodone | WAGMDL00085856 | WAGMDL00085858 | | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25562 | 3/25/2013 | FW: Controlled Substance Order Quantity Override Form | WAGMDL00092708 | WAGMDL00092709 | | | | | | | | | |
| P-25563 | 8/14/2013 | RE: Controlled Substance Order Quantity Override Form | WAGMDL00095568 | WAGMDL00095569 | | | | | | | | | |
| P-25564 | 8/13/2012 | RE: Controlled Substance Order Quantity Override Form | WAGMDL00101703 | WAGMDL00101706 | | | | | | | | | |
| P-25565 | 2/8/2013 | RE: 11137 generic lortab | WAGMDL00101769 | WAGMDL00101770 | | | | | | | | | |
| P-25566 | 11/12/2012 | RE: GFD Audit for store 2865 in Modesto, CA | WAGMDL00102390 | WAGMDL00102392 | | | | | | | | | |
| P-25567 | 2/14/2013 | Reports for DEA | WAGMDL00102645 | WAGMDL00102648 | | | | | | | | | |
| P-25568 | 4/11/2013 | FW: Controlled Substance Order Quantity Override Form | WAGMDL00106910 | WAGMDL00106912 | | | | | | | | | |
| P-25569 | 12/26/2012 | RE: Controlled Substance Order Quantity Override Form | WAGMDL00107173 | WAGMDL00107177 | | | | | | | | | |
| P-25570 | 12/31/2012 | FW: RxIntegrity Investigation for store 05814 | WAGMDL00107267 | WAGMDL00107271 | | | | | | | | | |
| P-25571 | 10/31/2012 | FW: Controlled Substance Order Quantity Override Form | WAGMDL00107384 | WAGMDL00107386 | | | | | | | | | |
| P-25572 | 8/23/2012 | FW: Controlled Substance Order Quantity Override Form | WAGMDL00107468 | WAGMDL00107469 | | | | | | | | | |
| P-25573 | 8/15/2012 | FW: Controlled Substance Order Quantity Override Form | WAGMDL00107473 | WAGMDL00107474 | | | | | | | | | |
| P-25574 | 10/12/2012 | FW: Walgreens 04243 | WAGMDL00107497 | WAGMDL00107500 | | | | | | | | | |
| P-25575 | 1/31/2013 | FW: Norco 7.5- 7158 | WAGMDL00107557 | WAGMDL00107564 | | | | | | | | | |
| P-25576 | 1/31/2013 | District 200 Hydrocodone 7.5-325 purchases | WAGMDL00107565 | WAGMDL00107565 | | | | | | | | | |
| P-25577 | 11/13/2012 | RE: can I see an example of what you faxed to DEA | WAGMDL00107582 | WAGMDL00107584 | | | | | | | | | |
| P-25578 | 3/1/2017 | RE: Opioid Medical Policy | WAGMDL00108483 | WAGMDL00108485 | | | | | | | | | |
| P-25579 | 9/21/2017 | RE: Controlled Substance Order Quantity Override Requests | WAGMDL00110737 | WAGMDL00110738 | | | | | | | | | |
| P-25580 | 10/5/2012 | RE: oxycodone | WAGMDL00127695 | WAGMDL00127695 | | | | | | | | | |
| P-25581 | 8/10/2017 | RE: C2 NDC - missing SOM limit | WAGMDL00128748 | WAGMDL00128750 | | | | | | | | | |
| P-25582 | 8/10/2017 | Not_in_SOM | WAGMDL00128751 | WAGMDL00128751 | | | | | | | | | |
| P-25583 | 12/13/2016 | Meeting Minutes - DMIT 1232 - 340B Consider DEA Limits - 12/13/2016 | WAGMDL00129005 | WAGMDL00129007 | | | | | | | | | |
| P-25584 | 7/8/2016 | RE: INC000016708337: Raised for 340B ordering | WAGMDL00129607 | WAGMDL00129610 | | | | | | | | | |
| P-25585 | 3/13/2013 | FW: Perrysburg C-II In-Stock Status | WAGMDL00131602 | WAGMDL00131602 | | | | | | | | | |
| P-25586 | 8/9/2012 | FW: Controlled Substance Order Quantity Override Form | WAGMDL00132758 | WAGMDL00132759 | | | | | | | | | |
| P-25587 | 8/16/2017 | CD orders- 2 | WAGMDL00183798 | WAGMDL00208716 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-----------------|-----------------|--|--|--|--|--|--|--|--|--|
| P-25589 | 10/12/2016 | Purdue Compass communication review requested | WAGMDL00234555 | WAGMDL00234559 | | | | | | | | | |
| P-25592 | 3/6/2013 | Red Flag to consider in the reponses | WAGMDL00237599 | WAGMDL00237605 | | | | | | | | | |
| P-25593 | 9/22/2014 | RE: HCP Formulary Items | WAGMDL00244813 | WAGMDL00244815 | | | | | | | | | |
| P-25594 | 4/8/2013 | New Hire Docs | WAGMDL00245867 | WAGMDL00245920 | | | | | | | | | |
| P-25600 | 10/1/2012 | FW: OXYCODONE no longer being ordered via PDQ | WAGMDL00252575 | WAGMDL00252576 | | | | | | | | | |
| P-25601 | 8/19/2013 | FW: ABC Call Recap Attachment ABC Store Visit Recap 7-16-13 | WAGFLAG00001076 | WAGFLAG00001078 | | | | | | | | | |
| P-25602 | 7/25/2018 | Merch SC Logistics Org Chart 7.24.18.vsd | WAGMDL00254645 | WAGMDL00254648 | | | | | | | | | |
| P-25603 | 12/23/2013 | RE: A Painful Dilemma | WAGMDL00267660 | WAGMDL00267667 | | | | | | | | | |
| P-25604 | 9/25/2012 | PDQ letter | WAGMDL00278104 | WAGMDL00278104 | | | | | | | | | |
| P-25605 | 10/5/2012 | FW: WAGs Line Limit C2 orders | WAGMDL00278108 | WAGMDL00278111 | | | | | | | | | |
| P-25606 | 1/15/2013 | RE: Tableau overview; Prescriber Dashboard User Guide | WAGFLAG00002633 | WAGFLAG00002641 | | | | | | | | | |
| P-25607 | 5/6/2013 | FW: ARCOS error Reports that need Correction | WAGMDL00282342 | WAGMDL00282345 | | | | | | | | | |
| P-25608 | 11/28/2012 | FW: DEA SERVES ORDER TO SHOW CAUSE TO THREE WALGREENS PHARMACIES | WAGMDL00282353 | WAGMDL00282354 | | | | | | | | | |
| P-25609 | 10/22/2012 | RE: Prescriber Leonard Haimes | WAGFLAG00007433 | WAGFLAG00007435 | | | | | | | | | |
| P-25610 | 8/1/1997 | ARCOS Registrant Handbook - V 1.0 (1997) DEA ARCOS Registrant Handbook | WAGMDL00282650 | WAGMDL00282841 | | | | | | | | | |
| P-25611 | 1/13/2017 | RE: CSOS Lock & Load | WAGMDL00282973 | WAGMDL00282981 | | | | | | | | | |
| P-25612 | 4/1/2013 | RE: 340B | WAGMDL00284079 | WAGMDL00284080 | | | | | | | | | |
| P-25613 | 4/17/2013 | CII Program Letter | WAGMDL00286210 | WAGMDL00286212 | | | | | | | | | |
| P-25614 | 4/1/2008 | Purchase Agmt for Wag Facilities_4-1-08_ABDC | WAGMDL00286213 | WAGMDL00286243 | | | | | | | | | |
| P-25615 | 4/3/2013 | Pharmaceutical Integrity Biosx | WAGMDL00289186 | WAGMDL00289188 | | | | | | | | | |
| P-25616 | 2/17/2015 | FW: Rx Integrity Internal Audit | WAGMDL00299885 | WAGMDL00299888 | | | | | | | | | |
| P-25617 | 4/8/2013 | FW: Blocking interstore transfers | WAGMDL00302946 | WAGMDL00302947 | | | | | | | | | |
| P-25618 | 3/20/2013 | FW: Cardinal Red Store Status | WAGMDL00303186 | WAGMDL00303187 | | | | | | | | | |
| P-25619 | 2/15/2013 | FW: draft communication | WAGMDL00303243 | WAGMDL00303245 | | | | | | | | | |
| P-25620 | 1/22/2016 | RE: Integrity Info Request Attachment Non-dispensing Pharmacist report for Jackie Donovan | WAGFLAG00024322 | WAGFLAG00024324 | | | | | | | | | |
| P-25621 | 5/22/2014 | RE: GFD Comments | WAGFLAG00028501 | WAGFLAG00028502 | | | | | | | | | |
| P-25622 | 6/25/2012 | Audit / Board of Pharmacy Inspection Report | WAGFLAG00069878 | WAGFLAG00069880 | | | | | | | | | |
| P-25623 | 7/17/2017 | RE: National TD GFD policy powerpoint; Stover- DM deck | WAGMDL00002899 | WAGMDL00002909 | | | | | | | | | |
| P-25624 | 9/12/2013 | RE: Cocktail example; Dur | WAGMDL00021191 | WAGMDL00021193 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25625 | 7/26/2017 | FW: REMINDER: (ACTION REQUIRED) PF Presentation Materials Attachment PF August 2017 PSTB_Rx Integrity PPT | WAGMDL00033704 | WAGMDL00033713 | | | | | | | | | |
| P-25626 | 2/7/2018 | RE: Advice on Dr issue | WAGMDL00042038 | WAGMDL00042039 | | | | | | | | | |
| P-25627 | 9/14/2016 | RE: scanning ID question | WAGMDL00057261 | WAGMDL00057263 | | | | | | | | | |
| P-25628 | 6/6/2012 | FW: Controlled Substance Order Quantity Override Process | WAGMDL00308178 | WAGMDL00308181 | | | | | | | | | |
| P-25629 | 10/10/2013 | Email Market 20 Attachment Market 20 (1) PPT | WAGMDL00060489 | WAGMDL00060506 | | | | | | | | | |
| P-25630 | 12/14/2012 | Draft 1 SOM war room process 12 14 12 | WAGMDL00308192 | WAGMDL00308212 | | | | | | | | | |
| P-25631 | 10/22/2012 | Email GFD PPT; Attachments Controlled Substance Action Plan (Market / District Leaders Version); Controlled Substance Action Plan (Stores Version) | WAGMDL00066600 | WAGMDL00066630 | | | | | | | | | |
| P-25632 | 10/19/2012 | WAG SOM | WAGMDL00308265 | WAGMDL00308266 | | | | | | | | | |
| P-25633 | 4/20/2018 | RE: Concern at 2670 RE: PA-C Leinweber | WAGMDL00090034 | WAGMDL00090036 | | | | | | | | | |
| P-25634 | 1/14/2013 | FW: Review application screens and proposed changes to make navigation easier | WAGMDL00308327 | WAGMDL00308349 | | | | | | | | | |
| P-25635 | 8/28/2017 | RE: Joseph Sierra | WAGMDL00090935 | WAGMDL00090936 | | | | | | | | | |
| P-25636 | 1/3/2018 | RE: Dr. Gary Heath | WAGMDL00091443 | WAGMDL00091444 | | | | | | | | | |
| P-25637 | 10/28/2017 | Re: Local MD under ACTIVE investigation - Please advise | WAGMDL00091641 | WAGMDL00091642 | | | | | | | | | |
| P-25638 | 6/4/2018 | RE: Dr. Behzad Aalaei | WAGMDL00091654 | WAGMDL00091655 | | | | | | | | | |
| P-25639 | 12/28/2012 | SIMS compass communication | WAGMDL00308497 | WAGMDL00308498 | | | | | | | | | |
| P-25640 | 2/16/2015 | RE: Rx Integrity Internal Audit | WAGMDL00312091 | WAGMDL00312093 | | | | | | | | | |
| P-25641 | 12/3/2012 | Review application screens and proposed changes to make navigation easier | WAGMDL00314367 | WAGMDL00314389 | | | | | | | | | |
| P-25642 | 5/8/2015 | FW: CVS and Dr Alexander in Seymour | WAGMDL00094723 | WAGMDL00094726 | | | | | | | | | |
| P-25643 | 6/3/2015 | FW: DR WITH OXY | WAGMDL00094759 | WAGMDL00094760 | | | | | | | | | |
| P-25644 | 1/22/2015 | Re: CVS refusing scripts from Comprehensive Pain and Headache Treatment Center | WAGMDL00094838 | WAGMDL00094839 | | | | | | | | | |
| P-25645 | 7/25/2013 | Re: DEA | WAGMDL00095830 | WAGMDL00095831 | | | | | | | | | |
| P-25646 | 4/9/2018 | RE: Kiosk Questions | WAGMDL00315889 | WAGMDL00315904 | | | | | | | | | |
| P-25647 | 3/21/2013 | RE: Dr. Kotsonis | WAGMDL00100077 | WAGMDL00100079 | | | | | | | | | |
| P-25648 | 3/15/2017 | RE: INFO: Dr. William Logan GFD Concerns | WAGMDL00103452 | WAGMDL00103456 | | | | | | | | | |
| P-25649 | 6/28/2012 | FW: czar doc from S. Thoss | WAGMDL00317097 | WAGMDL00317098 | | | | | | | | | |
| P-25650 | 5/17/2016 | RE: GFD Policy | WAGMDL00104540 | WAGMDL00104541 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25651 | 1/8/2013 | Prescriber Sanctioning Documents; Official Prescriber Sanction Letter; Sanctioned Prescriber Compass Communication; Prescriber Sanctioning FAQ | WAGMDL00297386 | WAGMDL00297390 | | | | | | | | | |
| P-25652 | 3/12/2013 | Email previous ppt Attachments TD GFDP_webinar v6 PPT; Questions TD GFD from pilot | WAGMDL00303474 | WAGMDL00303514 | | | | | | | | | |
| P-25653 | 8/5/2014 | RE: GFD report criteria; Market 7 Overview | WAGMDL00310337 | WAGMDL00310371 | | | | | | | | | |
| P-25654 | 10/12/2012 | 2012 Powerpoint: System Considerations - Computer Models, Algorithms, Statistics and More | WAGMDL00319188 | WAGMDL00319202 | | | | | | | | | |
| P-25655 | 5/24/2012 | Email Sorry this is so late....Attachments District Checklist for CII plus 2 Removal_vF; Store Action Plan CII Plus Two_vF | WAGMDL00317139 | WAGMDL00317155 | | | | | | | | | |
| P-25656 | 1/30/2014 | RE: Early Refill DUR for C2-C5 - Follow-up questions | WAGMDL00329835 | WAGMDL00329836 | | | | | | | | | |
| P-25657 | 4/26/2013 | RE: Communication Regarding C2 Transition | WAGMDL00324902 | WAGMDL00324905 | | | | | | | | | |
| P-25658 | 5/7/2008 | Re: Fw: Pharmacy Shrink Task Force | WAGMDL00324911 | WAGMDL00324914 | | | | | | | | | |
| P-25659 | 8/28/2015 | "Compliance with Compassion" - FL DM Good Faith Dispensing Training V4 | WAGMDL00389199 | WAGMDL00389211 | | | | | | | | | |
| P-25660 | 3/27/2009 | Re: Revised Suspicious Order Document | WAGMDL00325368 | WAGMDL00325378 | | | | | | | | | |
| P-25661 | 3/2/2016 | RE: Prescriber issue, C Morgan, McMinnville | WAGMDL00404572 | WAGMDL00404575 | | | | | | | | | |
| P-25662 | 4/29/2015 | cocktails; Federal Register - Vol. 77 No. 198, Part II - Holiday CVS, L.L.C., d/b/a CVS/Pharmacy Nos. 219 and 5195; Decision and Order and Denial of Request for Redactions; Notices | WAGMDL00405921 | WAGMDL00405954 | | | | | | | | | |
| P-25663 | 5/29/2013 | FW: Revised Draft Presentation | WAGMDL00330437 | WAGMDL00330443 | | | | | | | | | |
| P-25664 | 3/10/2014 | FW: GFD; Prescriber Profile Dr Frank Ling | WAGMDL00412285 | WAGMDL00412289 | | | | | | | | | |
| P-25665 | 5/16/2014 | Re: Potential Mail order rule for controlled drugs in Ohio | WAGMDL00333310 | WAGMDL00333313 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25666 | 3/9/2018 | Email RxIC Prescriber & DEA Projects Attachments RxIC RelayHealth COB Blocking 3-1-18 PPT; RxIC Master Prescriber System Updates 3-1-18 PPT; RxIC LexisNexis Master File Migration 3-1-18 PPT; RxIC LexisNexis - Master Prescriber 1-2-18 PPT; RxIC LexisNexis Prescriber Pilot 11-6-17 PPT; RxIC Cover Sheet - Prescriber DEA Block Message PPT | WAGMDL00422308 | WAGMDL00422321 | | | | | | | | | |
| P-25667 | 8/10/2012 | RE: NACDS Pharmacy Operations Committee -- Action Requested: DEA Interim Solution | WAGMDL00334305 | WAGMDL00334308 | | | | | | | | | |
| P-25668 | 2/18/2013 | Email New Enhancement Attachment Mail Controlled Substance Early Refills | WAGMDL00437787 | WAGMDL00437793 | | | | | | | | | |
| P-25669 | 2/27/2013 | Perrysburg CIII-CV - follow up | WAGMDL00335835 | WAGMDL00335837 | | | | | | | | | |
| P-25670 | 12/2/2013 | RE: Controlled Substance Special Order | WAGMDL00336103 | WAGMDL00336106 | | | | | | | | | |
| P-25671 | 2/20/2013 | Re: Perrysburg CIII-CV - follow up | WAGMDL00357519 | WAGMDL00357520 | | | | | | | | | |
| P-25672 | 3/19/2015 | TG Responsibilities; Rx Integrity Tools Reports | WAGMDL00442473 | WAGMDL00442477 | | | | | | | | | |
| P-25673 | 2/21/2013 | Re: Perrysburg CIII-CV - follow up | WAGMDL00357543 | WAGMDL00357548 | | | | | | | | | |
| P-25674 | 2/26/2013 | RE: Perrysburg CIII-CV - follow up | WAGMDL00358459 | WAGMDL00358462 | | | | | | | | | |
| P-25675 | 3/22/2013 | Re: Perrysburg CIII-CV - follow up | WAGMDL00358555 | WAGMDL00358557 | | | | | | | | | |
| P-25676 | 4/4/2013 | Re: C2 Customer List_WAG Perrysburg_Start 4.9.13_WAG225+3 | WAGMDL00358567 | WAGMDL00358570 | | | | | | | | | |
| P-25677 | 8/10/2017 | RE: question about reporting offices | WAGMDL00489440 | WAGMDL00489441 | | | | | | | | | |
| P-25678 | 4/9/2013 | RE: Walgreens Woodland Data - Red Stores | WAGMDL00358578 | WAGMDL00358580 | | | | | | | | | |
| P-25679 | 2/13/2012 | Quarterly DEA "Meeting Minutes" - February 10, 2012 | WAGMDL00358746 | WAGMDL00358750 | | | | | | | | | |
| P-25680 | 1/3/2018 | RE: Dr. Gary Heath | WAGMDL00490069 | WAGMDL00490070 | | | | | | | | | |
| P-25681 | 10/19/2017 | RE: Rx from Dr David M Kowal | WAGMDL00490225 | WAGMDL00490226 | | | | | | | | | |
| P-25682 | 4/5/2016 | RE: Doctor that May Need Investigation | WAGMDL00490674 | WAGMDL00490675 | | | | | | | | | |
| P-25683 | 12/22/2011 | 340B Discussion | WAGMDL00363134 | WAGMDL00363144 | | | | | | | | | |
| P-25684 | 4/17/2018 | FW: Prescriber Verification; RE: Controls BY MD | WAGMDL00495182 | WAGMDL00495186 | | | | | | | | | |
| P-25685 | 4/25/2014 | RE: MDP/MVP videoconference Attachment Good Faith Dispensing Western Op V2 PPT | WAGMDL00576462 | WAGMDL00576465 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25686 | 11/6/2012 | DEA Validation Procedures for Good Faith Dispensing of Controlled Substances | WAGMDL00582966 | WAGMDL00582966 | | | | | | | | | |
| P-25687 | 11/12/2013 | FW: CII orders | WAGMDL00363660 | WAGMDL00363663 | | | | | | | | | |
| P-25689 | 6/27/2013 | Compliance Issues | WAGMDL00363749 | WAGMDL00363750 | | | | | | | | | |
| P-25690 | 9/18/2014 | Analytics Metadata Survey and Interviews POC Report - Dave Jennings PPT | WAGMDL00672069 | WAGMDL00672081 | | | | | | | | | |
| P-25691 | 3/19/2013 | RE: January 2013 ARCOS Report Transmission Issue | WAGMDL00363767 | WAGMDL00363770 | | | | | | | | | |
| P-25692 | 8/14/2013 | RE: Arcos 7 Type for this month | WAGMDL00364632 | WAGMDL00364633 | | | | | | | | | |
| P-25693 | 7/17/2017 | RE: BCBSA Walgreens Catch Up re: Follow Ups and Next Steps | WAGMDL00374710 | WAGMDL00374719 | | | | | | | | | |
| P-25694 | 8/19/2014 | Market 5 GFD and Controlled Substance Trends PPT | WAGMDL00672331 | WAGMDL00672358 | | | | | | | | | |
| P-25695 | 11/2/2016 | FW: Drug Take Back Program | WAGMDL00375070 | WAGMDL00375071 | | | | | | | | | |
| P-25696 | 10/15/2012 | IMS Pilot demonstration - updated with presentation materials provided by IMS Calendar or Calendar; CS Ratings - WAG WB; IMS CS Ratings Offering WAG PILOT | WAGMDL00677965 | WAGMDL00678016 | | | | | | | | | |
| P-25697 | 6/19/2018 | RE: Policy Papers and Direction | WAGMDL00376065 | WAGMDL00376072 | | | | | | | | | |
| P-25699 | 1/8/2013 | GFDP - Top 500 Potential Stores | WAGMDL00700278 | WAGMDL00700278 | | | | | | | | | |
| P-25700 | 10/11/2013 | Market Leadership Meeting Oct 13 v11Edit | WAGMDL00708570 | WAGMDL00708593 | | | | | | | | | |
| P-25701 | 3/30/2016 | RE: Safe disposal_ Joint Op-ed_3 15 16 930p et | WAGMDL00377962 | WAGMDL00377967 | | | | | | | | | |
| P-25702 | 4/30/2013 | Market 22 Leadership Meeting | WAGMDL00708605 | WAGMDL00708624 | | | | | | | | | |
| P-25703 | 6/13/2016 | NACDS Take Back Policy Strategy- Thoughts? | WAGMDL00378634 | WAGMDL00378639 | | | | | | | | | |
| P-25704 | 11/29/2012 | November legal issues | WAGMDL00741585 | WAGMDL00741586 | | | | | | | | | |
| P-25705 | 2/2/2018 | RE: A request | WAGMDL00774440 | WAGMDL00774443 | | | | | | | | | |
| P-25706 | 10/22/2015 | FW: DSN A.M. - Obama announces massive push to curb opioid abuse, heroin use | WAGMDL00383497 | WAGMDL00383700 | | | | | | | | | |
| P-25707 | 12/18/2012 | Rx Advisor Approval Meeting; RCA Approval Minutes; Front Door-Cap Block request form v8 fv-DEA Sanctioned Presc; DEA Sanctioned Presc - screen; Blocks Per Store Per Day | WAGMDL00782363 | WAGMDL00782367 | | | | | | | | | |
| P-25708 | 3/10/2010 | Email DUR documentation for early refill of controlled substances Attachment Controlled Substance_Early Refill PPT | WAGMDL00784104 | WAGMDL00784116 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25709 | 5/21/2018 | FW: great to meet you- Disposal RX getting with Walgreens | WAGMDL00384341 | WAGMDL00384357 | | | | | | | | | |
| P-25710 | 2/25/2015 | RE: GFD question | WAGMDL00799324 | WAGMDL00799324 | | | | | | | | | |
| P-25711 | 1/12/2015 | FW: Doctor issue | WAGMDL00801881 | WAGMDL00801882 | | | | | | | | | |
| P-25712 | 4/30/2019 | RE: Discovery Session - GFD 2.0 Compliance Project; Calculating Total Daily Dose of Opioids For Safer Dosage; Target Drug Good Faith Dispensing Checklist; Controlled Substance Prescriptions & Good Faith Dispensing Policy; Target Drug Good Faith Dispensing Policy; DEA CS Training Tool | WAGMDL00859484 | WAGMDL00859521 | | | | | | | | | |
| P-25713 | 9/20/2017 | RE: WSB Following up CRM:0167829 | WAGMDL00385105 | WAGMDL00385110 | | | | | | | | | |
| P-25714 | 8/14/2017 | Re: For 5 pm call | WAGMDL00385259 | WAGMDL00385260 | | | | | | | | | |
| P-25715 | 10/31/2017 | FW: [EXTERNAL] Re: Joint Industry Letter - Edited Version | WAGMDL00385788 | WAGMDL00385789 | | | | | | | | | |
| P-25716 | 10/30/2017 | LETTER ON PHARMACY INDUSTRY JOINT EFFORT TO ADDRESS AND HELP PREVENT OPIOID MISUSE AND ABUSE | WAGMDL00385790 | WAGMDL00385791 | | | | | | | | | |
| P-25717 | 10/23/2017 | Draft SP statement for WH event | WAGMDL00385895 | WAGMDL00385896 | | | | | | | | | |
| P-25718 | 10/23/2017 | WAG statement WH opioid event 10-23-17 3 pm draftx | WAGMDL00385897 | WAGMDL00385897 | | | | | | | | | |
| P-25719 | 11/14/2012 | Resp't Ex. 226: DEA website printout, Knowing Your Customer/Suspicious Orders Reporting | WAGMDL00387625 | WAGMDL00387628 | | | | | | | | | |
| P-25720 | 7/18/2012 | Resp't Ex. 237-E - Loss Prevention Org Chart | WAGMDL00387633 | WAGMDL00387634 | | | | | | | | | |
| P-25721 | 12/20/2012 | Email Target Drug GFD V2 (qty increased) documents Attachments Target Drug Good Faith Dispensing Policy; Target Drug Good Faith Dispensing Policy | WAGMDL00862209 | WAGMDL00862214 | | | | | | | | | |
| P-25722 | 2/3/2014 | RE: R69 "What's New" Webinar; What's New in Intercom Plus Release 69 | WAGMDL00862251 | WAGMDL00862289 | | | | | | | | | |
| P-25723 | 8/6/2007 | 2007-8 DC13_Page_000261 | WAGMDL00390362 | WAGMDL00390363 | | | | | | | | | |
| P-25724 | 11/1/2012 | Controlled Substances Ordering - Evolution of Controlled Substance Ordering Process AND SOM Policy and Procedures | WAGMDL00395923 | WAGMDL00395936 | | | | | | | | | |
| P-25725 | 2/20/2012 | Resp Ex. 259-B - Controlled Substance Reporting | WAGMDL00395937 | WAGMDL00395964 | | | | | | | | | |
| P-25726 | 6/29/2016 | Pharmacy Losses Dashboard: HRxD | WAGMDL00878535 | WAGMDL00878535 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25727 | 4/6/2012 | Resp't Ex. 259-C Functional Requirements & (Macro) Design DEA Suspicious Ordering - Phase III (Controlled Substance Threshold) Project Number W0018238 Resp't Exhibit 259-C - DEA Suspicious Ordering - Phase III v.1.1 | WAGMDL00400342 | WAGMDL00400356 | | | | | | | | | |
| P-25728 | 2/28/2013 | FW: CII Processing Update | WAGMDL00407724 | WAGMDL00407726 | | | | | | | | | |
| P-25729 | 5/24/2013 | Re: current red store list | WAGMDL00413949 | WAGMDL00413950 | | | | | | | | | |
| P-25730 | 3/1/2016 | RE: Prescriber issue, C Morgan, McMinnville | WAGMDL00414646 | WAGMDL00414648 | | | | | | | | | |
| P-25731 | 11/15/2012 | Anderson DEA Fax template Jupiter DEA Fax Template Perrysburg DEA Fax Template Waxahachie DEA Fax Template Woodland DEA Fax Template Mt Vernon DEA Fax Template | WAGMDL00415363 | WAGMDL00415368 | | | | | | | | | |
| P-25733 | 3/18/2013 | FW: District Leader Meeting - March 18th, 2013 | WAGMDL00890004 | WAGMDL00890006 | | | | | | | | | |
| P-25734 | 10/7/2012 | DEA Update; DEA Board Briefing Document | WAGMDL00897151 | WAGMDL00897153 | | | | | | | | | |
| P-25736 | 11/14/2013 | RE: Kerr Drug Phase 2 and 3 Training; USA Pharmacy Training Program Guide03252013_MERGED | WAGMDL00913492 | WAGMDL00913538 | | | | | | | | | |
| P-25737 | 5/30/2012 | FW: Meeting Notes to Outline new Procedures for DCs | WAGMDL00429424 | WAGMDL00429426 | | | | | | | | | |
| P-25738 | 11/27/2012 | RE: 11/21 OSC Release: Audit Spurs Improvements At Health Department's Bureau of Narcotic Enforcement | WAGMDL00440895 | WAGMDL00440897 | | | | | | | | | |
| P-25739 | 7/2/2012 | FW: PMP pilots in IN & OH | WAGMDL00441530 | WAGMDL00441537 | | | | | | | | | |
| P-25740 | 2/5/2013 | Quarterly DEA Agenda for Feb 6th 10 a.m. and Meeting Minutes from November 15th; Quarterly November 15th 2012 Meeting Minutes Quarterly February 6th 2013 Meeting Agenda | WAGMDL00451632 | WAGMDL00451636 | | | | | | | | | |
| P-25741 | 4/28/2019 | RE: GFD 2.0 Compliance project; GFD 2.0 - Clinical GFD DUR | WAGMDL00918327 | WAGMDL00918344 | | | | | | | | | |
| P-25742 | 5/2/2014 | FW: Webinar; What's New in Intercom Plus Release 70 | WAGMDL00922086 | WAGMDL00922124 | | | | | | | | | |
| P-25743 | 10/14/2012 | Re: verifying pbr in GFD | WAGMDL00931151 | WAGMDL00931151 | | | | | | | | | |
| P-25744 | 3/2/2012 | FW: IC+ R65 Executive Summary; Intercom Plus Release 65 Executive Summary; JUNK | WAGMDL00973902 | WAGMDL00973904 | | | | | | | | | |
| P-25745 | 2/12/2013 | FW: CSOS Phase II ? | WAGMDL00478001 | WAGMDL00478002 | | | | | | | | | |
| P-25746 | 2/12/2013 | RE: CSOS Phase II ? | WAGMDL00478056 | WAGMDL00478057 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|------------------|------------------|--|--|--|--|--|--|--|--|--|
| P-25747 | 7/26/2012 | FW: DEA Meeting Minutes July 25, 2012 | WAGMDL00482264 | WAGMDL00482266 | | | | | | | | | |
| P-25748 | 1/31/2012 | INFO: Western Division Update 2.25.12 | WAGMDL00974031 | WAGMDL00974215 | | | | | | | | | |
| P-25749 | 6/11/2013 | FW: WALGREENS AGREES TO PAY A RECORD SETTLEMENT OF \$80 MILLION FOR CIVIL PENALTIES UNDER THE CONTROLLED SUBSTANCES ACT | WAGMDL00485056 | WAGMDL00485058 | | | | | | | | | |
| P-25751 | 6/7/2016 | RE: Your part of the Request List Prime | WAGMDL00987026 | WAGMDL00987192 | | | | | | | | | |
| P-25752 | 11/20/2015 | Retail Hub Portfolio Update: Week Ending 11-20; Retail Hub Weekly Portfolio Update | WAGMDL01043245 | WAGMDL01043355 | | | | | | | | | |
| P-25753 | 10/30/2019 | Business Outcomes and Capabilities for GFD 2.0 Phase 2; GFD 2.0 Process Flow- IT Discovery | WAGMDL01064499 | WAGMDL01064516 | | | | | | | | | |
| P-25754 | 9/13/2016 | FW: Update: Good Faith and Target Good Faith Dispensing Policies Reminder | WAGMDL01108982 | WAGMDL01108983 | | | | | | | | | |
| P-25755 | 9/25/2012 | RE: Please create these 2 lists; Ad-hoc reports - 09242012 | WAGMDL01133018 | WAGMDL01133020 | | | | | | | | | |
| P-25756 | 7/30/2018 | RE: Suspicious Prescribing Habits | WAGNYNS00020842 | WAGNYNS00020844 | | | | | | | | | |
| P-25757 | 3/22/2012 | Fw: Pharmacy Diversion Awareness Conference held by the DEA | WAGFLDEA00000609 | WAGFLDEA00000610 | | | | | | | | | |
| P-25760 | 5/14/2008 | 2008 DEA Quarterly Meetings | WAGMDL00491150 | WAGMDL00491152 | | | | | | | | | |
| P-25761 | 8/2/2012 | Requirements | WAGMDL00491251 | WAGMDL00491258 | | | | | | | | | |
| P-25762 | 2/1/2009 | Intercepted /Suspicious Store Orders Project #: P99999 Version 1.0 | WAGMDL00491863 | WAGMDL00491877 | | | | | | | | | |
| P-25763 | 3/13/2009 | Controlled Substance Threshold Project #: P09002 | WAGMDL00491896 | WAGMDL00491912 | | | | | | | | | |
| P-25764 | 4/20/2009 | MICRO-ORPB305 | WAGMDL00491918 | WAGMDL00491923 | | | | | | | | | |
| P-25765 | 6/1/2009 | P09002 - Macro Design | WAGMDL00491961 | WAGMDL00491989 | | | | | | | | | |
| P-25775 | 6/24/2008 | DEA Intercept Suspicious Order | WAGMDL00492032 | WAGMDL00492037 | | | | | | | | | |
| P-25776 | 9/25/2009 | P09002 Threshold Controlled Substance MACro Design II DEA Suspicious Ordering | WAGMDL00492038 | WAGMDL00492066 | | | | | | | | | |
| P-25786 | 10/1/2009 | DEA Suspicious Order Item Part II - Phase II | WAGMDL00492070 | WAGMDL00492072 | | | | | | | | | |
| P-25787 | 2/1/2009 | Controlled Substance Threshold Project #: P09002 Version 1.0 | WAGMDL00492132 | WAGMDL00492152 | | | | | | | | | |
| P-25789 | 8/30/2011 | DEA Statistics Aug.2011x | WAGMDL00492169 | WAGMDL00492169 | | | | | | | | | |
| P-25790 | 1/26/2012 | DEA Metrics Validation - Systems Order Cut/Reduced | WAGMDL00492178 | WAGMDL00492183 | | | | | | | | | |
| P-25792 | 2/22/2012 | ORPB306_updated_V1 3 | WAGMDL00492209 | WAGMDL00492211 | | | | | | | | | |
| P-25793 | 11/23/2011 | DEA Phase III - Questions & Comments2 | WAGMDL00492375 | WAGMDL00492376 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25794 | 9/23/2011 | DEA Phase III - Questions & Comments | WAGMDL00492378 | WAGMDL00492380 | | | | | | | | | |
| P-25795 | 6/5/2006 | Project Request Form - Stores | WAGMDL00493647 | WAGMDL00493648 | | | | | | | | | |
| P-25796 | 8/10/2015 | 20150810 Hensley Email re DEA Chemical Application More Info | WAGMDL00493727 | WAGMDL00493729 | | | | | | | | | |
| P-25797 | 8/2/2012 | CLAAD Policy Brief, July 31, 2012 | WAGMDL00515588 | WAGMDL00515589 | | | | | | | | | |
| P-25798 | 9/25/2012 | RE: APhA information request for FDA hydrocodone meeting | WAGMDL00517021 | WAGMDL00517023 | | | | | | | | | |
| P-25799 | 9/10/2012 | RE: APhA information request for FDA hydrocodone meeting | WAGMDL00517040 | WAGMDL00517044 | | | | | | | | | |
| P-25800 | 2/18/2013 | Perrysburg Plan - week of 2/18. | WAGMDL00524429 | WAGMDL00524430 | | | | | | | | | |
| P-25801 | 2/28/2013 | RE: CII Processing Update | WAGMDL00524815 | WAGMDL00524817 | | | | | | | | | |
| P-25802 | 4/3/2013 | FW: CII transition plan document | WAGMDL00525116 | WAGMDL00525119 | | | | | | | | | |
| P-25803 | 6/13/2013 | FW: Ordering Issues - Controlled Substances | WAGMDL00240837 | WAGMDL00240842 | | | | | | | | | |
| P-25804 | 3/26/2013 | FW: Perrysburg Accelerated C2 Plan | WAGMDL00528072 | WAGMDL00528073 | | | | | | | | | |
| P-25805 | 3/8/2013 | RE: Dear Colleague on Safe Prescribing Act of 2013 | WAGMDL00533039 | WAGMDL00533041 | | | | | | | | | |
| P-25806 | 2/28/2013 | CII jobber list & Red flag Store list for Perrysburg | WAGMDL00541412 | WAGMDL00541412 | | | | | | | | | |
| P-25807 | 2/19/2013 | MOA | WAGMDL00574919 | WAGMDL00574926 | | | | | | | | | |
| P-25808 | Undated | RX Sales by store | WAGMDL00851845 | WAGMDL00851845 | | | | | | | | | |
| P-25809 | 3/19/2013 | RE: Questions from 3/18 District Leader meeting | WAGMDL00574927 | WAGMDL00574930 | | | | | | | | | |
| P-25810 | 6/12/2013 | FW: Final MOA/Compliance Addendum | WAGMDL00575931 | WAGMDL00575934 | | | | | | | | | |
| P-25811 | Undated | Transactional Data | WAGMDL00851846 | WAGMDL00851846 | | | | | | | | | |
| P-25812 | 1/25/2013 | Status | WAGMDL00577118 | WAGMDL00577119 | | | | | | | | | |
| P-25813 | Undated | Ohio Ceiling Override Data | WAGMDL00852037 | WAGMDL00852037 | | | | | | | | | |
| P-25814 | 4/10/2012 | RE: Update - Response From HealthCare LP | WAGMDL00580316 | WAGMDL00580318 | | | | | | | | | |
| P-25815 | 4/6/2012 | FW: Update | WAGMDL00580319 | WAGMDL00580320 | | | | | | | | | |
| P-25816 | 5/30/2013 | FW: Stores (#3629, #4727, #6997, #3836, #4391 and #3099) | WAGMDL00583296 | WAGMDL00583301 | | | | | | | | | |
| P-25817 | 3/18/2013 | RE: Any time today to talk and get an update? | WAGMDL00585578 | WAGMDL00585583 | | | | | | | | | |
| P-25818 | Undated | Flagged Orders | WAGMDL00852038 | WAGMDL00852038 | | | | | | | | | |
| P-25819 | 5/28/2013 | FW: Compliance timeline | WAGMDL00585822 | WAGMDL00585825 | | | | | | | | | |
| P-25820 | 10/5/2011 | FW: Documents Held from Receiving through Shipping at DCs for CII and for CIII-CV | WAGMDL00586171 | WAGMDL00586176 | | | | | | | | | |
| P-25821 | 2/13/2013 | Perrysburg DEA Fax Template Susp Drug | WAGMDL00752231 | WAGMDL00752231 | | | | | | | | | |
| P-25822 | 1/6/2020 | Control Data_OH | WAGMDL00779463 | WAGMDL00779463 | | | | | | | | | |
| P-25823 | 2/6/2013 | Fw: DEA at Perrysburg Now | WAGMDL00818453 | WAGMDL00818455 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-----------------|-----------------|--|--|--|--|--|--|--|--|--|
| P-25824 | 6/13/2012 | PPT for tomorrow's 11:00 meeting | WAGMDL00589674 | WAGMDL00589679 | | | | | | | | | |
| P-25825 | 6/11/2020 | SORs (Summit and Cuyahoga) | WAGMDL00847636 | WAGMDL00847636 | | | | | | | | | |
| P-25826 | 1/17/2018 | FW: RX Kiosk Takeback program RFQ results | WAGMDL00591948 | WAGMDL00591951 | | | | | | | | | |
| P-25827 | 2/12/2013 | RE: Drug Reports | WAGMDL00847774 | WAGMDL00847778 | | | | | | | | | |
| P-25828 | 9/6/2017 | FW: Walgreens Partnership Agreement | WAGMDL00595580 | WAGMDL00595586 | | | | | | | | | |
| P-25829 | 5/19/2016 | RE: Drug Take Back Event recap | WAGMDL00600854 | WAGMDL00600860 | | | | | | | | | |
| P-25830 | 4/27/2016 | FW: Funding for Naloxone Training | WAGMDL00603118 | WAGMDL00603128 | | | | | | | | | |
| P-25831 | 1/19/2012 | RE: DEA reduced item ordered from Cardinal. | WAGNMAG00025728 | WAGNMAG00025729 | | | | | | | | | |
| P-25832 | 2/22/2013 | GFD Pilot – Drug Sales Trends | WAGFLAG00093644 | WAGFLAG00093650 | | | | | | | | | |
| P-25833 | 11/29/2012 | RE: Tolerance; Tolerance Limit | WAGMDL00609440 | WAGMDL00609443 | | | | | | | | | |
| P-25834 | 10/1/2018 | ARCOS Overall | WAGMDL00293631 | WAGMDL00293631 | | | | | | | | | |
| P-25835 | 12/29/2017 | RAD Rx Inventory Management PPT | WAGMDL00609618 | WAGMDL00609628 | | | | | | | | | |
| P-25836 | 10/24/2018 | ARCOS Total Data | WAGMDL00490979 | WAGMDL00490979 | | | | | | | | | |
| P-25837 | 5/8/2014 | Internal Audit of AmerisourceBergen Ordering, Receiving, and Invoice Processes | WAGMDL00610722 | WAGMDL00610732 | | | | | | | | | |
| P-25839 | 3/1/2017 | opioid study | WAGMDL00611377 | WAGMDL00611384 | | | | | | | | | |
| P-25840 | 2/5/2019 | Spreadsheet re ARCOS Data | WAGMDL00773926 | WAGMDL00773926 | | | | | | | | | |
| P-25841 | 6/19/2017 | FW: Walgreens-BCBSA Strategic Partnership Agreement - UPDATE | WAGMDL00612155 | WAGMDL00612157 | | | | | | | | | |
| P-25842 | 1/29/2016 | RE: DEA meeting | WAGMDL00613455 | WAGMDL00613467 | | | | | | | | | |
| P-25846 | 5/6/2016 | Mandatory Take Back amendment | WAGMDL00615477 | WAGMDL00615477 | | | | | | | | | |
| P-25847 | 5/3/2016 | Fwd: Urgent Drug Take-Back Issues | WAGMDL00615504 | WAGMDL00615509 | | | | | | | | | |
| P-25850 | 5/24/2018 | RE: Holaday Testimony | WAGMDL00616784 | WAGMDL00616787 | | | | | | | | | |
| P-25851 | 5/24/2012 | FW: [RxNews] Senators approve Manchin amendment to reclassify hydrocodone drugs | WAGMDL00617478 | WAGMDL00617481 | | | | | | | | | |
| P-25852 | 11/25/2013 | Micro - DEA 6 - Load 2 - ORPB393 - DEA _V1.0 | WAGMDL00624441 | WAGMDL00624451 | | | | | | | | | |
| P-25853 | 3/26/2014 | Micro - DEA 6 - Order on the fly_VOPB332_V1 | WAGMDL00624487 | WAGMDL00624497 | | | | | | | | | |
| P-25854 | 1/4/2017 | FW: Document Request | WAGMDL00625153 | WAGMDL00625160 | | | | | | | | | |
| P-25858 | 10/28/2011 | SOR | WAGMDL00850183 | WAGMDL00850184 | | | | | | | | | |
| P-25859 | 7/21/2011 | SOR | WAGMDL00850190 | WAGMDL00850191 | | | | | | | | | |
| P-25860 | 6/23/2011 | SOR | WAGMDL00850192 | WAGMDL00850193 | | | | | | | | | |
| P-25861 | 7/6/2011 | SOR | WAGMDL00850195 | WAGMDL00850196 | | | | | | | | | |
| P-25862 | 6/8/2011 | SOR | WAGMDL00851269 | WAGMDL00851270 | | | | | | | | | |
| P-25863 | 6/10/2020 | Flagged Order Production | WAGMDL00847635 | WAGMDL00847635 | | | | | | | | | |
| P-25864 | 2/22/2020 | Research Report | WAGNYS00055938 | WAGNYS00055994 | | | | | | | | | |
| P-25873 | 3/2/2012 | Fw: Recap of Drug Diversion Hearing | WAGMDL00642592 | WAGMDL00642594 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------|----------------|--|--|--|--|--|--|--|--|--|
| P-25874 | 3/2/2018 | FW: Language on Pharmacist Interventions to Prevent Prescription Drug Abuse | WAGMDL00644179 | WAGMDL00644182 | | | | | | | | | |
| P-25876 | 1/5/2010 | Resp't Ex. 259-E Cover Letters | WAGMDL00655723 | WAGMDL00655738 | | | | | | | | | |
| P-25877 | 2/1/2009 | Intercepted/Suspicious Store Orders | WAGMDL00658202 | WAGMDL00658216 | | | | | | | | | |
| P-25878 | 9/18/2008 | Cardinal SOM | WAGMDL00658228 | WAGMDL00658229 | | | | | | | | | |
| P-25879 | 7/28/2008 | Barb Martin handwritten notes | WAGMDL00658242 | WAGMDL00658242 | | | | | | | | | |
| P-25880 | 9/18/2008 | Handwritten Notes from Barb Martin | WAGMDL00658243 | WAGMDL00658243 | | | | | | | | | |
| P-25881 | 11/30/2018 | Martin handwritten notes | WAGMDL00658254 | WAGMDL00658255 | | | | | | | | | |
| P-25882 | 9/17/2012 | FW: CONTROL DRUG ADJUSTMENTS | WAGMDL00659076 | WAGMDL00659078 | | | | | | | | | |
| P-25884 | 7/17/2012 | Walgreen Co. Controlled Substance Anti-Diversion and Compliance Program | WAGMDL00659802 | WAGMDL00659856 | | | | | | | | | |
| P-25886 | 11/3/2012 | FW: SOM | WAGMDL00660341 | WAGMDL00660343 | | | | | | | | | |
| P-25888 | 7/12/2012 | iSTOP workgroup | WAGMDL00662135 | WAGMDL00662135 | | | | | | | | | |
| P-25889 | 3/26/2013 | Forest meeting notes and action items | WAGMDL00663366 | WAGMDL00663376 | | | | | | | | | |
| P-25892 | 9/14/2012 | FW: DEA at Jupiter DC 9/14/2012 | WAGMDL00667935 | WAGMDL00667935 | | | | | | | | | |
| P-25893 | 6/6/2012 | FW: Meeting Notes for Suspicious Ordering Phase 5-6/05/2012 | WAGMDL00670686 | WAGMDL00670694 | | | | | | | | | |
| P-25896 | 3/25/2011 | Analysis Data for Wayne.xls | WAGMDL00673894 | WAGMDL00673894 | | | | | | | | | |
| P-25897 | 2/15/2013 | 2013.02.15 - Letter to DEA re. Perrysburg DC (2435285_1_DC) | WAGMDL00674277 | WAGMDL00674279 | | | | | | | | | |
| P-25898 | 4/9/2013 | FW: PDF Image Attached | WAGMDL00674545 | WAGMDL00674549 | | | | | | | | | |
| P-25900 | 8/25/2009 | ORDER ITEM DETAIL SUSPICIOUS ORDER | WAGMDL00674550 | WAGMDL00674550 | | | | | | | | | |
| P-25901 | 8/25/2009 | ORDER ITEM DETAIL SUSPICIOUS ORDER | WAGMDL00674553 | WAGMDL00674553 | | | | | | | | | |
| P-25902 | 8/18/2010 | ORDER ITEM DETAIL SUSPICIOUS ORDER | WAGMDL00674562 | WAGMDL00674575 | | | | | | | | | |
| P-25903 | 2/17/2010 | THRESHOLD VIOLATIONS-WEEKLY | WAGMDL00674576 | WAGMDL00674594 | | | | | | | | | |
| P-25904 | 9/23/2009 | Threshold Violations - Monthly | WAGMDL00674619 | WAGMDL00674619 | | | | | | | | | |
| P-25905 | 9/23/2009 | Threshold Violations - Monthly | WAGMDL00674620 | WAGMDL00674620 | | | | | | | | | |
| P-25906 | 8/25/2009 | Threshold Violations - Monthly | WAGMDL00674623 | WAGMDL00674623 | | | | | | | | | |
| P-25907 | 2/14/2013 | Chris D Status 2-14-13x | WAGMDL00675586 | WAGMDL00675586 | | | | | | | | | |
| P-25908 | 8/30/2012 | RE: IMS Controlled Substance Reporting | WAGMDL00678523 | WAGMDL00678540 | | | | | | | | | |
| P-25910 | 3/30/2013 | Walgreen Letter - Final Draft | WAGMDL00682159 | WAGMDL00682166 | | | | | | | | | |
| P-25911 | 8/28/2018 | Urgent: GFD | WAGMDL00688181 | WAGMDL00688181 | | | | | | | | | |
| P-25912 | 8/13/2015 | RE: ceiling limit tool | WAGMDL00688364 | WAGMDL00688365 | | | | | | | | | |
| P-25913 | 6/8/2015 | FW: URGENT Re: *** Controlled Substance Ordering Immediate Action Required *** | WAGMDL00688373 | WAGMDL00688374 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---|---|--|--|--|--|--|--|--|--|--|
| P-25914 | 6/1/2015 | RE: Override Quantity Request Submitted for Approval | WAGMDL00688378 | WAGMDL00688378 | | | | | | | | | |
| P-25915 | 9/23/2013 | Controlled Substances Ordering System (CSOS) | WAGMDL00692141 | WAGMDL00692145 | | | | | | | | | |
| P-25918 | 1/31/2014 | Controlled Substances Ordering System (CSOS) Activation | WAGMDL00697865 | WAGMDL00697870 | | | | | | | | | |
| P-25920 | 2/8/2013 | FW: Important DEA Reminder | WAGMDL00698433 | WAGMDL00698434 | | | | | | | | | |
| P-25921 | 1/7/2013 | FW: Top 500 | WAGMDL00698453 | WAGMDL00698455 | | | | | | | | | |
| P-25922 | 10/7/2013 | FW: CANCELLED: Controlled Substances Ordering System (CSOS) | WAGMDL00699676 | WAGMDL00699677 | | | | | | | | | |
| P-25923 | 7/10/2013 | RE: PPT | WAGMDL00700032 | WAGMDL00700060 | | | | | | | | | |
| P-25924 | 9/3/2009 | Email | WAGMDL00425919 | WAGMDL00425922 | | | | | | | | | |
| P-25925 | 12/4/2018 | Goal Performance | WAGMDL00709450 | WAGMDL00709469 | | | | | | | | | |
| P-25927 | 2/8/2013 | Important DEA Reminder | WAGMDL00700236 | WAGMDL00700237 | | | | | | | | | |
| P-25928 | 8/10/2012 | Re: lpxrx | WAGMDL00700311 | WAGMDL00700312 | | | | | | | | | |
| P-25929 | 8/9/2012 | Re: lpxrx | WAGMDL00700314 | WAGMDL00700315 | | | | | | | | | |
| P-25930 | 6/21/2012 | Re: lpxrx report | WAGMDL00700940 | WAGMDL00700942 | | | | | | | | | |
| P-25931 | 10/10/2011 | CLI access and key control | WAGMDL00700974 | WAGMDL00700975 | | | | | | | | | |
| P-25932 | 4/22/2010 | lpxrx | WAGMDL00700993 | WAGMDL00700993 | | | | | | | | | |
| P-25933 | 7/11/2007 | Re: NSF CHECKS | WAGMDL00701013 | WAGMDL00701016 | | | | | | | | | |
| P-25934 | 4/9/2010 | Fw: Item from Kermit Crawford | WAGMDL00704351 | WAGMDL00704378 | | | | | | | | | |
| P-25937 | 5/9/2018 | Email | WAGMDL00383697 | WAGMDL00383700 | | | | | | | | | |
| P-25938 | 10/25/2013 | csos_webinar_v10_093013 CD edit | WAGMDL00707883 | WAGMDL00707914 | | | | | | | | | |
| P-25939 | 1/29/2013 | Chris D Status 1-28-13x | WAGMDL00708763 | WAGMDL00708763 | | | | | | | | | |
| P-25940 | 12/19/2013 | Chris D Status 12-19-13x | WAGMDL00708764 | WAGMDL00708764 | | | | | | | | | |
| P-25941 | 4/17/2014 | Chris D Status 4-17-14x | WAGMDL00708766 | WAGMDL00708766 | | | | | | | | | |
| P-25942 | 5/26/2012 | Fwd: INFO: Suspicious Drug process | WAGMDL00709301 | WAGMDL00709303 | | | | | | | | | |
| P-25943 | 11/30/2018 | 0389_001 | WAGMDL00709393 | WAGMDL00709393 | | | | | | | | | |
| P-25944 | 11/30/2018 | 0366_001 | WAGMDL00709431 | WAGMDL00709431 | | | | | | | | | |
| P-25945 | 11/13/2014 | Walgreens Internal Audit Documentation - Part II of III | WAGMDL00734289 | WAGMDL00734552 | | | | | | | | | |
| P-25947 | N/A | Article (News) - DEA Drug Fact Sheet Hydrocodone | P-GEN-0086 | P-GEN-0086 | | | | | | | | | |
| P-25948 | 2/7/2007 | Correspondence | P-GEN-0093 | P-GEN-0093 | | | | | | | | | |
| P-25956 | 11/13/2014 | Walgreens Internal Audit Documentation - Part II | WAGMDL00734929 | WAGMDL00735627 | | | | | | | | | |
| P-25957 | 10/2/2018 | ohio_current_ceiling_limits | WAGMDL00400359 | WAGMDL00400359 | | | | | | | | | |
| P-25959 | Undated | CV / Resume / Biography | Martin Personnel File - HIGHLY CONFIDENTIAL | Martin Personnel File - HIGHLY CONFIDENTIAL | | | | | | | | | |
| P-25963 | 8/28/2001 | Hathitrust Hearing | P-GEN-0047 | P-GEN-0047 | | | | | | | | | |
| P-25964 | 5/1/2002 | May 2002 GAO Report | P-GEN-0055 | P-GEN-0055 | | | | | | | | | |
| P-25968 | 6/15/2018 | Pleading | P-GEN-0067 | P-GEN-0067 | | | | | | | | | |
| P-25972 | 4/5/2012 | Jupiter/Perrysburg C2 Orders | WAGMDL00751658 | WAGMDL00751659 | | | | | | | | | |
| P-25973 | 4/10/2012 | RE: Suspicious Drug Order Report and on Line DEA Manual | WAGMDL00751806 | WAGMDL00751807 | | | | | | | | | |
| P-25974 | 5/29/2012 | RE: Suspicious Drug process | WAGMDL00751808 | WAGMDL00751810 | | | | | | | | | |
| P-25975 | 5/30/2012 | RE: Suspicious Drug process | WAGMDL00752192 | WAGMDL00752194 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-25976 | 12/22/2008 | Perrysburg - Internal Audit Report - 12/22/2008 | WAGMDL00757148 | WAGMDL00757163 | | | | | | | | | |
| P-25977 | 7/1/2011 | Document Request List - Perrysburg DC DEA Review - July 2011 | WAGMDL00757170 | WAGMDL00757171 | | | | | | | | | |
| P-25978 | 8/13/2012 | Controlled Substance Order Quantity Override Form | WAGMDL00757172 | WAGMDL00757187 | | | | | | | | | |
| P-25979 | 11/1/2012 | Document Request List Perrysburg DC DEA Review - November 2012 | WAGMDL00757188 | WAGMDL00757192 | | | | | | | | | |
| P-25980 | 7/11/2012 | Various Minutes of Meetings of the Board of Directors of Walgreen Co. | WAGSHARE00000001 | WAGSHARE00000043 | | | | | | | | | |
| P-25981 | 4/4/2012 | Handling Suspicious Drug Orders | WAGFLDEA00000027 | WAGFLDEA00000027 | | | | | | | | | |
| P-25983 | 8/12/1999 | Letter Agreement re that Joanie Smoot presentation "Current Trends and the Pharmacist's Role in the Treatment of Chronic Non-Malignant Pain". | PKY180524065 | PKY180524065 | | | | | | | | | |
| P-25984 | 12/21/1998 | Use of Opioids - A Pharmacist Responsibilities. "Legal Implications and the Use of Opioids". | PKY180836236 | PKY180836236 | | | | | | | | | |
| P-25985 | 1/5/1999 | Letter of Agreement between Walgreen Co and Purdue Pharma LP | PKY180836239 | PKY180836239 | | | | | | | | | |
| P-25988 | 11/6/2017 | Walgreens University Information | PPLPC014000362724 | PPLPC014000362773 | | | | | | | | | |
| P-25990 | 6/12/2015 | FW: APPROVED FOR USE: Walgreens email for Pharmacists 2015 | PPLPC031001349510 | PPLPC031001349545 | | | | | | | | | |
| P-25995 | 6/10/2013 | Settlement And Memorandum Agreement Walgreens/ DEA | P-WAG-0001 | P-WAG-0001 | | | | | | | | | |
| P-26014 | 12/27/2007 | Dear Registrant | P-WAG-02683 | P-WAG-02683 | | | | | | | | | |
| P-26017 | Undated | Deborah Bish LinkedIn | P-WAG-02739 | P-WAG-02739 | | | | | | | | | |
| P-26060 | 4/27/2001 | Purdue Memo from Seid to Jim Lang re: Walgreens Meeting April 25, 2001 | PDD1701892867 | PDD1701892870 | | | | | | | | | |
| P-26062 | 2/7/1997 | Email Re: Walgreens | PDD8801156563 | PDD8801156565 | | | | | | | | | |
| P-26063 | 8/8/2000 | Email btwn Purdue execs | PDD8801159660 | PDD8801159663 | | | | | | | | | |
| P-26064 | 5/29/1996 | Purdue Sales Bulletin to Entire Field Force re" Walmart Speakers Presentation." | PKY180257492 | PKY180257492 | | | | | | | | | |
| P-26065 | 5/11/2001 | Purdue Memo from Seid to Lang Re: CVS Pharmacy | PKY180267741 | PKY180267741 | | | | | | | | | |
| P-26069 | 4/18/2001 | Purdue Email RE: Rite Aid Program | PPLPC008000015973 | PPLPC008000015974 | | | | | | | | | |
| P-26300 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26301 | N/A | Plaintiffs 1006 Retail Drug Summary Report Summaries | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----|---|-----|-----|--|--|--|--|--|--|--|--|--|
| P-26302 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26303 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26304 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26305 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26306 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26307 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26308 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26309 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26310 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26311 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26312 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26313 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26314 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26315 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26316 | N/A | Plaintiffs 1006 Distribution Summary | N/A | N/A | | | | | | | | | |
| P-26317 | N/A | Plaintiffs 1006 Distribution and Dispensing Summaries | N/A | N/A | | | | | | | | | |
| P-26318 | N/A | Plaintiffs 1006 Dispensing Summaries | N/A | N/A | | | | | | | | | |
| P-26319 | N/A | Plaintiffs 1006 Dispensing Summaries | N/A | N/A | | | | | | | | | |
| P-26320 | N/A | Plaintiffs 1006 Dispensing Summaries | N/A | N/A | | | | | | | | | |
| P-26321 | N/A | Plaintiffs 1006 Dispensing Summaries | N/A | N/A | | | | | | | | | |
| P-26322 | N/A | Plaintiffs 1006 Dispensing Summaries | N/A | N/A | | | | | | | | | |
| P-26323 | N/A | Plaintiffs 1006 Dispensing Summaries | N/A | N/A | | | | | | | | | |
| P-26324 | N/A | Plaintiffs 1006 Walgreens Target Drug Good Faith Dispensing Checklist Summaries | N/A | N/A | | | | | | | | | |
| P-26325 | N/A | Plaintiffs 1006 Ohio Automated Rx Reporting System Summaries | N/A | N/A | | | | | | | | | |
| P-26326 | N/A | Plaintiffs 1006 Ohio Automated Rx Reporting System Summaries | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|-------------|-------------|--|--|--|--|--|--|--|--|--|
| P-26327 | N/A | Plaintiffs 1006 Ohio Automated Rx Reporting System Summaries | N/A | N/A | | | | | | | | | |
| P-26328 | N/A | Plaintiffs 1006 Walgreens Suspicious Control Drug Order Reports | N/A | N/A | | | | | | | | | |
| P-26329 | N/A | Plaintiffs 1006 CVS Item Review Report Summaries | N/A | N/A | | | | | | | | | |
| P-26330 | N/A | Walmart's Over-20 Report Summaries | N/A | N/A | | | | | | | | | |
| P-26331 | N/A | Walmart Refusal to Fill (RTF) and Blanket Refusal to Fill (BRTF) Summaries | N/A | N/A | | | | | | | | | |
| P-26376 | 2017 | Drug Therapy Monitoring System (DTMS)/ Prior Adverse Reaction (PAR) Process Manual | MSPN0002797 | MSPN0002837 | | | | | | | | | |
| P-26377 | 6/24/2021 | Medi-Span's response to questions | N/A | N/A | | | | | | | | | |
| P-26378 | 7/5/2013 | License Agreement Amendment | MSPN0001928 | MSPN0001939 | | | | | | | | | |
| P-26379 | 11/3/2014 | License Agreement Amendment | MSPN0001940 | MSPN0001949 | | | | | | | | | |
| P-26380 | 11/12/2004 | Second Amendment to the Licensing and Nondisclosure Agreement between MEDI-SPAN, a division of Wolters Kluwer Health, Inc. (MEDI-SPAN) and Walgreen Company | MSPN0001809 | MSPN0001810 | | | | | | | | | |
| P-26381 | 1/8/2009 | Third Amendment to the Licensing and Nondisclosure Agreement between Medi-Span, a part of Wolters Kluwer Health, Inc. ("Medi-Span") and Walgreen Co | MSPN0001811 | MSPN0001829 | | | | | | | | | |
| P-26382 | 6/14/2010 | Fourth Amendment to the Licensing and Nondisclosure Agreement between Medi-Span, a part of Wolters Kluwer Health, Inc. ("Medi-Span").and Walgreen Co. | MSPN0001830 | MSPN0001836 | | | | | | | | | |
| P-26383 | N/A | Monographs | MSPN0002879 | MSPN0002879 | | | | | | | | | |
| P-26384 | 1/9/2017 | Twelfth Amendment to the Licensing and Nondisclosure Agreement between Wolters Kluwer Clinical Drug Information, Inc., a subsidiary of Wolters Kluwer Health, Inc., assignee of Clinical Drug Information, LLC, a subsidiary of Wolters Kluwer Health, Inc. and Walgreen Company | MSPN0001790 | MSPN0001801 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-26385 | N/A | Monograph 1015 Excel Spreadsheet | N/A | N/A | | | | | | | | | |
| P-26386 | 8/1/2019 | Drug Therapy Monitoring System Reference Manual | MSPN0000872 | MSPN0000981 | | | | | | | | | |
| P-26387 | 11/1/2017 | Cross-Chek Version 2 Documentation Manual | MSPN0000151 | MSPN0000248 | | | | | | | | | |
| P-26388 | 2019 | Medi-Span Clinical Drug Interactions API Quick Start Guide | MSPN0002683 | MSPN0002687 | | | | | | | | | |
| P-26389 | 2015 | Drug Interactions API Documentation Manual | MSPN0002688 | MSPN0002769 | | | | | | | | | |
| P-26390 | 12/1/2020 | Medi-Span Clinical API Documentation Manual | MSPN0002219 | MSPN0002406 | | | | | | | | | |
| P-26391 | 10/1/2015 | Controlled Substances File Documentation Manual | MSPN0002026 | MSPN0002107 | | | | | | | | | |
| P-26392 | 2020 | Medi-Span Databases Overview | MSPN0002018 | MSPN0002025 | | | | | | | | | |
| P-26393 | N/A | Medi-Span Interaction Data Reports, Descriptions and Comments | MSPN0002883 | MSPN0002887 | | | | | | | | | |
| P-26394 | 7/21/2008 | LICENSE AGREEMENT between MEDI-SPAN, a part of Wolters Kluwer Health, Inc. and LICENSEE Giant Eagle | MSPN0001604 | MSPN0001609 | | | | | | | | | |
| P-26395 | N/A | Compilation of Various Inspection Reports and Related Documents | BOP_MDL2801875 | BOP_MDL2796431 | | | | | | | | | |
| P-26396 | N/A | Prescription Drug Investigations - Techniques and Workflow | BOP_MDL1603582 | BOP_MDL1603582 | | | | | | | | | |
| P-26397 | N/A | OAC - 4729-5-21 Manner of processing a prescription | N/A | N/A | | | | | | | | | |
| P-26398 | N/A | U.S. Census Data | N/A | N/A | | | | | | | | | |
| P-26399 | N/A | Database/Data Set: OARRS Produced Database | N/A | N/A | | | | | | | | | |
| P-26400 | 10/6/2015 | Ohio BOP Inspection Report | BOP_MDL2797911 | BOP_MDL2797978 | | | | | | | | | |
| P-26401 | 12/8/2014 | Multiple OH BOP Dangerous Drug Distributor Inspection Reports and a Prescription Room Barricade Inspection Report | BOP_MDL2799884 | BOP_MDL2799903 | | | | | | | | | |
| P-26403 | 12/18/2013 | Stakeholder Meeting Booklet | CVS-MDLT3-000030689 | CVS-MDLT3-000030796 | | | | | | | | | |
| P-26404 | 4/11/2014 | NACDS Observations -- Informational Booklet - Stakeholders Booklet 4-16-14 | CVS-MDLT3-000123978 | CVS-MDLT3-000124001 | | | | | | | | | |
| P-26568 | N/A | Rite Aid Dispensing Data from SLCG | Rite_Aid_OMDL_0064862 | Rite_Aid_OMDL_0064862 | | | | | | | | | |
| P-26571 | 3/10/2013 | Management Planner - New Prescriber DEA Edits | Rite_Aid_OMDL_0127062 | Rite_Aid_OMDL_0127064 | | | | | | | | | |
| P-26590 | 2/5/2016 | WAG-RAD emails discussing email from OH BOP RE CSI BIA 4729-5, 9 & 37 BIA - Dangerous Drugs - REVISED 2.5.2016 | WAGMDL00269157 | WAGMDL00269159 | | | | | | | | | |
| P-26653 | N/A | DOJ Presentation | WMT_MA_000001546 | WMT_MA_000001578 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-----------------------|-----------------------|--|--|--|--|--|--|--|--|--|
| P-26662 | 3/4/2021 | distribution transactional data spreadsheets | Rite_Aid_OMDL_0146924 | Rite_Aid_OMDL_0146924 | | | | | | | | | |
| P-26665 | 9/26/2016 | Email re: Blocking e-scripts | WMT_MA_000001455 | WMT_MA_000001457 | | | | | | | | | |
| P-26667 | 11/6/2013 | FY14 Outstanding Galahad Mitigation Plans | WMT_MDL_000085524 | WMT_MDL_000085528 | | | | | | | | | |
| P-26668 | 2/10/2012 | FW: Proposed wire posting to update the prescriber selection, search and addition; Prescriber Resources and Steps for Prescriber Search, Selection, Addition of Prescriber and DEA | WMT_MDL_000085561 | WMT_MDL_000085564 | | | | | | | | | |
| P-26669 | 12/11/2015 | Nelson email re ConnexUs cannot track OARRS access | WMT_MDL_000093465 | WMT_MDL_000093466 | | | | | | | | | |
| P-26670 | 9/13/2010 | HW memo re Prescriber NPI-DEA Information Lookup Website link | WMT_MDL_000099250 | WMT_MDL_000099251 | | | | | | | | | |
| P-26672 | 9/17/2012 | FW: DEA Conference | WMT_MDL_000185387 | WMT_MDL_000185390 | | | | | | | | | |
| P-26673 | 3/6/2018 | C. Slovarp email with OBW Format for CS Tour attachment | WMT_MDL_000244451 | WMT_MDL_000244481 | | | | | | | | | |
| P-26674 | 12/9/2010 | Clive Email re Activity Log Analysis | WMT_MDL_000264042 | WMT_MDL_000264043 | | | | | | | | | |
| P-26675 | 10/29/2008 | Relay Health Prescriber data presentation; RelayHealth Walmart Implementation Guide042309 | WMT_MDL_000294062 | WMT_MDL_000294094 | | | | | | | | | |
| P-26676 | 2/11/2015 | RE: BLASTING A FAX TO OH STORES/CLUBS | WMT_MDL_000302912 | WMT_MDL_000302913 | | | | | | | | | |
| P-26677 | 1/15/2016 | DEA Info; new_toolkit_4.8.16 (2); Controlled Substance Training Checklist; Refusal to Fill Form ARCHER Instructions; Controlled Substances Pharmacy Evaluation - Questions to ask Pharmacy Associates; Accessing Refusal to Fill Documentation for a Store; Controlled Substance Dispensing Report - Top Drugs and Specific Drug; Accessing Refusal to Fill Documentation for a Store | WMT_MDL_000309429 | WMT_MDL_000309454 | | | | | | | | | |
| P-26678 | 6/19/2012 | Lobbying against hydrocodone | WMT_MDL_000320491 | WMT_MDL_000320493 | | | | | | | | | |
| P-26680 | 8/8/2006 | Diversion Continuing Education Broadcast | WMT_MDL_000374283 | WMT_MDL_000374284 | | | | | | | | | |
| P-26681 | 8/2/2018 | Refusal to fill in Connexus | WMT_MDL_000404558 | WMT_MDL_000404559 | | | | | | | | | |
| P-26683 | 5/12/2010 | Email for Rx Mgrs and Pharmacists; Efficient Fill Intro email for RPhs | WMT_MDL_000420219 | WMT_MDL_000420223 | | | | | | | | | |
| P-26684 | 9/3/2010 | RE: Fast Movers and camera shots | WMT_MDL_000425955 | WMT_MDL_000425956 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-------------------------|-------------------------|--|--|--|--|--|--|--|--|--|
| P-26685 | 7/17/2014 | FW: DUR alert just discussed; FW: Illicit Drug Combo DUR | WMT_MDL_000433045 | WMT_MDL_000433048 | | | | | | | | | |
| P-26686 | 3/8/2014 | Suggestion from the Field | WMT_MDL_000436641 | WMT_MDL_000436642 | | | | | | | | | |
| P-26687 | 4/12/2019 | RE: RTF/BRTF Connexus update; Connexus Update with Refusal- To-Fill Tool; RTF Rollout - Pilot Dates | WMT_MDL_000445985 | WMT_MDL_000445990 | | | | | | | | | |
| P-26688 | 3/6/2019 | RE: Archer Question- Centrally Blocked Prescribers | WMT_MDL_000446514 | WMT_MDL_000446522 | | | | | | | | | |
| P-26691 | 4/28/2017 | Fwd: Prescriber Contact | WMT_MDL_000462343 | WMT_MDL_000462344 | | | | | | | | | |
| P-26692 | 10/16/2017 | RE: Notice of Central Prescriber Block | WMT_MDL_000468143 | WMT_MDL_000468150 | | | | | | | | | |
| P-26693 | 12/22/2016 | RE: Illicit Drug Combo DUR | WMT_MDL_000473559 | WMT_MDL_000473562 | | | | | | | | | |
| P-26695 | 1/27/2017 | RE: DUR for Combo Meds | WMT_MDL_000478224 | WMT_MDL_000478226 | | | | | | | | | |
| P-26696 | 4/23/2018 | Email re: Trinity combo DUR | WMT_MDL_000478267 | WMT_MDL_000478270 | | | | | | | | | |
| P-26698 | 11/12/2010 | RE: Walmart.com, Bentonville, AR: 1st P&P Review Report Request For Time Extension Has Been Received Pending Approval; Connexus System DUR Procedure Guide | WMT_MDL_000496939 | WMT_MDL_000497143 | | | | | | | | | |
| P-26699 | 8/4/2009 | Prescription Monitoring Program Powerpoint REVISED; Prescription Monitoring Program (PMP) Powerpoint | WMT_MDL_000499613 | WMT_MDL_000499614 | | | | | | | | | |
| P-26700 | 10/31/2018 | NarxCare and Scores | WMT_MDL_000500100 | WMT_MDL_000500101 | | | | | | | | | |
| P-26702 | 10/2/2018 | Sam's regional meeting; Opioid Stewardship | WMT_MDL_000501771 | WMT_MDL_000501772 | | | | | | | | | |
| P-26703 | 5/22/2018 | Current state of IROC H&W Operations | WMT_MDL_000508025 | WMT_MDL_000508027 | | | | | | | | | |
| P-26704 | 1/11/2019 | Core PP; 01-10-19 Master Training PP | WMT_MDL_000508343 | WMT_MDL_000508391 | | | | | | | | | |
| P-26707 | 12/22/2015 | YBM Awards 2016 MHWD Nominations | WMT_MDL_000641328 | WMT_MDL_000641329 | | | | | | | | | |
| P-26708 | 12/21/2016 | PM conference call 12/21; RUN your Business | WMT_MDL_000691464 | WMT_MDL_000691467 | | | | | | | | | |
| P-26709 | 11/4/2017 | RX Notes | WMT_MDL_000691809 | WMT_MDL_000691818 | | | | | | | | | |
| P-26711 | 3/7/2016 | RE: RE: Refusal to fill reporting | WMT_MDL_001004133 | WMT_MDL_001004135 | | | | | | | | | |
| P-26712 | 9/27/2013 | Nelson email re RTF question | WMT_MDL_001075183 | WMT_MDL_001075184 | | | | | | | | | |
| P-26713 | 1/6/2017 | FW: Analysis of Cocktail DUR | WMT_MDL_001198303 | WMT_MDL_001198306 | | | | | | | | | |
| P-26714 | 11/21/2014 | Re: H&W MIP Communication - Review Requested | WMT_MDL_001208089 | WMT_MDL_001208093 | | | | | | | | | |
| P-26715 | 3/31/2017 | Walmart Form 10-K, Securities and Exchange Commission | WMT_MDL_TRIAL_000004591 | WMT_MDL_TRIAL_000004638 | | | | | | | | | |
| P-26716 | 10/23/2013 | CCTV Update Final | WMT_MDL_000510894 | WMT_MDL_000510931 | | | | | | | | | |
| P-26717 | 12/14/2006 | Pharmacy Diversion Training | WMT_MDL_000281337 | WMT_MDL_000281339 | | | | | | | | | |
| P-26718 | 11/18/2015 | Diversion Training 08-26-14 | WMT_MDL_000669319 | WMT_MDL_000669320 | | | | | | | | | |
| P-26719 | 11/10/2013 | Re: Important Drug Diversion Information | WMT_MDL_001007067 | WMT_MDL_001007069 | | | | | | | | | |
| P-26720 | 12/27/2014 | RE: 1480 Narcotics | WMT_MDL_001182763 | WMT_MDL_001182764 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|--------------------|--------------------|--|--|--|--|--|--|--|--|--|
| P-26721 | 7/27/2016 | RE: Question [Suspicious Doctor, Lack of Training] | WMT_MDL_001200515 | WMT_MDL_001200516 | | | | | | | | | |
| P-26722 | 12/28/2015 | RE: Store/Club - 2175, BRANSON WEST, MO Order Evaluation | WMT_MDL_001308302 | WMT_MDL_001308303 | | | | | | | | | |
| P-26723 | 2/16/2018 | Question regarding time built in to Workplace for Opioid Stewardship | WMT_MDL_000694295 | WMT_MDL_000694295 | | | | | | | | | |
| P-26724 | 11/6/2014 | Comments10-2014.docx | WMT_MDL_000976997 | WMT_MDL_000977051 | | | | | | | | | |
| P-26725 | 10/23/2014 | CII Toolkit (2013-11-18 to 2014-10-23) | WMT_MDL_000057242 | WMT_MDL_000057242 | | | | | | | | | |
| P-26726 | 7/23/2015 | RE: Dr. Moyer | WMT_MDL_000991984 | WMT_MDL_000991984 | | | | | | | | | |
| P-26727 | 7/23/2015 | RE: Store 3066 | WMT_MDL_001074081 | WMT_MDL_001074083 | | | | | | | | | |
| P-26728 | 8/15/2015 | POA for Controlled substance filling | WMT_MDL_001073961 | WMT_MDL_001073962 | | | | | | | | | |
| P-26729 | 9/14/2015 | RE: MD under investigation by DEA | WMT_MDL_001203945 | WMT_MDL_001203947 | | | | | | | | | |
| P-26730 | 10/7/2015 | FW: Patient with Oxycodone 30mg | WMT_MDL_001091750 | WMT_MDL_001091751 | | | | | | | | | |
| P-26731 | 10/21/2015 | RE: Prescriber scope of practice | WMT_MDL_001074259 | WMT_MDL_001074260 | | | | | | | | | |
| P-26732 | 6/8/2016 | RE: questionable prescribing | WMT_MDL_000962344 | WMT_MDL_000962345 | | | | | | | | | |
| P-26733 | 6/22/2016 | Controlled substance growth at 5988 | WMT_MDL_001185775 | WMT_MDL_001185777 | | | | | | | | | |
| P-26734 | 6/24/2016 | Re: md under investigation | WMT_MDL_001198746 | WMT_MDL_001198748 | | | | | | | | | |
| P-26735 | 7/1/2016 | Best practices for Refusal to Fill of controlled substance prescriptions. | WMT_MDL_001185920 | WMT_MDL_001185920 | | | | | | | | | |
| P-26736 | 7/29/2016 | Refusal to fill Best practices | WMT_MDL_001185918 | WMT_MDL_001185919 | | | | | | | | | |
| P-26737 | 10/6/2016 | RE: Pain Clinic prescribing concerns | WMT_MDL_001185939 | WMT_MDL_001185941 | | | | | | | | | |
| P-26738 | 12/12/2016 | FW: Refusal to Fill verbiage | WMT_MDL_000502921 | WMT_MDL_000502922 | | | | | | | | | |
| P-26739 | 2/13/2017 | Q1goals | WMT_MDL_000096586 | WMT_MDL_000096586 | | | | | | | | | |
| P-26740 | 7/23/2015 | RE: Dr. Moyer | WMT_MDL_001074077 | WMT_MDL_001074077 | | | | | | | | | |
| P-26741 | | POM 813 - Controlled Substance Discrepancy Reporting CII-CV v2 eff 7-20-2018 to current (1-2-2019) | WMT_MDL_000056879 | WMT_MDL_000056880 | | | | | | | | | |
| P-26742 | 5/2/2013 | Diversion_Analytics_Governance_Doc_021113_-_Version_4_DOCX[1] | WMT_MDL_000463401 | WMT_MDL_000463405 | | | | | | | | | |
| P-26743 | 3/26/2009 | Policy Update - Resuming Release Schedule | WMT_MDL_000325558 | WMT_MDL_000325564 | | | | | | | | | |
| P-26744 | 11/24/2009 | [Unnamed Presentation] | WMT_MDL_000496536 | WMT_MDL_000496536 | | | | | | | | | |
| P-26745 | 5/24/2006 | POM 912 - Diversion v3.1 eff 2012-01-28 to expired | WMT_IN_AG_00001817 | WMT_IN_AG_00001823 | | | | | | | | | |
| P-26746 | 2/11/2020 | IROC One Page.docx | WMT_MDL_000443288 | WMT_MDL_000443290 | | | | | | | | | |
| P-26747 | 6/19/2018 | Opioid Stewardship | WMT_MDL_000055755 | WMT_MDL_000055762 | | | | | | | | | |
| P-26748 | 9/17/2015 | Suspicious Order Report; Suspicious Order Report - 1951 | WMT_MDL_000416017 | WMT_MDL_000416018 | | | | | | | | | |
| P-26750 | 9/17/2015 | RE: Store 1951 Suspicious Order Remediation | WMT_MDL_000985637 | WMT_MDL_000985638 | | | | | | | | | |
| P-26751 | 10/13/2015 | Order Needing Review - Store 36 | WMT_MDL_001308241 | WMT_MDL_001308242 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|---|---|--|--|--|--|--|--|--|--|--|
| P-26752 | 5/17/2016 | Suspicious Order Report; SOM Regulatory Reporting Form - Store 1951 | WMT_MDL_000416009 | WMT_MDL_000416010 | | | | | | | | | |
| P-26754 | 10/21/2016 | RE: Store/Club - 1951, ONTARIO, OR Order Evaluation | WMT_MDL_000982149 | WMT_MDL_000982149 | | | | | | | | | |
| P-26755 | 1/31/2018 | Opioid Stewardship presentation | WMT_MDL_000385330 | WMT_MDL_000385330 | | | | | | | | | |
| P-26756 | 7/27/2020 | CT3 Walmart Resps Objs to Plts 1st Combined ROGs. | N/A | N/A | | | | | | | | | |
| P-26757 | 12/22/2020 | Walmart Complaint | N/A | N/A | | | | | | | | | |
| P-26758 | 5/18/2020 | NarxCare Video | WMT_MDL_000385342 | WMT_MDL_000385342 | | | | | | | | | |
| P-26759 | 5/18/2020 | NarxCare Video | WMT_MDL_000385343 | WMT_MDL_000385343 | | | | | | | | | |
| P-26760 | 5/18/2020 | NarxCare Video | WMT_MDL_000385344 | WMT_MDL_000385344 | | | | | | | | | |
| P-26761 | 5/18/2020 | NarxCare Video | WMT_MDL_000385345 | WMT_MDL_000385345 | | | | | | | | | |
| P-26762 | 5/18/2020 | NarxCare Video | WMT_MDL_000385346 | WMT_MDL_000385346 | | | | | | | | | |
| P-26763 | 5/18/2020 | NarxCare Video | WMT_MDL_000385347 | WMT_MDL_000385347 | | | | | | | | | |
| P-26764 | 5/18/2020 | NarxCare Video | WMT_MDL_000385348 | WMT_MDL_000385348 | | | | | | | | | |
| P-26765 | 5/18/2020 | NarxCare Video | WMT_MDL_000385349 | WMT_MDL_000385349 | | | | | | | | | |
| P-26766 | N/A | Over 20 Reports | Compilation Exhibit - See Attachment to P-26766 | Compilation Exhibit - See Attachment to P-26766 | | | | | | | | | |
| P-26767 | N/A | RTF, BRTF, and blocked prescriber lists and webforms | Compilation Exhibit - See Attachment to P-26767 | Compilation Exhibit - See Attachment to P-26767 | | | | | | | | | |
| P-26768 | N/A | CII Utilization Reviews | Compilation Exhibit - See Attachment to P-26768 | Compilation Exhibit - See Attachment to P-26768 | | | | | | | | | |
| P-26769 | N/A | SOM data, store order data, KYC, Reddwerks and Buzzeo data sets | Compilation Exhibit - See Attachment to P-26769 | Compilation Exhibit - See Attachment to P-26769 | | | | | | | | | |
| P-26770 | 6/11/2021 | Frank Lazzerini Ohio Court of Appeals Order Affirming Conviction 2021-Ohio-1998 | N/A | N/A | | | | | | | | | |
| P-26771 | 7/6/2017 | Howard Diamond Indictment ED Texas; US v. Diamond | N/A | N/A | | | | | | | | | |
| P-26772 | 3/4/2020 | Martin Escobar Ohio Indictment | N/A | N/A | | | | | | | | | |
| P-26773 | 7/27/2016 | FW: Miranda_Concept Charter Completion_Controlled Substances Initiatives | WMT_MDL_000003098 | WMT_MDL_000003102 | | | | | | | | | |
| P-26774 | 12/4/2014 | RE: 6045_Hydro_Threshold | WMT_MDL_000008625 | WMT_MDL_000008625 | | | | | | | | | |
| P-26775 | 6/22/2016 | Oversight Deck - CS | WMT_MDL_000010434 | WMT_MDL_000010435 | | | | | | | | | |
| P-26776 | 9/11/2015 | XMPP, 2 Users, 34 Messages, 19 Minutes | WMT_MDL_000020712 | WMT_MDL_000020714 | | | | | | | | | |
| P-26777 | 12/13/2013 | Updated DEA Workgroup Email; HDMA 20081113_icg | WMT_MDL_000021071 | WMT_MDL_000021086 | | | | | | | | | |
| P-26778 | 1/11/2016 | FW: Agenda - November 17th Oversight Committee Presentation | WMT_MDL_000047261 | WMT_MDL_000047264 | | | | | | | | | |
| P-26779 | 10/2/2015 | Areas of Focus - Week 35 | WMT_MDL_000048216 | WMT_MDL_000048217 | | | | | | | | | |
| P-26780 | 8/16/2016 | H&W logistics analysis | WMT_MDL_000138060 | WMT_MDL_000138063 | | | | | | | | | |
| P-26781 | 3/4/2018 | CSDT Project DC Recap | WMT_MDL_000155501 | WMT_MDL_000155508 | | | | | | | | | |
| P-26782 | 3/9/2016 | FW: Materials for Eighth Annual NACDS RxIMPACT Program | WMT_MDL_000284227 | WMT_MDL_000284306 | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|--|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-26783 | 1/11/2016 | Oversight Committee Deck; January 2016 Oversight Meeting | WMT_MDL_000369625 | WMT_MDL_000369625 | | | | | | | | | |
| P-26784 | 12/21/2006 | FW: Follow-Up from PS/Government Relations & Asset Protection Monthly meeting | WMT_MDL_000384449 | WMT_MDL_000384456 | | | | | | | | | |
| P-26785 | 8/15/2011 | FW: WIRE Updates | WMT_MDL_000402301 | WMT_MDL_000402378 | | | | | | | | | |
| P-26786 | 8/28/2018 | FW: NACDS Policy Council | WMT_MDL_000468242 | WMT_MDL_000468251 | | | | | | | | | |
| P-26787 | 6/8/2015 | v2 Langman - 2917 New Technology Requests | WMT_MDL_000530418 | WMT_MDL_000530423 | | | | | | | | | |
| P-26788 | 2015 | Controlled Substance Webinar Training | WMT_MDL_000530424 | WMT_MDL_000530424 | | | | | | | | | |
| P-26789 | 9/17/2015 | WV Wholesaler lawsuit | WMT_MDL_001008940 | WMT_MDL_001008941 | | | | | | | | | |
| P-26790 | 9/1/2015 | RE: 6013 Orders | WMT_MDL_000047933 | WMT_MDL_000047936 | | | | | | | | | |
| P-26791 | 11/20/2009 | Attorney Client Privilege: Meeting; RX Presentation-McKinsey; Book1 | WMT_MDL_000062718 | WMT_MDL_000062761 | | | | | | | | | |
| P-26792 | 1/11/2016 | Oversight Committee Deck; January 2016 Oversight Meeting | WMT_MDL_000138509 | WMT_MDL_000138510 | | | | | | | | | |
| P-26793 | 6/15/2018 | First Notice of Deposition Pursuant to Rule 30(B)(6) and Document Request Pursuant to Rule 30(B)(2) and Rule 34 to Wal-Mart Incorporated D/B/A Walmart and Sam's Club | N/A | N/A | | | | | | | | | |
| P-26794 | 6/15/2018 | Second Notice of Deposition Pursuant to Rule 30(B)(6) and Document Request Pursuant to Rule 30(B)(2) and Rule 34 to Defendant Wal-Mart Incorporated D/B/A Walmart and Sam's Club | N/A | N/A | | | | | | | | | |
| P-26795 | 11/30/2018 | Walmart Responses to Plaintiffs (First) Combined Discovery Requests to National Retail Pharmacies Defendants | N/A | N/A | | | | | | | | | |
| P-26796 | N/A | Data housed with SLCG | WMT_MDL_000012776 | WMT_MDL_000012776 | | | | | | | | | |
| P-26797 | N/A | Data housed with SLCG | WMT_MDL_000024968 | WMT_MDL_000024968 | | | | | | | | | |
| P-26798 | 7/12/2019 | 20190712 Lazzerini daily-jeff.com-UPDATE Judge calls Frank Lazzerini Dr Frankenstein.pdf | WAGMDL_T1_TX00011942 | WAGMDL_T1_TX00011945 | | | | | | | | | |
| P-26799 | 7/29/2014 | Bay Village doctor, Lorenzo Lalli, sentenced to a year in prison for running "pill mill" | MCKPUB00000306 | MCKPUB00000306 | | | | | | | | | |
| P-26800 | 10/12/2016 | E.D.TX_4:16cr-40_Randall Wade Criminal Judgment | N/A | N/A | | | | | | | | | |
| P-26801 | 10/12/2016 | E.D.TX_4:16cr-40_Randall Wade Factual Basis | N/A | N/A | | | | | | | | | |
| P-26802 | 10/12/2016 | E.D.TX_4:16cr-40_Randall Wade Indictment.pdf | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|----------------------------------|----------------------------------|--|--|--|--|--|--|--|--|--|
| P-26803 | 1/21/2020 | Egisto Salerno DOJ Press Release | TEVA_CAOC_14206675 | TEVA_CAOC_14206675 | | | | | | | | | |
| P-26804 | 6/6/2018 | Frank Bynes S.D.GA Indictment u.s._v._bynes_jr._18-cr-00153 | N/A | N/A | | | | | | | | | |
| P-26805 | 2/7/2017 | James Prommersberger OHBOP Press Release Boardman Podiatrist Indicted on 79 Charges including Drug Trafficking | N/A | N/A | | | | | | | | | |
| P-26806 | 6/7/2021 | James Prommersberger Plea of Guilty, Mahoning County, Ohio v. Prommersberger, 19-cr-115 | N/A | N/A | | | | | | | | | |
| P-26807 | 2/19/2018 | Miranda Johnson Google Alert, Arrested/ Indicted Prescribers | WMT_MDL_000525021 | WMT_MDL_000525025 | | | | | | | | | |
| P-26808 | N/A | Track 3 Reddwerks Thresholds Order Monitoring Data | WMT_MDL_000286239 | WMT_MDL_000286239 | | | | | | | | | |
| P-26809 | N/A | Track 3 Buzzeo Order Monitoring Data | WMT_MDL_000286240 | WMT_MDL_000286240 | | | | | | | | | |
| P-27695 | 7/23/2009 | FW: SOM Report | IQVIA-CVS-000000512 | IQVIA-CVS-000000513 | | | | | | | | | |
| P-27808 | 4/28/2009 | Re: Supernus hearing memo | PPLPC053000032588 | PPLPC053000032590 | | | | | | | | | |
| P-27880 | N/A | DEA Update Notes | MNK-T1_0008504653 | MNK-T1_0008504657 | | | | | | | | | |
| P-27929 | N/A | Centers for Disease Control and Prevention | N/A | N/A | | | | | | | | | |
| P-27945 | N/A | Database/Data Set: Walgreens Flagged Ohio Orders Data | N/A | N/A | | | | | | | | | |
| P-27946 | N/A | Database/Data Set: Walgreens Ohio CSO Override History Data | N/A | N/A | | | | | | | | | |
| P-27947 | N/A | Database/Data Set: Walgreens Ohio Current Ceiling Limits Data | N/A | N/A | | | | | | | | | |
| P-27951 | N/A | Database/Data Set: Medispan Data Price Rx Pro | N/A | N/A | | | | | | | | | |
| P-27952 | N/A | Database/Data Set: First Databank | N/A | N/A | | | | | | | | | |
| P-27953 | N/A | Database/Data Set: Anonymized High MME Patients Claims Data | N/A | N/A | | | | | | | | | |
| P-28014 | 3/1/2007 | Memorandum Legal Guidance on Reporting Suspicious Orders Pursuant to 21 C.F.R. 1301.74(b) | CAH_MDL_PRIORPROD_DEA12_00000609 | CAH_MDL_PRIORPROD_DEA12_00000610 | | | | | | | | | |
| P-28119 | N/A | Masters v. DEA Decision | N/A | N/A | | | | | | | | | |
| P-28121 | N/A | Masters v DEA, 2016 WL 1321983 | N/A | N/A | | | | | | | | | |
| P-28123 | N/A | 21 USCA s 801, 812, 821 & 823 | N/A | N/A | | | | | | | | | |
| P-28124 | 1970 | HR 91-1444 - Comprehensive Drug Abuse Prevention & Control Act House Report | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------------------|----------------------------------|--|--|--|--|--|--|--|--|--|
| P-28143 | 3/14/2017 | "Too Many Bodies in Ohio Morgue, So Coroner Gets Death Trailer" article | N/A | N/A | | | | | | | | | |
| P-28202 | N/A | Annual Performance Review for Managers | N/A | N/A | | | | | | | | | |
| P-28207 | N/A | Hearing before Subcommittee on oversight and investigations | N/A | N/A | | | | | | | | | |
| P-28211 | 4/16/2019 | NWDA Controlled Substances Manual | HDA_MDL_000219360 | HDA_MDL_000219632 | | | | | | | | | |
| P-28214 | 6/6/2012 | "American Pain: The Largest US Pill Mills Rise and Fall" Bloomberg | N/A | N/A | | | | | | | | | |
| P-28215 | N/A | "The opioid epidemic_ How Congress and drug company lobbyists worked to neutralize the DEA" - Washington Post article | N/A | N/A | | | | | | | | | |
| P-28219 | 2018 | 2018 DEA Controlled Substance Quotas 21 CFR 1303, Fed. Reg p 17329 from DOJ, DEA Diversion Control Division | N/A | N/A | | | | | | | | | |
| P-28221 | 6/1/2018 | "Debunking the Myths of Controlled Substance Quotas, June 1, 2018 interview with J Rannazzisi Pharmacy Times | N/A | N/A | | | | | | | | | |
| P-28282 | 6/4/2014 | US DEA PowerPoint "Prescription Opioids to Heroin: A Natural Progression," June 14, 2014 | DEA_Rannazzisi-00003481 | DEA_Rannazzisi-00003489 | | | | | | | | | |
| P-28288 | 2006 | Walgreens - 10ks 2006- present | N/A | N/A | | | | | | | | | |
| P-28294 | 2017 | HBO Documentary "Warning this Drug will kill you" 2017 | N/A | N/A | | | | | | | | | |
| P-28295 | 1/1/2004 | Chemical Handler 754 Manual A Guide to Chemical Control Regulations | CAH_MDL_PRIORPROD_DEA07_01198690 | CAH_MDL_PRIORPROD_DEA07_01198758 | | | | | | | | | |
| P-28346 | N/A | Youtube video with Portenoy explaining how he would use Porter and Jick and other studies to destigmatize opioids | N/A | N/A | | | | | | | | | |
| P-28365 | 10/24/1970 | Comprehensive Drug Abuse Prevention and Control Act of 1970, Public Law 91-513, October 27, 1970, | N/A | N/A | | | | | | | | | |
| P-40001 | 5/8/2018 | Combating the Opioid Epidemic Examining Concerns About Distribution and Diversion | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|----------------------|----------------------|--|--|--|--|--|--|--|--|--|
| P-41748 | 11/13/2019 | U.S. Department of Justice Title 21 Code of Federal Regulations part 1301- registration of manufacturers, distributors, and dispensers of controlled substances | N/A | N/A | | | | | | | | | |
| P-41749 | 6/19/2020 | U.S. Department of Justice Title 21 part C- Registration of manufacturers, distributors, and dispensers of controlled substances | N/A | N/A | | | | | | | | | |
| P-41750 | 6/19/2020 | Code of Federal Regulations Title 21 | N/A | N/A | | | | | | | | | |
| P-41752 | 11/13/2019 | U.S. Code 802 definitions | N/A | N/A | | | | | | | | | |
| P-41758 | 6/19/2020 | 21 U.S. Code 822- Persons required to register | N/A | N/A | | | | | | | | | |
| P-41759 | 6/19/2020 | ARCOS data | N/A | N/A | | | | | | | | | |
| P-41760 | 6/19/2020 | ARCOS data | N/A | N/A | | | | | | | | | |
| P-42067 | 6/17/2015 | Diversion Investigators Manual 2011 QBDIManual | CAH_MDL2804_01483146 | CAH_MDL2804_01483530 | | | | | | | | | |
| P-42145 | N/A | Title 21 CFR 1306.04 Purpose of issue of prescription | N/A | N/A | | | | | | | | | |
| P-42146 | N/A | Title 21 CFR 1306.06 Persons entitled to fill prescriptions | N/A | N/A | | | | | | | | | |
| P-42147 | 10/12/2012 | Holiday CVS, L.L.C., d/b/a CVS/Pharmacy Nos. 219 and 5195; Decision and Order | N/A | N/A | | | | | | | | | |
| P-42199 | 8/3/2020 | Craig J. McCann, Ph.D, CFA Raw ARCOS data | N/A | N/A | | | | | | | | | |
| P-42346 | 2/9/2012 | FW: DEA Guidance Letters, etc.; Email re: DEA Question; Summary of DEA Comments 6--4-08 draft v 2 RC comments | CAH_MDL2804_03234502 | CAH_MDL2804_03234577 | | | | | | | | | |
| P-42387 | 4/12/2019 | Re: In Re: National Prescription Opiate Litigation, letter to Linda Singer from the U.S. Department of Justice regarding James E. Rafalski | N/A | N/A | | | | | | | | | |
| P-42554 | 1/17/2017 | Administrative Memorandum of Agreement | MCKMDL00355350 | MCKMDL00355363 | | | | | | | | | |
| P-42883 | N/A | 21 U.S.C.A. § 801 | N/A | N/A | | | | | | | | | |
| P-42885 | N/A | 21 C.F.R. § 1301.74 | N/A | N/A | | | | | | | | | |
| P-42946 | 10/22/2016 | Investigation_ The DEA slowed enforcement while the opioid epidemic grew out of control - The Washington Post | N/A | N/A | | | | | | | | | |
| P-42962 | 9/6/2006 | Federal Register Part V; 21 CFR Part 1306 | N/A | N/A | | | | | | | | | |
| P-42966 | 3/28/2011 | Administrative Memorandum of Agreement between DEA and The Harvard Drug Group, LLC | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|---|---------------------|---------------------|--|--|--|--|--|--|--|--|--|
| P-42972 | 2001 | Chemical Handler's Manual (2001) | N/A | N/A | | | | | | | | | |
| P-42983 | 4/1/2009 | Settlement and Release Agreement and Administrative Memorandum of Agreement between DEA and Masters Pharmaceutical, Inc. | N/A | N/A | | | | | | | | | |
| P-43087 | 5/8/2012 | Charles Ornstein, et al., American Pain Foundation Shuts Down as Senators Launch Investigation of Prescription Narcotics, ProPublica | N/A | N/A | | | | | | | | | |
| P-43146 | 1/4/2001 | 2001 Email between Purdue execs discussing the impact of JCAHO standards on pain management | PDD8801183361 | PDD8801183364 | | | | | | | | | |
| P-43168 | 9/27/1995 | OxyContin Launch Plan | PURCHI-003286781 | PURCHI-003286781 | | | | | | | | | |
| P-43484 | 3/18/2016 | Deborah Dowell et al., CDC Guideline for Prescribing Opioids for Chronic Pain – United States, 2016, 65 Morbidity and Mortality Weekly Report 1 | N/A | N/A | | | | | | | | | |
| P-43537 | 4/21/2021 | Rannazzisi - Touhy Request | N/A | N/A | | | | | | | | | |
| P-43621 | 11/1/2018 | "National Drug Code Dictionary," Drug Enforcement Administration, November 2018 | PLTF_2804_000117160 | PLTF_2804_000117714 | | | | | | | | | |
| P-43623 | 1/1/2018 | "NDC/NHRIC Labeler Codes," U.S. Food & Drug Administration, January 2018 | N/A | N/A | | | | | | | | | |
| P-43624 | 8/1/2017 | Opioid Oral Morphine Milligram Equivalent (MME) Conversion Factors," Centers for Disease Control and Prevention | N/A | N/A | | | | | | | | | |
| P-43625 | 11/1/2018 | Full Replacement Monthly NPI File," Centers for Medicare and Medicaid Services | N/A | N/A | | | | | | | | | |
| P-43771 | 4/20/2018 | Suspicious Order Reports produced by the DEA | DEA_000000001 | DEA_000000001 | | | | | | | | | |
| P-44607 | N/A | Sharon Hartman LinkedIn profile | N/A | N/A | | | | | | | | | |
| P-44610 | 8/9/2013 | Complaint of the United States, USDC, Eastern District of Wisconsin, 09-CV-720 (Denk vs. PharMerica) and 11-CV-706 (Beeders vs. PharMerica) | N/A | N/A | | | | | | | | | |
| P-44611 | 1/15/2010 | First Amended Complaint, Denk vs. PharMerica | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|------------|---|-----|-----|--|--|--|--|--|--|--|--|--|
| P-44612 | 5/11/2015 | U.S. Department of Justice, Drug Enforcement Administration, Memorandum of Agreement with PharMerica Corporation | N/A | N/A | | | | | | | | | |
| P-44613 | 5/14/2015 | Press release dated May 14, 2015, Long-Term Care Pharmacy to Pay 31.5 Million to Settle Lawsuit Alleging Violations of Controlled Substances Act and False Claims Act | N/A | N/A | | | | | | | | | |
| P-44630 | N/A | Tab Printout | N/A | N/A | | | | | | | | | |
| P-44631 | N/A | Tab Printout | N/A | N/A | | | | | | | | | |
| P-44632 | N/A | Tab Printout | N/A | N/A | | | | | | | | | |
| P-44637 | 12/31/2011 | Pain Care Forum, 2012 Meetings Schedule (last updated December 2011) | N/A | N/A | | | | | | | | | |
| P-44654 | N/A | US Department of Justice Clovis Pharmacy Owner Agrees to Pay \$200,000 In Civil Penalties To Resolve Controlled Substances Act Claim | N/A | N/A | | | | | | | | | |
| P-44656 | N/A | Justice News - Costco Wholesale to Pay \$11.75 Million to Settle Allegations of Lax Pharmacy Controls | N/A | N/A | | | | | | | | | |
| P-44657 | 2/9/2017 | DEA - Kaiser Permanente Pays \$850,000 Settlement | N/A | N/A | | | | | | | | | |
| P-44660 | N/A | House Hearing 107 Congress | N/A | N/A | | | | | | | | | |
| P-44661 | N/A | Federal Register Vol. 83, No. 76 4-19-18 | N/A | N/A | | | | | | | | | |
| P-44662 | 1970 | HathiTrust Drug Abuse Control Amendments 1970 | N/A | N/A | | | | | | | | | |
| P-44663 | 3/13/1971 | Proposed Rulemaking, Part 301 Federal Register Vol. 36, No. 50 | N/A | N/A | | | | | | | | | |
| P-44664 | 4/24/1971 | Rules & Regulations Title 21 Food and Drugs Federal Register Vol. 36 4/24/71 | N/A | N/A | | | | | | | | | |
| P-44665 | N/A | Reservation of Rights 730 Cardinal Health's Third Supplemental Objections | N/A | N/A | | | | | | | | | |

| | | | | | | | | | | | | | |
|---------|-----------|--|-------------------|-------------------|--|--|--|--|--|--|--|--|--|
| P-44666 | 9/10/2008 | Federal Register Vol. 73 9/10/08 08-33 | N/A | N/A | | | | | | | | | |
| P-44667 | N/A | NWDA Develops DEA Compliance Institute to Reduce Industry Exposure to Fines | N/A | N/A | | | | | | | | | |
| P-44668 | 3/20/2009 | DEA Letter 9/24/06 - Southwood Pharm Revocation SOM (Exhibit MNK-T1_0000421086- 89) | MNK-T1_0000421082 | MNK-T1_0000421107 | | | | | | | | | |